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Abstract 
Sialic acids are negatively charged sugars that are often located at the terminal end of 
glycan chains on cell surface and secreted molecules, allowing them to play crucial roles 
in cellular biology. Sialyltransferases are enzymes of the glycosyltransferase family that 
play an integral role in the biosynthesis of sialic acid containing oligosaccharides and 
glycoconjugates. Abnormal sialylation is strongly associated with cancer, with 
hypersialylation of up to 30–40% observed, along with significant upregulation of 
sialyltransferase activity. This has been directly correlated with an increased metastatic 
potential of tumours, avoidance of apoptotic pathways and resistance to therapy.  
Inhibition of sialyltransferases has drawn considerable interest due to its 
therapeutic potential, particularly in the area of anti-metastatic agents to be used in the 
treatment of cancer. Of these, analogues that are structurally similar to the transition state 
exhibit the highest inhibitory activity. To improve synthetic accessibility and 
pharmacokinetics of previously reported inhibitors, the replacement of the charged 
phosphodiester linker with a potential neutral isostere such as a carbamate or a 
1,2,3-triazole has been investigated. The replacement of the cytidine moiety with uridine 
will also be explored as a potential avenue for selectivity and because of the synthetic 
advantage it holds over cytidine. 
To investigate the effect of changing the phosphodiester linker to a neutral 
carbamate or 1,2,3-trizaole extensive computational modelling was undertaken with the 
human ST6Gal I crystal structure. Molecular docking and molecular dynamics 
simulations provided an insight into the binding mode of previously reported 
phosphodiester-linked sialyltransferase inhibitors and demonstrated that targeting the 
proposed sialyl acceptor site is a viable option for producing selective inhibitors. The 
x 
potential for a carbamate or 1,2,3-triazole linker as an isosteric replacement for the 
phosphodiester in transition-state analogue sialyltransferase inhibitors was established 
using molecular docking. Molecular dynamics simulations supported these findings with 
hydrogen bond and hydrophobic contact analysis of the dynamic systems, demonstrating 
that compounds with the alternate linkers could maintain key interactions with the human 
ST6Gal I active site. To examine the effect of changing the linker on an energetic level, 
free energy perturbation calculations were performed. These calculations provided 
energetic evidence to suggest that the carbamate and 1,2,3-triazole were slightly more 
favourable than the phosphodiester. Further exploration with free energy component, 
quasi-harmonic and cluster analysis suggested that there is an enthalpy-entropy 
compensation accounting for the replacement of the flexible charged phosphodiester with 
a neutral and rigid isostere. An additional free energy perturbation calculation that 
explored the change of cytidine to uridine in a carbamate-linked inhibitor was performed 
and demonstrated that this was a viable strategy. Overall, these simulations provide a 
strong rationale for the use of a carbamate or 1,2,3-triazole as phosphodiester isosteres 
and uridine in place of cytidine in the development of novel inhibitors of human ST6Gal I.  
To build upon and validate the computational work of this study a series of 
carbamate-linked compounds were synthesised, with this work totalling in 73 novel 
compounds being produced. In the preparation of these compounds key 
α-hydroxyphosphonate and 5′-amino nucleosides were prepared. Appropriate carbamate 
coupling conditions were required to be developed as part of this work, with 4-nitrophenyl 
chloroformate providing optimal yields. Issues with decomposition during deprotection 
forced the original acetonide protection of the 2′ and 3′ ribose hydroxyls to be 
re-examined with allyloxycarbonyl protecting groups being favoured over 
tert-butyldimethylsilyl and benzyloxycarbonyl groups. Using the developed protecting 
xi 
strategy, 26 target compounds were prepared as sodium salts ready for biological 
evaluation. The inhibitory activities against recombinant human ST6Gal I was evaluated 
at 10 μM, with all compounds exhibiting activity. Of these compounds three were 
identified as promising inhibitors, with preliminary Ki values ranging from 0.9 μM to 
12 μM. Whilst this activity is less than that of reported phosphodiester-linked inhibitors, 
we were able to maintain promising levels of activity with compounds that are relatively 
synthetically tractable, which demonstrates that both carbamate and uridine modifications 
are viable changes to the classical model of ST inhibitors that warrant further exploration. 
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Preface 
Chapter 1 presents a general introduction to sialyltransferase enzymes and how 
their inhibition has potential for use as an anti-metastatic agent in the treatment of cancer. 
This chapter provides an overview of the previous work undertaken in the field on the 
development of transition-state analogue inhibitors and the aims of this thesis. 
Chapter 2 is an overview of the computational methods used and referred to 
throughout this dissertation. The dissertation is then presented in journal article style with 
each subsequent chapter (Chapters 3–5) presented as a complete manuscript. Further 
unpublished synthetic findings (Chapter 6) that provide background context to the 
Journal of Medicinal Chemistry manuscript that constitutes Chapter 5 has also been 
included.  
This style is deemed appropriate to the multi-disciplinary and collaborative nature 
of the project, which allow the chapters to either stand alone or together as a coherent 
whole. A foreword will occur at the start of each chapter to introduce the manuscript to 
the reader and link the manuscript to the central theme of this thesis, which is “the 
rational design of inhibitors that target sialyltransferases”.  
After the presentation of the findings of this thesis (Chapters 3–6) a general 
conclusion (Chapter 7) is provided to bring all the findings together as a coherent whole 
along with providing future recommendations. This concluding discussion is then 
followed by the Appendices. Due to the journal article style of this dissertation references 
are provided at the end of each chapter. 
xvii 
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1.1 Sialic Acid and its Biological Roles 
Sialic acid is one of the body’s most important sugars next to glucose.1 Sialic acid (also 
known as neuraminic acid, Neu, 1.1, Figure 1.1) is a broad term that refers to a subset of 
nine-carbon α-keto aldonic acids, which have been observed in vertebrates, echinoderms, 
protostomes, protozoa, fungi and some bacteria.1-2 The structure of sialic acid, first 
determined in 1955,3 contains an amino group at the C5 position and a carboxylate group 
(pKa = 2.2) at the C1 position, which provides the structure with a negative charge at 
physiological pH.4 However, this form of sialic acid does not exist in nature. Instead, 
there are more than 50 known structural variations, the majority based on neuraminic 
acid, with a small number being derivatives of 2-keto-3-deoxy-nonulosonic acid (1.2, 
Figure 1.1).1-2 The most widespread sialic acid in nature is N-acetylneuraminic acid 
(Neu5Ac, 1.3, Figure 1.1), which is acetylated at the C5 amino group.4 
 
Figure 1.1: The sialic acids. R represents a glycan chain. 
 
Sialic acids are negatively charged and are often located at the terminal end of 
glycan chains on cell surface and secreted molecules (Figure 1.2), allowing them to play 
crucial roles in cellular biology.4-5 These functions are mainly related to cellular and 
molecular recognition events, such as activation or inhibition of intracellular and 
intramolecular interactions, cell-cell recognition, receptor binding, protein-lectin 
interactions, protein targeting, cell adhesion, immune responses and fertilisation.6-9 The 
highest concentration of sialic acid in the human body is in the brain, where it is an 
integral part of ganglioside structure. As a result, sialic acid is a crucial nutrient in brain 
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development and cognition, which is reflected in human breast milk having high 
concentrations of sialic acids.10-11  
As well as the crucial roles that sialic acid plays in the regular function within the 
human body, they also play significant roles in viral infection, inflammatory diseases12-13 
and tumour proliferation, migration and metastasis.14-17 Having roles in various disease 
states encourages the exploration of the biosynthetic pathways involving sialic acid as 
potential therapeutic targets. This thesis follows this ideology by focusing on the 
development of novel anti-metastatic compounds via the inhibition of the biosynthetic 
pathway mediated by the family of enzymes known as sialyltransferases (STs). 
 
Figure 1.2: Sialic acids (Sia) are typically found at the terminal position of glycans and glycosphingolipids 
attached to the cell surface and to secreted glycoproteins. Ac, O-acetyl ester; Fuc, fucose; Gal, galactose; 
GalNAc, N-acetylgalactosamine; Glc, glucose; GlcNAc, N-acetylglucosamine; Man, mannose; S, sulphate 
ester. Figure replicated with permission from Varki.18 
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1.2 Sialyltransferases as Therapeutic Targets 
1.2.1 Sialyltransferases 
Sialyltransferases are enzymes of the glycosyltransferase (GT) family that play an 
integral role in the biosynthesis of sialic acid containing oligosaccharides and 
glycoconjugates.6-7 STs are primarily anchored within the Golgi apparatus’ membrane, 
with a catalytic domain present within the lumen, although catalytically active soluble 
forms can be generated in vivo by proteolytic cleavage at the stem region.6 Glycosylation 
catalysed by STs uses the sugar nucleotide donor cytidine 5′-monophosphate Neu5Ac 
(CMP-Neu5Ac, 1.4) and an oligosaccharide or glycoconjugate terminated by a galactose 
(Gal), N-acetylgalactosamine (GalNAc), or another sialic acid residue as the acceptor.2, 6  
Based on protein sequence homology, STs have been classified into six GT 
families in the CAZy (carbohydrate-active enzymes) database (http://www.cazy.org).19 
All eukaryotic and viral STs are grouped in the GT29 family, whereas bacterial STs have 
been grouped into five families: GT4, GT38, GT42, GT52 and GT80.6 In humans, there 
are 20 different STs that are classified into one of four groups based on the position and 
identity of the glycosyl acceptor to which sialic acid is transferred: ST3Gal I–VI, ST6Gal 
I–II, ST6GalNAc I–VI, and ST8Sia I–VI (Figure 1.3).6-7, 20 
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Figure 1.3: The four reported sialyltransferase classes: ST3Gal, ST6Gal, ST6GalNAc, ST8Sia. R 
represents a glycan chain of a glycoconjugate. The different linkages are highlighted with colour. 
 
1.2.2 Sialylation in Cancer  
Abnormal sialylation is strongly associated with cancer (Figure 1.4), with 
hypersialylation of up to 30–40% observed, along with significant upregulation of ST 
activity. This has been directly correlated with an increased metastatic potential of 
tumours and poor patient prognosis.14, 21 Upregulation of STs has also been shown to 
produce cellular resistance in both paclitaxel and cisplatin treatment of human ovarian 
and colorectal cancer cell lines, along with reducing treatment efficacy.22 Thus the critical 
role of STs in the process of tumour metastasis as well as drug resistance demonstrates 
that inhibitors of STs could be used either alone as anti-metastatic agents, or in 
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combination with existing drugs to enhance their sensitivity against resistant tumours.23 
The overexpression of ST is observed in various cancers with high levels observed in the 
highly prevalent lung cancer, ovarian cancer and breast cancer.23 These three cases are 
taken as examples and discussed in the following sections. 
 
Figure 1.4: Aberrant sialylation favours tumour growth and progression. Several factors (e.g., oncogenes 
or hormones) increase the expression of STs and downregulate the expression of sialidases (Neu) in 
cancerous cells. As a result, sialylated glycan (sialoglycans) synthesis in the Golgi system by STs is 
enhanced and hydrolysis of sialoglycans by sialidases in the lysosome is decreased, leading to accumulation 
of hypersialylated structures on the cell surface. The high expression of sialoglycans impairs apoptotic 
signalling by the Fas receptor or integrins following detachment from the extracellular matrix (ECM); 
facilitates binding to the ECM or selectins, allowing migration/tissue invasion and metastasis formation, 
respectively; and mediates resistance to therapy. Figure replicated with permission from Büll et al.14  
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1.2.2.1 Lung Cancer 
The well known tumour-associated antigen Sialyl Lewisx (SLex) is found in elevated 
levels in lung cancer. SLex facilitates cell adhesion to the endothelium, enabling the 
process of extravasation and metastasis to occur.24 During the biosynthesis of SLex the 
STs of the ST3Gal subfamily (particularly III, IV and VI) play a key role. It has been 
found that the expression levels of both SLex and ST3Gal III are inversely correlated with 
lung cancer patient survival.25 Studies have also shown that ST3Gal I, which is 
overexpressed in highly metastatic lung cancer cells such as A549 and CL1-5, is not 
detected in normal human bronchial epithelial cells.26 Thus, inhibition of STs, in 
particular the ST3Gal subfamily, has emerged as a new target for the treatment of early 
lung cancer and to aid in understanding the progression to more aggressive phenotypes.23 
1.2.2.2 Ovarian Cancer 
The link between epithelial ovarian cancer, which constitutes 90% of ovarian cancer 
cases, and the ST family has been reported in a number of studies.22, 27-30 For example, it 
has been shown using ovarian cancer models (as well as pancreatic and colon cancer 
models) that sialylation of ST6Gal I promotes a cancer stem cell (CSC) phenotype, with 
the activity of ST6Gal I critical for CSC behaviours including tumour spheroid growth, 
chemoresistance and tumour initiating potential.31 Additionally, overexpression of 
ST6Gal I in these models was suggested to promote cancer cell metastasis through altered 
sialylation patterns affecting the function of β1 integrin.32-33 ST6Gal I was also shown to 
have an important role in galectin regulation, via the sialylation of their galactose-
containing substrates.34-35 For instance, α-2,6 sialylation of the galectin substrates Fas36 
and TNFR130 death receptors has been shown to hinder apoptosis. 
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In addition to upregulated ST6Gal I, it has also been shown that there is an altered 
expression and a significant increase in α-2,3-linked sialylated proteins in ovarian cancer 
patients, that is directly correlated to increased expression of ST3Gal I.27 It has been 
demonstrated that this plays a significant role in ovarian cancer cell migration and 
peritoneal dissemination due to ST3Gal I’s role in epidermal growth factor receptor 
signalling.37 Another of the ST3Gal family, ST3Gal III, was expressed at elevated levels 
in cisplatin resistant ovarian cancer cells with high invasive and metastatic capabilities. 
Knockdown studies with these cell lines confirmed that ST3Gal III played a major role 
in cisplatin resistance,38 although the exact mechanism of action is still to be determined. 
1.2.2.3 Breast Cancer 
ST overexpression plays a key role in breast cancer progression, aggressiveness, 
metastasis and drug resistance.23 Recent studies of treatment-resistant breast cancer from 
xenograft models identified high levels of the sialyl-glycolipid stage specific embryonic 
antigen 4. The biosynthesis of this antigen requires ST3Gal II, which was also found to 
be overexpressed in these models.39 ST6GalNAc V has also been found to be a key 
mediator of breast cancer metastasis to the brain in a study that coupled gene expression 
analysis with functional analysis. ST6GalNAc V is normally restricted to the brain and 
its atypical expression in breast cancer cells is thought to facilitate passage of the tumour 
through the blood-brain barrier.40 COX-2 has been shown to be involved in the 
upregulation of ST3Gal I in MDA-MB-231 breast cancer cell lines. Overexpression of 
ST3Gal I leads to increased sialylation of core 1 Gal-β-1,3-GalNAc glycan. Sialylated 
core 1 glycans are barely expressed by normal mammary cells, they are instead found on 
proteins expressed by leukocytes. Expression analysis of 74 primary breast cancers 
showed a significant correlation between ST3Gal I and COX-2, suggesting that the 
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malignant characteristics attributed to COX-2 in breast cancer could be related to tumour 
cell surface sialylation it induces via the promotion of ST3Gal I overexpression.41  
1.2.3 Sialylation in Other Diseases  
In contrast to the hypersialylation that is common in many cancers, a range of other 
human disease states can be attributed to hyposialylation of specific substrates. For 
example a range of neurological and memory disorders including Alzheimer’s,42-45 
autism,46 bipolar disorder,47 chronic stress,48 depression49 and schizophrenia50-51 exhibit 
a hyposialylation caused by the down regulation of various STs (particularly of the 
ST8Sia family). Reduced ST activity has also been shown to affect the immune system 
and allergies.52-54 These cases where hyposialylation is associated with a specific disease 
state demonstrate the importance of developing subtype selective ST inhibitors to 
minimise potential side effects of inhibiting cell surface sialylation. 
1.3 Sialyltransferase Structure and Function 
1.3.1 Structural Characterisation of Sialyltransferases  
The primary sequence of STs contains four characteristic regions.55 The first is a short 
N-terminal cytoplasmic domain, followed by a transmembrane domain that extends to a 
stem region and a larger C-terminal catalytic domain that faces the lumen of the Golgi 
apparatus (Figure 1.5).56 Within the catalytic domain of eukaryotic STs, there is 
significant sequence conservation in four domains, known as sialyl motifs L (large), S 
(small), III and VS (very small).57-58 Residues of motifs L and III are involved in binding 
the donor substrate, motif S in both donor and acceptor binding with motif VS 
participating in the catalytic reaction.56 
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Figure 1.5: The structure of hST6Gal I (PDB id 4JS2)55 with sialyl motifs L (red), III (blue), S (yellow) 
and VS (orange) highlighted. The co-crystallised ligand CMP is represented as pipes. The soluble catalytic 
domain extends via a stem region from a short N-terminal cytoplasmic and transmembrane domain. 
 
To date there is a relatively small amount of structural information that has been 
reported in the literature for STs due to them being membrane proteins, which leads to 
difficulties in obtaining suitable levels of stable and soluble protein for crystallisation 
purposes.59 The majority of data for STs is from pathogenic Gram-negative bacteria, with 
crystal structures from seven different species reported.27-35 Each bacterial structure has 
shown one of the two types of protein folds typical of all nucleotide-activated GT 
families, denoted as GT-A and GT-B. Both categories contain Rossmann folds, that is a 
six-stranded parallel β-sheet linked to two pairs of α-helices.55 GT-A contains two fused 
Rossmann folds, whereas GT-B consists of two Rossmann folds which are flexibly 
linked.55 The crystal structures of the GT42 family of STs from the bacterium 
Campylobacter jejuni Cst-I and Cst-II, have a similar overall GT-A fold but significantly 
differ in their lid regions, which accounts for their different acceptor specificity.60-62 The 
crystal structures of STs from four bacteria of the GT80 family, the α-2,3-ST from 
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Photobacterium phosphoreum,63 and the α-2,6-STs from Pasteurella multocida,64-68 
Vibrionaceae Photobacterium sp. JT-ISH-22469 and Photobacterium damselae,70 
indicated they have a GT-B fold. Also the crystal structure of the structure-guided active 
site redesign to an α-2,6-ST of the GT80 family α-2,3-ST from Pasteurella dagmatis71 
has also been released. From the GT52 family, the multifunctional α-2,3/2,6-
lipoligosaccharide ST from the bacterium Neisseria meningitides adopts a GT-B fold but 
also exhibits a novel domain swap of N-terminal residues to create a functional 
homodimeric form.72 A majority of these structures were complexed with cytidine 
5′-monophosphate (CMP) or a sialyl acceptor, providing insights into the binding of 
substrates and catalytic mechanism of these structures. However, large differences in the 
primary sequence of bacterial and eukaryotic STs has made it difficult to apply these 
findings to eukaryotic STs.59 
In terms of eukaryotic STs, which belong to the GT29 family, there is 
comparatively limited mammalian structural information. Until 2009, only conformation 
and protein-ligand contact surfaces identified using NMR were available.73-74 The first 
mammalian ST crystal structure published was that of porcine ST3Gal I (pST3Gal I) in 
2009, which was solved both in the apo and CMP bound state.59 This structure consists 
of a single Rossmann domain, with weak homology with a GT-A member, the bacterial 
ST Cst-II.59 From this observation the fold of the mammalian GT29 STs was proposed as 
a new subclass known as the GT-A variant 2 fold,59 which was also observed in the 
subsequently determined structures of rat (rST6Gal I)75 and human ST6Gal I 
(hST6Gal I),55 hST8Sia III76 and hST6GalNAc II.77 All of the mammalian structures 
published are of the soluble catalytic domains with the cytoplasmic domain, 
transmembrane domain and a portion of the stem region deleted. 
Chapter 1: Introduction 
11 
Comparing the key mammalian structures (pST3Gal I, hST6Gal I, hST8Sia III 
and hST6GalNAc II) it can be seen that the highly conserved sialyl motif sequence 
elements comprise the core of the protein fold (Figure 1.6).77 The bound CMP based 
ligands in each crystal structure all share equivalent positions, reflecting the conservation 
of the sialyl motif underlying the CMP-Neu5Ac binding site. However, there is an 
exploitable difference that has been identified in this pocket by the modelling of surface 
hydrophobicity of these pockets by our research group.78 This modelling demonstrated 
that for both pST3Gal I (85% homology to hST3Gal I) and hST8Sia III, there was a 
sub-pocket adjacent to the 2′-hydroxyl on the ribose ring. This pocket was much smaller 
and more offset in both hST6Gal I and hST6GalNAc II highlighting the potential to 
explore 2′-substituted derivatives as potentially selective inhibitors.78 This has been 
shown experimentally with 2′-O-methyl CMP derivatives showing inhibition against 
ST3Gals and ST8Sias and no activity against ST6Gals.79 There are also substantial 
differences outside the sialyl motif areas, in particular in those regions involved in the 
acceptor substrate recognition. Being a key point of difference across ST subtypes 
encourages the targeting of these regions in the pursuit of selective inhibitors. 
The structures described above, as well as the details on ligand binding they 
demonstrate, provides an exciting opportunity for the rational design of novel and 
potentially selective ST inhibitors using computational modelling. The modelling 
described in this thesis80-81 was undertaken with the hST6Gal I structure with work being 
undertaken on the more recently published hST6GalNAc II and hST8Sia III78 being 
explored by other members of our group.  
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Figure 1.6: The four known mammalian ST structures (pST3Gal I, PDB id 2WNB;59 hST6Gal I, PDB id 
4JS2;55 hST6GalNAc II, PDB id 6APL;77 and hST8Sia III, PDB id 5BO9376) displayed as either surface or 
cartoon representations. Two orientations are shown for each protein, including a view of the respective 
enzyme active site (top view) or a side view rotated 90°. The bound CMP donor analogues (pST3Gal I, 
hST6Gal I, and hST6GalNAc II) or CMP-Neu5Ac donor (hST8Sia III) and glycan acceptor complexes 
(pST3Gal I, hST6Gal I and hST8Sia III) are shown as pipes. The sialyl motif sequence elements are also 
shown in top and side views. The bottom panel of the figure shows an overlay of the aligned structures and 
sialyl motif sequences of all four STs. Figure replicated with permission from Moremen et al.77 
 
1.3.2 Mechanism of Sialyltransferase Catalysed Reactions  
STs undertake their function (Figure 1.7) via the nucleophilic attack on the sialic acid 
anomeric carbon by a deprotonated hydroxy of the acceptor facilitated by a catalytic base, 
generally a histidine.75-82 This generates an oxocarbenium-like transition state, followed 
by CMP acting as a leaving group. The negatively charged leaving group has been 
proposed to be stabilised by positive dipoles of helices and suitably positioned tyrosine 
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residues within the active site.55, 59, 76 The β-configuration at the anomeric carbon of the 
donor is inverted to the α-configuration in the final product.82 These aspects suggest that 
STs function as inverting GTs utilising an SN2-like direct displacement mechanism.83-84 
These mechanistic insights have been supported by mutagenic studies with pST3Gal I85 
and hST8Sia III76 and with models of the Michaelis complex generated from the substrate 
binding modes observed in the crystal structures of hST6Gal I55 and hST8Sia III.76 
 
Figure 1.7: Proposed reaction scheme for the catalytic action of STs. R represents the terminal Gal, GalNAc 
or sialic acid residue of a glycan chain. B represents the catalytic base residue, which is generally a histidine. 
 
1.4 Inhibitors of Sialyltransferases 
Inhibition of STs has drawn considerable interest due to its therapeutic potential, 
particularly in the area of anti-metastatic agents to be used in the treatment of cancer. 
Compounds ranging from those isolated from natural sources and high throughput 
screening to those specifically designed to mimic ST substrates have been reported in the 
literature. Many of these compounds showed only moderate to weak ST inhibition 
ranging from micromolar to millimolar activity and as such will not be discussed further 
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in this chapter (representative examples shown in Figure 1.8, 1.5–1.16).26, 86-90 However, 
an extensive overview of recent advancements in the development of ST inhibitors, can 
be found in the 2017 review by Szabo and Skropeta.23 The work contained within this 
thesis will focus on the preparation of novel analogues that are structurally similar to the 
proposed oxocarbenium ion-like transition state of the donor CMP-NeuAc (Figure 1.7), 
which have been shown to be the most potent class of ST inhibitors (low micromolar to 
low nanomolar activity) at the time of writing. The work on this class of compounds is 
highlighted in the following section.  
 
Figure 1.8: Examples of ST inhibitors identified from nature (1.5–1.14)26, 86-89 and from high throughput 
screening (1.15 and 1.16).90 Ki and IC50 values have been measured against the enzyme indicated.  
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1.4.1 First Generation Transition-State Analogue Inhibitors  
During the 1990s, the Schmidt research group first pioneered the use of transition-state 
analogues as inhibitors of STs. They conducted extensive research and found those 
inhibitors that incorporated a 2-deoxy-2,3-didehydro-N-acetylneuraminic acid 
(Neu5Ac2en) moiety in the place of sialic acid are amongst the most potent. These 
compounds were proposed to mimic the transition state with the C2–C3 double bond of 
Neu5Ac2en mimicking the planar anomeric carbon of the oxocarbenium transition state. 
An extra carbon between the anomeric carbon and CMP leaving group was also 
incorporated to replicate the increased distance between these components in the 
transition state.91-92 From this series the most potent compound was the (R)-isomer 1.17 
(Figure 1.9), which exhibited inhibitory activity in the submicromolar range for rat 
ST6Gals (Ki = 0.35 μM; Note: further classification of the subtype was not available or 
common at the time, thus mixtures will be referred to as ST6Gals, ST3Gals, etc.).91 
Derivatives with structural variations of the glycerol side chain of the Neu5Ac2en moiety 
produced the greatest inhibitory activity. Of these, the phenoxy derivative 1.18 
(Figure 1.9, Ki = 29 nM), showed the greatest inhibition of rat liver ST6Gals and is the 
most potent transition-state analogue inhibitor of this type reported.93  
To generate more synthetically accessible inhibitor derivatives, those which 
incorporate planar aryl or heteroaryl rings as a replacement of the Neu5Ac2en moiety 
were examined. From this series the phenyl derivative 1.19 (Figure 1.9, Ki = 0.20 μM) 
exhibited comparable activity to the parent compound 1.17.94-95 Derivatives of 1.19 were 
further explored by Skropeta et al.,96 where the (R)-isomer of the 3-phenoxy derivative 
1.20 was the most potent inhibitor of rat liver ST6Gals (Figure 1.9, Ki = 70 nM) and is 
used as the lead compound for this study.96  
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Figure 1.9: ST transition-state analogue inhibitors (1.17-1.20). Ki values are against rat liver ST6Gals. An 
orange circle on 1.17 highlights the region that mimics the oxocarbenium transition state and carboxylate 
group. 
 
1.4.2 Variations of First Generation Transition-State Analogue Inhibitors  
Further developments on the first generation of transition-state analogue ST inhibitors 
can be divided into three main areas: variations on the nucleoside, the sialic acid mimic 
or the phosphodiester linker, as discussed below. 
1.4.2.1 The Nucleoside Fragment  
Variations in the nucleoside fragment of transition-state analogues have been limited, 
however analogues of the natural donor CMP-NeuAc (1.4) with nucleoside variations 
have been investigated. These inhibitors generally contain a cytidine component, often 
considered essential to binding, and of these the CMP-quinic acid derivative 1.21 
(Figure 1.10) is the most potent (Ki = 20  μM, rat liver ST6Gals).97-98 Other examples bear 
a 5-fluorouracil moiety in place of cytidine such as the sialic acid-nucleoside conjugate 
KI-8110 (1.22, Figure 1.10),99 which was originally considered a ST inhibitor due to 
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indirect evidence of reduced cell surface sialylation on treated cells. However, it was later 
found to inhibit CMP-Neu5Ac transport into the Golgi.100 
Nucleosides themselves have also been tested as inhibitors with CMP (1.23), 
cytidine 5′-diphosphate (CDP, 1.24) and cytidine 5′-triphosphate (CTP, 1.25) shown to 
exhibit inhibition against rat liver ST6Gal I (Ki = 50, 19 and 16 μM respectively, Figure 
1.10).101 Uracil and resorcinol derivatives show reduced affinity for rat liver ST6Gals.97 
Adenine derivatives have generally showed negligible inhibition activity against rat liver 
ST3Gals102 or human serum ST6Gals.101 5-Methylcytosine derivatives have shown to 
have weak inhibitory effects for STs (chimeric human ST3Gal III/IV, ST6Gal I and 
ST8Sia II/III/IV).79  
Alterations to the ribose fragment have also been explored and have revealed 
potential for selectivity between different STs. For example, 2′-O-methyl-CMP (1.26, 
Figure 1.10) at 250 μM promoted 84% inhibition against ST3Gal III, 81% against 
ST8Sia II, 80% against ST8Sia IV and no inhibition against ST6Gal I.79 This result 
suggests that exploitable variations within the active site around the 2ʹ-hydroxyl exists, 
as seen in the crystal structures (see section 1.3.1). 2′-Deoxycytidine (1.27, Figure 1.10) 
was evaluated against human serum ST6Gal activity and showed weak 32.5% inhibition 
at 10 mM. In the same study ara-CMP (1.28) and ara-CTP (1.29) exhibited weak 
competitive inhibition (Ki = 1.10 and 0.50 mM respectively, Figure 1.10) suggesting 
ribose stereochemistry at the 2ʹ-position is important for activity.101 Replacement of the 
furan ring by a 1,3-dioxolane moiety resulted in inactive compounds (IC50 > 100 μM) 
against rat liver ST3Gals.102 
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Figure 1.10: Examples of recent developments of ST inhibitors (1.21–1.29) with variations made to the 
nucleoside fragment when compared to the first-generation transition-state analogue inhibitors. Inhibition 
data against a mixture of rat liver ST6Gals is indicated for 1.21, 1.23–1.25 and 1.27–1.29. All values 
indicated for 1.26 have been made against the pure enzyme indicated. 
 
1.4.2.2 The Sialic Acid Mimic 
The most effective modifications in transition-state analogue inhibitors have been made 
to the sialic acid mimic. Building upon the work of Schmidt’s group, compounds with a 
fluorescein-based tag attached to the 3- or 4-position of the aromatic ring (1.30, 
Figure 1.11) were reported in 2014. The binding affinity of these probes was evaluated 
against rST3Gal II, hST6Gal I, hST8Sia II–IV and bacterial PmST1 and Pd2,6ST(N) 
with inhibition in the nanomolar range.103-104 Cell-based assays with the labelled 
compounds provided evidence that these compounds reached locations inside the cell 
surrounding the nucleus and possibly the trans-Golgi network. Based on the chemical 
structure the authors suggest that a membrane receptor may facilitate uptake of the 
compounds.103 
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Equipotent analogues to the 3-phenoxy derivative 1.20 (Figure 1.9, Ki = 19 nM 
against recombinant hST6Gal I),105-106 which incorporate cyclopentane in place of sialic 
acid have also been reported by the Ye group in 2015.105 These transition-state analogues 
mimic the planar nature of the oxocarbenium-ion transition state through the restricted 
conformations available to a cyclopentane. Of this series the more elaborately substituted 
cyclopentyl derivatives proved the best examples, with the most potent of the series 
compound 1.31 (Figure 1.11) exhibiting a Ki of 28 nM against recombinant hST6Gal I. 
In a similar vein, in 2017, the same group also investigated mimicking the oxocarbenium 
transition state using an amide rather than an aromatic ring.106 From the limited number 
of compounds in this study it was found that both cyclic aliphatic (1.32, Ki = 20 nM)  and 
aromatic (1.33, Ki = 16 nM) amide substituents showed similar potencies.  
 
Figure 1.11: Examples of recent developments of ST inhibitors (1.30–1.33) with modifications made 
compared to the first-generation transition-state analogue inhibitors. All inhibition values indicated for 
1.30–1.33 have been made against the pure enzyme indicated. 
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1.4.2.3 The Phosphodiester Linker 
The replacement of the phosphodiester linker of reported potent transition-state analogue 
ST inhibitors has been undertaken by several research groups to probe the influence of 
other heteroatoms on interactions with the active site and determine whether this charged 
group is required for activity. Compounds where the natural phosphodiester linkage is 
replaced by a phosphoramidate have been prepared. Whalen et al. prepared 
phosphoramidate-linked ST inhibitors originating from amino acids in 2003.107 All 
compounds from this series were active on the submicromolar or micromolar level with 
the most potent being the tryptophan derivative 1.34 (Figure 1.12), which was weakly 
active against rat liver ST3Gals (Ki = 300 μM) and ST6Gals (Ki = 730 μM).107 Skropeta 
et al. prepared phosphoramidate-linked ST inhibitors from α-aminophosphonates in 2003, 
with the (R)-isomer 1.35 the most potent inhibitor of rat liver ST6Gals (Figure 1.12, 
Ki = 68 μM).108 The analogous (R)-phosphodiester 1.19 (Figure 1.9) shows 
approximately two orders of magnitude higher affinity against rat liver ST6Gals.108  
To determine the importance of the charged phosphodiester linker, derivatives 
where this has been replaced with non-charged linkers have been examined. Kumar 
et al.109 prepared derivatives of 1.17 (Figure 1.9) where the phosphodiester was replaced 
with non-charged linkers such as a 1,2,3-triazole and a sulfamide (1.36 and 1.37 
respectively, Figure 1.12) in 2013. Both the 1,2,3-triazole- and sulfamide-linked 
compounds were shown to be weak inhibitors of α-2,3-ST (Cst06) from Campylobacter 
jejuni.109 Kumar et al. also prepared a derivative of 1.19 (Figure 1.9), which saw the 
phosphodiester replaced with a sulfamide in 1.38 (Figure 1.12). This compound was also 
shown to be a weak inhibitor of Cst06.109 These compounds had an increased distance 
between the CMP and sialic acid mimic compared to that of the potent 
phosphodiester-linked inhibitors reported by Schmidt, which could also contribute to the 
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weak activity. The 1,2,3-triazole-linked compounds, such as 1.39 (Figure 1.12), produced 
by Lee et al, maintain the three atom distance observed for the phosphodiester linker.102 
As a result a reasonable level of activity is maintained with 1.39 for rat liver ST3Gals 
(Ki = 37.5 μM),102 despite the compound lacking a phosphonate or carboxylate group, 
which are known to contribute to the potency of transition-state analogue ST inhibitors. 
 
Figure 1.12: Transition-state analogue inhibitors (1.34–1.39) that have had the phosphodiester linker 
replaced. Ki values against rat liver STs are indicated for 1.34, 1.35 and 1.39 with percent inhibition at 
500 μM against α-2,3-ST (Cst06) from Campylobacter jejuni shown for compounds 1.36–1.38. 
 
1.4.3 Structure-Activity Relationship  
Comparing the inhibition data from the most active transition-state (and donor) analogue 
ST inhibitors, a SAR can be derived (Table 1.1). Most ST inhibitors have been tested 
against the mammalian ST6Gal subfamily with only variations on the nucleoside 
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fragment tested against ST3Gal and ST8Sia. The SAR relationships discussed for the 
sugar mimic and linker generally refer to activity observed with the ST6Gal subfamily.  

















Neu5Ac2en, aryl ring or aliphatic 
ring (cyclopentyl or amide) 




X O >> NH > CH2 
Y PO(OH)2 > COOH > OH > H 
Z O for sugar based mimics 
R1 PhO > HO(CH2)2O > glycerol 
R2 NHAc > OH > =O 
R3 OH for sugar based mimics 




The cytidine moiety plays a key role in the interaction of analogues with the 
ST6Gals, as any slight change was generally observed to decrease (often dramatically) 
the enzyme affinity. However, 5-flurouridine was shown to be tolerated. The ST3Gal and 
ST8Sia families tolerated changes to a much greater extent with substitution at the 
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2′-position of the ribose tolerated. The ST8Sias were also able to tolerate substitutions at 
the 5-position of the cytosine ring (Table 1.1).  
The linker between the nucleoside and the sialic acid mimic is also critical for 
activity. While the phosphodiester group provides optimal activity, many different neutral 
functional groups have shown to be tolerated but have afforded inhibitors exhibiting 
lower potency. It is difficult to attribute this loss of activity to a loss of the charged 
phosphodiester as the length of linker also appears to have an impact on binding affinity. 
The optimal linker length is three atoms between the cytidine moiety and sialic acid 
mimic. Replacing the hydrogen bond acceptor of the linker atom closest to the sialic 
mimic (position X) with a hydrogen bond acceptor or an ethylene was also shown to 
decrease activity (Table 1.1). 
The sialic acid mimic should have a negative charge or an acidic group 
(position Y), with a phosphonate most favoured. The configuration of the carbon atom 
between the charged group Y and linker atom X can be either sp2 or sp3, incorporating 
the presence of a stereocentre. When a sp3 centre is used at this position R isomers tend 
to be slightly favoured but generally the difference in stereochemistry at this position has 
a relatively small effect on binding and can be substituent dependent. The best results for 
mimicking sialic acid are more varied with the most potent inhibitors using substituted 
Neu5Ac2en moiety, an aromatic ring or aliphatic ring derivatives. What appears to be 
common amongst these three classes is conformational restriction, particularly around the 
anomeric carbon. Position R1 on the aromatic ring corresponds to the polyhydroxylated 
side chain of sialic acid, with phenoxy derivatives at this position providing the greatest 
affinity. Positions R2 and R3 of the aromatic ring could be interesting points to exploit in 
the future for selectivity (Table 1.1).  
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1.5 Rational Design of Novel Transition-State Analogue ST Inhibitors 
1.5.1 Rational Drug Design 
High throughput screening is widely used by the pharmaceutical industry in hit 
identification. The lead compounds derived from optimisation of the high throughput 
screening-supplied hits are often difficult to transform into drugs. This is because efficient 
optimisation is difficult as leads generally lack sufficient diversity and provide no 
information about the way they interact with the target receptor.110  
To combat this, many research groups have dedicated efforts towards rational 
drug (or structure-based drug) design of compounds to identify novel ligands for 
pharmaceutical targets. Rational drug design is based upon supplementing traditional 
ligand-based pharmacophore information with insight into a lead compound’s 
protein-ligand interactions that can be gained from data such as X-ray crystallography. 
This insight facilitates targeted optimisation of lead compounds. For example, rational 
drug design can facilitate accurate modifications to be made to adjust a 
pharmacokinetic/toxicological profile while maintaining binding affinity. The design of 
selective compounds, particularly over closely related enzyme subtypes, can also be aided 
by taking a rational drug design approach.111-114 This approach will be applied here in the 
design of novel transition-state analogue ST inhibitors. 
1.5.2 Rationale Behind Inhibitor Design 
The charged phosphodiester linkage of transition-state analogue ST inhibitors, while 
contributing to potency (see section 1.4), potentially may contribute to low 
bioavailability, loss of activity due to cleavage by phosphatases or instability in the ST 
active site.109, 115 It was also earlier suspected that the charged nature of this linker would 
result in poor cellular permeability. However, this has been shown not to be an issue as 
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recent work has demonstrated that phosphodiester derivatives bearing a fluorescent probe 
(e.g. 1.30, Figure 1.11) are able to cross the cellular membrane via a vesicular uptake 
mechanism.103 In addition to the proposed pharmacokinetic issues, the synthesis of the 
phosphodiester-linked inhibitors utilises a challenging approach employing the 
condensation an α-hydroxyphosphonate (αHP, 1.40) and a cytidine phosphitamide (1.41) 
and subsequent oxidation (Scheme 1.1).96, 105-106 Preparation of 1.41 incorporates the use 
of 1H-tetrazole (only available as dilute CH3CN solutions in Australia), which is highly 
explosive creating safety concerns.  
 
Scheme 1.1: Preparation of phosphodiester-linked transition-state analogue ST inhibitors from 
α-hydroxyphosphonate (1.40) and cytidine phosphitamide (1.41) 
 
To overcome the suspected pharmacokinetic issues and improve synthetic 
accessibility, replacing the phosphodiester linker, preferably with uncharged examples, 
should be explored both synthetically and computationally. Previous examples of 
phosphodiester replacements in ST inhibitors have been discussed above (see section 
1.4.2.3), with the optimal length of linker being 3 atoms. In this thesis a 1,2,3-triazole and 
a carbamate are explored as the linking units.  
The replacement of the cytidine moiety (see section 1.4.2.1) with uridine will also 
be explored. Uridine has been selected for this purpose based on several factors. Firstly, 
is that uridine may open a route to selectivity for specific STs. This hypothesis is based 
on the exocyclic amino group of CMP not engaging in specific contacts with the protein 
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in the pST3Gal I crystal structure.59 Kuhn et al. propose that this would allow the non-
natural donor substrate uridine-5’-monophosphate Neu5Ac to be accepted by the protein, 
which is less likely for hST6Gal I.55 Uridine also offers a synthetic advantage over 
cytidine as it has one less group that requires protecting/deprotecting allowing for target 
compounds to be produced in fewer steps. 
1.5.2.1 1,2,3-Triazole Linker  
The 1,2,3-triazole motif is a suitable choice for a potential phosphodiester isostere to 
improve the synthetic accessibility. The copper catalysed “click” reaction utilised to 
produce the 1,2,3-triazole has the benefits of being high yielding, stereospecific and 
robust as well as being environmentally friendly.116 In terms of replicating a 
phosphodiester, the 1,2,3-triazole has previously been used for transition-state analogue 
ST inhibitors (1.36 and 1.39, Figure 1.12)109,102 as well as isosteres of pyrophosphate117 
and phosphodiester linkers of oligonucleotides.118 Including an unnatural linker into ST 
inhibitors provides a non-labile alternative therefore increasing chemical and enzymatic 
stability when compared to the phosphodiester used in the natural substrate.119 Two of the 
nitrogen atoms that are part of the triazole ring bear lone pairs of electrons, which are two 
possible hydrogen-bond acceptor sites that can replicate the hydrogen bond acceptor 
capability of oxygen atoms of the phosphodiester linkage. 
Our research group has created a library of 1,2,3-triazole-linked derivatives and 
evaluated them as potential ST inhibitors. 102, 109 The cytotoxicity of these compounds was 
evaluated against MIAPaCa-2 (pancreatic), MCF-7 (breast) and SKOV3 (ovarian) cancer 
cell lines, as well as RAW264.7 a macrophage cell line, all of which are known to 
overexpress STs. No toxicity was observed at concentrations up to 300 µM, which is 
expected as cell surface sialylation affects cell motility rather than viability. This allows for 
the exploration of anti-metastatic activity without the complication of cell toxicity.120  
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The derivatives were also evaluated against hST8Sia II using a fluorimetric assay by 
R. Gerardy-Schahn at the Hannover Medical School.121 The inhibition data can be analysed 
as two SAR studies, the first being around the nucleoside (Figure 1.13, 1.42–1.50). From 
the enzyme inhibition data, a cytidine moiety (1.42, 97%) is the most preferential 
nucleoside with more potent inhibition observed when compared to those inhibitors with 
thymidine (1.49, 56%) and uridine (1.50, 51%). Conversely though when the 5- (1.43, 
94%) or the 2′-position (1.44, 91%) of the uridine contains a fluorine, the potency of 
cytidine is replicated. Interestingly, as with 1.44 (91%), other variations at the 2′-position 
of uridine are also well tolerated by hST8Sia II as demonstrated by the 2′-deoxyruridine 
(1.45, 88%) and the 2′-O-methoxy (1.47, 76%) derivatives. Steric hinderance around the 
ribose as represented by the acetonide derivatives 1.46 and 1.48 (78% and 75% 
respectively) appears to be tolerated by hST8Sia II, but this needs to be confirmed with 
further assays.120 
 
Figure 1.13: Percentage inhibition data of 1,2,3-triazole-linked derivatives, with varied nucleoside (1.42–
1.50), at 100 μM against hST8Sia II.120  
The second SAR that could be gained was around the sialic acid mimic of the 
uridine-based inhibitors (Figure 1.14, 1.51-1.58). Several trends can be concluded from 
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this set of data, based on the type of aromatic ring used and how it is substituted. 
3,4-Disubstituted aryl motifs promoted greater potency as shown by the activity of the 
4-fluoro-3-phenoxy derivative 1.51 (98%) and the 4-methoxy-3-phenoxy derivative 
1.53 (87%) when compared to the 3-phenoxy derivative 1.50 (51%, Figure 1.13). This 
trend can also be seen with the greater potency of the 4-methoxy-3-cyclopentoxy 
analogue 1.56 (65%) when compared to the 3-cyclopentoxy analogue 1.57 (42%). Of the 
4-position aryl substituents examined, fluorine afforded the greatest potency. 
Non-aromatic, 3-postion aryl substituents resulted in weaker activity compared to their 
aromatic counterparts, with the cyclic 3-cyclopentoxy derivative 1.57 (42%) showing a 
smaller effect on potency when compared to the 3-propoxy derivative 1.58 (24%).  
The use of a heterocyclic scaffold to mimic the sialic acid fragment proved to 
be beneficial as shown by the 2-benzothienyl derivative 1.54 (87%) and the indolic 
analogues 1.52 and 1.55 (96% and 87% respectively). Incorporating heterocycles as 
sialic acid mimics represents a novel approach in the preparation of ST inhibitors. 
Different heterocycles and substituent patterns upon these heterocyclic scaffolds are 
currently being explored by our group.  
The ester group present in the indole derivative 1.52 fulfilled its role in 
mimicking the carboxylic acid group of the natural donor CMP-Neu5Ac 1.4. The 
presence of the ester contributed to an increase in potency of 1.52 by approximately 
10% compared to the corresponding indole-based derivative 1.55, which is lacking the 
functional group. The lack of a carboxylic acid mimic, particularly a phosphonate, was 
a result of the synthetic pathway. When this pathway was utilised to prepare 
phosphonate containing derivatives, decomposition of the alkyne intermediate (bearing 
the corresponding protected phosphonic acid) was observed.120 Our group is currently 
investigating the use of a different synthetic approach to allow for the installation of a 
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phosphonate in place of the hydroxyl group to gain the expected benefits to ST 
inhibition (Table 1.1).  
 
Figure 1.14: Percentage inhibition data of 1,2,3-triazole-linked derivatives, with varied sialic acid mimic 
(1.51–1.58), at 100 μM against hST8Sia II.120  
 
1.5.2.2 Carbamate Linker 
Molecules containing carbamates play a significant role in medicinal chemistry.122 
Structurally, carbamates have amide-ester hybrid-like features and, in general displays 
very good chemical and proteolytic stabilities. As well as their stability, their capability 
to permeate cell membranes has resulted in carbamates being widely utilised as peptide 
bond isosteres. The carbamate functionality also imposes a degree of conformational 
restriction as a result of the delocalisation of non-bonded electrons on the nitrogen into 
the carboxyl component. Clinically approved examples of carbamate containing drugs 
include Rivastigmine (Figure 1.15, 1.59), which reversibly inhibits the metabolism of 
acetylcholinesterase and butyrylcholinesterase, and is used to treat dementia; and HIV 
protease inhibitors Ritonavir, Amprenovir, and Atazanavir (Figure 1.15, 1.60–1.62).122 
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Figure 1.15: Clinically approved drugs Rivastigmine (1.59), Ritonavir (1.60), Amprenavir (1.61) and 
Atazanavir (1.62) containing a carbamate motif (highlighted in blue).  
 
The carbamate motif is a suitable choice for a potential phosphodiester isostere to 
improve synthetic accessibility. A number of relatively straightforward reactions can be 
performed to generate carbamates using a wide range of alkoxycarbonylating agents that 
were developed as low-cost and benign alternatives to the previously used phosgene 
based routes.122 However, there is no current reported evidence of carbamates being used 
as isosteres of phosphodiesters. Carbamates do, however, have potential to be an isosteric 
replacement, as many of the advantages discussed above in relation to carbamates as 
peptide isosteres would be beneficial in this case. More specifically a carbamate moiety 
would be expected to have similar hydrogen bonding capabilities to a phosphodiester 
group and will maintain the three-atom distance between the cytidine moiety and 
Neu5Ac-mimic observed in reported phosphodiester-linked ST inhibitors (Table 1.1). 
However, orientation of the carbamate linker will play a significant role as demonstrated 
in the phosphoramidate-linked ST inhibitors from α-aminophosphonates (e.g. 1.35, 
Figure 1.12) where the replacement of the O of the phosphodiester linker closest to the 
sialic acid mimic with an NH resulted in a two orders of magnitude decrease in potency.108 
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Another important consideration with the use of a carbamate linker is stability, as 
the carbamate moiety can be used as a labile group for prodrugs. Carbamates are typically 
stable but can be hydrolysed by esterases. The OH-catalysed hydrolysis of carbamates is 
strongly dependent on both the pKa of the proton on the leaving group (ROH) and the 
degree of substitution on the nitrogen of the carbamate ester. In the case of alcohols, both 
the N-monosubstituted and N,N-disubstituted carbamates are chemically stable toward 
hydrolysis. Whereas in the case of phenols (which have a lower pKa) only 
N,N-disubstituted carbamates are chemically stable toward hydrolysis. 
1.5.2.3 Characterisation of Protein-Ligand Interactions of ST Inhibitors 
Due to the first human ST crystal structures only being published in the last five years, 
the interactions of reported inhibitors with human STs is limited. The only ST inhibitors 
that have been co-crystallised with a human ST (and all other STs reported) are the donor 
analogues CMP, CDP, CTP and CMP-3-F-Neu5Ac.55, 76-77 There is also the unpublished 
hST8Sia III 2.15 Å resolution structure that has been deposited into the PDB in 2016 by 
the Strynadka group, which is co-crystallised with a phosphodiester-linked derivative 
similar to those published by the Schmidt group (PDB id 5CXY). This transition-state 
analogue shared a similar binding mode to that observed for CMP-3-F-Neu5Ac, CTP and 
CDP in the Strynadka group’s previous structures.76  
At the time of writing, there are three reported computational works, all of which 
emanate from this thesis, that explore the interactions between human STs and potential 
transition-state analogue inhibitors. Two of these publications explore the interactions of 
potential inhibitors with hST6Gal I as described in Chapters 3 and 4.80-81 The third 
applies the computational methodologies developed as part of this thesis to characterise 
the interactions of potential inhibitors with hST8Sia III.78  
Chapter 1: Introduction 
32 
There have been a small number of studies with non-human STs, which utilise 
computational techniques to characterise the protein-ligand interactions of potential ST 
inhibitors. For instance, Grewal et al. generated homology models for hST6GalNAc I, 
hST3Gal III and hST8Sia I using the pST3Gal I crystal structure as a template, and 
evaluated potential binding sites for the natural products curcumin and resveratrol.123 
Chen et al. has undertaken molecular docking to examine whether a lithocholic acid 
analogue, Lith-O-Asp (1.7, Figure 1.8), could form a stable structure with pST3Gal I and 
thus demonstrated that this compound had the potential to inhibit ST activity.87 Preidl et 
al. undertook molecular docking with the crystal structure of the bacterial ST from 
Pasteurella multocida and pST3Gal I, to aid in the design of their fluorescent transition-
state analogue inhibitors (e.g. 1.30, Figure 1.11).103 Finally, Crous and Naidoo published 
classical molecular dynamics (MD) simulations and free energy perturbation (FEP) 
calculations that examined three donor analogue inhibitors and their binding interactions 
with pST3Gal I. Using these calculations they highlighted the importance of the 
electrostatic interactions provided by the carboxylate group for enzyme binding 
affinity.124 In addition to computational studies, NMR studies with rST6Gal I and spin 
labelled analogues of CMP-Neu5Ac and N-acetyllactosamine (LacNAc) have also 
provided insight into the binding site.73-74 
1.6 Thesis Aims 
The aim of this doctoral study is to produce ST inhibitors with favourable 
pharmacokinetic properties and that are more synthetically accessible than classical ST 
inhibitors by the replacement of the charged phosphodiester linker of the lead compound 
1.20 (Figure 1.9) with a neutral linker, such as a 1,2,3-triazole (1.63) or a carbamate 
(1.64). We also aim to explore uridine as a synthetically beneficial replacement of 
cytidine, as well as potential source of selectivity (Figure 1.16). The recently published 
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ST structural information provides exciting opportunities for rational design. Thus, we 
will utilise various computational modelling techniques to characterise protein-ligand 
interactions and binding free energy of key potential inhibitors with hST6Gal I to guide 
our rational design.  
Thus the specific aims of this thesis are:  
1. To characterise the binding mode of reported and novel inhibitors targeting hST6Gal I 
using molecular docking and classical MD simulations (Chapter 3). 
2. To examine the relative changes in binding free energy to hST6Gal I, when the 
phosphodiester linker of lead compound 1.20 is replaced with a 1,2,3-triazole or 
carbamate moiety (Chapter 4). 
3. To develop synthetic protocols to produce carbamate-linked transition-state analogue ST 
inhibitors with a focus on uridine- and cytidine-based derivatives. ST inhibitory activity 
of these compounds will be evaluated both in-house and through international 
collaborations (Chapters 5 and 6). 
 
Figure 1.16: Proposed 1,2,3-triazole- (1.63) and carbamate- (1.64) linked transition-state analogue ST 
inhibitors explored by the Skropeta research group.  
 
These aims were addressed across the following five chapters that have resulted 
in one published book chapter, two published manuscripts and one prepared manuscript 
to date. Chapter 2 presents computational methods utilised in subsequent chapters of this 
thesis. Chapter 3 presents the characterisation of the binding mode of reported and novel 
inhibitors targeting hST6Gal I using molecular docking and classical MD simulations. 
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Chapter 4 explores the implications on binding free energy to hST6Gal I when 
phosphodiester linker of the lead compound 1.20 is replaced with a carbamate or 
1,2,3-triazole. In Chapters 5 and 6, the development of synthetic protocols to produce 
carbamate-linked inhibitors derived from both cytidine and uridine. The resulting 
biological evaluation is also contained within Chapter 5. A conclusion and future 
directions are provided in Chapter 7, which ties together the overall assessment of the 
implication of replacing the phosphodiester linker traditionally used in transition-state 
analogue ST inhibitors. 
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FOREWORD TO CHAPTER 2 
This thesis describes my work, which aimed to produce transition-state analogue ST 
inhibitors with favourable pharmacokinetic properties and that are more synthetically 
accessible than the previously reported. To achieve this, computational modelling will be 
performed to aid in the rational design of these novel compounds. 
Here, Chapter 2 presents a brief introduction to the computational glycobiology 
methodologies that were used in the subsequent chapters of this thesis. This includes 
background information on molecular docking (Chapter 3), MD simulations 
(Chapters 3–5), free energy calculations (Chapters 4 and 5) and methods to assess the 
effect of entropy on a ligand binding to a target (Chapter 4). Relevant sections of the 
book chapter published in Advances in Protein Chemistry and Structural Biology that I 
co-authored are contained within this chapter. 
Montgomery, A. P.*; Xiao, K.*; Wang, X.; Skropeta, D.; Yu, H., Chapter Two - Computational 
glycobiology: Mechanistic studies of carbohydrate-active enzymes and implication for inhibitor design. In 
Advances in Protein Chemistry and Structural Biology, Tatyana, K.-C., Ed. Academic Press: 2017; Vol. 
109, pp 25–76. *These authors contributed equally. 
Permissions regarding copyrights have been obtained. 
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2.1 Introduction 
In the last decade, glycobiology has attracted significant interest and a great effort has 
been made to the study of the structure, mechanism and function of carbohydrate-active 
enzymes (CAZy),1 resulting in a boom in CAZy-based synthetic methodologies and 
therapeutics. However, a thorough understanding of the catalytic mechanisms remains a 
significant challenge, which influences the realisation of the full potential of CAZy. As a 
perfect complement to experimental studies, computational glycobiology is a powerful 
and robust tool in probing the reaction pathway and providing structural, energetic, and 
electronic details of CAZymatic reactions.2-4 A major challenge in computational 
glycobiology is the development of algorithms and models that can accurately replicate 
the highly heterogeneous electrostatic environment and capture the complex energetic 
landscapes of carbohydrate structure along the reaction pathways. It is also important that 
the molecular factors that modulate the pKa values of ionisable groups in enzymes can be 
accurately described as this is crucial to the identification of the catalytically competent 
protonation states. Ultimately, these mechanistic investigations are driven by the goal to 
help in the rational design of selective and potent inhibitors targeting CAZys for 
therapeutic applications, where computer-aided drug design using advanced free energy 
calculations is increasingly playing an important role.5  
This chapter will briefly survey key methodology used in this thesis to characterise 
the binding mode of reported and novel inhibitors targeting hST6Gal I (Chapters 3 and 
4) and to examine the relative changes in binding free energy to hST6Gal I, when the 
phosphodiester linker of lead compound 1.20 (Figure 1.9, see p. 16) is replaced with a 
1,2,3-triazole or carbamate moiety (Chapter 4) or when the cytidine of is replaced with 
uridine (Chapter 5).  
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2.2 Computational Methodologies 
2.2.1 Molecular Docking 
Molecular docking can predict both covalent6 and non-covalent binding7 of a ligand to a 
receptor, with the aim of determining bound conformations and binding affinities. The 
work contained within this dissertation solely uses molecular docking as a tool to predict 
the non-covalent binding of ligands, hence all discussion referring to molecular docking 
herein will be based on this use. 
The main advantage of using molecular docking to characterise protein-ligand 
interactions is that the calculations are computationally cheap and thus calculations can 
be undertaken in a short space of time. This makes molecular docking amenable for the 
virtual screening of a large libraries of potential inhibitors. However, the cost of this is 
that the scoring function, which approximates the binding affinities of each mode, is not 
universally accurate and the effects of receptor flexibility and explicit solvation on 
binding affinity is neglected.7 This means that the binding modes produced by docking 
programs must be evaluated to ensure that they are reasonable and the processes 
undertaken extensively validated to ensure the binding affinities obtained have meaning. 
In this thesis, the program used to undertake molecular docking is AutoDock Vina.8 
2.2.2 Classical Molecular Dynamics Simulations 
2.2.2.1 Classical Force Fields and Molecular Modelling 
Biochemistry can be depicted by the way atoms move, interact with each other, bind to 
form larger assemblies, and to fulfil certain functions within a cell.9 These processes are 
dictated by their thermodynamics and kinetics. When calculations aim at collective 
properties arising from several different conformations of a molecule, such as 
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thermodynamic averages, quantum mechanical methods are too computationally 
expensive.9 Thus the more computationally accessible treatment of biomolecular systems 
via classical molecular mechanics is favoured when quantum mechanical effects can be 
approximated or neglected.10 
In molecular mechanics, molecular motion can be treated as classical motion in 
potentials, known as force fields, applied only to the nuclei of molecules without 
explicitly considering electrons.10 These classical force fields are derived from quantum 
mechanics but parameterised against experimental data and thus encompass the collected 
knowledge about molecular motion. The classical force field is generally comprised of 
five terms, three of which correspond to bonded factors and two correspond to non-
bonding factors (Eq. 2.1).11-12 The bonding terms include covalent bond stretching, bond 
angle bending and dihedral (torsional) interactions.11-12 The non-bonding terms represent 
the potential energy associated with van der Waals and electrostatic interactions between 
atoms. The van der Waals interactions are usually modelled by the Lennard-Jones 
potential and electrostatics are modelled by Coulombic interactions between the atoms 
pairs bearing partial charges.11-12 
𝑉𝑡𝑜𝑡𝑎𝑙 =  ∑
1
2
 𝑘𝑏(𝑏 − 𝑏0)2bonds +  ∑
1
2
 𝑘𝜃(𝜃 −  𝜃0)2angles + ∑ 𝑘𝜙[1 + cos(𝑛𝜙 − 𝛿0)]dihedrals +

















]nonbonded               Eq. 2.1 
There are different classical force fields developed, based on the choice of different 
experimental and computational data, and intended for diverse types of calculations. All 
work within this thesis employs the use of the CHARMM C36 force field.13 
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2.2.2.2 Force Field Generation 
To obtain meaningful results from simulations, accurate force fields are required. The 
force fields that are generally used are optimised to model biomolecular systems, 
including lipids, nucleic acids and proteins. As a result these force fields only cover a 
restricted set of small organic compounds, and although models of additional compounds 
can be generated by analogy, the accuracy of the resulting models can be limited.14 The 
challenges are even greater for compounds that have no close analogues within the 
popular biomolecular force fields, presenting a significant challenge for drug design. This 
issue can be addressed by having an algorithmic procedure to automatically parameterise 
any given molecule in a way that is consistent with a specific force field.14 The general 
AMBER force field (GAFF),15 CHARMM general force field (CGenFF),16 GROMOS 
automated topology builder (ATB)17-19 and OPLS LigParGen20-22 have enabled the 
objective and automatic parameterisation of novel drug like small molecules. However, 
a particular concern is the compatibility for using these in conjunction with the 
CHARMM force field,13 though previous benchmark simulations indicated that the effect 
may be minor.23 
Recently the general automated atomic model parameterisation (GAAMP) 
method for generating force field parameters for small molecules compatible with 
CHARMM and the CGenFF has been developed.14 This method is a fully general and 
automatic method to parameterise atomic models of small molecules based on ab initio 
quantum mechanical data. Parameterisation with the GAAMP method begins with the 
CGenFF as the initial model and optimises the force field, with particular focus on the 
partial charges, dihedral parameters and the interactions with water.14 The force fields for 
the general lead structure of phosphodiester-, 1,2,3-triazole- and carbamate-linked ST 
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inhibitors utilised in the MD simulations and FEP calculations described in Chapters 4 
and 5 of this thesis have been optimised using the GAAMP methodology.  
2.2.2.3 Molecular Dynamics Simulations 
Classical MD simulations allow for the prediction of the time evolution of a molecular 
system by applying Newton’s equations of motion (Eq. 2.2 and 2.3) for all atoms, to 
sample thermodynamically accessible conformations.11 This generates trajectories 
(configuration as a function of time) for all atoms in the system,11 from which a variety 









In a MD simulation, the position (ri) of each atom is initially based on available 
experimental structures or homology models, with the force (Fi) acting on each atom 
calculated (Eq. 2.2) from the force field (Eq. 2.1).24 From Newton’s laws of motion 
(Eq. 2.3), the movement of each atom can be simulated,24 allowing the prediction of the 
velocity and position of each atom at each chosen time step. This procedure is then 
repeated for every time step of the simulation to propagate the trajectory.24 The classical 
MD simulations undertaken as part of this study will be performed using NAMD.25 
To generate reliable results there are several important considerations that need to 
be made when undertaking classical MD simulations. The first is the accuracy of the force 
field that is used. In this work, one of the most widely used and validated biomolecular 
force fields CHARMM C36 was used.13 The second consideration that needs to be made 
is that sufficient sampling is undertaken to ensure that the properties of interest converge. 
Eq. 2.2 
Eq. 2.3 
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As a result, the simulations undertaken as part of this work were monitored for 
convergence and analysis was only performed on the portion of the simulation that had 
converged. The consideration is that the model is properly validated, which can be 
achieved by comparison to reported experimental data. In this thesis the protocols used 
for the MD simulations were validated by comparing the hydrogen bonds and 
hydrophobic contacts observed in simulations of each ST in complex with its 
co-crystallised substrate, to the crystal structure. The simulations were further validated 
with the results from the biological data. 
2.2.3 Binding Free Energy Calculations 
Protein-ligand binding is of key importance to both biological function and 
pharmaceutical activity. Achieving the desired therapeutic effect of a compound is 
dependent on the magnitude of binding affinity to the target receptor. Thus, designing 
tight-binding ligands whilst maintaining biological efficacy and safety is the principal 
objective of drug discovery projects.5 The accurate prediction of protein-ligand binding 
free energies is the key target of computer-aided drug design. A variety of free energy 
simulation methods, including FEP, thermodynamic integration and λ dynamics, employ 
an analysis of all-atom MD or Monte Carlo simulations to determine the relative free 
energy difference between two similar ligands via either a chemical or an alchemical 
path.26-27 In most cases, the calculation of relative binding free energies is sufficient and 
is favoured as a significant reduction in computational effort is required when compared 
to calculating the absolute binding free energy.28 
The calculation of the free energy along a thermodynamic pathway by employing 
alchemical transformations is widely used in the calculation of relative binding free 
energies between different ligands. The alchemical transformations are usually performed 
using the double-decoupling method in which two separate calculations are carried out 
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for decoupling the ligand from the solution and receptor environments.29 The calculations 
are performed based on a thermodynamic cycle, such as that shown in Figure 2.1. In this 
cycle ΔΔG between different compounds (ΔG1 and ΔG3) is calculated by subtraction of 
ΔG2 and ΔG4, which is the free energy (ΔG) associated with the alchemical transformation 
of one inhibitor to another in complex with the protein or in aqueous solution. 
 
Figure 2.1: The thermodynamics cycle used to calculate ΔΔG, where P represents the protein of interest 
and L1/L2 represent the different inhibitors of interest. The horizontal legs correspond to the ΔG associated 
with binding affinities whereas the vertical legs correspond to the ΔG for the alchemical transformation of 
L1 to L2. The binding free energy difference for L1 and L2 can be calculated according to Eq. ΔΔG = ΔG2 
– ΔG4. 
 
Alternatively, the standard binding free energy of a ligand to a protein can be 
calculated through a combination of an alchemical transformation and a geometric 
transformation.30-32 However, this still presents a daunting challenge, even with modern 
computing facilities. FEP coupled with replica-exchange MD has been developed to 
improve the sampling and accelerate the convergence of the free energy calculations.33-34 
In this thesis the method selected for the calculation of relative binding free 
energies was FEP. The relative free energy between two states A and B can be expressed 
as an ensemble average as follows: 
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∆𝐹𝐵𝐴 =  𝐹𝐵 − 𝐹𝐴  





∫ exp (− ℋ𝐵 − ℋ𝐴𝑘𝐵𝑇




The ensemble average in equation 2.4 only converges if the two probability 
distributions for the A and B state overlap. This is only possible if the change between 
the A and B states is not too large. As a result, a coupling parameter (λ) approach is 
adopted. In this approach state A and B are connected by making the Hamiltonian ℋ a 
function of the coupling parameter λ, with the transformation essentially achieved 
through a series of perturbations for which two states overlap sufficiently. To calculate 
the relative free energy between the two states the Hamiltonian is parametrised so that 
ℋ(λA) = ℋ𝐴 represents state A and ℋ(λB) = ℋ𝐵 state B. Therefore using λ, the change 
between states A and B is split into many N smaller changes (Eq. 2.5) that require N 
separate simulations at a fixed λ. 







Binding free energy calculations performed with implicit solvent models can also 
be considered. By regarding solvent effects implicitly, using continuum solvent methods 
the computationally intensive evaluation of individual contributions of a large number of 
solvent molecules can be avoided. The computational cost can be further reduced by 
considering only the end-point states in the free energy calculations. End-point, implicit 
solvent approaches therefore have the advantage of a relatively low computational cost, 
while important solvent effects are still regarded.27, 35-37 The most well-known methods 
of this style are the Molecular Mechanics/Poisson–Boltzmann Surface Area approach or 
the Molecular Mechanics/Generalised Born Surface Area approach.38-39  
Eq. 2.4 
Eq. 2.5 
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2.2.4 Assessing the Impact of Entropy 
It is clear from equation 2.6 that for a given (bio)chemical process (e.g. ligand binding), 
even assuming a minor change of free energy (ΔG), can involve a substantial change in 
the enthalpy (ΔH) and entropy components (ΔS). Additionally, even a small change in 
the entropic term will typically (e.g. at 298K) result in a large change in free energy.40-41 
∆𝐺 = ∆𝐻 − 𝑇∆𝑆 
The determination of free energy changes by computational methodologies has 
become a standard procedure, though entropies are rarely considered.42-43 There are two 
main reasons behind this: first, the calculation of entropy is computationally expensive as 
it  requires sampling of the complete phase space. Second, when considering an entropy 
change term ΔS even a small error on this value will produce (multiplied times T) a large 
error on the corresponding free energy. Therefore accuracy and numerical issues are also 
hindering the extension of currently available techniques from free-energy to entropy 
calculations.42-43 
There are two main ways to calculate entropy and its differences, with both being 
utilised in Chapter 4 of this thesis. The first method relies on using currently available 
free energy methods to obtain the free-energy differences between two states (e.g. 
different temperatures) of the same system to back calculate the entropic component.42-44 
This represents a challenging task as to obtain entropy differences in this manner requires 
an accurate estimate of an ensemble average that includes the complete Hamiltonian of 
the entire system and not just the part of the Hamiltonian that differs between the two 
states. The entropy will be calculated from the respective FEP simulations in this work. 
The second method focuses on conformational entropies, where only internal 
non-diffusive degrees of freedom are considered.45-47 Therefore, the main limitation of 
Eq. 2.6 
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this approach is the difficulty in comparing calculated entropies with experimental ones, 
which include contributions of all system degrees of freedom and their correlations. 
Changes in configurational entropy in this thesis will be calculated using the 
quasi-harmonic approximation.45-47  
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3.1 Introduction  
STs are enzymes of the GT family that play an integral role in the biosynthesis of sialic 
acid containing oligosaccharides and glycoconjugates.1-2 STs are anchored within the 
Golgi apparatus’ membrane, with a catalytic domain present in the lumen (Figure 1.5, see 
p. 9).1 Generally in glycosylation reactions catalysed by STs, the sugar nucleotide donor 
is CMP-Neu5Ac and the acceptor is an oligosaccharide or glycoconjugate terminated by 
a Gal, GalNAc, or another sialic acid residue.1, 3 STs are classified based on the position 
of the glycosyl acceptor that sialic acid is transferred. In humans these are ST3, ST6 and 
ST8, which form an α-glycosidic bond between the C2 atom of sialic acid and the 3′-, 6′- 
or 8′-hydroxyl group of the acceptor, respectively.1-2, 4 
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The focus of this work, hST6Gal I, is one of the two subfamilies of the ST6 family, 
that catalyse the transfer of a sialic acid residue to the 6′-hydroxyl group of the terminal 
Gal residues of the disaccharide Galβ[1,4]GalNAc. This disaccharide can be found free 
or as a terminal N-acetyllactosamine unit of N- or O-linked oligosaccharides.2, 5 
hST6Gal I (Figure 1.5, see p. 9) belongs to the GT29 family of GTs, which is comprised 
of eukaryotic and viral STs (http://www.cazy.org).6  
The first sequence data of ST6Gal I was determined from a cDNA clone from rats 
in 1987,7 with the sequence of hST6Gal I described three years later.8 The primary 
sequence of hST6Gal I, like all other eukaryotic STs, contains four characteristic regions: 
a short N-terminal cytoplasmic domain, followed by a transmembrane domain that 
extends to a stem region and a larger C-terminal catalytic domain that faces the lumen of 
the Golgi apparatus (Figure 1.5, see p. 9).9 Within the catalytic domain there are four 
regions that show significant sequence conservation across eukaryotic STs (Figure 1.5, 
see p. 9), known as sialyl motifs L, S, III and VS.10 Residues of motifs L (Trp181–Gly224; 
hST6Gal I numbering) and III (Tyr354–Gln357) are involved in binding the donor 
substrate;11 motif S residues (Pro321-Phe343) are involved in both donor and acceptor 
binding, while motif VS residues (His370–Glu375) participate in the catalytic reaction.12 
The first 80 residues of hST6Gal I, comprising the cytoplasmic domain, transmembrane 
domain and stem region, can be deleted without affecting activity.12-13 
There were two decades between the identification of the primary sequence and 
reporting of structural data of mammalian ST6Gal I, with ligand conformation and 
protein-ligand contact surfaces identified using NMR appearing in 2007 and 2009.14-15 
The first mammalian ST crystal structure published was that of pST3Gal I16 in 2009, 
while the first mammalian ST6Gal I crystal structures that came from rat17 and human 
(PDB id: 4JS1, 4JS2)9 were published in 2013. In addition to these, crystal structures of 
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hST8Sia III were published in 2015.18 All of the mammalian structures published are of 
the soluble catalytic domains with the cytoplasmic domain, transmembrane domain and 
a portion of the stem region deleted. 
hST6Gal I adopts the GT-A (variant 2) fold, a seven-stranded central β-sheet 
flanked by multiple α-helices, and exhibits three disulphide bonds Cys142-Cys406, 
Cys184-Cys335 and Cys353-Cys364. The hST6Gal I crystal structure revealed that CMP 
binds with the ribose in a 3′-endo conformation created via interactions with the first and 
last residues of a SerSerGly sequence within the sialyl motif S (see Appendix Figure A1). 
The disulphide bond Cys353-Cys364 is contained within a well-defined loop, packing on 
top of the nucleoside. The glycan binding observed, showed the 6’-hydroxyl of the 
acceptor close to His370, a potential catalytic residue.9 Mutation carried out upon the 
equivalent histidine (His367) of rST6Gal I resulted in no detectable catalytic activity,17 
which supports the conclusion that His370 is a catalytic residue in hST6Gal I.  
It has been proposed that the mechanism of hST6Gal I (Figure 3.1) proceeds via 
nucleophilic attack on the sialic acid anomeric carbon by the deprotonated Gal 
6′-hydroxyl of the disaccharide Galβ[1,4]GalNAc acceptor, facilitated by the catalytic 
His370.17, 19 This generates an oxocarbenium-like transition state, with the CMP portion 
acting as a leaving group. The β-configuration at the anomeric carbon of the donor is 
inverted in the final product.19 These aspects suggest that hST6Gal I functions as an 
inverting GT, utilising an SN2-like direct displacement mechanism.5, 20 This is supported 
by a model of the Michaelis complex generated from the glycan binding mode observed 
in the crystal structure of hST6Gal I.9  
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Figure 3.1: Proposed reaction scheme for the catalytic action of hST6Gal I. R represents a glycan chain of 
a glycoconjugate.  
 
Depending on the substrate targeted by hST6Gal I, α-2,6-sialylation can modulate 
protein conformation, oligomerisation and/or receptor internalisation.21 Overexpression 
of hST6Gal I is observed in many different types of cancers including lung, cervical, 
ovarian, breast and colon carcinoma.21-22 It has been suggested that the overexpression of 
hST6Gal I promotes cancer cell metastasis through altered sialylation patterns affecting 
the function of β1 integrin.23-24 hST6Gal I also has an important function in the regulation 
of galectins, via the sialylation of their galactose-containing substrates.21, 25 For instance, 
α-2,6 sialylation of the galectin substrates, Fas and TNFR1 death receptors, has been 
shown to hinder the apoptosis process, thus identifying hST6Gal I overexpression as a 
potential inhibitor of cell death pathways.21, 25  
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The overexpression of hST6Gal I in various cancers has lead to the hypothesis 
that it can serve as a target for the development of new anti-cancer therapeutics. This has 
resulted in the development of a diverse range of ST inhibitors.26-28 Of these, analogues 
that are structurally similar to the proposed oxocarbenium ion-like transition state 
(Figure 3.1) exhibit the highest affinity to STs.29-30 Transition-state analogue inhibitors 
incorporating a Neu5Ac2en moiety are amongst the most potent inhibitors, with the C2–
C3 double bond mimicking the planar anomeric carbon of the oxocarbenium transition 
state.31 An extra carbon between the anomeric carbon and CMP leaving group oxygen 
was also incorporated to mimic the increased distance between these two atoms in the 
transition state.29, 31 Derivatives with structural variations of the glycerol side chain of the 
Neu5Ac2en moiety produced the greatest inhibitory activity. Of these, phenoxy 
derivative 3.1 (Figure 3.2, Ki = 29 nM), showed the greatest inhibition of rat liver 
ST6Gals and is one of the most potent transition-state analogue ST inhibitors reported to 
date.32 Derivatives that incorporate an aryl replacement of the Neu5Ac2en moiety have 
comparable activity to the phenoxy derivative 3.1 and are more synthetically 
accessible.29-30, 33 Of these compounds the (R)-isomer of the phenoxy derivative 3.2 was 
the most potent inhibitor of rat liver ST6Gals (Figure 3.2, Ki = 70 nM) and is used as the 
lead compound herein.29   
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Figure 3.2: Development of the phosphodiester-linked lead compound (3.2) and the proposed 
1,2,3-triazole- (3.3) and carbamate- (3.4) linked derivatives. Reported Ki values expressed for compounds 
3.132 and 3.229 are determined against rat liver ST6Gals.  
 
The charged phosphodiester linkage of transition-state analogue ST inhibitors, 
while contributing to potency,34 is generally thought to introduce pharmacokinetic issues 
such as: poor cellular permeability, low bioavailability and potential loss of activity due 
to cleavage by phosphatases.35-36 In this study, to produce potent ST inhibitors that are 
readily accessible and with favourable pharmacokinetic properties, the replacement of the 
charged phosphodiester linker of the lead compound 3.2 with a neutral linker, such as a 
rigid 1,2,3-triazole or a flexible carbamate has been investigated. The 1,2,3-triazole motif 
is a suitable choice as it has previously been shown to be an applicable phosphodiester 
isostere in transition-state analogue ST inhibitors,35, 37 as well as being used as isosteres 
of pyrophosphate linkers38 and phosphodiester linkers of oligonucleotides.39 To date, 
there are a paucity of examples of carbamates being used as isosteres of phosphodiesters. 
Carbamates do, however, have potential to be an isosteric replacement, as this group has 
similar hydrogen bonding capabilities to a phosphodiester group and will maintain the 
three-atom distance between the cytidine moiety and sialic acid-mimic observed in 
reported phosphodiester-linked ST inhibitors. To investigate the potential binding effects 
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of replacing the phosphodiester linker in derivatives with 1,2,3-triazoles (e.g. 3.3; Figure 
3.2) and carbamates (e.g. 3.4; Figure 3.2), molecular docking and MD simulations with a 
model of hST6Gal I were undertaken. Insight into this binding may suggest novel 
molecular structures and design strategies for the future development of 
clinically-relevant and selective ST inhibitors. 
3.2 Methods 
3.2.1 Molecular Docking Setup 
A selection of reported and newly designed inhibitors were docked into the binding site 
of the hST6Gal I crystal structure (PDB id: 4JS2)9 and snapshots sampled from every 
20 ns of MD simulations (see below) with AutoDock Vina version 1.1.2.40 The structure 
of hST6Gal I was prepared for docking with AutoDockTools 1.5.6 (ADT).41 The 
three-dimensional structures of the inhibitors studied were prepared with ChemDraw 14.0 
and Avogadro v1.1.1.,42 with ADT used to assign both rigid and rotatable bonds and to 
remove non-polar hydrogen atoms. PROPKA 3.143 was used to predict the protonation 
state of active site residues and ionisable ligand groups at pH 7.0. Docking was performed 
in a 30 Å × 30 Å × 30 Å box centred at the active site highlighted in the hST6Gal I-CMP 
crystal structure (PDB id: 4JS2).9 The dimension was chosen to ensure it was big enough 
to accommodate the largest ligands and their interacting residues. In all the docking 
calculations, the receptor is kept rigid and no explicit waters have been included. The 
docking procedure was validated by re-docking of CMP to replicate the 
crystallographically determined hST6Gal I-CMP complex.9  
3.2.2 Molecular Dynamics Simulation Setup 
The crystal structure of hST6Gal I (PDB id: 4JS2)9 was taken as the initial structure for 
the simulations and was prepared using VMD version 1.9.1.44 An overview of all 
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simulations is given in Table 3.1. Simulation of the hST6Gal I-CMP complex, using the 
starting coordinates provided by the crystal structure was undertaken to validate the MD 
simulation protocols used. To probe flexibility in the apo state, the hST6Gal I protein in 
the absence of a ligand was also simulated. Simulation of hST6Gal I inhibitor complexes 
with reported phosphodiester-linked compounds 3.1 and 3.2 and the proposed 
carbamate-linked derivative (R)-3.4 (Figure 3.2) was undertaken to determine if a 
carbamate linker was a suitable replacement for the phosphodiester linker used in 
previously reported inhibitors of rST6Gal I. The initial structure for the hST6Gal I 
inhibitor complexes was taken from the docking studies detailed above.  
Table 3.1: Overview of all MD simulationsa 








Apo - 100 10 90 
CMP1 CMP 100 10 90 
CMP2 CMP 100 10 90 
CMP3 CMP 100 10 90 
PL1 Phosphodiester-linked inhibitor 3.1 100 10 90 
PL2 Phosphodiester-linked inhibitor 3.2 100 10 90 
CAR1 Carbamate-linked inhibitor (R)-3.4 100 10 90 
CAR2 Carbamate-linked inhibitor (R)-3.4 100 10 90 
aThe systems consist of approximately 49 000 atoms with a box size of 81 Å × 81 Å × 81 Å 
 
Preparation of each simulation involved solvating the system in a box of water 
molecules, which extended approximately 9 Å from the surface of the protein. Due to the 
hST6Gal I active site being solvent exposed, solvation of the active site was not 
specifically considered for any case. Each box was neutralised with counter ions of Na+, 
with the salt (NaCl) concentration set to 0.15 mol/L. Simulations were carried out using 
the NAMD 2.9 package.45 The protein was represented with the non-polarisable 
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CHARMM PARAM36 force field.46 Each ligand, if not represented in this force field, 
had a parameter and topology file generated with the GAFF47 using AmberTools13.48 All 
of the systems were simulated in periodic boundary conditions using the Langevin 
algorithm for maintaining the temperature at 298.15 K, and the Langevin Piston 
Nosé-Hoover method49-50 for keeping the pressure constant at 1.0 bar. The electrostatic 
interactions were calculated using the Particle Mesh Ewald method.51 The van der Waals 
forces were treated with a cut-off of 12 Å and a smoothening function between 10 and 
12 Å. All of the covalent bonds involving hydrogen were kept rigid with the RATTLE 
algorithm.52 The integration time step was set to 1.0 fs, 2.0 fs and 4.0 fs for bonded, non-
bonded and long range electrostatics respectively. Equilibrium simulations for all systems 
were initially undertaken. During these simulations a harmonic restraint was placed upon 
all carbon alpha (Cα) atoms of hST6Gal I, with a decreasing force constant from 32.0 to 
1.0 kcal/mol/Å2 over 10 ns. This decrease was achieved gradually by halving the force 
constant for each respective 1 ns interval until a force constant of 1.0 kcal/mol/Å2 was 
obtained (i.e. 32.0, 16.0 … 1.0 kcal/mol/Å2). A force constant of 1.0 kcal/mol/Å2 was 
then applied for the remainder of the 10 ns thermal equilibration. The simulations were 
further continued for 90 ns without any restraints. To perform trajectory analysis 
snapshots were saved every ps (i.e. every 1000 steps). 
3.2.3 Analysis 
The docking protocols outlined above were validated by replication of the experimentally 
determined binding mode of the mono-deprotonated CMP in the reported hST6Gal I 
crystal structure (see Appendix Figure A2).9 To assess the ability of AutoDock Vina to 
rank potential hST6Gal I inhibitors in terms of their enzyme binding affinities, focused 
docking of selected reported inhibitors into the active site of hST6Gal I was undertaken.  
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To determine the optimal binding mode for each ligand investigated the top 
ranked models, based on the scoring function for binding affinities in AutoDock Vina 
were examined in VMD.44 Evaluation of the optimal binding mode was firstly based upon 
comparison to the position of CMP component of the inhibitors investigated in relation 
to residues that were highlighted as important for CMP binding in the crystal structure of 
hST6Gal I.9 This was followed by comparison of the sialic acid mimic position in relation 
to residues highlighted as interacting with the sialic acid component of CMP-3-F-Neu5Ac 
in a model of the Michaelis complex generated for hST6Gal I.9 For each compound the 
arithmetic mean binding affinity of the optimal binding mode was reported (Table 3.2–
3.3). Two-tailed t-tests were used to determine whether differences in the mean binding 
affinities were significant, with significance defined as P < 0.05 (see Appendix Table A1–
A7). 
To monitor the global properties of the structural evolution during MD 
simulations, atomic positional root-mean-square deviations (RMSD) with respect to a 
reference structure and the atomic positional root-mean-square fluctuations (RMSF) were 
calculated using VMD.44 
Hydrogen bond interactions in the hST6Gal I inhibitor complex simulations were 
analysed according to a geometric criterion. A hydrogen bond was defined by a minimum 
donor-hydrogen-acceptor angle of 120º and a maximum heavy atom distance of 3 Å. 
Hydrophobic contacts were also analysed according to a geometric criterion of a 
maximum distance of 4 Å between hydrophobic atom pairs. To identify these interactions 
CHARMM version 38a146 was utilised.  
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3.3 Results and Discussion 
3.3.1 Structural Flexibility of the Apo and Holo Form of hST6Gal I 
To assess the structural stability and fluctuations of the recently reported hST6Gal I 
crystal structure9 in both the apo and holo forms, MD simulations were performed. The 
Apo, CMP2 and CMP3 simulation RMSDs for Cα converged at 1.5 Å with CMP1 
converging at 2.5 Å (see Appendix Figure A3), indicating no significant change in the 
structure of the protein backbone. It should be noted that during the CMP simulations the 
CMP ligand remained tightly associated with the expected binding site. RMSFs for the 
Cα atoms, were comparable across the Apo and three CMP simulations (see Appendix 
Figure A4). Each simulation showed consistently larger RMSF values for the flexible 
loop between Tyr355 and Tyr369. 
3.3.2 Probing the Interactions Between Reported Inhibitors and hST6Gal I 
Snapshots from the Apo and CMP1 simulations were used to dock reported inhibitors 
(3.1–3.2 and 3.5–3.11, Table 3.2) with comparable results obtained with each condition. 
Results from CMP2 and CMP3 simulations were not included as no significant difference 
in binding affinity or binding mode was observed between the docking into the snapshots 
of each CMP simulation.  
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(R)-3.1 −10.0 ± 0.2 −9.6 ± 0.1 0.02932 −10.3 
 
(R)-3.2 −10.0 ± 0.2 −9.7 ± 0.2 0.07029 −9.8 
 
(R)-3.5 −9.7 ± 0.1 −9.4 ± 0.2 0.2529 −9.1 
(S)-3.5 −9.3 ± 0.2 −9.3 ± 0.2 0.2229 −9.1 
 
(R)-3.6 −9.1 ± 0.2 −9.1 ± 0.1 0.2033 −9.2 
(S)-3.6 −8.9 ± 0.1 −8.8 ± 0.1 1.033 −8.2 
 
3.7 −8.4 ± 0.1 −8.5 ± 0.1 5.753 −7.2 
 
3.8 −8.6 ± 0.1 −8.6 ± 0.1 4431 −6.0 
 
3.9 −8.2 ± 0.1 −7.9 ± 0.1 37054 −4.7 
 
3.10 −8.0 ± 0.2 −7.8 ± 0.1 75031 −4.3 
 
3.11 −8.2 ± 0.1 −7.9 ± 0.1 200031 −3.7 
aArithmetic mean binding affinity ± standard error of the mean (SEM) obtained from docking into six 
snapshots of MD simulation. bDocking carried out on the snapshots from the Apo MD simulations cDocking 
carried out on the snapshots from the CMP1 simulations. dEstimated using ∆𝐺 = 𝑅𝑇𝑙𝑛(𝐾i) where R = 
1.9872 × 10-3 kcal/K/mol, T = 300 K and Ki values were reported. 
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For both the Apo and CMP1 cases the AutoDock Vina scoring function for the 
more potent inhibitors (3.1–3.2, 3.5–3.8) was unable to differentiate between compounds 
that exhibited similar Ki values (Table 3.2). For the less potent inhibitors (3.9–3.11) the 
AutoDock Vina scoring function was unable to differentiate between any of these 
compounds despite the large differences in Ki observed experimentally (Table 3.2). This 
suggests that obtaining a perfect ranking of docked compounds using this protocol is 
unlikely, which is consistent with the error reported in the systematic benchmarking 
studies for AutoDock Vina.40 Encouragingly though, the scoring function was generally 
able to predict a significant difference between inhibitors of nanomolar, submicromolar, 
micromolar and submillimolar Ki (see Appendix Table A1–A2), providing confidence 
that an indication of relative binding affinity between compounds could be obtained. In 
addition, experimentally reported trends were also observed in the docking studies such 
as: no significant difference in binding affinity between the Neu5Ac2en containing 3.1 
and its more synthetically accessible counterpart 3.2 being observed;29-30, 33 and a 
3-phenoxy substituted inhibitor (e.g. 3.2) exhibiting greater binding affinity than the 
analogous unsubstituted inhibitor (e.g. 3.6).29 
For all compounds except 3.1, the binding affinity results obtained from docking 
into the Apo and CMP1 MD sampled structures were not significantly different (see 
Appendix Table A3). However, in terms of the positioning of the inhibitors, docking 
using the MD sampled structures of the CMP1 simulation generally produced binding 
modes that were more consistent. This was particularly evident in the docking into the 
80 ns and 100 ns snapshots, where CMP1 docking conditions produced binding modes 
where the CMP moiety of each inhibitor reflected the interactions highlighted within the 
hST6Gal I crystal structure,9 which was not consistently the case for the Apo docking 
conditions. This can be rationalised in that during the Apo simulation hST6Gal I relaxed 
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back to the apo form, from the starting “induced-fit” form of the co-crystallised 
CMP-hST6Gal I structure. 
3.3.3 Probing the Interactions Between 1,2,3-Triazole- and Carbamate-Linked 
Compounds and hST6Gal I  
Based on the results discussed above, docking of the 1,2,3-triazole- (3.3, 3.12–3.22) and 
carbamate-linked compounds (3.4, 3.23–3.33) was undertaken using MD snapshots from 
the CMP1 simulation (Table 3.3). Of the compounds docked there were six ((R)-3.3, 
(R)-3.4, 3.12, 3.16, 3.23 and 3.27) that only differed from the literature inhibitors 
examined by the replacement of the phosphodiester linker with either a 1,2,3-triazole or 
carbamate. The mean binding affinities for all analogous compounds, except for the 
phosphodiester-linked 3-trifluoromethyl (S)-3.5 (Table 3.2) and the corresponding 
1,2,3-triazole (S)-3.12, were not significantly different (see Appendix Table A4). For 
these 1,2,3-triazole- and carbamate-linked compounds the position within the active site 
(Figure 3.3a) was also comparable to those obtained for their phosphodiester-linked 
counterparts, indicating that these linkers may be feasible replacements of the reported 
phosphodiester linker. This docking study also shows generally no significant difference 
between analogous carbamate- and 1,2,3-triazole-linked compounds (see Appendix Table 
A5). This suggests that in most cases there may be no preference for either a flexible 
carbamate- or rigid 1,2,3-triazole linker as an isostere for the phosphodiester linker.  
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Affinity Triazolea (kcal/mol) 
Cpd 
Mean Binding Affinity 
Carbamatea (kcal/mol) 
 
(R)-3.3 −9.7 ± 0.1 (R)-3.4 −9.8 ± 0.2 
(S)-3.3 −9.9 ± 0.1 (S)-3.4 −9.8 ± 0.2 
 
(R)-3.12 −9.7 ± 0.2 (R)-3.23 −9.5 ± 0.1 
(S)-3.12 −9.9 ± 0.1 (S)-3.23 −9.7 ± 0.2 
 
(R)-3.13 −9.4 ± 0.2 (R)-3.24 −9.1 ± 0.2 
(S)-3.13 −9.8 ± 0.2 (S)-3.24 −9.1 ± 0.2 
 
(R)-3.14 −9.1 ± 0.1 (R)-3.25 −8.8 ± 0.1 
(S)-3.14 −9.4 ± 0.2 (S)-3.25 −9.0 ± 0.2 
 
(R)-3.15 −9.1 ± 0.2 (R)-3.26 −8.8 ± 0.1 
(S)-3.15 −9.2 ± 0.2 (S)-3.26 −8.9 ± 0.1 
 
(R)-3.16 −9.3 ± 0.2 (R)-3.27 −9.0 ± 0.1 
(S)-3.16 −9.1 ± 0.2 (S)-3.27 −8.9 ± 0.1 
 
(R)-3.17 −9.1 ± 0.2 (R)-3.28 −8.8 ± 0.1 
(S)-3.17 −8.7 ± 0.1 (S)-3.28 −8.6 ± 0.2 
 
(R)-3.18 −8.9 ± 0.2 (R)-3.29 −8.7 ± 0.2 
(S)-3.18 −9.1 ± 0.2 (S)-3.29 −8.7 ± 0.2 
 
(R)-3.19 −9.0 ± 0.1 (R)-3.30 −8.8 ± 0.1 
(S)-3.19 −9.2 ± 0.1 (S)-3.30 −9.0 ± 0.1 
 
(R)-3.20 −9.7 ± 0.1 (R)-3.31 −9.2 ± 0.3 
(S)-3.20 −9.6 ± 0.2 (S)-3.31 −9.1 ± 0.1 
 
(R)-3.21 −9.8 ± 0.2 (R)-3.32 −9.1 ± 0.2 
(S)-3.21 −10.0 ± 0.3 (S)-3.32 −9.6 ± 0.2 
 
(R)-3.22 −9.7 ± 0.2 (R)-3.33 −9.1 ± 0.2 
(S)-3.22 −9.5 ± 0.2 (S)-3.33 −9.2 ± 0.1 
aArithmetic mean of binding affinity ± SEM obtained from docking into six snapshots of CMP1 simulation. 
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Figure 3.3: (a) Comparison of binding modes obtained using AutoDock Vina between the 
phosphodiester-linked lead compound 3.2 (purple) and the 1,2,3-triazole- (R)-3.3 (green) and 
carbamate-linked (R)-3.4 (orange) derivatives. Compounds pictured are the binding modes obtained from 
docking into the 40 ns snapshot of the CMP1 simulation. The backbone of hST6Gal I is shown as grey 
ribbons and the central α-helix that has a positively polarised dipole is marked with an asterix. (b) Surface 
model of hST6Gal I highlighting the two possible binding pockets for the sialic acid mimic of the proposed 
inhibitors. The compounds shown are 3-phenoxy carbamate-linked (S)-3.4 and the 3-trifluoromethyl 
phosphodiester-linked (R)-3.5 docked into the 40 ns snapshot of the CMP1 simulation. The predicted sialyl 
accepter site is circled in blue with the predicted sialic acid donor site circled in orange. 
 
The triazole and carbamate compounds generally demonstrated no significant 
difference between the (R)- and (S)-configured diastereomers of the same compound (see 
Appendix Table A6–A7), consistent with earlier findings reported in the literature.29, 32 
This counterintuitive result, observed both experimentally, and in silico appears to be 
related with the sufficient space available within the active site to accommodate the 
different stereochemistry, whilst maintaining proximity to residues that are expected to 
be key in binding of the inhibitors. 
Different substituents upon the aryl portion of the 1,2,3-triazole- and 
carbamate-linked compounds were also examined (Table 3.3 and Appendix Table A5–
A7). The use of methoxy (3.13 and 3.24) and propoxy (3.14 and 3.25) 3-substituents 
resulted in comparable predicted binding affinity to the corresponding unsubstituted 
triazole 3.16 and carbamate 3.27. However, the use of a 3-phenoxy (3.3 and 3.4) 
3-substituent exhibited a significant increase in predicted binding affinity when compared 
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to the analogous unsubstituted triazole 3.16 and carbamate 3.27, as observed 
experimentally for the corresponding phosphodiester-linked compounds.29 The other 
3-substituent examined was trifluoromethyl. For both isomers of the 3-trifluoromethyl 
carbamate 3.23 there was a significant increase in predicted binding affinity compared to 
the corresponding unsubstituted carbamate 3.27. In contrast the (S)-configured 
diastereomer of 3-trifluoromethyl triazole 3.12 had a significantly larger predicted 
binding affinity than the corresponding unsubstituted triazole 3.16, which was not 
observed for the (R)-configured diastereomer of 3.12. Comparing each of the 
3-substituents shows that for the carbamate-linked inhibitors the 3-phenoxy 
diastereomers (3.4) showed a significant increase in predicted binding affinity compared 
to 3-methoxy (3.24) and 3-propoxy (3.25) diastereomers, whereas no significant 
difference was observed for 3-trifluoromethyl diastereomers (3.23). These trends were 
not observed for the 1,2,3-triazole-linked inhibitors with the only the (R)-configured 
diastereomer of the 3-phenoxy triazole 3.3 shown to have significant improvement over 
the (R)-configured diastereomer of 3-propoxy triazole 3.14. The 4-substituted methoxy 
triazole (3.15) and carbamate (3.26) showed comparable binding with the non-substituted 
counterparts (3.16 and 3.27 respectively). It should be noted that this method is providing 
an indication of relative binding affinity between compounds and further exploration of 
substituents and substituent patterns needs to be undertaken before any definite 
conclusions can be drawn. 
Compounds where a hydroxyl, methyl carbonate and methyl sulphonamide were 
trialled at the position of the phosphonate group of 3.16 and 3.27, were also examined 
(Table 3.3 and Appendix Table A5–A7). For both the triazole (3.17–3.19) and carbamate 
(3.28–3.30) examples, no significant difference was observed between these compounds 
and the corresponding phosphodiester compounds, suggesting that these groups may also 
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be potential isosteres. Although it should be noted that experimentally a charged group at 
this position, in particular a phosphonate, has been shown to produce the most potent 
inhibitors.31 Not being able to replicate this experimental trend can be attributed to the 
accuracy of the scoring function used in AutoDock Vina.40  
Derivatives that are structurally different to the 3-phenoxy structure of the lead 
compound (3.2) were also examined (Table 3.3 and Appendix Table A5–A7). For 
instance the 1,2,3-triazole-linked indolone (3.20), 4-tolylsulphonamide (3.21) and 
2,3-dihydro-1H-indenol (3.22) derivatives produced docking results that are comparable 
to the 3-phenoxy structure 3.3. Interestingly, the corresponding carbamate-linked 3.31–
3.33 did not exhibit the same trend, with only the (R)-configured diastereomer of the 
indolone derivative 3.31, the (S)-configured diastereomer of the 4-tolylsulphonamide 
3.32 and 2,3-dihydro-1H-indenol derivatives 3.33 having comparable results to the 
3-phenoxy structure 3.4. This suggests that these structurally different derivatives benefit 
more from the rigidity provided by a 1,2,3-triazole linker. 
3.3.4 Key Features of hST6Gal I Inhibitor Complexes 
The general binding mode observed for all of the docked compounds exhibits a number 
of trends based on the different components of these structures. The CMP moiety of each 
compound reflected the interactions highlighted within the hST6Gal I crystal structure 
(see Appendix Figure A1).9 The 1,2,3-triazole or carbamate linker were generally in the 
proximity of residues such as Asn212, Tyr354 and His370, which is an analogous position 
to that observed for the phosphodiester linker in compounds 3.1–3.2 and 3.5–3.9. The 
groups that were mimicking the carboxylate of the natural donor, such as a phosphonate, 
were shown to be positioned in proximity to a central α-helix that has a positively 
polarised dipole (marked with an asterix in Figure 3.3a), that has been proposed to interact 
with the carboxylate.9, 17 The different functionalities examined for the sialic acid mimic 
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portion of the compounds were either located within or oriented towards one of two 
binding pockets (Figure 3.3b), both of which could be exploited in the future design of 
inhibitors of hST6Gal I. The first pocket was occupied by compounds such as the 
unsubstituted benzyls (3.16 and 3.27) and those bearing substituents such as 
3-trifluoromethyl (3.5, 3.12 and 3.23) or 3-methoxy (3.13 and 3.24). This pocket is 
thought to be one that the sialic acid of the sialyl donor could be accommodated within, 
based on the docking results obtained for CMP-3-F-Neu5Ac (3.7) and CMP-Neu5Ac 
(3.8). In compounds bearing larger substituents, such as a phenoxy (3.1–3.4) or a 
3-propoxy (3.14 and 3.25), these groups were located within or oriented towards the 
predicted sialyl acceptor site. This provides a rationale for the exploration of a potential 
route to selectivity, as each ST subfamily would be expected to have differences in this 
region to accommodate the different sialyl acceptors.  
3.3.5 Molecular Dynamics Simulations of hST6Gal I Inhibitor Complexes 
To characterise important binding interactions between hST6Gal I and potential 
inhibitors, four all-atom MD simulations were performed in addition to those for CMP 
discussed previously. Two of these simulations utilised the reported potent 
phosphodiester-linked (R)-isomers, 3.1 (PL1) and 3.2 (PL2). The remaining two 
simulations were of the analogous carbamate-linked (R)-3.4 (CAR1 and CAR2), with 
1,2,3-triazole-linked inhibitors to be examined in future studies (see Chapter 4). The PL1 
and PL2 simulation RMSDs for Cα converged at 1.5 Å, with CAR1 and CAR2 
converging at 2.0 Å (see Appendix Figure A5), indicating no significant change in the 
structure of the protein backbone. It was noted that across all simulations each ligand 
remained tightly associated with the hST6Gal I active site. RMSFs for the Cα atoms, were 
consistent across all simulations (see Appendix Figure A6). Each simulation showed 
consistently larger RMSF values for the flexible loop between Tyr355 and Tyr369 and 
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the region that lies between Gln235 and Asn250. This region is adjacent to the portion of 
the active site that is expected to interact with the sialyl acceptor and the large fluctuation 
is most likely a result of the phenoxy being within the proposed sialyl acceptor site. 
Interactions in the ligand–protein complexes analysed were characterised by 
monitoring the hydrogen bonds and hydrophobic contacts (see Appendix Table A8–A15). 
The simulations with CMP in complex with hST6Gal I reproduced all hydrogen bonding 
interactions observed in the crystal structure (see Appendix Figure A1).9 Additional 
interactions observed include Lys376 acting as a hydrogen bond donor to the pyridine 
like nitrogen of the cytosine ring and Glu375 acting as a hydrogen bond acceptor to the 
2′-hydroxyl group of the ribose. The water molecules shown to interact with CMP in the 
crystal structure were not observed, with two different bridging interactions from an 
oxygen of the phosphate group, to Ser189 and Tyr356 observed instead. Hydrophobic 
contacts that were observed were most significant with the cytosine ring, which was 
shown to interact with Ala190 and also have a proposed π-stacking interaction with 
Tyr354. The ribose ring was shown to have hydrophobic interactions with Ser189, 
Phe211 and Leu372.  
The PL1, PL2 and CAR simulations each revealed a number of consistent 
hydrogen bond and hydrophobic contacts with the hST6Gal I active site. These 
interactions have been schematically illustrated in Figure 3.4. The respective compounds 
of each simulation were shown to maintain the majority of the CMP moiety interactions 
that were observed in the CMP simulations, with a notable absence of the proposed 
π-stacking of the cytosine ring with Tyr354 in all cases. Additional water bridge 
interactions with the CMP moiety were also observed, with the interaction between the 
free amine of the cytosine ring and the backbone carbonyl of Val352 present in all 
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simulations and the backbone NH of Gly324 and the 3’-hydroxyl of the ribose observed 
in all simulations except CAR1.  
 
Figure 3.4: Schematic representation of conserved hydrogen bonding (a) and hydrophobic contacts (b) 
observed in the PL1, PL2 and CAR simulations. The consistent components of each inhibitor are shown as 
chemical structures. The red box represents the different linkers and the blue box represents the different 
sialic acid mimic. Dashed lines indicate the interacting atoms shown in Appendix Table A10–A15 and “W” 
represents a single molecule of water. 
 
As well as the CMP moiety, each compound examined had two other conserved 
regions, the phosphonate and the 3-phenoxy substituent. The conserved phosphonate 
component was shown to hydrogen bond with Tyr354 in all simulations and Asn233 in 
all simulations except PL2 (Figure 3.4). This does not correlate with the position generally 
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observed in the docking studies, suggesting another potential position for the phosphonate 
has been captured. The 3-phenoxy substituent for all compounds examined was shown to 
have hydrophobic contacts with Asn233, Gln235, Trp257, Pro259, Tyr275 and Tyr369 
(Figure 3.4), which are present in the proposed sialyl acceptor binding site. This provides 
a further rationale for the exploration of 3-phenoxy type substituents to target the 
proposed sialyl acceptor binding site as a potential route to the development of selective 
hST6Gal I inhibitors. 
The two components of the compounds studied that were not consistent are the 
sialic acid mimic and the linking group. The sialic acid mimic in the PL1 simulation, 
Neu5Ac2en was shown to have limited interactions with hST6Gal I. Replacement of this 
moiety in the PL2 and CAR simulations with an aryl ring did not result in any significant 
change in interactions, which is consistent with the comparable activity of compounds 
3.1 and 3.2 that has been observed experimentally.29-30, 33 Consistent interactions were 
observed when comparing the phosphodiester linker of the inhibitors in the PL1 and PL2 
simulations to the carbamate linker in the CAR simulations (Figure 3.4). These 
interactions include hydrogen bonding with Tyr354 and Asn212, which were consistent 
across all simulations and water bridged interactions with Ser323 and His370 that were 
consistent across PL1 and CAR simulations. The similarity in interactions observed for 
the carbamate linker and the phosphodiester linker in these simulations provides further 
evidence that a carbamate linker may be a suitable isosteric replacement for the 
phosphodiester linkers used in reported ST inhibitors.  
3.3.6 Implication for Inhibitor Design 
To further examine the promising trends that have been observed in this study, more 
rigorous calculations of binding free energy beyond that of molecular docking can be 
undertaken using techniques such as FEP.55 Relative binding free energies between the 
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different linkers or different substitution patterns will provide insights into their effects 
on binding and guide the experimental optimisation process. This work is currently 
undertaken in our lab and will be reported in the future (see Chapter 4).  
In previously published work, the utilisation of uncharged isosteres of phosphate 
in protein tyrosine phosphatase inhibitors, has shown promising results for increasing cell 
permeability and preventing cleavage by phosphatases.36 Additionally, triazole linkers 
have been shown to be an applicable phosphodiester isostere in transition-state analogue 
ST inhibitors,35, 37 suggesting that utilisation of uncharged isosteres may be a suitable 
strategy for overcoming these pharmacokinetic concerns. Recent work by Preidl et al. has 
demonstrated that derivatives of phosphodiester-linked transition-state analogue ST 
inhibitors bearing a fluorescent probe are able to cross the cellular membrane via a 
vesicular uptake mechanism,56 indicating that cell permeability may not be an issue for 
these compounds. However, in vivo it is expected that these phosphodiester-linked 
compounds would still be susceptible to phosphatase activity, which can be overcome 
with a neutral isostere. As demonstrated in this study both 1,2,3-triazole and carbamate 
are potentially suitable isosteres for this purpose.  
Improvements to the pharmacokinetic properties of transition-state analogue ST 
inhibitors that could be gained by the introduction of a neutral 1,2,3-triazole or carbamate 
linker could logically be improved further by also replacing the charged phosphonate 
group with a neutral isostere. However, for phosphodiester-linked transition-state 
analogues it has been demonstrated experimentally that a charged group at this position, 
in particular a phosphonate, produces the most potent inhibitors.31 In order to maintain 
the phosphonate but still produce potential pharmacokinetic benefits, a neutral prodrug 
approach could be undertaken. The use of phosphonate prodrugs has been shown to be 
successful in producing several potent and selective nucleoside analogues that have 
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clinical applications in the HIV, hepatitis B, and hepatitis C virus fields.57 A prodrug 
strategy as well as the incorporation of a neutral linker, as described in this study, could 
produce improvements to the pharmacokinetic properties of transition-state analogue ST 
inhibitors, and thus should be investigated further on a synthetic and biological level. 
3.4 Conclusions 
Molecular docking and MD simulations were performed to investigate the replacement 
of the charged phosphodiester linker used in reported transition-state analogue ST 
inhibitors with a neutral isostere, such as a carbamate or a 1,2,3-triazole. With the 
molecular docking protocols used, eleven reported inhibitors and both the (R)- and 
(S)-configured diastereomers of twelve of each 1,2,3-triazole- and carbamate-linked 
derivatives were examined. This study successfully replicated experimental trends for 
reported inhibitors and furthermore demonstrated the potential for both the use of a 
carbamate or 1,2,3-triazole linker as an isosteric replacement for the phosphodiester in 
transition-state analogue ST inhibitors. MD simulations of four different ligands 
complexed with hST6Gal I were performed and interactions in the complexes were 
characterised by monitoring hydrogen bonds and hydrophobic contacts over the course 
of the simulation. This analysis replicated all the hydrogen bonding interactions observed 
in the hST6Gal I-CMP complex crystal structure and demonstrated that in a dynamic 
system the phenoxy substituent of compounds 3.1, 3.2 and (R)-3.4 are oriented towards 
the proposed sialyl acceptor site, encouraging the targeting of this site as a potential route 
to design selective hST6Gal I inhibitors. Furthermore, it demonstrated that the carbamate 
linker of (R)-3.4 maintains the interactions with hST6Gal I observed for the 
phosphodiester linker in the simulations of the reported inhibitors 3.1 and 3.2. Overall, 
these simulations provide not only a rationale for the synthetic and biological evaluation 
of 1,2,3-triazole- and carbamate-linked transition-state analogue ST inhibitors, but also 
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provide an insight into binding of these compounds, which can aid in the design of future 
ST inhibitors.  
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as a carbamate or a 1,2,3-triazole. This chapter describes the use of MD simulations with 
optimised force fields to examine the binding interactions of (R)- and (S)-diastereomers 
of carbamate and 1,2,3-triazole-linked ST inhibitors. In addition, FEP calculations and 
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4.1 Introduction  
Sialic acid is one of the body’s most important sugars next to glucose.1 Sialylation, the 
addition of sialic acid to cell surface molecules via the GT enzymes known as STs, is 
integral to cell function, governing numerous important biological processes including 
cell–cell recognition, protein targeting, cell adhesion, and fertilisation.2-4 However, 
abnormal sialylation is strongly associated with cancer, with hypersialylation of up to 30–
40% seen in many cancers, along with marked upregulation of ST activity. This has been 
directly correlated with an increased metastatic potential of tumours and poor patient 
prognosis.5-6 Upregulation of STs has also been shown to produce cellular resistance in 
both paclitaxel and cisplatin treatment in human ovarian and colorectal cancer cell lines, 
along with reducing treatment efficacy.7 Thus the critical role of STs in the process of 
tumour metastasis as well as drug resistance demonstrates that inhibitors of STs could be 
Chapter 4: Enthalpy-Entropy Compensation in Sialyltransferase Inhibitor Design 
85 
used either alone as anti-metastatic agents, or in combination with existing drugs to 
enhance their sensitivity against resistant tumours.8  
In humans, there are 20 different STs each of which share a common sugar 
nucleotide donor, CMP-Neu5Ac.2, 9 STs are classified into one of four groups based on 
the position and identity of the glycosyl acceptor (Gal, GalNAc or sialic acid) to which 
sialic acid is transferred: ST3Gal I-VI, ST6Gal I-II, ST6GalNAc I-VI, and ST8Sia I-VI.2-3 
Each ST subtype controls the synthesis of specific sialylated structures with unique 
biological roles, therefore it is crucial that selective inhibitors are developed. 
Herein we focus on hST6Gal I, which is one of the two subfamilies of the ST6 
family that belongs to the GT29 family (http://www.cazy.org).10 hST6Gal I catalyses the 
transfer of a Neu5Ac residue to the 6ʹ-hydroxyl group of the terminal Gal residues of the 
disaccharide Galβ[1,4]GalNAc.3, 11 hST6Gal I mediated sialylation can modulate protein 
conformation, oligomerisation and/or receptor internalisation,12 depending on the 
substrate targeted. Overexpression of hST6Gal I is observed in several types of cancers 
including lung, cervical, ovarian, pancreatic, breast and colon carcinoma.13-16 It has been 
recently reported that hST6Gal I promotes a CSC phenotype, with the activity of 
hST6Gal I critical for CSC behaviours including tumour spheroid growth, 
chemoresistance and tumour initiating potential.16 Additionally, overexpression of 
hST6Gal I has been suggested to promote cancer cell metastasis through altered 
sialylation patterns affecting the function of β1 integrin.17-18 hST6Gal I also has an 
important role in galectin regulation, via the sialylation of their galactose-containing 
substrates.12-13 For instance, α-2,6 sialylation of the galectin substrates Fas19 and TNFR120 
death receptors have been shown to hinder the apoptosis process, thus identifying 
hST6Gal I overexpression as an inhibitor of cell death pathways. It has also been recently 
demonstrated that hST6Gal I has a role in promoting tumour cell survival within 
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serum-depleted environments, such as those within the hypovascularised regions of large, 
solid tumours.21 
The catalytic mechanism of hST6Gal I (see Figure 3.1, p. 59) follows a classical 
SN2-like direct displacement mechanism for inverting GTs.11, 22 It is facilitated by the 
catalytic base His370, which promotes the nucleophilic attack on the sialyl donor 
anomeric carbon by deprotonating the galactose 6ʹ-hydroxyl of the acceptor.23-24 This 
generates an oxocarbenium-like transition state, followed by CMP acting as a leaving 
group. The β-configuration at the anomeric carbon of the donor is inverted in the final 
product.24 This is supported by a model of the Michaelis complex generated from the 
glycan binding mode observed in the crystal structure of hST6Gal I.25 
The overexpression of hST6Gal I in various cancers has resulted in the 
development of a diverse range of ST inhibitors.26-28 Of these, analogues mimicking the 
proposed oxocarbenium ion-like transition state of the donor (see Figure 3.1, p. 59) 
exhibit the highest affinity to STs.29-30 Transition-state analogue inhibitors incorporating 
a Neu5Ac2en moiety are amongst the most potent inhibitors. The transition state-like 
characteristics are captured with the C2–C3 double bond mimicking the planar anomeric 
carbon and an extra carbon between the anomeric carbon and CMP leaving group to 
mimic the elongated distance in the transition state.29, 31 Various strategies have been 
adopted to increase the potencies of these inhibitors. Derivatives which explore variations 
of the glycerol side chain of the Neu5Ac2en moiety produced the greatest inhibitory 
activity. Of these, phenoxy derivative 4.1 (Figure 4.1) is one of the most potent 
transition-state analogue inhibitors reported to date (Ki = 29 nM for rat liver ST6Gals).32 
More synthetically assessable derivatives that incorporate an aryl replacement of the 
Neu5Ac2en moiety have comparable activity to the phenoxy derivative 4.1.29-30, 33 Of 
these the (R)-isomer of the 3-phenoxy derivative 4.2 (Figure 4.1) was a potent inhibitor 
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of rat liver ST6Gals (Ki = 70 nM)29 and hST6Gal I (Ki = 19 nM)34 and is the lead 
compound herein. Recently, cyclopentyl34 and amide35 ST inhibitors have been reported 
with comparable nanomolar activity to the phenoxy lead derivative (4.2) against 
hST6Gal I. 
Many of the above inhibitors were designed with limited knowledge of the target 
ST structure. The recent characterisation of the mammalian ST crystal structures, in 
particular that of hST6Gal I25 and hST8Sia III,36 has facilitated the use of computational 
modelling to aid in the design of new selective ST inhibitors. In this work, we use 
computational modelling to investigate the effect of replacing the charged phosphodiester 
linkage of transition-state analogue ST inhibitors. This is being investigated, as while 
contributing to potency37 the phosphodiester linkage may potentially contribute to low 
bioavailability, loss of activity due to cleavage by phosphatases or instability in the ST 
active site.38-39 To build upon our previous work (Chapter 3),40-41 MD simulations and 
binding free energy calculations via the FEP method will be undertaken to investigate the 
effect of replacing the phosphodiester linker of our lead compound 4.2, with either a 
1,2,3-triazole (4.3; Figure 4.1) or carbamate (4.4; Figure 4.1), has on binding to 
hST6Gal I. Force field parameters compatible with the CHARMM PARAM36 force field 
for the ligands will be developed.42 Through equilibrium MD simulations the conserved 
interactions as well as potential differences between each compound will be compared. 
Furthermore, relative binding free energy calculations will be used to study the effect of 
the linker on binding affinity. 
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Figure 4.1: Development of the phosphodiester-linked lead compound (4.2) and the analogous 
1,2,3-triazole- (4.3) and carbamate- (4.4) linked derivatives.  
 
4.2 Methods 
4.2.1 Force Field Development 
Force fields generated from the CGenFF43 using the paramchem interface 
(https://cgenff.paramchem.org) for the phosphodiester-linked 4.2 and the corresponding 
1,2,3-triazole-linked 4.3 and carbamate-linked 4.4 derivatives (Figure 4.1) were 
optimised using the GAAMP method.44 The partial atomic charges (see Appendix Figure 
B1 and Table B1) and identified “soft” dihedrals, which were not already represented in 
the CHARMM and CGenFF force fields or that experienced a significant penalty score 
from paramchem, were optimised (see Appendix Figure B2).  
4.2.2 Molecular Dynamics Simulations 
All MD simulations were prepared using VMD version 1.9.2.45 An overview of all 
simulations is given in Appendix Table B2. Simulation of hST6Gal I (PDB id: 4JS2) 
inhibitor complexes with the reported phosphodiester-linked compound 4.2 and the 
proposed 1,2,3-triazole- and carbamate-linked derivatives (4.3 and 4.4 respectively; 
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Figure 4.1) were undertaken to determine if a carbamate or 1,2,3-triazole is a suitable 
replacement for the phosphodiester linker used in previously reported inhibitors. The 
initial structure for the hST6Gal I inhibitor complexes was taken from previously reported 
docking studies (Chapter 3).40 Additionally, simulations of each inhibitor in a water box 
were also performed to determine the effect of linker flexibility. Prior to simulation being 
undertaken, PROPKA 3.146 was used to predict the protonation state of hST6Gal I 
residues and ionisable ligand groups at pH 7.0. 
Preparation of each simulation involved solvating the system in a box of water 
molecules, which extended approximately 9 Å from the surface of the protein, resulting 
in each system being solvated in an 82 Å × 82 Å × 82 Å cubic TIP3P47 water box. Due to 
the hST6Gal I active site being solvent exposed, solvation of the active site was not 
specifically considered for any case.  Each box was neutralised with counter ions of Na+ 
and Cl-, with the NaCl concentration set to 0.15 mol/L. Simulations were carried out using 
the NAMD 2.9 package.48 The protein was represented with the non-polarisable 
CHARMM PARAM36 force field.49 The force field for each ligand were those optimised 
using the GAAMP method.44 All systems were simulated in periodic boundary conditions 
using the Langevin algorithm for maintaining the temperature at 298.15 K, and the 
Langevin Piston Nosé–Hoover method50-51 for maintaining a constant pressure of 1.0 bar. 
The electrostatic interactions were calculated using the Particle Mesh Ewald method.52 
The van der Waals forces were treated with a cut-off of 12 Å and a smoothening function 
between 10 Å and 12 Å. All of the covalent bonds involving hydrogen were kept rigid 
with the RATTLE algorithm.53 The integration time step was set to 1.0 fs, 2.0 fs and 4.0 
fs for bonded, non-bonded and long-range electrostatics, respectively.  
Equilibrium simulations for all hST6Gal I inhibitor complex systems were 
initially undertaken. During these simulations, a harmonic restraint was placed upon all 
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Cα atoms of hST6Gal I, with a decreasing force constant from 32.0 to 1.0 kcal/mol/Å2 
over 10 ns. This decrease was achieved gradually by halving the force constant for each 
respective 1 ns interval until a force constant of 1.0 kcal/mol/Å2 was obtained (i.e. 32.0, 
16.0 … 1.0 kcal/mol/Å2). A force constant of 1.0 kcal/mol/Å2 was then applied for the 
remainder of the 10 ns thermal equilibration. The simulations were further continued for 
90 ns without any restraints (see Appendix Table B2). The inhibitor only simulations (see 
Appendix Table B2) were performed for 20 ns with a harmonic restraint placed upon one 
atom of the corresponding ligand, with a force constant of 32 kcal/mol/Å2. To perform 
trajectory analysis, snapshots were saved every ps (i.e. every 1000 steps). Replicates of 
each simulation from different starting coordinates were generated by starting each 
simulation with three different initial minimisation steps (i.e. 2000, 2500 and 3000 steps) 
and initiated with different velocities. In total, 2.2 μs of MD simulations were performed. 
4.2.3 Simulation Trajectory Analysis 
To monitor the global properties of the structural evolution during MD simulations, the 
RMSD with respect to a reference structure and the RMSF were calculated using VMD.45  
Hydrogen bond interactions were analysed according to a geometric criterion. A 
hydrogen bond was defined by a minimum donor–hydrogen–acceptor angle of 120° and 
a maximum heavy atom distance of 3 Å. Hydrophobic contacts were also analysed 
according to a geometric criterion of a maximum distance of 4 Å between hydrophobic 
atom pairs. To identify these interactions CHARMM version 38a154 was utilised. 
The quasi-harmonic approximation55-57 was used to examine the loss of 
configurational entropy of each ligand upon binding to hST6Gal I. This analysis was 
performed, using CHARMM version 38a1,54 for trajectories encompassing 11–100 ns 
(11–55 ns and 56–100 ns were also performed to monitor convergence; See Appendix 
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Table B3) of each ligand in complex with hST6Gal I and trajectories encompassing 1–
20 ns (1–10ns and 11–20ns were also performed to monitor convergence; See Appendix 
Table B3) of the ligand simulations. Prior to the analysis, the Cartesian coordinates of the 
ligands were aligned after least-squares fit superposition of the heavy atoms of all 
configurations onto the initial structure, to eliminate the overall translation and rotation. 
The change in configurational entropy (ΔSconf) was determined based on the following 
relationship: 
Δ𝑆𝑐𝑜𝑛𝑓 = 𝑆(𝑐𝑜𝑚𝑝𝑙𝑒𝑥) − 𝑆(𝑓𝑟𝑒𝑒)  
Using the structures obtained from the MD simulations, conformational cluster 
analysis was performed for the ligands using MMTSB tools.58 Clusters were identified 
using k-means clustering with an RMSD threshold for ligand heavy atoms of 1.6 Å. For 
each simulation, cluster analysis was based on combined trajectories of every 10 ps of 
triplicate simulations. This resulted in 27000 structures used in the analysis of the 
complexed simulations and 6000 structures for the ligand only simulations.  
4.2.4 Free Energy Perturbation Calculations 
All FEP calculations described herein were carried out using the NAMD 2.10 package.48 
The simulation parameters were as per the MD simulation method described above (see 
section 4.2.2). Depending on the calculation the starting structure was taken from the 
hST6Gal I-inhibitor simulations of the (R)-diastereomers of either the 
phosphodiester-linked lead compound (R)-4.2 or the carbamate-linked derivative (R)-4.4 
and temperature was maintained at either 288.15 K or 298.15 K (see Appendix Table B2). 
Each calculation utilised a dual ligand approach, where a ligand is mutated to an 
analogue in the hST6Gal I binding site and the reverse mutation is performed 
simultaneously on the analogue in bulk water in the same system (Figure 4.2). This 
Eq. 4.1 
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approach has been undertaken to minimise potential electrostatic finite-size effects posed 
by the change in charge state when the (R)-diastereomer of the phosphodiester-linked lead 
compound 4.2 (net charge of -2e) is perturbed to the (R)-diastereomer of either the 
1,2,3-triazole- 4.3 or carbamate-linked 4.4 derivatives (net charge of -1e; Figure 4.2).59-60 
In this approach, the overall charge of the system remains constant. This allows for the 
reduction of errors arising from the large solvation energy of charged ligands and 
potential artefacts from the use of periodic boundary conditions.61-62 A similar approach 
has been successfully employed to handle changes in charge state in several different 
biomolecular systems.63  
Using the dual ligand approach, the change in the binding free energy due to linker 
mutation with perturbation from phosphodiester to carbamate (Figure 4.2) as an example 
can be expressed as: 
 
ΔΔ𝐺𝑏 = Δ𝐺𝑏𝐶 − Δ𝐺𝑏𝑃 





In the FEP method, one introduces a hybrid Hamiltonian, ℋ(λ)=(1 – λ) ℋ0 + λℋ1, 
where H0 represents the Hamiltonian for the initial state and H1 for the final state. The 
interval between 0 and 1 is divided into n subintervals (λi, where i = 1,…, n – 1), and for 
each subinterval the free energy difference is calculated from the ensemble average, 
ΔΔGex,i = –kBT ln<exp[–(ℋ(λi+1) – ℋ(λi))/kBT>λi. The free energy difference between 
initial and final states is obtained from the sum, ΔΔG = Σi ΔΔGex,i. Alchemical 
transformations were carried out with 20 uniformly distributed λ values between 0 and 1 
Eq. 4.2 
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(0.0, 0.05, 0.1, … , 0.9, 0.95, 1.0), with the transformation simulated in reverse directions 
beginning from the 0.u5 λ values (e.g. 0.0 ⟵ 0.05 ⟶ 0.1). To prevent the occurrence of 
singularities at values of λ where an atom disappears/appears, a soft-core potential with 
α = 4.0 Å2 was used to reshape the Lennard-Jones potential into a form that effectively 
eliminates the singularity when λ approaches either 0 or 1.64-65 
Each λ window underwent an initial 5000 energy minimisation steps followed by 
1 ns equilibration simulation to provide starting coordinates. Each window was then 
subsequently simulated for multiple nanoseconds with a harmonic restraint placed on the 
centre of mass of hST6Gal I. A harmonic restraint was also applied to one atom from the 
ligand in the bulk. These restraints were applied to prevent association of the ligand in 
the bulk and hST6Gal I and had no effects on the calculated binding free energy 
difference. Both restraints used a force constant of 32 kcal/mol/Å2. In total 1.02 μs of FEP 
simulations were performed. 
 
Figure 4.2: The thermodynamic cycle used (a) and a schematic representation of the perturbation 
performed (b) in the phosphodiester to carbamate FEP calculations. Phos and the yellow circle represent 
the phosphodiester-linked lead compound (R)-4.2, Carb and the red square represent the carbamate-linked 
derivative (R)-4.4, and E represents hST6Gal I.  
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4.3 Results and Discussion 
4.3.1 1,2,3-Triazole- and carbamate-linked (R)- and (S)-diastereoisomers maintain 
consistent binding site contacts with hST6Gal I when compared to their 
phosphodiester derivative.  
Hydrogen bond and hydrophobic contact analysis of phosphodiester- and 
carbamate-linked (R)-diastereomers has previously been published (Chapter 3).40 These 
simulations were performed using ligand force fields generated using the GAFF66 and 
with hST6Gal I represented with the non-polarisable CHARMM PARAM36 force field.49 
In this work, a force field parameterisation compatible with the CHARMM PARAM36 
force field was carried out for the ligands. We have undertaken simulation of both the 
(R)- and (S)-diastereoisomers of the phosphodiester- (4.2), 1,2,3-triazole- (4.3) and 
carbamate-linked (4.4) derivatives (Figure 4.1) in complex with hST6Gal I with the newly 
developed force field.  
The MD simulations of each complex showed a stable trajectory with the 
positional RMSD of backbone Cα atoms being 1.5–2.0 Å for each simulation (see 
Appendix Figure B3–B8). RMSFs for the Cα atoms, were generally consistent across all 
simulations (see Appendix Figure B3–B8). Larger RMSF values, across each simulation, 
were observed for the flexible loop between Tyr355 and Tyr369. Large RMSF values 
were also observed for the regions between Gln235–Asn250 and Ser260–Ile295, which 
comprise the portion of the active site that is expected to interact with the sialyl acceptor. 
This can most likely be attributed to the phenoxy being within the proposed sialyl 
acceptor site. Across all simulations each ligand remained tightly associated with the 
hST6Gal I active site. However, there was some variation in ligand position within this 
active site, which can be seen in the RMSD values that correspond to the heavy atoms of 
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each ligand (see Appendix Figure B3–B8). These fluctuations can be attributed to the 
3-phenoxy substituent, which depending upon the simulation either rotated to maintain 
contacts with the sialyl acceptor site or only weakly interacted with peripheral residues 
of this pocket, resulting in positional fluctuation. 
Interactions in the hST6Gal I-ligand complexes analysed were characterised by 
monitoring the hydrogen bonds and hydrophobic contacts (see Appendix Table B4–B15). 
Each simulation revealed similar interactions with the hST6Gal I active site, which have 
been schematically illustrated in Figure 4.3. 
The cytidine moiety of each simulation’s respective compound maintained the 
hydrogen bonding interactions that were observed in the hST6Gal I crystal structure.25 
An additional interaction observed in all simulations was Lys376 acting as a hydrogen 
bond donor to the pyridine like nitrogen of the cytosine ring. There was also Ser189 acting 
as a hydrogen bond donor with the oxygen embedded within the furan ring in the 
simulations of the (S)-diastereomers (Figure 4.3b). The hydrophobic contacts that were 
observed were most significant with the cytosine ring, which was shown to interact with 
Ala190 and have a proposed π-stacking interaction with Tyr354. The ribose ring was 
generally shown to have hydrophobic interactions with Phe211 and Leu372. It should be 
noted that in the simulations of the (R)-diastereomers only (Figure 4.3a), a water bridge 
interaction between the free amine of the cytosine ring and the backbone carbonyl of 
Val352 was also observed.  
In addition to the CMP moiety, each compound had two other conserved regions, 
the phosphonate and the sialic acid mimic. For the simulation involving the 
(R)-diastereomers the phosphonate was shown to hydrogen bond with His370 in all 
simulations and, Ala368 and Tyr369 in all simulations except TC1 (see Appendix 
Table B8). The phosphonate in the simulations of the (S)-diastereomers occupied a 
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different orientation within the hST6Gal I active site and was shown to hydrogen bond 
with Tyr354 in all simulations. This difference between the diastereomers is to be 
expected as the phosphonate is a substituent at the only varied chiral centre. This could 
also be an explanation to the higher level of potency observed for (R)-4.2 compared to 
(S)-4.2 when tested against rST6Gals,29 which has been shown to have a high level of 
homology to the human equivalent.23  
The sialic acid mimic consists of two components, the aryl ring and its 3-phenoxy 
substituent. The 3-phenoxy substituent for the majority of the simulations was shown to 
be in, or oriented towards, the proposed sialyl acceptor site through observed hydrophobic 
contacts with Asn233, Gln235, Trp257, Pro259, Tyr275 and Tyr369. This was most 
evident for the (S)-diastereomers. More variation in this group’s position was observed 
for the (R)-diastereomers, with the phenoxy generally orientated to interact only with the 
residues on the periphery of the pocket, being Asn233, Tyr369 and His370. Notably of 
the three different classes of linker observed, it was the 1,2,3-triazole that showed both 
the (R)- and (S)-diastereomers with the same 3-phenoxy interactions (see Appendix Table 
B9 and B11), suggesting the added rigidity of the linker favours direction towards the 
proposed sialyl acceptor site. This is an important finding, as this site is expected to vary 
between the different ST subtypes, particularly those with different sialyl acceptors, and 
thus presents a potential route to the development of selective hST6Gal I inhibitors. 
The aryl ring of the sialic acid mimic was shown to have limited interactions with 
hST6Gal I, with the (R)-diastereomers showing hydrophobic contacts with Tyr369 and 
His370 and the (S)-diastereomers with Leu236. Despite being limited these interactions 
are nevertheless important in directing the 3-phenoxy towards the proposed sialyl 
acceptor site. This is clearly highlighted in the CL2 simulations (see Appendix Table B2) 
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where this aryl ring is shown to interact with Cys353, Tyr354 and Cys364 in a binding 
mode that does not see the 3-phenoxy within the proposed sialyl acceptor site. 
The only component of the potential ST inhibitors examined that varied was the 
group that links the CMP moiety to the sialic acid mimic. Consistent interactions were 
observed when comparing the phosphodiester linker to the 1,2,3-triazole and carbamate 
linkers. In the simulations of the (R)-diastereomers, hydrogen bonds of the linkers with 
Asn212 and Tyr354 were observed. In the simulations of the (S)-diastereomers hydrogen 
bonds of the linkers with Asn212 were observed.  
Analysis of the hydrogen bond and hydrophobic contacts of both the (R)- and 
(S)-diastereomers of the three different classes of compounds, has demonstrated that no 
matter which linker is used, key interactions of cytidine and the sialic acid mimic with 
the hST6Gal I active site are able to be maintained. These results confirm our previous 
findings40 and provide further evidence that a carbamate or a 1,2,3-triazole may be a 
suitable isosteric replacement for the phosphodiester linkers that have been used in 
reported ST inhibitors. 
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Figure 4.3: Schematic representation of conserved hydrogen bonds and hydrophobic contacts observed in 
the (R)-diastereomer- (a) and (S)-diastereomer-hST6Gal I complex (b) simulations. The consistent 
components of each inhibitor are shown as chemical structures. The orange box represents the different 
linkers. Interacting hST6Gal I residues are represented as circles which are colour coded based on 
interaction type as follows: Red = hydrogen bond donor; Green = hydrogen bond acceptor; Blue = water 
bridged hydrogen bond; Grey = hydrophobic contact; Pink = hydrogen bond and hydrophobic contact. 
Dashed lines indicate hydrophobic contacts and dotted lines represent the hydrogen bonds shown in 
Supplementary Table B4–B15. 
 
4.3.2 Binding free energy calculations confirm 1,2,3-triazole and carbamate as 
isosteres of the phosphodiester linker.  
To build upon the results observed in the MD simulations on the thermodynamic level, 
FEP calculations were performed to study the relative binding affinities for compounds 
with three different linkers. These simulations involved the alchemical transformations 
of the phosphodiester-linked (R)-4.2 to either the 1,2,3-triazole- (R)-4.3 or 
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carbamate-linked (R)-4.4 derivatives. To close the thermodynamic cycle to monitor the 
convergence, an additional transformation of the carbamate-linked (R)-4.4 to the 
1,2,3-triazole-linked (R)-4.3 was also performed. The results of the FEP calculations are 
summarised in Table 4.1.  
Table 4.1: Difference in binding free energy to hST6Gal I of proposed ST inhibitors  
 ΔΔGb ΔΔHbc -TΔΔSbc 
Alchemical Transformation 288 Ka 298 Kb - - 
4.2 → 4.4 −1.1 ± 0.8 −1.7 ± 0.4 10 ± 30 −20 ± 30 
4.2 → 4.3 −0.3 ± 0.3 −1.4 ± 0.9 40 ± 30 −40 ± 30 
4.4 → 4.3 −0.7 ± 1.0 −0.5 ± 0.3 −10 ± 30 10 ± 30 
Running average of ΔΔGb (kcal/mol) calculated at a288.15 K and b298.15 K, error 
reported is the SEM. cThe ΔΔHb (kcal/mol) and −TΔΔSb (kcal/mol) are calculated 
through finite-temperature difference from the ΔΔGb values for both the simulations 
carried out at 288.15 K and 298.15 K. The values reported are those for 298.15 K, 
error reported is the SEM. 
 
The ΔΔGb values observed for the 288 K and 298 K calculations form a 
thermodynamic cycle which closes within a reasonable error of −1.5 kcal/mol and 
−0.8 kcal/mol respectively. These calculations indicate that there is only a slight 
difference in the free energy of binding between the carbamate- and 1,2,3-triazole-linked 
derivatives, with the 1,2,3-triazole favoured. It was also demonstrated that when the 
phosphodiester linker of the lead compound is perturbed to either a carbamate or a 
1,2,3-triazole, a slightly more favourable binding to hST6Gal I is observed (−1.7 kcal/mol 
and −1.4 kcal/mol respectively at 298.15 K), with the carbamate being slightly more 
preferential. 
This result is surprising as the charge of the phosphodiester linker has been 
previously thought to be important for binding, but to what extent is currently 
unknown29, 32, 34-35, 38. It is expected that replacing the charged phosphodiester group with 
a neutral isostere could potentially result in the loss of favourable interactions with the 
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binding site that are mediated by this charge. For example, in the MD simulations the 
phosphodiester linker was involved in three additional water mediated interactions that 
were not observed in those of the carbamate- and 1,2,3-triazole-linked derivatives (see 
Appendix Table B4, B8, B12). Therefore, one would expect an impact on the binding free 
energy (ΔGb), particularly through enthalpy (ΔHb), if the charged phosphodiester linker 
were to be replaced. Based on the relatively similar binding free energies for compounds 
with three different linkers, we hypothesise that the more rigid isosteric linkers might 
achieve comparable binding affinities through a favourable entropy compensation. 
The error analyses for the FEP simulations were carried out by calculated the SEM 
based on each ns simulation segment (Table 4.1) and all simulations converged with an 
error of < 1.0 kcal/mol. RMSD of both protein backbone and complexed ligand were also 
monitored. RMSDs for Cα of hST6Gal I converged between 1.5 Å and 2.0 Å indicating 
that no significant change in the structure of the protein backbone occurred as one linker 
was perturbed to another. Across all simulations each ligand remained tightly associated 
with the hST6Gal I active site, with RMSD values that fluctuated between 1.0 Å and 
3.0 Å observed. As with the MD simulations discussed above, this fluctuation was 
influenced by the 3-phenoxy substituent, with it remaining fixed in the sialyl acceptor site 
for the lower RMSDs observed and with it orientated towards the sialyl acceptor site but 
not constantly located within it when larger RMSDs were observed.  
4.3.3 Relative rigidity of the 1,2,3-triazole and carbamate linkers compensate for 
the enthalpic penalty that results from replacing the phosphodiester.  
To test our enthalpy-entropy compensation hypothesis proposed based on the FEP 
calculations, we calculated ΔΔHb and ΔΔSb from the ΔΔGb values observed at two 
different temperatures (Table 4.1).67 From this analysis, we were able to demonstrate that 
the replacement of the charged phosphodiester linker with either a neutral carbamate or 
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1,2,3-triazole indeed results in an enthalpic penalty (a positive ΔΔHb). In both cases this 
penalty was compensated for by a favourable entropy (a negative ΔΔSb). This supports 
our hypothesis of the resulting molecular rigidity created by the inclusion of a carbamate 
or 1,2,3-triazole in place of a phosphodiester compensates for the enthalpic penalty. For 
the perturbation from the carbamate to the 1,2,3-triazole, the opposite relationship was 
observed where changing to a triazole was enthalpically favourable which compensated 
for an entropic penalty.  
The effect of the entropic component of binding free energy to hST6Gal I has also 
been demonstrated through quasi-harmonic analysis of the trajectories obtained from the 
MD simulations performed (Table 4.2). This analysis has shown that for both the (R)- and 
(S)-diastereomers, the phosphodiester-linked lead compound 4.2 has a larger 
configurational entropy penalty upon binding to hST6Gal I when compared to the 
1,2,3-triazole- 4.3 and carbamate-linked 4.4 derivatives. Though the quasi-harmonic 
analysis only captures the configurational entropy of the ligands upon binding, while 
neglecting contributions from other factors, the relatively large difference observed 
supports the entropic compensation that was captured in the component analysis of the 
ΔΔGb values (Table 4.1). It can also be seen that there is comparatively a very small 
difference (that is within error) between the -TΔSconf values for the carbamate and 
1,2,3-triazole (Table 4.2). However, the 1,2,3-triazole does exhibit a slightly larger value 
for both the (R)- and (S)-diastereomers supporting the entropic penalty observed when a 
carbamate is perturbed to a 1,2,3-triazole (Table 4.1).  
Comparing the diastereomers it can be seen while there are no major differences 
between the diastereomers, the (S)-diastereomer in all three cases has a slightly larger 
entropic penalty for binding to hST6Gal I. This result reflects the slight differences in the 
binding modes of the diastereomers observed during the analysis of the MD simulations.  
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Table 4.2: Configurational entropy change upon binding of phosphodiester-linked (4.2), 
1,2,3-triazole-linked (4.3) and carbamate-linked (4.4) derivatives to hST6Gal I 
Cpd ΔSconf (kcal/mol/K)a -TΔSconf (kcal/mol)b 
(R)-4.2 −0.125 ± 0.009 37 ± 3 
(S)-4.2 −0.14 ± 0.02 41 ± 6 
(R)-4.3 −0.08 ± 0.01 23 ± 4 
(S)-4.3 −0.09 ± 0.01 27 ± 4 
(R)-4.4 −0.067 ± 0.007 20 ± 2 
(S)-4.4 −0.09 ± 0.02 25 ± 6 
aArithmetic mean ΔSconf ± SEM obtained from triplicate 
simulations of each compound. bArithmetic mean ΔSconf 
× −298.15 K ± SEM obtained from triplicate simulations 
of each compound. 
 
Overall both the free energy component analysis and the quasi-harmonic analysis 
have demonstrated that the conformational restriction, and thus entropic favourability for 
binding, imparted by the 1,2,3-triazole and carbamate linkers when compared to the 
phosphodiester linker is enough to compensate the resulting enthalpic penalty. This result 
has provided a strong rationale for the use of these two groups as isosteres of the 
phosphodiester in the development of potential inhibitors of hST6Gal I. Interestingly, 
while we have demonstrated the benefit of introducing conformational restriction to 
binding, there appears to be a limit to what can be tolerated. This is reflected in the 
carbamate being shown to be slightly more entropically favourable than the 1,2,3-triazole 
(Table 4.1–4.2).  
4.3.4 Conformational cluster analysis demonstrates different linker flexibilities. 
Additional clustering analysis was performed for the ligand conformations in the 
hST6Gal I-ligand complex and in the aqueous solution. The most dominant cluster for 
each complex simulation (see Appendix Figure B9) showed similar positions for the 
cytidine and phenoxy substituents for both the (R)- and (S)-diastereomers. This supports 
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the findings of the analysis of the protein–ligand interactions (Figure 4.3). The 
conformations of these structures also provide an indication of the differing levels of 
flexibility of each linker, with the conformation of the 1,2,3-triazole derivatives being 
much more rigid and elongated when compared to the phosphodiester- and 
carbamate-linked counterparts. However, this conformational difference is much more 
obvious in the distribution of cluster population obtained from the ligand in water box 
simulations (see Appendix Figure B10). The distribution for the (R)-diastereomers shows 
the phosphodiester-linked ligand samples a much larger conformational space than both 
its carbamate- and 1,2,3-triazole-linked counterparts, as evidenced by the number of 
clusters identified. The distribution for the (S)-diastereomers shows a similar trend, 
however the difference between the phosphodiester and carbamate derivatives is not as 
large. The increased flexibility of the phosphodiester derivatives compared to the 
1,2,3-triazole- and carbamate-linked derivatives provides further evidence to support the 
enthalpy-entropy compensation hypothesis. 
It is worth noting that though the binding free energy differences are converged 
within 1.0 kcal/mol, a proper error propagation significantly increases the uncertainties 
in the enthalpic component (''Hb) and entropic component (-T''Sb) (Table 4.1). 
Nevertheless, our calculations have demonstrated that these three types of inhibitors with 
different linkers have similar potencies against hST6Gal I. Complementary analyses 
based on binding entropy calculations, quasi-harmonic and conformational cluster 
analyses highlighted the potential role of entropy in the binding of transition state-based 
hST6Gal I inhibitors. Experimentally, we are synthesising both the 1,2,3-triazole- and 
carbamate-linked derivatives (Chapters 5 and 6) and their predicted potency will be 
validated with experimental inhibition rates and kinetic constants. The enthalpy-entropy 
compensation hypothesis can be validated by examining the temperature-dependent data. 
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4.4 Conclusion 
MD simulations and FEP calculations were performed to investigate the replacement of 
the charged phosphodiester linker used in reported transition-state analogue ST inhibitors 
with a neutral isostere, such as a carbamate or a 1,2,3-triazole. MD simulations of the 
(R)- and (S)-diastereomers of three ligands, which only differed in the linker, complexed 
with hST6Gal I or in a water box were performed. Hydrogen bonds and hydrophobic 
contacts of the ligands with hST6Gal I were monitored over the course of the simulations 
and have demonstrated that no matter which linker is used, important interactions with 
the active site are able to be maintained. These results confirmed the findings of our 
previous work,40 which was undertaken with a different set of force fields. Free energy 
perturbation calculations demonstrated that when the phosphodiester linker was perturbed 
to either a carbamate or a 1,2,3-triazole a slightly more favourable binding to hST6Gal I 
was observed, with the carbamate being marginally more preferential. This result was a 
surprise considering the perceived importance of the phosphodiester linker. We 
rationalise this observation with a hypothesis of an enthalpy-entropy compensation, 
which is supported with free energy component analysis, quasi-harmonic and cluster 
analysis. These analyses demonstrated that the conformational restriction, and thus 
entropic favourability for binding, imparted by the 1,2,3-triazole and carbamate linkers, 
when compared to the phosphodiester linker, is enough to compensate the resulting 
enthalpic penalty. The results of these simulations have provided a strong rationale for 
the use of a carbamate or 1,2,3-triazole as an isostere of the phosphodiester. We are 
currently exploring both potential isosteres synthetically with the aim to develop novel 
inhibitors of hST6Gal I, improve synthetic accessibility and address potential 
pharmacokinetic problems.  
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FOREWORD TO CHAPTER 5 
This chapter is a full research article prepared for submission to the Journal of Medicinal 
Chemistry. Building upon the computational modelling described in Chapters 3 and 4, 
this chapter describes the synthesis and biological evaluation of carbamate-linked 
nucleosides as potential transition-state analogue ST inhibitors. Herein the preparation 
and characterisation of the key αHP and nucleoside fragments as well as the synthesis of 
target carbamate-linked compounds is described. FEP calculations and analysis of 
receptor-ligand interactions were used to rationalise the replacement of the cytidine 
moiety used in previously reported ST inhibitors with uridine. This manuscript also 
describes the biological evaluation of the 26 newly synthesised inhibitors with results 
showing that both the carbamate and uridine modifications are viable changes to the 
classical model of ST inhibitors. Supporting information for this chapter can be found in 
Appendix C (p. 260). 
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5.1 Abstract  
Cell surface glycoconjugates terminated by sialic acid are important in many biological 
events such as cell-cell recognition, receptor binding, protein-lectin interactions, cell 
adhesion, immune responses and fertilisation. It has been reported that the upregulation of 
ST activity and the resulting hypersialylation of the cell surface has been correlated with 
tumour growth, metastasis and drug resistance. Therefore, developing inhibitors of STs 
would provide valuable leads for the discovery of novel anticancer drugs. Herein, we have 
investigated the replacement of the charged phosphodiester linker of reported transition-state 
analogue ST inhibitors with a neutral carbamate in an effort to address potential 
pharmacokinetic issues of the charged phosphodiesters and to improve synthetic tractability. 
We have also explored replacement of cytidine with uridine to further ease synthesis and 
used free energy calculations to show this was a viable strategy. Hence a series of 
carbamate-linked compounds were synthesised by coupling various α-HPs with 5ʹ-amino 
nucleosides. Their inhibitory activities against recombinant hST6Gal I were assayed, and 
three promising inhibitors were identified with Ki’s ranging from 0.9 μM to 12 μM. These 
results show the carbamate linker and a uridine nucleoside as viable alternatives to be 
explored as a new generation of ST inhibitors. 
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5.2 Introduction 
Sialic acid (N-acetylneuraminic acid, Neu5Ac) is one of the human body’s most important 
sugars next to glucose.1 These negatively charged nine-carbon α-keto aldonic acids are 
located at the terminal end of glycan chains on cell surface and secreted molecules, bestowing 
them with crucial roles in cellular biology.2-3 These functions are mainly related to cellular 
and molecular recognition events, such as activation or inhibition of intracellular and 
intramolecular interactions, cell-cell recognition, receptor binding, protein-lectin 
interactions, protein targeting, cell adhesion, immune responses and sperm-egg 
fertilisation.4-7 The biosynthesis of sialic acid containing glycoconjugates in humans is 
mediated by 20 STs anchored within the Golgi apparatus’ membrane with the catalytic 
domain present within the lumen.4-5 Sialylation catalysed by STs uses the sugar nucleotide 
donor CMP-Neu5Ac and an oligosaccharide or glycoconjugate terminated by a Gal, GalNAc, 
or another sialic acid residue as the acceptor.4, 8 
Upregulation of ST activity and the resulting modified cell surface sialylation is 
strongly associated with cancer, with hypersialylation of 40% and above seen in many 
cancers.9 This has been directly correlated with an increased metastatic potential of tumours, 
facilitation of apoptotic avoidance mechanisms and poor patient prognosis.10-11 
Hypersialylation as a result of ST upregulation also results in cellular resistance to 
chemotherapeutics in ovarian,12-14 colorectal,15 and cervical cancer,16 hepatocellular 
carcinoma,17 pancreatic ductal adenocarcinoma18 and myeloid leukaemia19 thus reducing 
treatment efficacy. Exposure to radiation has also been shown to induce increased expression 
of hST6Gal I and reduce radiation-induced cell death in colon cancer.20 Thus, the critical role 
of STs in tumour growth, progression and treatment resistance demonstrates the importance 
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of investigating this family of enzymes as a potential new anti-cancer drug target with the 
dual benefit of targeting metastasis and drug resistance with a non-toxic agent. 
A wide number of inhibitors ranging from those isolated from natural sources and 
high throughput screening to those specifically designed to mimic ST substrates have been 
reported, as reviewed recently.9 Of these, analogues mimicking the proposed oxocarbenium 
ion-like transition state of the donor (Figure 5.1a) exhibit the highest affinity to STs.21-22 The 
most potent being those incorporating a Neu5Ac2en, where the C2–C3 double bond mimics 
the planar anomeric carbon and an extra carbon between the anomeric carbon and CMP 
leaving group mimics the elongated distance in the transition state.21, 23 Variations made to 
the glycerol side chain of the Neu5Ac2en moiety resulted in the greatest increase in inhibitory 
activity, with the phenoxy derivative 5.1 (Figure 5.1b) the most potent of the series (Ki = 
29 nM; rat liver ST6Gals).24 More synthetically accessible derivatives that incorporate an 
aryl replacement of the Neu5Ac2en exhibited comparable activity.21-22, 25 Of these the 
(R)-isomer of the 3-phenoxy derivative 5.2 (Figure 5.1b) was a potent inhibitor of both rat 
liver ST6Gals (Ki = 70 nM)21 and hST6Gal I (Ki = 19 nM)26 and is used as our lead compound 
herein. Recently, derivatives that mimic the transition state using a cyclopentyl26 (5.3) or 
amide27 (5.4) have been reported with comparable Ki’s to the 3-phenoxy lead derivative 5.2.  
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Figure 5.1: (a) General mechanism of sialylation catalysed by sialyltransferases. (b) Reported transition-state 
analogue inhibitors 5.1–5.4.21, 24, 26-27 
 
The charged phosphodiester linkage of the potent transition-state analogue ST 
inhibitors such as those highlighted in Figure 5.1b is thought to be a major contributor to 
potency.21-22, 25 However, it may also lead to low bioavailability and loss of activity due to 
cleavage by phosphatases or instability in the ST active site.28-29 The charged nature of the 
linker may lead to poor cellular permeability, although recent reports of phosphodiester 
derivatives bearing a fluorescent probe have suggested such charged compounds may be able 
to cross cellular membrane via a vesicular uptake mechanism.30 In addition to 
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pharmacokinetic issues, the synthesis of the phosphodiester-linked inhibitors utilises a 
technically demanding approach employing the condensation of an α-HP and a highly 
air-sensitive cytidine phosphitamide and subsequent oxidation.21, 26-27  
To overcome these issues, we have replaced the phosphodiester linker with an 
uncharged carbamate, which can be readily achieved using a wide range of 
alkoxycarbonylating agents.31 Structurally, the carbamate functionality is related to an 
amide-ester hybrid and in general displays very good chemical and proteolytic stability. 
Although not widely used as isosteres of phosphodiesters, their capability to permeate cell 
membranes has resulted in carbamates being widely utilised as peptide bond isosteres,31 
which would also provide advantages in this case. More specifically a carbamate moiety 
would be expected to have similar hydrogen bonding capabilities to a phosphodiester group 
and will maintain the three-atom distance between the cytidine moiety (Figure 5.2) and 
Neu5Ac-mimic observed in reported phosphodiester-linked ST inhibitors (Figure 5.1b). 
We have demonstrated previously using molecular docking and MD simulations that 
carbamate- (and 1,2,3-triazole-) linked derivatives have comparable interactions to their 
phosphodiester-linked counterparts with the hST6Gal I active site (Chapters 3 and 4).32-33 
Using FEP calculations we have shown that these compounds can successfully mimic the 
charged phosphodiester linkage with a comparable binding affinity through an 
enthalpy-entropy compensation (Chapter 4).34 
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Figure 5.2: The possible binding interactions of a carbamate and phosphodiester linker. White arrows represent 
hydrogen bond acceptors and black arrows represent hydrogen bond donors. 
 
Herein, we have also explored the replacement of the cytidine moiety with uridine 
based on several factors. Firstly, uridine may open a route to selectivity for specific STs as 
the exocyclic amino group of CMP does not engage in specific contacts with the protein in 
the pST3Gal I crystal structure.35 Kuhn et al. proposed that this would allow the non-natural 
donor substrate uridine-5’-monophosphate Neu5Ac to be accepted by the protein, which is 
less likely for hST6Gal I.36 Uridine also offers a synthetic advantage over cytidine as it has 
one less group that requires protecting/deprotecting allowing for target compounds to be 
produced in fewer steps. 
Herein, the phosphodiester linker of classical ST inhibitors has been replaced with a 
carbamate, along with uridine in place of cytidine and the effects investigated both 
computationally and experimentally. Additionally, the difference of diastereomers and 
various substituents of the aryl sialic acid mimic, particularly at the 3-position, were also 
explored. The target compounds could be prepared from the appropriately protected 
precursors, arising from two key building blocks: the 5′-aminonucleoside and the α-HP. After 
these compounds were synthesised, the inhibitory activity of these target molecules was 
evaluated against recombinant hST6Gal I. 
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5.3 Results and Discussion 
5.3.1 Free Energy Calculation 
Building on previous computational studies demonstrating the feasibility of using carbamates 
and 1,2,3-triazoles as phosphodiester isosteres,32-34 we have performed FEP calculations to 
compare the relative binding affinity of cytidine- and uridine-based carbamate inhibitors with 
hST6Gal I.36 Alchemical transformation of the cytidine-based inhibitor (R)-5.5 to the 
uridine-based inhibitor (R)-5.6 in complex with hST6Gal I and in solution was performed 
(Figure 5.3). Combining the data from all simulations, the ΔΔGb value observed for this 
transformation was −1.2 ± 0.3 kcal/mol (see Appendix Table C1–C2). This suggests that 
replacing the cytidine in carbamate-linked inhibitors with a uridine would not have a 
significant impact on binding to hST6Gal I, with uridine potentially being slightly 
preferential. This is surprising as cytidine was previously thought to be an essential 
component of a potent ST inhibitor.21, 37  
 
Figure 5.3. The perturbation of cytidine-based (R)-5.5 to uridine-based (R)-5.6 performed during FEP 
calculation of ΔΔGb to hST6Gal I. 
 
To help rationalise the result observed during the FEP calculation, an additional 15 ns 
of MD simulation was performed for uridine-based inhibitor (R)-5.6. From these trajectories 
the hydrogen bonds and hydrophobic contacts of the uridine component and the binding 
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pocket were analysed and compared to those previously reported34 for the cytidine 
component of (R)-5.5 (Figure 5.4). This comparison showed that a majority of interactions 
were maintained between the two nucleoside components, which supports the FEP 
calculations and suggests hST6Gal I can accommodate uridine-based derivatives. Based on 
the outcomes of these calculations we prepared a series of uridine-based compounds. 
 
Figure 5.4: Comparison of interactions with hST6Gal I between the (a) cytidine component of (R)-5.534 and 
the (b) uridine component of (R)-5.6. Consistent interactions were observed between the remaining components 
of (R)-5.5 and (R)-5.6. Interacting hST6Gal I residues are represented as circles which are colour coded based 
on interaction type as follows: Red = hydrogen bond donor; Green = hydrogen bond acceptor; Blue = water 
bridged hydrogen bond; Orange = hydrogen bond donor and acceptor; Grey = hydrophobic contact. Dashed 
lines indicate hydrophobic contacts and dotted lines represent the hydrogen bonds shown in Supplementary 
Table C3–C4. 
 
5.3.2 Synthesis of Sialic Acid Mimic 
The sialic acid mimics for the target compounds synthesised in this work are α-HPs that are 
derived from commercially available aldehydes. The benzyl protecting group was selected 
for the phosphonate as it can be easily removed under catalytic hydrogenation conditions. 
Based on reported methods,23, 38 the aldehydes were reacted with dibenzyl phosphite and 
triethylamine in dichloromethane (CH2Cl2) to give the desired α-HP as a racemic mixture 
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(Scheme 5.1), as the diastereoisomeric final products could be readily separated using reverse 
phase HPLC (RP-HPLC).21, 26-27 Using the method highlighted in Scheme 5.1, desired α-HPs 
were obtained in good to excellent yields of 51%–92%. When comparing the yields of the 
α-HPs (5.7–5.18) it can be seen that the electronic nature of the substituent has a distinct 
impact on the yield, with those substituents that increase the electrophilic nature of the 
aldehyde favouring higher yields. 
 
Scheme 5.1: Synthesis of αHPs 5.7–5.18. Reagents and conditions: (a) dibenzyl phosphite, triethylamine, 
CH2Cl2, rt, overnight. 
 
5.3.3 Synthesis of the Nucleoside Fragment 
The requisite nucleoside fragments were prepared from commercially available cytidine and 
uridine. Numerous protecting groups were trialled for uridine (Chapter 6) with the 
allyloxycarbonyl (Alloc) protecting group being the most favourable. For the cytidine 
derivatives, benzyloxycarbonyl (Cbz) protecting groups were utilised to facilitate global 
deprotection. 
Alloc protected derivatives were prepared by the initial 5′-selective installation of an 
azide via a Mitsunobu reaction to give 5.19.39 This was followed by the reaction with allyl 
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chloroformate to give the Alloc protected 5′-azidouridine 5.20 that was subjected to a 
Staudinger reduction to give the corresponding 5′-aminouridine 5.21 (Scheme 5.2). These 
three steps were performed in an overall yield of 61%. 
 
Scheme 5.2: Synthesis of Alloc protected 5′-aminouridine 5.21. Reagents and conditions: (a) 
Triphenylphosphine, DIAD, HN3, THF, 0ºC–rt, 17 h, 97 %; (b) allyl chloroformate, pyridine, 20ºC–rt, 30 min, 
90%; (c) (i) triphenylphosphine, THF, rt, 2 h; (ii) H2O, reflux, 6 h, 70% over two steps. 
 
To prepare the required cytidine fragment, the Cbz protected 5′-hydroxycytidine 
derivative 5.22 was synthesised from cytidine based on reported methods.40 Compound 5.22 
was then subjected to azidonation under Mitsunobu conditions to yield 5.23, which was 
subsequently reduced under Staudinger conditions to produce the key Cbz protected 
5′-aminocytidine fragment 5.24 in an overall yield from cytidine of 33% (Scheme 5.3). 
 
Scheme 5.3: Synthesis of Cbz protected 5′-aminocytidine 5.24. Reagents and conditions: (a) 
Triphenylphosphine, DIAD, HN3, THF, 0ºC–rt, 18 h, 97 %; (b) (i) triphenylphosphine, THF, rt, 2 h; (ii) H2O, 
reflux, 5 h, 50% over two steps.  
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5.3.4 Synthesis of Target Molecules 
Coupling of the α-HP building blocks 5.7–5.18 and 5′-aminonucleoside derivatives 5.21 or 
5.24 was performed using 4-nitrophenyl chloroformate (4-NPC) in the presence of 
triethylamine and a catalytic amount of DMAP (Scheme 5.4–5.5). Using this method, the 
fully protected carbamate coupled derivatives were obtained as a 1:1 mixture of two 
diastereoisomers in 22–73% yield (Table 5.1). The fully protected uridine-based derivatives 
5.25a–l required two deprotection steps (Scheme 5.4), both performed in excellent yields 
(Table 5.1). The first deprotection step was the removal of Alloc protecting groups using 
Pd(PPh3)4, with dimedone used as an allyl scavenger. Partially deprotected derivatives 
5.26a–l subsequently had benzyl protecting groups removed using 10% Pd/C and one 
atmosphere of H2 to produce the crude mixture of target uridine-based compounds 5.27a–l. 
The Cbz and benzyl protected cytidine-based derivative 5.28 underwent a global deprotection 
using 10% Pd/C and an atmosphere of H2 to produce the crude mixture of the target 
cytidine-based compound 5.29 (Scheme 5.5). The 1:1 diastereomeric mixtures of compounds 
5.27a–l and 5.29 were separated by preparative RP-HPLC, converted to their corresponding 
sodium salt via ion exchange (IR 120 Na+), and lyophilised to produce the final stereopure 
products (Table 5.1), designated s and l, as white powders in excellent yields (s stands for 
the diastereoisomer with the shorter retention time and l stands for the diastereoisomer with 
the longer retention time by HPLC). 
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Scheme 5.4: Synthesis of uridine-based target compounds 5.27a–l-s and 5.27a–l-l (refer to Table 5.1 for R 
group identity). Reagents and conditions: (a) (i) 5.7–5.18, 4-NPC, triethylamine, DMAP, CH2Cl2, 0ºC–rt, 3 h; 
(ii) 5.21, rt, 24 h; (b) Pd(PPh3)4, dimedone, THF, rt, 30 min; (c) (i) 10% Pd/C, 1 atm. H2, rt, 1 h; (ii) RP-HPLC; 
(iii) IR 120 Na+.  
 
 
Scheme 5.5: Synthesis of cytidine-based target compounds 5.29-s and 5.29-l. Reagents and conditions: (a) (i) 
5.7, 4-NPC, triethylamine, DMAP, CH2Cl2, 0ºC–rt, 3 h; (ii) 5.24, rt, 24 h; (b) (i) 10% Pd/C, 1 atm. H2, rt, 1 h; 
(ii) RP-HPLC; (iii) IR 120 Na+.  
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Table 5.1: Yields for the preparation of 5.27a–l and 5.29 and inhibition dataa against recombinant hST6Gal I. 
R Coupling Product Alloc Deprotection Cbz/Bn Deprotectionb Inhibition at 10 μM  
 
5.28: 23% - 
5.29a-s: 89% 2.2% 
5.29a-l: 92% 6.3% 
 
5.25a: 49% 5.26a: 81% 
5.27a-s: 90% 19.9% 
5.27a-l: 92% 28.2% 
 
5.25b: 38% 5.26b: 84% 
5.27b-s: 96% 1.1% 
5.27b-l: 97% 1.8% 
 5.25c: 40% 5.26c: 76% 
5.27c-s: 80% 34.6% 
5.27c-l: 83% 58.9% 
 
5.25d: 22% 5.26d: 68% 
5.27d-s: 72% 36.6% 
5.27d-l: 70% 18.0% 
 
5.25e: 36% 5.26e: 91% 
5.27e-s: 83% 7.2% 
5.27e-l: 93% 30.9% 
 
5.25f: 38% 5.26f: 87% 
5.27f-s: 94% 29.8% 
5.27f-l: 82% 23.6% 
 5.25g: 62% 5.26g: 85% 
5.27g-s: 85% 18.1% 
5.27g-l: 88% 7.1% 
 
5.25h: 51% 5.26h: 71% 
5.27h-s: 93% 12.7% 
5.27h-l: 81% 7.9% 
 
5.25i: 38% 5.26i: 92% 
5.27i-s: 87% 19.0% 
5.27i-l: 84% 78.0% 
 5.25j: 44% 5.26j: 80% 
5.27j-s: 90% 7.1% 
5.27j-l: 81% 15.2% 
 
5.25k: 36% 5.26k: 97% 
5.27k-s: 86% 66.4% 
5.27k-l: 88% 13.2% 
 
5.25l: 73% 5.26l: 70% 
5.27l-s: 68% 5.9% 
5.27l-l: 70% 6.9% 
aFor details of the procedures, see Appendix C. bYield of sodium salts displayed. 
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5.3.5 Enzymatic Assay  
Assessment of the activity of carbamate-linked compounds 5.27a–l and 5.29 against 
recombinant hST6Gal I (aa 44–406) was performed based on the CMP-Glo™ assay from 
Promega as detailed by Das et al.41 CMP-Neu5Ac was used as the sialic acid donor and 
LacNAc used as the acceptor. CMP produced as a by-product of the ST reaction was detected 
using a luciferase producing luminescence with a liner response to the concentration of CMP. 
Luminescence was detected using a POLARstar Omega plate reader. With acceptor 
concentration set at 1 mM, the Km for CMP-Neu5Ac was calculated to be 37 ± 5 µM for 
hST6Gal I (see Appendix Figure C15), which was comparable to reported data.26, 42-43 The 
inhibition rates of all compounds at 10 μM (with 1 mM of acceptor and 100 μM 
CMP-Neu5Ac) was initially obtained (Table 5.1), and for those compounds with over 50% 
inhibition, Ki’s were determined (Table 5.2). Lineweaver–Burk double reciprocal plots 
suggest that the inhibitors are exhibiting a mixed mode of inhibition (see Appendix Figure 
C16–C18). As shown in Table 5.1 all compounds tested were active at 10 μM.  
For most compounds in the series the comparable activity between the s- and 
l-isomers demonstrates that the stereochemistry of the αHP fragment is not an essential 
consideration. This reflects what has been previously reported for phosphodiester-linked 
inhibitors.21 The importance of substituent identity and position on the αHP fragment can be 
seen by comparing the inhibitory activity of unsubstituted derivatives 5.27j to the various 
substituents explored, which identified a number of key trends that are discussed below.  
For the 3-substituted derivatives the alkyl ethers were beneficial for activity, with the 
3-cyclopentoxy derivative 5.27i-l (Ki = 12 ± 6 μM) providing some of the best activity 
observed. The 3-phenoxy derivatives 5.27a were not as effective as the 3-cyclopentoxy 
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derivatives 5.27i and produced comparable levels of activity to both the 3-propoxy (5.27e) 
and 3-methoxy (5.27f) derivatives. This was surprising given the 3-phenoxy substituent in 
previously reported phosphodiester-linked compounds such as 5.1 and 5.2 (Figure 5.1b) was 
the most potent towards hST6Gal I. This suggests that the conformation imparted by the more 
rigid carbamate linker when compared to the phosphodiester of previously reported 
compounds results in these compounds interacting with the hST6Gal I active site in a 
different manner. When 3-substitution was coupled with a substituent in the 4-position a 
decrease in activity was observed (5.27a vs 5.27b and 5.27h vs 5.27i). However, when there 
were only substituents at the 4-postion, activity was maintained in the case of the methoxy 
substituent (5.27g vs 5.27h) or significantly improved in the case of the fluoro substituent 
(5.27b vs 5.27c). In fact, the fluoro derivative 5.27c-l (Ki = 0.9 ± 0.3 μM) was one of the most 
potent compounds in the series with a 41-fold greater affinity for hST6Gal I than 
CMP-Neu5Ac.  
The other most promising compound in this series was the structurally unique 
2-benzothiophene derivative 5.27k-s (Ki = 4 ± 2 μM), which had a 9-fold greater affinity for 
hST6Gal I than CMP-Neu5Ac. To our knowledge heterocycles such as that of 5.27k-s have 
not been used as sialic acid mimics in the context of ST inhibition and hence warrant further 
exploration. It should be noted that the substantial difference in activity between 5.27k-s, its 
diastereoisomer 5.27k-l and both diastereoisomers of the 3-benzothiophene derivative 5.27l 
suggest that both stereochemistry and regiochemistry are important considerations if 
heterocycles are explored in the future. 
Comparing the activity of the cytidine-based (5.29) and uridine-based (5.27a) 
inhibitors demonstrates that there is no impact on the change of nucleoside, with 5.27a being 
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a more potent inhibitor hST6Gal I. This validates the results of the FEP calculations 
discussed above (Figure 5.3) and provides a rationale for exploring other alternatives to 
cytidine, which was previously considered essential for activity.21-22, 25-26  
The activity of the three most potent compounds in this series ranges from Ki values 
of 0.9 μM to 18 μM. This activity ranges from one to three orders of magnitude less than that 
of reported phosphodiester linked inhibitors of hST6Gal I.26-27 However, as we have been 
able to maintain promising levels of activity with compounds that are relatively synthetically 
tractable when compared to those previously reported, it can be seen that carbamate-linked 
ST inhibitors viable options that warrant further exploration. 
Table 5.2: Affinity of CMP-Neu5Ac (Km) to recombinant hST6Gal I and inhibition dataa 
 
Compound R Inhibition at 10 μM Km or Ki (μM) Km/Ki 
CMP-Neu5Ac - - 37 ± 5 - 
5.27c-l  58.9% 0.9 ± 0.3 41 
5.27i-l 
 
78.0% 12 ± 6 3 
5.27k-s 
 
66.4% 4 ± 2 9 
aFor details of the procedures, see Appendix C. 
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5.4 Conclusions 
Herein, we examined the replacement of the phosphodiester linker and cytidine of classical 
ST inhibitors with a carbamate and uridine respectively. Additionally, the difference of 
diastereomers and various substituents of the aryl sialic acid mimic, particularly at the 
3-position, were also explored. FEP calculations demonstrated that for carbamate-linked 
compounds bound to hST6Gal I that uridine was a viable alternative to cytidine. Based on 
this finding we designed and synthesised 26 carbamate-linked compounds by coupling α-HPs 
with 5′-amino nucleosides. The synthesised compounds were evaluated against recombinant 
hST6Gal I, with the results obtained validating the results of the FEP calculations and 
identifying three promising compounds (5.27c-l, 5.27i-l and 5.27k-s). These results show 
that both the carbamate and uridine modifications are viable changes to the classical model 
of ST inhibitors that are worth further exploration. The identification of the benzothiophene 
containing inhibitors 5.27k-s as one of the most potent compounds of our series suggests that 
various heterocycles should be explored in the future. As well as this, compounds of this 
series are under investigation against other ST subtypes with promising compounds from this 
series under investigation in cell-based models of cancer.  
5.5 Experimental Section 
5.5.1 Relative Binding Free Energy Calculation 
The FEP calculation describing the alchemical transformation of the cytidine-based inhibitor 
(R)-5.5 to the uridine based inhibitor (R)-5.6 was prepared using VMD version 1.9.2.44 and 
carried out using the NAMD 2.10 package.45 The change in the binding free energy with the 
perturbation from cytidine to uridine (Figure 5.5) can be expressed as: 
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ΔΔ𝐺𝑏 = Δ𝐺𝑏𝑈𝑟𝑖 − Δ𝐺𝑏
𝐶𝑦𝑡  





In the FEP method, one introduces a hybrid Hamiltonian, ℋ(λ)=(1 – λ) ℋ0 + λℋ1, 
where H0 represents the Hamiltonian for the initial state and H1 for the final state. The interval 
between 0 and 1 is divided into n subintervals (λi, where i = 1,…, n – 1), and for each 
subinterval the free energy difference is calculated from the ensemble average, ΔΔGex,i = –
kBT ln<exp[–(ℋ(λi+1) – ℋ(λi))/kBT>λi. The free energy difference between initial and final 
states is obtained from the sum, ΔΔG = Σi ΔΔGex,i. Alchemical transformations were carried 
out with 20 uniformly distributed λ values between 0 and 1 (0.0, 0.05, 0.1, … , 0.9, 0.95, 1.0), 
with the transformation simulated in both the forward (0 ⟶ 1) and backward (1 ⟶ 0) 
directions. To prevent the occurrence of singularities at values of λ where an atom 
disappears/appears, a soft-core potential with α = 4.0 Å2 was used to reshape the 
Lennard-Jones potential into a form devoid of singularity when λ approaches either 0 
or 1.46-47 
 
Figure 5.5: The thermodynamic cycle used in the cytidine to uridine FEP simulations to calculate ΔΔGb (see 
Eq. 5.1). Cyt represents the cytidine-based inhibitor (R)-5.5, Uri represents the uridine-based inhibitor (R)-5.6 
and E represents hST6Gal I. 
Eq. 5.1 
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The starting structure for each λ window was generated from the hST6Gal I-inhibitor 
molecular dynamics simulations of the cytidine-based inhibitor (R)-5.5, described in our 
previous work.34 Each λ window simulation for both the complex and ligand only systems 
were solvated in an 82 Å × 82 Å × 82 Å cubic TIP3P48 water box. Each box was neutralised 
with counter ions of Na+ and Cl-, with the salt (NaCl) concentration set to 0.15 mol/L. The 
protein was represented with the non-polarisable CHARMM PARAM36 force field.49 The 
force field used for the ligands were those optimised in our previous work using the GAAMP 
method.34, 50 All systems were simulated in periodic boundary conditions using the Langevin 
algorithm for maintaining the temperature at 298.15 K, and the Langevin Piston Nose–
Hoover method51-52 for maintaining a constant pressure of 1.0 bar. The electrostatic 
interactions were calculated using the Particle Mesh Ewald method.53 The van der Waals 
forces were treated with a cut-off of 12 Å and a smoothening function between 10 and 12 Å. 
All of the covalent bonds involving hydrogen were kept rigid with the RATTLE algorithm.54 
The integration time step was set to 1.0 fs, 2.0 fs and 4.0 fs for bonded, non-bonded and 
long-range electrostatics, respectively.  
Each λ window underwent an initial 5000 energy minimisation steps followed by 1 ns 
equilibration simulation to provide starting coordinates. Each window was then subsequently 
simulated for 2 ns with a harmonic restraint placed on the centre of mass of hST6Gal I for 
the complex simulations. A harmonic restraint was also applied to one atom from the ligand 
in bulk simulations. Both restraints used a force constant of 32 kcal/mol/Å2. ΔΔGb and the 
associated errors were calculated using the ParseFEP plugin55 in VMD, which was used to 
combine the results of the forward and backward simulations with the Bennett 
acceptance-ratio.56 
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To examine the hydrogen bond interactions that uridine-based inhibitors have with 
the hST6Gal I active site the λ window 1.0 from the backwards simulation was extended to 
15 ns. Hydrogen bond interactions were analysed according to a geometric criterion. A 
hydrogen bond was defined by a minimum donor–hydrogen–acceptor angle of 120° and a 
maximum heavy atom distance of 3 Å. Hydrophobic contacts were also analysed according 
to a geometric criterion of a maximum distance of 4 Å between hydrophobic atom pairs. To 
identify these interactions VMD version 1.9.2.44 was utilised. 
5.5.2 General Chemistry 
All solvents and reagents were purchased from Sigma Aldrich Chemical Company (St Louis, 
MO, USA), Carbosynth (Berkshire, UK), Ajax Fine Chemicals and ChemSupply (Gillman, 
SA). All solvents used were of analytical (AR) grade or higher. When necessary, the 
purification of solvents and starting materials was carried out using standard procedures. 
Unless otherwise noted all reactions were undertaken under anhydrous conditions with an 
atmosphere of N2 in oven-dried glassware. Reactions were monitored by TLC using Merck 
Silica Gel 60 F254 aluminium backed plates and spots visualised under UV (254 nm) light 
and/or by staining with acidic ceric ammonium molybdate. Solvents were evaporated under 
reduced pressure using a Büchi rotary evaporator at 40ºC (water bath). Column 
chromatography was performed under ‘flash’ conditions on Silica Gel 60 (40–63 μm mesh). 
1H, 13C, 31P, 19F and 2D NMR spectra were acquired on a Varian VNMRS PS54 500 MHz, 
Varian Unity Inova 300 MHz, Bruker Advance Neo 500 MHz or a Bruker Advance 400 MHz 
spectrophotometer. 1H and 13C NMR chemical shifts (in ppm) were calibrated with the 
solvent residual peak or TMS. 31P NMR chemical shifts (in ppm) were calibrated with an 
external reference of 85% H3PO4 in D2O. 19F NMR chemical shifts (in ppm) were calibrated 
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with an external reference of 0.05% α,α,α-trifluorotoluene in CDCl3. High resolution 
electrospray ionisation mass spectra (HRMS) were performed on a Waters XEVO G2 Q-TOF 
spectrometer, with leucine enkephalin (LeuEnk) as an internal standard. Infrared spectra were 
obtained on either a Shimadzu IRAffinity – 1 FTIR spectrophotometer or a Bruker Vortex 
70 FTIR spectrophotometer. Optical rotation was determined by a Jasco P-2000 polarimeter. 
Melting points were obtained using a Büchi Melting Point M-560 apparatus and are 
uncorrected. Analytical RP-HPLC was performed with a Shimadzu Prominence-I LC-2030C 
system with a PDA detector (190–800 nm), using a Luna C18 (2) 100Å (Phenomenex, 3 μm, 
4.6 mm x 150 mm) column or a Shim-Pack GIS (Shimadzu, 5 μm, 4.6 mm x 150 mm) 
column. Preparative RP-HPLC was performed on a Shimadzu Prominence LC-20AP system 
with a PDA detector (190–800 nm), using a Prep C18 (Shimadzu, 5 μm, 20 mm x 150 mm) 
column. The purity of all final compounds was determined to be ≥ 95% based on 1H NMR 
data and analytical HPLC. Please note as 2D NMR data has not been provided NMR 
assignments are not provided herein according to the ACS Guidelines for the Journal of 
Medicinal Chemistry. 
5.5.3 Synthesis of α-Hydroxyphosphonates  
The synthesis of all α-HPs was based on the method of Wong et al.38 To a mixture of dibenzyl 
phosphite (1.1 equiv.) and the desired benzaldehyde (1 equiv.) in CH2Cl2, was added 
triethylamine (2 equiv.). The reaction mixture was stirred at rt for 14 h and monitored by 
TLC. Upon completion, the reaction mixture was diluted with CH2Cl2, washed with saturated 
NaHCO3 solution and brine. The organic phase was separated, dried with anhydrous MgSO4, 
filtered and the filtrate evaporated, with the resultant product purified by column 
chromatography. 
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Dibenzyl α-hydroxy(3-phenoxy)benzylphosphonate (5.7). 
From 3-phenoxybenzaldehyde (300 mg, 1.51 mmol): purification by column 
chromatography (ethyl acetate:hexane, 1:1, Rf = 0.43) to give 5.7 (417 mg, 60%) as a white 
solid. mp 65.0–68.0ºC. 1H NMR (500 MHz, CDCl3) δ 7.24–7.31 (m, 12H), 7.19–7.22 (m, 
3H), 7.13 (br s, 1H), 7.08 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 8.5 Hz, 2H), 5.02 (d, JH,P = 10.0 
Hz, 1H), 4.89–5.00 (m, 4H). The spectral data match those reported.26 
Dibenzyl α-hydroxy(4-fluoro-3-phenoxy)benzylphosphonate (5.8). 
From 4-fluoro-3-phenoxybenzaldehyde (500 mg, 2.31 mmol): purification by column 
chromatography (ethyl acetate:petroleum spirit, 2:3, Rf = 0.14) to give 5.8 (1.11 g, 92%) as 
a white solid. mp 71.0–73.0ºC. 1H NMR (500 MHz, CDCl3) δ 7.04–7.30 (m, 16H), 6.90 (d, 
J = 8.0 Hz, 2H), 4.90–5.00 (m, 5H). 13C NMR (125 MHz, CDCl3) δ 157.3, 154.2 (dd, JC,F = 
247.9 Hz, JC,P = 3.8 Hz), 143.7 (d, JC,F = 12.4 Hz), 136.0 (d, JC,P = 6.3 Hz), 133.05–133.16 
(m), 129.8, 128.8, 128.72, 128.69, 128.12, 128.06, 123.5–123.6 (m), 123.4, 120.7–120.8 (m), 
117.5, 117.1, 116.9, 70.5 (d, JC,P = 158.4 Hz), 68.8–68.9 (m), 68.7 (d, JC,P = 6.6 Hz). 
31P NMR (162 MHz, CDCl3) δ 22.54 (d, JP,F = 6.5 Hz).19F NMR (235.3 MHz, 
CDCl3) δ −68.81 (d, JF,P = 2.4 Hz). HRMS (ESI) calcd for C27H25FO5P [M + H]+, 479.1424; 
Found 479.1425. IR (FTIR) νmax 3307, 1505, 1489, 1208, 991, 740, 724, 698.  
Dibenzyl α-hydroxy(4-fluoro)benzylphosphonate (5.9). 
From 4-fluorobenzaldehyde (1.00 g, 8.06 mmol): purification by column chromatography 
(ethyl acetate:petroleum spirit, 7:3, Rf = 0.55) to give 5.9 (2.54 g, 82%) as a white solid. mp 
102.0–104.0ºC. 1H NMR (500 MHz, CDCl3) δ 7.37–7.40 (m, 2H), 7.18–7.28 (m, 10H), 6.94–
6.97 (m, 2H), 5.04 (d, JH,P = 10.0 Hz, 1H), 4.88–5.00 (m, 4H). 13C NMR (125 MHz, CDCl3) 
δ 162.7 (dd, JC,F = 245.3 Hz, JC,P = 3.8 Hz), 136.12 (d, JC,P = 3.4 Hz), 136.07 (d, 
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JC,P = 3.4 Hz), 132.29–132.33 (m), 129.1 (dd, JC,P = 8.4 Hz, JC,F = 5.5 Hz), 128.7, 128.63, 
128.58, 128.5, 128.04, 127.99, 115.3 (dd, JC,F = 21.3 Hz, JC,P = 2.8 Hz), 70.5 (d, 
JC,P = 159.1 Hz), 68.8 (d, JC,P = 7.1 Hz), 68.5 (d, JC,P = 7.4 Hz). 31P NMR (162 MHz, CDCl3) 
δ 22.74 (d, JP,F = 4.9 Hz). 19F NMR (235.3 MHz, CDCl3) δ −50.94 (d, JF,P = 2.4 Hz). HRMS 
(ESI) calcd for C21H21O4PF [M + H]+, 387.1161; Found 387.1160. IR (FTIR) νmax 3230, 
1601, 1506, 1220, 101, 732, 695. 
Dibenzyl α-hydroxy(3-fluoro)benzylphosphonate (5.10). 
From 3-fluorobenzaldehyde (500 mg, 4.03 mmol): purification by column chromatography 
(ethyl acetate:petroleum spirit, 1:1 Rf = 0.44) to give 5.10 (1.06 g, 68%) as a white solid. mp 
78.0–79.0ºC. 1H NMR (400 MHz, CDCl3) δ 7.16–7.33 (m, 13H), 6.96–7.01 (m, 1H), 5.05 
(d, JH,P = 12.0 Hz, 1H), 4.91–5.02 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 163.3 (dd, 
JC,F = 244.0 Hz, JC,P = 3.0 Hz), 139.1 (dd, JC,F = 8.0 Hz, JC,P = 3.0 Hz), 136.03 (d, JC,P = 
3.0 Hz), 135.97 (d, JC,P = 3.0 Hz), 129.9 (dd, JC,F = 8.0 Hz, JC,P = 3.0 Hz), 128.73, 128.71, 
128.69, 128.67, 128.2, 128.1, 122.9 (dd, JC,P = 6.0 Hz, JC,F = 3.0 Hz), 115.2 (dd, 
JC,F = 21.0 Hz, JC,P = 3.0 Hz), 114.3 (dd, JC,F = 23.0 Hz, JC,P = 6.0 Hz), 70.7 (dd, JC,P = 
158.0 Hz, JC,F = 2.0 Hz), 68.9 (d, JC,P = 7.3 Hz), 68.7 (d, JC,P = 7.3 Hz). 31P NMR (162 MHz, 
CDCl3) δ 22.43 (d, JP,F = 8.1 Hz). 19F NMR (235.3 MHz, CDCl3) δ −49.90 (d, JF,P = 23.5 
Hz). HRMS (ESI) calcd for C21H21O4FP [M + H]+, 387.1161; Found 387.1161. IR (FTIR) 
νmax 3231, 1243, 1224, 1202, 734, 690. 
Dibenzyl α-hydroxy(3-propoxy)benzylphosphonate (5.11). 
From 3-propoxybenzaldehyde (300 mg, 1.82 mmol): purification by column 
chromatography (ethyl acetate:hexane, 1:1, Rf = 0.21) to give 5.11 (587 mg, 75%) as a white 
solid. mp 56.0–57.5ºC. 1H NMR (500 MHz, CDCl3) δ 7.21–7.32 (m, 11H), 7.01 (br s, 2H), 
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6.85 (d, J = 8.5 Hz, 1H), 5.03 (d, JH,P = 10.0 Hz, 1H), 4.87–4.98 (m, 4H), 3.81 (td, J = 6.5 Hz, 
J = 1.5 Hz, 2H), 3.17 (br s, 1H), 1.76 (sxt, J = 7.1 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H). 13C NMR 
(75 MHz, CDCl3) δ 159.1 (d, JC,P = 3.8 Hz), 137.6 (d, JC,P = 2.3 Hz), 136.0–136.1 (m), 129.2 
(d, JC,P = 2.3 Hz), 128.5, 128.4, 128.33, 128.30, 127.90, 127.87, 119.3 (d, JC,P = 6.0 Hz), 
114.9 (d, JC,P = 2.3 Hz), 112.7 (d, JC,P = 5.3 Hz), 69.3, 71.1 (d, JC,P = 158.3 Hz), 68.6 (d, JC,P 
= 8.3 Hz), 68.3 (d, JC,P = 8.3 Hz), 22.5, 10.5. 31P NMR (162 MHz, CDCl3) δ 23.00. HRMS 
(ESI) calcd for C24H27O5PNa [M + Na]+, 449.1494; Found 449.1515. IR (FTIR) νmax 3430, 
2978, 1232, 999, 729, 692. 
Dibenzyl α-hydroxy(3-methoxy)benzylphosphonate (5.12). 
From 3-methoxybenzaldehyde (300 mg, 2.22 mmol): purification by column 
chromatography (ethyl acetate:hexane, 2:3, Rf = 0.45) to give 5.12 (584 mg, 67%) as a white 
solid. mp 77.5–80.0ºC (lit. mp 76–78ºC).57 1H NMR (500 MHz, CDCl3) δ 7.21–7.31 (m, 
11H), 7.01–7.03 (m, 2H), 6.81 (d, J = 8.0 Hz, 1H), 5.04 (d, JH,P = 11.0 Hz, 1H), 4.97–4.84 
(m, 4H), 3.64 (s, 3H). The spectral data match those reported.57 
Dibenzyl α-hydroxy(4-methoxy)benzylphosphonate (5.13). 
From 4-methoxybenzaldehyde (500 mg, 3.67 mmol): purification by column 
chromatography (ethyl acetate:hexane, 1:1, Rf = 0.34) to give 5.13 (884 mg, 60%) as a white 
solid. mp 103.0–105.0ºC (lit. mp 104–105ºC).57 1H NMR (300 MHz, CDCl3) δ 7.48 (d, 
J = 7.3 Hz, 2H), 7.31 (br s, 10H), 6.86 (d, J = 8.5 Hz, 2H), 5.87 (br s, 1H), 5.16 (d, 
JH,P = 10.5 Hz, 1H), 4.88–5.03 (m, 4H), 3.73 (s, 3H). The spectral data match those 
reported.57 
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Dibenzyl α-hydroxy(3-cyclopentoxy-4-methoxy)benzylphosphonate (5.14). 
 From 3-cyclopentoxy-4-methoxybenzaldehyde (700 mg, 3.18 mmol): purification by 
column chromatography (ethyl acetate:petroleum spirit, 1:1, Rf = 0.23) to give 5.14 (789 mg, 
51%) as a white solid. mp 116.5–119.2ºC. 1H NMR (400 MHz, CDCl3) δ 7.27–7.32 (m, 8H), 
7.20–7.22 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.80 (d, JH,P = 8.0 Hz, 
1H), 4.85–4.99 (m, 5H), 4.61–4.62 (m, 1H), 3.83 (s, 3H), 1.75–1.81 (m, 6H), 1.54 (br s, 
2H).13C NMR (100 MHz, CDCl3) δ 150.2 (d, JC,P = 3.0 Hz), 147.8 (d, JC,P = 2.0 Hz), 136.2–
136.3 (m), 128.68, 128.63, 128.52, 128.55, 128.11, 128.06, 119.8 (d, JC,P = 8.0 Hz), 113.8–
113.9 (m), 111.8 (d, JC,P = 2.0 Hz), 80.4, 71.1 (d, JC,P = 159.0 Hz), 68.5–68.6 (m), 56.2, 
32.92, 32.87, 24.2. 31P NMR (162 MHz, CDCl3) δ 22.20. HRMS (ESI) calcd for 
C27H31O6PNa [M + Na]+, 505.1756; Found 505.1769. IR (FTIR) νmax 3309, 2962, 1515, 
1233, 989, 738, 698. 
Dibenzyl α-hydroxy(3-cyclopentoxy)benzylphosphonate (5.15). 
From 3-cyclopentoxybenzaldehyde (973 mg, 5.11 mmol): purification by column 
chromatography (ethyl acetate:petroleum spirit, 3:2, Rf = 0.30) to give 5.15 (1.42 g, 61%) as 
a white solid. mp 55.7–59.3ºC. 1H NMR (500 MHz, CDCl3) δ 7.15–7.27 (m, 11H), 6.98–
7.01 (m, 2H), 6.78 (d, J = 8.2 Hz, 1H), 4.85–5.07 (m, 5H), 4.59–4.62 (m, 1H), 1.68–1.81 (m, 
6H), 1.49–1.56 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 158.1 (d, JC,P = 2.4 Hz), 137.9, 
136.22 (d, JC,P = 1.5 Hz), 136.18 (d, JC,P = 1.5 Hz), 129.3 (d, JC,P = 2.0 Hz), 128.51, 128.47, 
128.4, 128.3, 128.0, 127.9, 119.2 (d, JC,P = 5.9 Hz), 115.8 (d, JC,P = 2.8 Hz), 114.1 (d, 
JC,P = 5.7 Hz), 79.1, 71.1 (d, JC,P = 159.0 Hz), 68.7 (d, JC,P = 6.8 Hz), 68.4 (d, JC,P = 7.3 Hz), 
32.83, 32.78, 24.1. 31P NMR (162 MHz, CDCl3) δ 23.31. HRMS (ESI) calcd for 
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C26H29O5PNa [M + Na]+, 475.1650; Found 475.1629. IR (FTIR) νmax 3290, 2965, 1599, 
1255, 989, 736, 694. 
Dibenzyl α-hydroxybenzylphosphonate (5.16). 
From benzaldehyde (500 mg, 4.72 mmol): purification by column chromatography (ethyl 
acetate:hexane, 1:1, Rf = 0.24) to give 5.16 (1.53 g, 88%) as a white solid. mp 115.0–116.0ºC 
(lit. mp 117–118ºC).57 1H NMR (300 MHz, CDCl3) δ 7.20–7.46 (m, 15H), 5.04 (d, JH,P = 
10.5 Hz, 1H), 4.84–4.96 (m, 4H). The spectral data match those reported.57 
Dibenzyl α-hydroxy(benzo[b]thiophen-2-yl)methylphosphonate (5.17). 
From benzo[b]thiophene-2-carboxaldehyde (1.00 g, 6.16 mmol): recrystallisation from ethyl 
acetate gave 5.17 (1.67 g, 65%) as a white crystalline solid. mp 155.3–156.6ºC. 1H NMR 
(400 MHz, CDCl3) δ 7.78–7.80 (m, 1H), 7.66–7.68 (m, 1H), 7.22–7.36 (m, 13H), 5.33 (d, 
JH,P = 12.0 Hz, 1H), 4.99–5.10 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 140.0 (2 x s), 139.8 
(2 x s), 139.5 (2 x s), 135.95–136.06 (m), 128.72, 128.70, 128.67, 128.3, 128.2, 124.59–
124.60 (2 x s), 124.5, 123.89–123.91 (2 x s), 123.1–123.2 (2 x s), 122.5, 69.0–69.1 (m), 68.1 
(d, JC,P = 164.0 Hz). 31P NMR (162 MHz, CDCl3) δ 21.02. HRMS (ESI) calcd for 
C23H21O4PSNa [M + Na]+, 447.0796; Found 447.0804. IR (FTIR) νmax 3189, 1457, 1200, 
1006, 727, 695. 
Dibenzyl α-hydroxy(benzo[b]thiophen-3-yl)methylphosphonate (5.18). 
From benzo[b]thiophene-3-carboxaldehyde (250 mg, 1.54 mmol); recrystallisation from 
ethyl acetate gave 5.18 (339 mg, 52%), as a white crystalline solid. mp 117.7–110.3ºC. 
1H NMR (400 MHz, CDCl3) δ 7.82–7.85 (m, 2H), 7.67 (d, J = 3.4 Hz, 1H), 7.22–7.36 (m, 
10H), 7.11–7.13 (m, 2H) 5.44 (d, JH,P = 10.6 Hz, 1H), 4.80–5.07 (m, 4H). 13C NMR 
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(100 MHz, CDCl3) δ 140.5, 137.4 (d, JC,P = 6.1 Hz), 136.1 (d, JC,P = 5.8 Hz), 135.9 (d, 
JC,P = 5.8 Hz), 131.4, 128.71, 128.65, 128.63, 128.59, 128.2, 128.1, 125.9 (d, JC,P = 7.5 Hz), 
124.8, 124.4, 122.8, 122.7, 68.82 (d, JC,P = 3.3 Hz), 68.75 (d, JC,P = 3.3 Hz), 66.6 (d, 
JC,P = 164.1 Hz). 31P NMR (162 MHz, CDCl3) δ 22.66. HRMS (ESI) calcd for C23H21O4PSNa 
[M + Na]+, 447.0796; Found 447.0808. IR (FTIR) νmax 3274, 1497, 1254, 989, 764, 696. 
5.5.4 Synthesis of Nucleoside Fragments  
5′-Azido-5′-deoxyuridine (5.19). 
A solution of hydrazoic acid (HN3, ~2.5 M) was prepared by the slow addition of sulfuric 
acid (4.50 mL) to a suspension of NaN3 (10.6 g, 164 mmol) in H2O (5.30 mL) and toluene 
(64.8 mL) at 0ºC. The mixture was stirred for 30 min, at which time Na2SO4 was observed 
as a precipitate. The toluene layer was decanted, to be used immediately in the following 
reaction.   
Uridine (2.00 g, 8.19 mmol) was suspended in dry THF (80 mL) under an atmosphere of N2. 
Triphenylphosphine (6.44 g, 24.6 mmol) and the freshly prepared HN3 (49 mL, 123 mmol) 
were added to the suspension, which had been cooled to 0ºC, followed by the dropwise 
addition of diisopropyl azodicarboxylate (DIAD, 5.20 mL, 24.6 mmol). Subsequently the 
reaction mixture was allowed to warm to rt and stir for 17 h. After this time the reaction 
mixture was concentrated under reduced pressure. The resulting residue was dissolved in 
minimal amount of CH2Cl2 and extracted into H2O. After washing with CH2Cl2 the crude 
product was obtained by concentrating the aqueous phase, with the aid of a toluene azeotrope. 
The crude product was purified via column chromatography (CH2Cl2:methanol (MeOH), 9:1, 
Rf = 0.44) to afford 5.19 (2.11 g, 97%) as a white foam. mp 151.2–152.8ºC, (lit. mp 151.5–
152.5ºC).58 1H NMR (500 MHz, MeOH-d4) δ 7.71 (d, J = 8.0 Hz, 1H), 5.84 (d, J = 4.0 Hz, 
Chapter 5: Synthesis and Evaluation of Carbamate-Linked Sialyltransferase Inhibitors 
137 
1H), 5.74 (d, J = 8.0 Hz, 1H), 4.22 (t, J = 5.6 Hz, 1H), 4.10 (t, J = 5.6 Hz, 1H), 4.05–4.08 
(m, 1H), 3.69 (dd, J = 13.5 Hz, J = 3.0 Hz, 1H), 3.60 (dd, J = 13.5 Hz, J = 4.5 Hz, 1H). The 
spectral data match those reported.39  
2′,3′-O-Bis(allyloxycarbonyl)-5′-azido-5′-deoxyuridine (5.20). 
Allyl chloroformate (9.81 g, 82.0 mmol) was added dropwise over a 10 min interval to a 
solution of 5.19 (2.20 g, 8.20 mmol) in pyridine (13.1 mL, 164 mmol), which had been 
cooled to −20ºC. The reaction mixture was allowed to warm to rt and was stirred for 30 min. 
Volatiles were removed under reduced pressure and the residue was dissolved in CH2Cl2. 
The product was partitioned between ethyl acetate and H2O. The organic layer was washed 
with brine and was then dried with MgSO4 and concentrated under reduced pressure. The 
resulting crude product was purified by column chromatography (CH2Cl2:ethyl acetate, 3:2, 
Rf = 0.75) to give 5.20 (3.23 g, 90%) as an off-white gum. mp 43.2–46.8ºC. [α]D25 +30.6 (c 
= 1.5, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.20 (br s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 5.97 
(d, J = 5.0 Hz, 1H), 5.86–5.96 (m, 2H), 5.81 (d, J = 8.0 Hz, 1H), 5.26–5.40 (m, 6H), 4.59–
4.68 (m, 4H), 4.30 (d, J = 2.5 Hz, 1H), 3.78 (dd, J = 13.5 Hz, J = 2.5 Hz, 1H), 3.67 (dd, 
J = 13.5 Hz, J = 4.0 Hz, 1H). 13C NMR (125 MHz, CDCl3) δ 162.9, 153.9, 153.8, 150.2, 
140.4, 131.01, 130.96, 119.70, 119.68, 103.7, 88.6, 80.2, 75.6, 73.6, 69.6, 69.5, 51.7. HRMS 
(ESI) calcd for C17H19N5O9Na [M + Na]+, 460.1075; Found 460.1078. IR (FTIR) νmax 2107, 
1750, 1688, 1232, 1080, 908.  
2′,3′-O-Bis(allyloxycarbonyl)-5′-amino-5′-deoxyuridine (5.21). 
To a solution of 5.20 (3.23 g, 7.39 mmol) in dry THF, triphenylphosphine (3.88 g, 
14.8 mmol) was added with the resulting solution allowed to stir at rt. After 2 h a few drops 
H2O was added and the solution was heated at reflux for 6 h. Upon completion volatiles were 
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removed under reduced pressure and the subsequent crude purified by column 
chromatography (CH2Cl2:MeOH, 9:1, Rf = 0.33) to yield 5.21 (2.13 g, 70%) as a white solid. 
mp 48.2–49.5ºC. [α]D25 −4.0 (c = 1.0, MeOH). 1H NMR (500 MHz, DMSO-d6) δ 7.93 (d, 
J = 8.0 Hz, 1H), 5.86–5.98 (m, 3H), 5.69 (d, J = 8.0 Hz, 1H), 5.49 (t, J = 5.0 Hz, 1H), 5.24–
5.37 (m, 5H), 4.56–4.69 (m, 4H), 4.11–4.14 (m, 1H), 2.98 (dd, J = 15.0 Hz, J = 3.5 Hz, 1H), 
2.92 (dd, J = 15.0 Hz, J = 3.5 Hz, 1H). 13C NMR (125 MHz, DMSO-d6) δ 162.9, 153.3, 
153.1, 150.5, 142.1, 131.75, 131.63, 118.7, 102.4, 87.4, 81.3, 75.1, 73.9, 68.7, 68.5, 41.8. 
HRMS (ESI) calcd for C17H21N3O9 [M + H]+, 412.1356; Found 412.1351. IR (FTIR) νmax 
2107, 1750, 1688, 1232, 1080, 902. 
2′,3′-O-N4-Tris(benzyloxycarbonyl)-5′-deoxycytidine (5.22). 
Cytidine (1.00 g, 4.12 mmol) and imidazole (700 mg, 10.3 mmol) were dissolved in a 
minimum of DMF. Once dissolved tert-butyldimethylsilyl (TBDMS) chloride (682 mg, 
4.52 mmol) was slowly added. The resulting mixture was stirred at rt under an atmosphere 
of N2 and judged to be complete by TLC after 16 h. Upon completion the reaction solution 
was poured onto crushed ice with NaCl added, with the subsequent precipitate collected via 
vacuum filtration. The crude 5′-O-TBDMS-protected cytidine and DMAP (1.38 g, 
12.3 mmol) were dissolve in CH2Cl2 and the resulting suspension was cooled to 0ºC. Benzyl 
chloroformate (1.8 mL, 12.3 mmol) was added dropwise and the suspension stirred at rt. 
After 16 h the solution was diluted with CH2Cl2 and washed with H2O, followed by NaHCO3 
and brine. The organic phase was collected, dried with MgSO4 and concentrated under 
reduced pressure. The resulting crude product was purified by column chromatography 
(CHCl3:ethyl acetate, 4:1, Rf = 0.58) to produce the completely protected cytidine derivative 
(2.18 g, 70%) as a clear solid. The clear solid (1.96 g, 2.58 mmol) was dissolved in THF 
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(15 mL) and glacial acetic acid (0.2 mL, 3.10 mmol) was added. The reaction mixture was 
cooled to 0ºC and 1.0 M TBAF in THF (2.8 mL, 2.84 mmol) was added in a dropwise 
manner. The resulting reaction mixture was allowed to gradually warm to rt over 2 h and left 
to stir at rt for an additional 16 h. After such time, the volatile reactants were removed under 
reduced pressure with the resulting crude product was purified by column chromatography 
(CHCl3:ethyl acetate, 4:1, Rf = 0.26) to produce 5.22 (1.60 g, 96%) as a white solid. mp 96.0–
97.1ºC. 1H NMR (500 MHz, CDCl3) δ 8.28 (br s, 1H), 8.07 (d, J = 7.0 Hz, 1H), 7.26–7.37 
(m, 16H), 5.94 (d, J = 4.6 Hz, 1H), 5.73 (t, J = 4.6 Hz, 1H), 5.52 (t, J = 5.0 Hz, 1H), 5.13–
5.18 (m, 2H), 5.04–5.11 (m, 4H), 4.28 (br s, 1H), 4.20 (br s, 1H), 3.97 (d, J = 12.5 Hz, 1H), 
3.81 (d, J = 12.5 Hz, 1H). Spectral data match those reported.40 
5′-Azido-2′,3′-O-N4-tris(benzyloxycarbonyl)-5′-deoxycytidine (5.23). 
5.22 (1.60 g, 2.48 mmol) was suspended in dry THF (50 mL), with triphenylphosphine 
(1.95 g, 7.43 mmol) and the freshly prepared HN3 (14.9 mL, 37.1 mmol; see 5.19 for details) 
were added to the suspension, which had been cooled to 0ºC. To the cooled suspension, 
DIAD (1.57 mL, 7.43 mmol) was added slowly in a dropwise manner. Subsequently the 
reaction mixture was allowed to warm to r.t and stirred for 18 h. After this time, the reaction 
mixture was concentrated under reduced pressure and the crude product was purified via 
column chromatography (CH2Cl2:ethyl acetate, 4:1, Rf = 0.68) to afford 5.23 (1.62 g, 97%) 
as a white foam. mp 56.5–59.2ºC. [α]D25 +13.2 (c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) 
δ 8.00 (br s, 1H), 7.84 (d, J = 7.5 Hz, 1H), 7.28–7.37 (m, 16H), 5.93 (d, J = 2.5 Hz, 1H), 
5.51–5.52 (m, 1H), 5.34 (t, J = 5.5 Hz, 1H), 5.20 (s, 2H), 5.05–5.12 (m, 4H), 4.32 (br s, 1H), 
3.77 (dd, J = 13.0 Hz, 2.5 Hz, 1H), 3.67 (dd, J = 13.0 Hz, 4.0 Hz, 1H). 13C NMR (125 MHz, 
CDCl3) δ 163.0, 154.6, 153.93, 153.91, 152.3, 145.1, 135.0, 134.66, 134.63, 128.9, 128.8, 
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128.74, 128.69, 128.54, 128.47, 128.48, 128.46, 95.7, 91.2, 80.1, 76.6, 73.4, 70.6, 68.2, 51.3. 
HRMS (ESI) calcd for C33H30N6O10 [M + Na]+, 693.1921; Found 693.1931. IR (FTIR) νmax 
3263, 1739, 1669, 1262, 1194.  
5′-Amino-2′,3′-O-N4-tris(benzyloxycarbonyl)-5′-deoxycytidine (5.24). 
To a solution of 5.23 (1.62 g, 2.48 mmol) in dry THF, triphenylphosphine (1.30 g, 
4.96 mmol) was added with the resulting solution allowed to stir at rt. After 2 h a few drops 
H2O was added and the solution was heated at 60ºC for 5 h. Upon completion volatiles were 
removed under reduced pressure and the subsequent crude purified by column 
chromatography (CH2Cl2:MeOH, 95:5, Rf = 0.28) to yield 5.24 as a white solid (800 mg, 
50%). mp 68.0–71.3ºC. [α]D25 −18.4 (c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 8.71 
(d, J = 7.4 Hz, 1H), 7.28–7.38 (m, 15H), 7.20 (d, J = 7.4 Hz, 1H), 6.29 (d, J = 4.0 Hz, 1H), 
5.52–5.54 (m, 1H), 5.32–5.35 (m, 1H), 5.20 (s, 2H), 5.04–5.12 (m, 4H), 4.48–4.51 (m, 1H), 
3.58 (d, J = 16.1 Hz, 1H), 3.38 (d, J = 16.1 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 162.6, 
155.0, 154.0, 153.9, 152.4, 145.6, 136.0, 134.71, 134.69, 128.7, 128.61, 128.56, 128.4, 
128.34, 128.28, 95.0, 88.1, 81.4, 77.6, 74.2, 70.3–70.4 (m), 67.9, 50.7. HRMS (ESI) calcd 
for C33H32N4O10Na [M + Na]+, 667.2016; Found 667.2050. IR (FTIR) νmax 3288, 2924, 1749, 
1649, 1555, 1495, 1271, 1197, 1060, 784, 736, 696. 
5.5.5 Carbamate Coupling  
4-NPC (1.1 equiv.) was added dropwise to a solution of dibenzyl α-HP (1 equiv.), an excess 
of triethylamine (2 equiv.) and a catalytic amount of DMAP (0.1 equiv.) in dry CH2Cl2 at 
0°C. The ice bath was removed and the solution stirred at rt for 3 h. Upon completion, 
5′-aminonucleoside (1.2 equiv.; 5.21 or 5.24) was added and the reaction was stirred at rt for 
24 h. Upon completion the reaction mixture was washed with water and brine. The organic 
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phase was separated and then dried with anhydrous MgSO4, filtered and evaporated, with the 
resultant crude product purified by column chromatography. 
(Bis(benzyloxy)phosphoryl)(3-phenoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin- 
5′-yl)carbamate (5.25a).  
From 5.7 (234 mg, 638 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.35) to afford 5.25a (281 mg, 49%) as a white solid. mp 52.5–55.0ºC. [α]D25 −8.1 
(c = 0.7, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.06–7.32 (m, 18H), 6.91–6.96 (m, 2H), 
6.06 (d, JH,P = 14.0 Hz, 1H), 5.83–5.96 (m, 2H), 5.59–5.74 (m, 2H), 5.47–5.53 (m, 2H), 5.25–
5.37 (m, 5H), 4.85–5.05 (m, 4H), 4.56–4.64 (m, 4H), 4.14–4.20 (m, 1H), 3.39–3.60 (m, 2H). 
13C NMR (100 MHz, CDCl3) δ 162.8, 157.4 (2 x d, JC,P = 2.0 Hz), 156.96–157.03 (2 x s), 
155.0–155.3 (m), 153.85–153.90 (m), 149.95–149.99 (2 x s), 142.0–142.1 (2 x s), 136.0–
136.2 (m), 135.7–135.8 (2 x s), 131.11–131.14 (2 x s), 131.0 (m), 129.9, 128.67, 128.65, 
128.62, 128.56, 128.5, 128.07, 128.05, 128.01, 123.5–123.6, 122.6–122.7, 119.7, 119.46–
119.50 (2 x s), 119.1–119.2, 118.2–118.3 (m), 103.2, 92.4–92.5 (2 x s), 80.3, 75.93–75.97 (2 
x s), 73.1–73.2 (2 x s), 71.4–71.5 (2 x d, JC,P = 170.0 Hz), 69.5, 69.4, 68.6–68.9 (m), 41.85–
42.01 (2 x s). 31P NMR (162 MHz, CDCl3) δ 19.51–19.56 (2 x s). HRMS (ESI) calcd for 
C45H44N3O15PNa [M + Na]+, 920.2402; Found 920.2404. IR (FTIR) νmax 1689, 1231, 1007, 
739.  
(Bis(benzyloxy)phosphoryl)(4-fluoro-3-phenoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbony-
l)uridin-5′-yl)carbamate (5.25b).  
From 5.8 (281 mg, 588 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.50) to afford 5.25b (206 mg, 38%) as an off-white solid. mp 70.0–73.0ºC. 
[α]D25 −9.8 (c = 1.9, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.19 (br s, 1H), 7.03–7.30 (m, 
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17H), 6.90 (d, J = 8.3 Hz, 2H), 5.98 (d, JH,P = 12.4 Hz, 1H), 5.83–5.94 (m, 2H), 5.65–5.74 
(m, 2H), 5.43–5.54 (m, 2H), 5.25–5.38 (m, 5H), 4.86–5.05 (m, 4H), 4.55–4.66 (m, 4H), 4.14–
4.19 (m, 1H), 3.40–3.58 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 162.86–162.91 (2 x s), 
157.17–157.21 (2 x s), 154.9–155.1 (m), 154.5 (d, JC,F = 249.0 Hz), 153.8–153.9 (m), 
149.96–150.02 (2 x s), 143.6–143.8 (m), 142.2–142.4 (m), 135.9–136.1 (m), 131.08–131.15 
(2 x s), 130.96–131.02 (2 x s), 130.7–130.8 (2 x s), 129.8–129.9 (2 x s), 128.6–128.8 (m), 
128.0–128.1 (m), 124.3, 123.3–123.4 (2 x s), 121.5, 119.73, 119.48–119.54 (2 x s), 117.35–
117.40 (2 x s), 117.2 (d, JC,F = 18.0 Hz), 103.2, 92.7–92.8 (2 x s), 80.2–80.3 (2 x s), 75.8–
75.9 (2 x s), 73.1–73.4 (2 x s), 70.8–70.9 (2 x d, JC,P = 171. 0 Hz), 69.5, 69.4, 68.6–69.0 (m), 
42.0. 31P NMR (162 MHz, CDCl3) δ 19.38–19.46 (2 x d, JP,F = 4.9 Hz). 19F NMR 
(235.3 MHz, CDCl3) δ −67.57 – −67.79 (2 x d, JF,P = 1.9 Hz). HRMS (ESI) calcd for 
C45H43N3O15PFNa [M + Na]+, 938.2308; Found 938.2311. IR (FTIR) νmax 1685, 1231, 986, 
734.  
(Bis(benzyloxy)phosphoryl)(4-fluorophenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin-5′- 
yl)carbamate (5.25c)  
From 5.9 (196 mg, 506 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
8:2, Rf = 0.48) to afford 5.25c (165 mg, 40%) as a white solid. mp 80.9–81.6ºC. [α]D25 −5.4 
(c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.80 (br s, 1H), 7.38–7.41 (m, 2H), 7.23–
7.31 (m, 8H), 7.12–7.18 (m, 3H), 6.94–6.99 (m, 2H), 6.00–6.07 (m, 2H), 5.83–5.93 (m, 2H), 
5.63–5.68 (2 x d, J = 8.0 Hz, 1H), 5.56–5.57 (m, 1H), 5.49–5.54 (m, 1H), 5.24–5.36 (m, 5H), 
4.80–5.09 (m, 4H), 4.54–4.65 (m, 4H), 4.17–4.19 (m, 1H), 3.40–3.56 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 163.3, 162.96–163.00 (2 x d, JC,F = 246.0 Hz), 155.1–155.3 (m), 
153.79–153.84 (m), 150.2, 142.0–142.2 (2 x s), 135.8–136.1 (m), 131.0–131.1 (2 x s), 130.9, 
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129.7–130.0 (m), 129.45–129.54 (m), 128.61, 128.58, 128.55, 128.51, 128.04, 128.00, 
127.97, 127.95, 119.61–119.63 (2 x s), 119.38–119.43 (2 x s), 115.6 (d, JC,F = 21.0 Hz), 
103.2, 92.0–92.1 (2 x s), 80.2, 75.7–75.9 (2 x s), 73.2–73.3 (2 x s), 70.9–71.0 (2 x d, 
JC,P = 173.0 Hz), 69.5, 69.3, 68.6–68.9 (m), 41.9–42.1 (2 x s). 31P NMR (162 MHz, CDCl3) 
δ 19.84–19.91 (m). 19F NMR (235.3 MHz, CDCl3) δ −49.98 – −50.22  (2 x d, JF,P = 2.4 Hz). 
HRMS (ESI) calcd for C39H39N3O14FPNa [M + Na]+, 846.2051; Found 846.2077. IR (FTIR) 
νmax 1751, 1222, 994, 871.  
(Bis(benzyloxy)phosphoryl)(3-fluorophenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin-5′- 
yl)carbamate (5.25d).  
From 5.10 (299 mg, 755 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf  = 0.52) to afford 5.25d (136 mg, 22%) as a white solid. mp 76.0–77.5ºC. [α]D25 −3.1 
(c = 6.7, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.46 (br s, 1H), 7.10–7.30 (m, 14H), 6.97–
7.01 (m, 1H), 6.06 (d, JH,P = 16.0 Hz, 1H), 5.83–5.94 (m, 3H), 5.63–5.67 (2 x d, J = 8.0 Hz, 
1H), 5.49–5.54 (m, 2H), 5.25–5.38 (m, 5H), 4.84–5.07 (m, 4H), 4.55–4.66 (m, 4H), 4.16–
4.19 (m, 1H), 3.42–3.58 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 163.0, 162.75–162.78 
(2 x d, JC,F = 245.0 Hz), 155.0–155.2 (m), 153.8–153.9 (m), 150.1, 142.1–142.2 (2 x s), 
135.8–136.3 (m), 131.08–131.12 (2 x s), 131.0, 130.1 (d, JC,F = 8.0 Hz), 128.67, 128.65, 
128.62, 128.58, 128.11, 128.09, 128.05, 123.4–123.7 (m), 119.7, 119.42–119.47 (2 x s), 
115.6–115.9 (m), 114.8–115.0 (2 x d, JC,F = 22.0 Hz), 103.2, 92.4, 80.2, 75.8–75.9 (2 x s), 
73.2, 71.05–71.14 (2 x d, JC,P = 170.0 Hz), 69.5, 69.3, 68.7–69.1 (m), 41.9–42.1 (2 x s). 
31P NMR (162 MHz, CDCl3) δ 19.26–19.29 (2 x s). 19F NMR (235.3 MHz, CDCl3) δ −49.92 
– −50.03 (2 x s). HRMS (ESI) calcd for C39H40N3O14PNa [M + Na]+, 828.2140; Found 
828.2144. IR (FTIR) νmax 1677, 1207, 947, 781, 734, 688. 
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(Bis(benzyloxy)phosphoryl)(3-propoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin- 
5′-yl)carbamate (5.25e).  
From 5.11 (372 mg, 617 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.26) to afford 5.25e (268 mg, 36%) as a white solid. mp 60.1–61.1ºC. [α]D25 −2.2 
(c = 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.33 (br s, 1H), 7.15–7.31 (m, 11H), 7.12 
(d, J = 8.0 Hz, 1H), 6.96–7.01 (m, 1H), 6.95–6.97 (m, 1H), 6.82–6.88 (m, 1H), 6.06–6.07 
(2 x d, JH,P = 16.0 Hz, 1H), 5.84–5.94 (m, 2H), 5.78–5.81 (m, 1H), 5.67 (d, J = 8.0 Hz, 0.5H), 
5.59 (d, J = 8.0 Hz, 0.5H), 5.51–5.54 (m, 1H), 5.46–5.50 (m, 1H), 5.26–5.36 (m, 5H), 4.79–
5.07 (m, 4H), 4.55–4.66 (m, 4H), 4.17 (br s, 1H), 3.75–3.87 (s, 2H), 3.39–3.60 (m, 2H), 1.75 
(sxt, J = 7.4 Hz, 2H), 0.990–0.994 (2 x t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 
162.89–162.93, 159.2, 155.1–155.4 (m), 153.86–153.9 (m), 150.0, 142.0–142.1 (2 x s), 
136.0–136.2 (m), 134.9–135.0 (2 x s), 131.07–131.10 (2 x s), 130.9, 129.6, 128.63, 128.59, 
128.56, 128.50, 128.47, 128.1, 128.04, 127.99, 120.0–120.1 (2 x d, JC,P = 5.5 Hz), 119.7, 
119.46–119.49 (2 x s), 115.2–115.3 (2 x s), 113.7–114.0 (2 x d, JC,P = 5.6 Hz), 103.2, 92.2–
92.3 (2 x s), 80.2, 75.95–76.03 (2 x s), 73.0–73.2 (2 x s), 71.6–71.7 (2 x d, JC,P = 170.0 Hz), 
69.53, 69.40, 69.3, 68.6–68.9 (m), 41.7–42.0 (2 x s), 22.6, 10.6. 31P NMR (162 MHz, CDCl3) 
δ 19.94. HRMS (ESI) calcd for C42H46N3O15PNa [M + Na]+, 886.2564. Found 886.2590. IR 
(FTIR) νmax 2963, 1693, 1224, 1094, 808, 732. 
(Bis(benzyloxy)phosphoryl)(3-methoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin- 
5′-yl)carbamate (5.25f).  
From 5.12 (400 mg, 1.06 mmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.26) to afford 5.25f (317 mg, 38%) as a white solid. mp 64.7–65.5ºC. [α]D25 −9.7 
(c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.25 (br s, 1H), 7.17–7.31 (m, 11H), 7.10 
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(d, J = 8.0 Hz, 1H), 7.01 (d, J = 7.6 Hz, 1H), 6.98 (s, 1H), 6.83–6.86 (m, 1H), 6.07 (d, JH,P = 
14.0 Hz, 1H), 5.85–5.93 (m, 2H), 5.79 (bs, 1H), 5.67 (d, J = 8.0 Hz, 0.5H), 5.60 (d, J = 8.0 
Hz, 0.5H), 5.47–5.50 (m, 2H), 5.26–5.37 (m, 5H), 4.80–5.07 (m, 4H), 4.58–4.64 (m, 4H), 
4.16–4.20 (m, 1H), 3.72 (s, 3H), 3.42–3.61 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 162.8–
162.9, 159.6–159.7, 155.2–155.3 (2 x d, JC,P = 11.4 Hz), 153.8–153.9 (m), 150.0, 142.1–
142.2 (2 x s), 135.9–136.2 (m), 135.0–135.1 (2 x s), 131.09–131.07 (2 x s), 130.9, 129.6–
129.7 (2 x d, JC,P = 1.5 Hz), 128.7, 128.62, 128.59, 128.55, 128.54, 128.51, 128.11, 128.06, 
128.03, 128.00, 120.2–120.3 (2 x d, JC,P = 5.5 Hz), 119.7, 119.5, 114.5–114.6 (2 x s), 113.2–
113.5 (2 x d, JC,P = 5.5 Hz), 103.18–103.21 (2 x s), 92.6–92.7 (2 x s), 80.2, 76.0–76.1 (2 x s), 
72.9–73.0 (2 x s), 71.5–71.6 (2 x d, JC,P = 170.0 Hz), 69.5, 69.4, 68.7–69.0 (m), 55.29–55.33 
(2 x s), 41.6–41.8 (2 x s). 31P NMR (162 MHz, CDCl3) δ 19.89. HRMS (ESI) calcd for 
C40H42N3O15PNa [M + Na]+, 858.2251; Found 858.2214. IR (FTIR): νmax 2930, 1688, 1236, 
1028, 808, 733. 
(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin- 
5′-yl)carbamate (5.25g).  
From 5.13 (454 mg, 1.14 mmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.50) to afford 5.25g (592 mg, 62%) as a white solid. mp 48.3–51.7ºC. [α]D25 −1.5 
(c = 1.6, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.41 (br s, 1H), 7.36–7.37 (m, 2H), 7.26–
7.32 (m, 8H), 7.15–7.19 (m, 2H), 7.10 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 6.00–
6.04 (m, 1H), 5.84–5.92 (m, 3H), 5.59–5.67 (m, 1H), 5.47–5.51 (m, 2H), 5.33–5.37 (m, 4H), 
5.26–5.30 (m, 1H), 4.74–5.10 (m, 4H), 4.56–4.66 (m, 4H), 4.18 (br s, 1H), 3.78–3.79 (2 x s, 
3H), 3.39–3.58 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 162.9, 160.1–160.2 (2 x s), 155.3–
155.4 (m), 153.85–153.92 (m), 150.1, 142.1–142.2 (2 x s), 135.9–136.3 (m), 131.06–131.09 
Chapter 5: Synthesis and Evaluation of Carbamate-Linked Sialyltransferase Inhibitors 
146 
(2 x s), 130.9, 129.5–129.7 (2 x d, JC,P = 6.3 Hz), 128.5–128.7 (m), 128.1, 128.0, 127.9, 
125.4–125.5 (2 x s), 119.7, 119.50–119.54 (2 x s), 114.1, 103.21–103.24 (2 x s), 92.6, 80.2, 
75.9–76.1 (2 x s), 72.9–73.1 (2 x s), 71.27–71.30 (2 x d, JC,P = 172. 5 Hz), 69.0, 68.9, 68.6–
68.8 (m), 55.38–55.40 (2 x s), 41.6–41.9 (2 x s). 31P NMR (162 MHz, CDCl3) 20.43. HRMS 
(ESI) calcd for C40H42N3O15PNa [M + Na]+, 858.2246; Found 858.2241. IR (FTIR) νmax 
2917, 2848, 1701, 1236, 1081, 808.  
(Bis(benzyloxy)phosphoryl)(3-cyclopentoxy-4-methoxyphenyl)methyl(2′, 3′-O-bis(allyloxy- 
carbonyl)uridin-5′-yl)carbamate (5.25h). 
From 5.14 (226 mg, 469 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.38) to afford 5.25h (220 mg, 51%) as an off-white solid. mp 74.7–75.3ºC. 
[α]D25 −1.0 (c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.10 (br s, 1H), 7.27–7.31 (m, 
8H), 7.09–7.20 (m, 3H), 6.96–7.00 (m, 2H), 6.79 (d, J = 8.0 Hz, 1H), 6.00–6.02 (d, 
JH,P = 15.0 Hz, 1H), 5.85–5.94 (m, 2H), 5.62–5.69 (m, 2H), 5.48–5.51 (m, 2H), 5.27–5.38 
(m, 5H), 4.76–5.09 (m, 4H), 4.60–4.65 (m, 5H), 4.18 (br s, 1H), 3.82–3.83 (2 x s, 3H), 3.37–
3.64 (m, 2H), 1.77–1.85 (m, 6H), 1.54 (br s, 2H). 13C NMR (125 MHz, CDCl3) δ 162.69–
162.74 (2 x s), 155.2–155.4 (m), 153.85–153.93 (m), 150.5–150.6 (2 x d, JC,P = 2.5 Hz), 
149.97–150.01 (2 x s), 147.7, 142.1–142.2 (2 x s), 136.0–136.3 (m), 131.06–131.10 (2 x s), 
130.9, 128.7, 128.60, 128.56, 128.51, 128.46, 128.11, 128.05, 128.03, 127.97, 125.7 (d, 
JC,P = 6.3 Hz), 120.7–120.9 (2 x d, JC,P = 7.5 Hz), 119.8, 119.5–119.6 (2 x s), 114.5–114.7 (2 
x d, JC,P = 5.0 Hz), 111.8, 103.3, 92.6–92.8 (2 x s), 80.39–80.44 (2 x s), 80.21–80.24 (2 x s), 
76.0–76.1 (2 x s), 72.99–73.03 (2 x s), 71.5–71.6 (2 x d, JC,P = 172.5 Hz), 69.5, 69.4, 68.5–
68.7 (m), 56.1–56.2 (2 x s), 41.7–41.9 (2 x s), 32.8, 24.2. 31P NMR (162 MHz, CDCl3) δ 
Chapter 5: Synthesis and Evaluation of Carbamate-Linked Sialyltransferase Inhibitors 
147 
20.38. HRMS (ESI) calcd for C45H51N3O16P [M + H]+, 920.3007; Found 920.3010. IR 
(FTIR) νmax 2928, 1692, 1235, 1028, 808. 
(Bis(benzyloxy)phosphoryl)(3-cyclopentoxyphenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)ur- 
idin-5′-yl)carbamate (5.25i). 
From 5.15 (221 mg, 487 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.67) to afford 5.25i (165 mg, 38%) as a white solid. mp 71.2–73.6ºC. [α]D25 −1.5 
(c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.55 (br s, 1H), 7.12–7.33 (m, 12H), 6.94–
6.99 (m, 2H), 6.79–6.83 (m, 1H), 6.06–6.07 (2 x d, JH,P = 13.9 Hz, 1H), 5.85–5.93 (m, 3H), 
5.59–5.70 (m, 1H), 5.53–5.55 (m, 1H), 5.48 (br s, 1H), 5.25–5.36 (m, 5H), 4.78–5.10 (m, 
4H), 4.56–4.66 (m, 5H), 4.16–4.20 (m, 1H), 3.40–3.58 (m, 2H), 1.72–1.87 (m, 6H), 1.56 
(br s, 2H). 13C NMR (125 MHz, CDCl3) δ 163.1, 158.2, 155.2–155.4 (m), 153.8–153.9 (m), 
150.1, 141.9–142.0 (2 x s), 135.9–136.2 (m), 134.8–134.9, 131.06–131.08 (2 x s), 130.9, 
129.6, 128.60, 128.56, 128.53, 128.46, 128.4, 128.1, 128.01, 127.99, 127.96, 119.74–119.78 
(m), 119.66, 119.45–119.4 (2 x s), 116.1–116.2 (2 x s), 114.8–115.0 (2 x d, JC,P = 5.7 Hz), 
103.2, 92.0–92.2 (m), 80.1, 79.25–79.28, 75.9–76.0 (2 x s), 73.0–73.2 (2 x s), 71.56–71.63 
(2 x d, JC,P = 170.9 Hz), 69.47–69.50 (2 x s), 69.3, 68.6–68.9 (m), 41.7–42.0 (2 x s), 32.8, 
32.9, 24.1. 31P NMR (162 MHz, CDCl3) δ 20.05. HRMS (ESI) calcd for C44H48N3O15PNa 
[M + Na]+, 912.2721; Found 912.2706. IR (FTIR) νmax 3299, 2960, 1689, 1233, 991, 782, 
734, 696.  
(Bis(benzyloxy)phosphoryl)(phenyl)methyl(2′, 3′-O-bis(allyloxycarbonyl)uridin-5′-yl)carb- 
amate (5.25j). 
From 5.16 (310 mg, 843 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf  = 0.40) to afford 5.25j (301 mg, 44%) as a white solid. mp 70.0–72.0ºC. [α]D25 −2.5 
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(c = 2.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.78 (br s, 1H), 7.43 (br s, 2H), 7.24–7.33 
(m, 11H), 7.20 (br s, 1H), 7.16 (br s, 1H), 7.08–7.10 (m, 1H), 6.075–6.080 (2 x d, 
JH,P = 14.0 Hz, 1H), 5.87–5.93 (m, 2H), 5.58–5.68 (m, 2H), 5.47–5.50 (m, 2H), 5.27–5.37 
(m, 5H), 4.78–5.06 (m, 4H), 4.60–4.67 (m, 4H), 4.18 (br s, 1H), 3.40–3.61 (m, 2H). 13C NMR 
(125 MHz, CDCl3) δ 163.20–163.23 (2 x s), 155.2–155.4 (2 x d, JC,P = 11.3 Hz), 153.79–
153.82 (m), 150.1, 141.8–142.0 (2 x s), 135.9–136.2 (m), 133.5–133.6 (2 x s), 131.0, 130.9, 
128.9, 128.8, 128.6, 128.51, 128.45, 128.01, 127.95, 127.9, 119.6, 119.39–119.43 (2 x s), 
103.1, 91.6–91.8 (2 x s), 80.13–80.09 (2 x s), 75.8–75.9 (2 x s), 73.1–73.2 (2 x s), 71.5–71.6 
(2 x d, JC,P = 170.0 Hz), 69.4, 69.3, 68.5–69.0 (m), 41.8–42.1 (2 x s). 31P NMR (162 MHz, 
CDCl3) δ 19.97. HRMS (ESI) calcd for C39H40N3O14PNa [M + Na]+, 828.2140; Found 
828.2144. IR (FTIR) νmax 1681, 1208, 980, 734, 693. 
(Bis(benzyloxy)phosphoryl)(benzo[b]thiophen-2-yl)methyl(2′, 3′-O-bis(allyloxycarbonyl)ur-
idin-5′-yl)carbamate (5.25k).  
From 5.17 (229 mg, 540 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf  = 0.40) to afford 5.25k (257 mg, 36%) as a white solid. mp 96.6–99.0ºC. [α]D25 −2.6 
(c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.23 (br s, 1H), 7.76–7.78 (m, 1H), 7.65–
7.70 (m, 1.5H), 7.53–7.56 (m, 0.5H), 7.44–7.48 (m, 1H), 7.35–7.38 (m, 1H), 7.17–7.33 (m, 
11H), 7.10–7.11 (2 x d, J = 10.0 Hz, 1H), 6.41 (d, JH,P = 15.0 Hz, 1H), 5.83–5.94 (m, 2H), 
5.66 (d, J = 8.0 Hz, 0.5H), 5.58–5.60 (m, 1.5H), 5.47–5.52 (m, 2H), 5.24–5.38 (m, 4H), 4.92–
5.14 (m, 4H), 4.54–4.65 (m, 4H), 4.16–4.21 (m, 1H), 3.42–3.66 (m, 2H). 13C NMR 
(125 MHz, CDCl3) δ 162.8, 155.0–155.2 (m), 153.8–153.9 (m), 150.0–150.1 (2 x s), 142.0–
142.1 (2 x s), 140.3, 139.23 (d, JC,P = 5.0 Hz), 139.16, 135.8–136.2 (m), 133.0, 132.2–132.3 
(2 x s), 132.09–132.07 (2 x s), 131.05–131.10 (2 x s), 130.9, 128.7, 128.61, 128.58, 128.57, 
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128.20, 128.17, 128.14, 128.12, 125.1–125.3 (m), 124.5–124.9 (m), 124.2, 122.4, 119.7, 
119.47–119.52 (2 x s), 103.21–103.24 (2 x s), 92.2–92.5 (2 x s), 80.15–80.21 (2 x s), 75.9–
76.0 (2 x s), 73.1–73.2 (2 x s), 69.5, 69.3–69.4 (2 x s), 69.0–69.1 (m), 68.5 (d, JC,P = 
177.5 Hz), 41.8–42.1 (2 x s). 31P NMR (162 MHz, CDCl3) δ 18.26. HRMS (ESI) calcd for 
C41H40N3O14PSNa [M + Na]+, 884.1866; Found 884.1908. IR (FTIR) νmax 2929, 1693, 1200, 
1007, 733, 661. 
(Bis(benzyloxy)phosphoryl)(benzo[b]thiophen-3-yl)methyl(2′, 3′-O-bis(allyloxycarbonyl)ur-
idin-5′-yl)carbamate (5.25l).  
From 5.18 (258 mg, 608 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.49) to afford 5.25l (384 mg, 73%) as a white solid. mp 80.0–83.0ºC. [α]D25 −20.0 
(c = 0.1, CHCl3). 1H NMR (400 MHz, CDCl3) 7.93–7.98 (m, 1H), 7.78–7.83 (m, 1H), 7.72–
7.73 (m, 1H), 7.00–7.33 (m, 13H), 6.54 (d, JH,P = 14.2 Hz, 1H), 5.81–5.99 (m, 3H), 5.43–
5.56 (m, 3H), 5.52–5.36 (m, 5H), 4.96–5.12 (m, 4H), 4.51–4.64 (m, 4H), 4.14–4.19 (m, 1H), 
3.39–3.57 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 163.0, 155.3–155.5 (m), 153.9, 153.8, 
150.1, 141.8–141.9 (2 x s), 140.1–140.2 (2 x s), 137.4–137.5 (2 x s), 135.6–136.2 (m), 
131.07–131.10 (2 x s), 130.9, 128.6, 128.51, 128.47, 128.4, 128.13, 128.05, 128.0, 127.9, 
127.7–127.8 (2 x s), 124.76–124.81 (2 x s), 124.5–124.6 (2 x s), 122.7–122.8 (m), 119.6, 
119.4, 103.1, 91.8–91.9 (2 x s), 80.1–80.2 (2 x s), 75.8–75.9 (2 x s), 73.16–73.19 (2 x s), 
69.5, 69.3, 68.7–69.0 (m), 66.4 (d, JC,P = 176.6 Hz), 41.9–42.0 (2 x s). 31P NMR (162 MHz, 
CDCl3) δ 19.57–19.61 (2 x s). HRMS (ESI) calcd for C41H40N3O14PSNa [M + Na]+, 
884.1866; Found 884.1888. IR (FTIR) νmax 3064, 1753, 1688, 1232, 991. 
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(Bis(benzyloxy)phosphoryl)(3-phenoxyphenyl)methyl(N4, 2′, 3′-O-bis(benzyloxycarbonyl)c-
ytidin-5′-yl)carbamate (5.28).  
From 5.7 (423 mg, 918 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.91) to afford 5.28 (242 mg, 23%) as a white solid. mp 57.7–60.0ºC. [α]D25 −10.0 
(c 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.52 (br s, 1H), 7.50–7.54 (m, 1H), 7.13–7.32 
(m, 31H), 7.02–7.05 (m, 1H), 6.87–6.92 (m, 3H), 6.48–6.52 (m, 1H), 6.08–6.10 (2 x d, 
JH,P = 14.0 Hz, 1H), 5.68 (br s, 1H), 5.52–5.55 (2 x d, J = 2.5 Hz, 1H), 5.35–5.42 (m, 1H,), 
5.15 (s, 2H), 4.79–5.08 (m, 8H), 4.25 (br s, 1H), 3.46–3.61 (m, 2H). 13C NMR (125 MHz, 
CDCl3) δ 163.4, 157.3, 156.88–156.90 (2 x s), 155.1–155.3 (m), 154.78–154.80 (2 x s), 
153.92–153.95 (m), 152.4–152.5 (2 x s), 146.5–146.6 (2 x s), 135.9–136.2 (m), 135.8, 
135.1–135.2, 134.8, 134.6, 129.9, 129.8, 128.3–128.7 (m), 127.8–128.0 (m), 123.4, 122.4–
122.6 (2 x d, JC,P = 5.1 Hz), 119.0–119.1 (2 x s), 118.75–118.80 (2 x s), 118.1–118.2 (m), 
95.8, 94.2–94.3 (2 x s), 80.3–80.5 (2 x s), 76.3–76.4 (2 x s), 73.9–74.1 (2 x s), 71.16–71.19 
(2 x d, JC,P = 170.0 Hz), 70.4, 70.27–70.31 (2 x s), 68.8–69.0 (2 x d, JC,P = 6.6 Hz), 68.5–68.7 
(2 x d, JC,P = 6.5 Hz), 67.86–67.90 (2 x s), 42.2. 31P NMR (162 MHz, CDCl3) δ 19.74–19.77 
(2 x s). HRMS (ESI) calcd for C61H55N4O16PNa [M + Na]+, 1153.3248; Found 1153.3279. 
IR (FTIR) νmax 2919, 1754, 1666, 1566, 1510, 1254, 1034.  
5.5.6 Alloc Deprotection  
A suspension of Alloc protected carbamate (5.25a–l), Pd(PPh3)4 (15mol%) and dimedone 
(8 equiv.) in dry THF was stirred at rt. Upon consumption of starting material (generally after 
30 min) volatiles were removed under reduced pressure and the subsequent crude purified by 
column chromatography. 
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(Bis(benzyloxy)phosphoryl)(3-phenoxyphenyl)methyl(uridin-5′-yl)carbamate (5.26a). 
From 5.25a (174 mg, 194 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.05) to afford 5.26a (138 mg, 81%) as a white solid. mp 66.0–67.0ºC. [α]D25 +4.8 
(c = 4.4, MeOH). 1H NMR (400 MHz, CDCl3) δ 10.20 (br s, 1H), 7.01–7.26 (m, 18H), 6.84–
6.92 (m, 2H), 6.25–6.29 (m, 1H), 6.04–6.10 (m, 1H), 5.54–5.62 (m, 2H), 4.78–5.00 (m, 4H), 
4.19–4.22 (m, 1H), 4.04–4.10 (m, 1H), 3.99–4.00 (m, 1H), 3.29–3.49 (m, 2H). 13C NMR 
(100 MHz, CDCl3) δ 163.8, 157.4–157.5 (2 x s), 156.88–156.93 (2 x s), 155.5 (d, 
JC,P = 12.1 Hz), 151.0, 141.5–141.8 (2 x s), 135.6–135.9 (m), 130.0, 128.74, 128.69, 128.0, 
127.9, 123.7, 122.5–122.6 (2 x s), 119.0–119.2 (2 x s), 118.2–118.3 (m), 102.8, 92.6–93.1 (2 
x s), 82.65–82.69 (2 x s), 73.9–74.0 (2 x s), 71.2–71.3 (2 x d, JC,P = 173.0 Hz), 70.8–71.0 (2 
x s), 68.9–69.1 (m), 42.7–43.0 (2 x s). 31P NMR (162 MHz, CDCl3) δ 19.74–19.77 (2 x s). 
HRMS (ESI) calcd for C37H36N3O11PNa [M + Na]+, 752.1985; Found 752.1980. 
IR (FTIR) νmax 3313, 2924, 1665, 1245, 1053, 734, 689. 
(Bis(benzyloxy)phosphoryl)(4-fluoro-3-phenoxyphenyl)methyl(uridin-5′-yl)carbamate 
(5.26b). 
From 5.25b (152 mg, 162 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.27) to afford 5.26b (105 mg, 84%) as a white solid. mp 70.0–71.5  C. [α]D25 −1.4 
(c = 3.6, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.19 (br s, 1H), 7.02–7.26 (m, 17H), 6.82–
6.85 (m, 2H), 6.18 (br s, 1H), 5.96–6.02 (m, 1H), 5.52–5.63 (m, 2H), 4.79–5.01 (m, 4H), 
4.22 (br s, 1H), 4.08 (bs, 1H), 3.99 (bs, 1H), 3.32–3.55 (m, 2H). 13C NMR (125 MHz, CDCl3) 
δ 163.9, 157.1, 155.3 (d, JC,P = 10.9 Hz), 154.4 (d, JC,F = 250.8 Hz), 151.0–151.1 (2 x s), 
143.5–143.7 (m), 141.5–141.7 (2 x s), 135.5–135.7 (m), 130.5, 129.9, 128.74, 128.69, 
128.02, 127.95, 124.3, 123.39–123.42 (2 x s), 121.4–121.5 (2 x s), 117.3–117.4 (m), 102.7, 
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92.5–92.8 (2 x s), 82.5–82.6 (2 x s), 73.9, 70.88–70.92 (2 x s), 70.57–70.61 (2 x d, 
JC,P = 172.1 Hz), 68.9–69.1 (m), 42.9–43.0 (2 x s). 31P NMR (162 MHz, CDCl3) δ 19.29–
19.47 (2 x d, JP,F = 4.0 Hz). 19F NMR (235.3 MHz, CDCl3) δ −67.14 – −67.18 (2 x s). HRMS 
(ESI) calcd for C37H35N3O11PFNa [M + Na]+, 770.1891; Found 770.1873. IR (FTIR) νmax 
3313, 2924, 1665, 1245, 1053, 986, 734.  
(Bis(benzyloxy)phosphoryl)(4-fluorophenyl)methyl(uridin-5′-yl)carbamate (5.26c). 
From 5.25c (165 mg, 200 μmol): purification by column chromatography (ethyl 
acetate:MeOH, 95:5; Rf = 0.24) to afford 5.26c (100 mg, 76%) as a white solid. mp 91.6–
92.7ºC. [α]D25 +3.9 (c = 1.0, CHCl3). 1H NMR (500 MHz, CDCl3) δ 10.32–10.37 (2 x br s, 
1H), 7.16–7.34 (m, 11H), 7.06–7.07 (m, 2H), 6.85–6.92 (m, 2H), 6.41 (br s, 1H), 6.03–6.09 
(m, 1H), 5.55–5.64 (m, 2H), 4.60–5.03 (m, 4H), 4.20 (br s, 1H), 4.01–4.05 (m, 2H), 3.33–
3.49 (m, 2H). 13C NMR (125 MHz, CDCl3): δ 164.2, 162.9–163.0 (2 x d, JC,F = 245.0 Hz), 
155.5 (d, JC,P = 11.3 Hz), 151.08–151.13, 141.5, 135.8 (d, JC,P = 5.0 Hz), 135.6 (d, 
JC,P = 6.3 Hz), 129.8–130.0 (m), 129.4, 128.7, 128.6, 128.02, 127.99, 127.95, 115.6–115.7 
(2 x d, JC,F = 21.3 Hz), 102.6, 91.6–91.8 (2 x s), 82.51–82.55 (2 x s), 74.0, 70.98–71.02 (2 x 
s), 70.79–70.84 (2 x d, JC,P = 172.5 Hz), 68.9–69.0 (m), 42.9–43.1 (2 x s). 31P NMR 
(162 MHz, CDCl3) δ 19.95–20.01 (2 x s). 19F NMR (235.3 MHz, CDCl3) δ −49.57 – −49.68 
(2 x d, JF,P = 2.4 Hz). HRMS (ESI) calcd for C31H31N3O10PFNa [M + Na]+, 678.1629; Found 
678.1628. IR (FTIR) νmax 3312, 1702, 1245, 1094, 1030, 808, 732.  
(Bis(benzyloxy)phosphoryl)(3-fluorophenyl)methyl(uridin-5′-yl)carbamate (5.26d). 
From 5.25d (193 mg, 234 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.17) to afford 5.26d (101 mg, 68%) as a white solid. mp 88.8–91.6ºC. [α]D25 +3.6 
(c = 1.0, MeOH). 1H NMR (400 MHz, CDCl3) δ 10.28–10.34 (br s, 1H), 7.05–7.30 (m, 14H), 
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6.86–6.94 (m, 1H), 6.42–6.46 (m, 1H), 6.03–6.11 (m, 1H), 5.54–5.66 (m, 2H), 4.76–5.07 (m, 
4H), 4.20–4.22 (m, 1H), 3.95–4.07 (m, 2H), 3.30–3.50 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ 164.16–164.19 (2 x s), 162.7 (d, JC,F = 246.8 Hz), 155.5 (d, JC,P = 10.8 Hz), 150.1–151.2 
(2 x s), 142.3–142.5 (2 x s), 136.09–136.13 (2 x s), 135.7–135.8 (m), 135.6 (d, JC,P = 5.9 Hz), 
130.2–130.3 (m), 128.72, 128.67, 128.1, 128.0, 123.5, 115.8–115.9 (m), 114.7–115.0 (m), 
102.6, 91.7–92.0 (2 x s), 82.5, 74.0, 70.9–71.0 (2 x s), 70.9 (d, JC,P = 165.0 Hz), 69.0–69.1 
(m), 42.8–43.1 (2 x s). 31P NMR (162 MHz, CDCl3) δ 19.50–19.56 (2 x s). 19F NMR (235.3 
MHz, CDCl3) δ −49.27 – −49.38 (2 x s). HRMS (ESI) calcd for C31H31N3O10PFNa 
[M + Na]+, 678.1629; Found 678.1626. IR (FTIR) νmax 3312, 1702, 1245, 1015, 734. 
(Bis(benzyloxy)phosphoryl)(3-propoxyphenyl)methyl(uridin-5′-yl)carbamate (5.26e). 
From 5.25e (205 mg, 237 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.15) to afford 5.26e (150 mg, 91%) as a white solid. mp 56.3–57.7ºC. [α]D25 +6.8 
(c = 1.0, MeOH). 1H NMR (400 MHz, CDCl3) δ 10.27–10.31 (2 x br s, 1H), 7.08–7.29 (m, 
12H), 6.95–6.99 (m, 1H), 6.89–6.90 (m, 1H), 6.76–6.81 (m, 1H), 6.35 (br s, 1H), 6.05–6.11 
(m, 1H), 5.33–5.67 (m, 2H), 4.73–4.98 (m, 4H), 4.19 (br s, 1H), 4.02 (br s, 2H), 3.66–3.78 
(m, 2H), 3.32–3.48 (m, 2H), 1.65–1.73 (m, 2H), 0.91–0.96 (m, 3H). 13C NMR (100 MHz, 
CDCl3) δ 164.1, 159.2, 155.6 (d, JC,P = 10.5 Hz), 151.0, 141.2–141.3 (2 x s), 135.7–135.9 
(m), 134.9, 129.7, 128.64, 128.56, 128.5, 128.00, 127.96, 127.9, 119.8–119.9 (m), 115.2–
115.3 (2 x s), 113.9–114.0 (m), 102.7, 91.6–91.7 (2 x s), 82.5–82.6 (2 x s), 74.0, 71.4–71.5 
(2 x d, JC,P = 169.0 Hz), 70.9–71.0 (2 x s), 69.5, 68.8–69.0 (m), 42.8–43.0 (2 x s), 22.6, 10.6. 
31P NMR (162 MHz, CDCl3) δ 20.05–20.07 (2 x s). HRMS (ESI) calcd for C34H38N3O11PNa 
[M + Na]+, 718.2142; Found 718.2175. IR (FTIR) νmax 3299, 2934, 1679, 1239, 992, 735, 
693. 
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(Bis(benzyloxy)phosphoryl)(3-methoxyphenyl)methyl(uridin-5′-yl)carbamate (5.26f). 
From 5.25f (267 mg, 319 μmol): purification by column chromatography (CH2Cl2:MeOH, 
9:1; Rf = 0.42) to afford 5.26f as a white solid (184 mg, 87%). mp 79.8–81.4ºC. [α]D25 −0.7 
(c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 10.34 (br s, 1H), 7.08–7.28 (m, 12H), 6.91–
6.99 (m, 2H), 6.74–6.80 (m, 1H), 6.38–6.41 (m, 1H), 6.05–6.12 (m, 1H), 5.62–5.66 (m, 1H), 
5.58 (d, J = 8.0 Hz, 0.5H), 5.51 (d, J = 8.0 Hz, 0.5H), 4.73–4.97 (m, 4H), 4.18 (br s, 1H), 
4.01–4.04 (m, 2H), 3.59–3.61 (2 x s, 3H), 3.35–3.45 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ 164.21–164.24 (2 x s), 159.6–159.7 (m), 155.6 (d, JC,P = 11.0 Hz), 151.0–151.1 (2 x s), 
141.3, 135.8 (d, JC,P = 6.0 Hz), 135.7 (d, JC,P = 6.0 Hz), 134.9, 129.67–129.72, 128.64, 
128.58, 128.0, 127.9, 120.0–120.2 (m), 114.4–114.6 (2 x s), 113.4–113.5 (m), 102.5–102.6 
(2 x s), 91.5–91.7 (2 x s), 82.5–82.6 (2 x s), 74.0, 71.3–71.4 (2 x d, JC,P = 170.0 Hz), 70.9–
71.0 (2 x s), 68.9–69.0 (m), 55.21–55.24 (2 x s), 42.8–43.0 (2 x s). 31P NMR (162 MHz, 
CDCl3) δ 20.03–20.07 (2 x s). HRMS (ESI) calcd for C32H34N3O11PNa [M + Na]+, 690.1829; 
Found 690.1827. IR (FTIR) νmax 3312, 1702, 1245, 1094, 808, 732. 
(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl(uridin-5′-yl)carbamate (5.26g). 
From 5.25g (147 mg, 176 μmol): purification by column chromatography (ethyl 
acetate:MeOH, 9:1, Rf = 0.62) to afford 5.26g (99.5 mg, 85%) as an off-white solid. mp 72.0–
75.0ºC. [α]D25 +5.4 (c = 0.8, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.12–10.21 (2 x br s, 
1H), 7.30–7.33 (m, 2H), 7.20–7.25 (m, 8H), 7.09–7.10 (m, 3H), 6.76–6.80 (2 x d, J = 8.0 Hz, 
2H), 6.25–6.30 (m, 1H), 6.02–6.06 (2 x d, JH,P = 13.5 Hz, 1H), 5.51–5.60 (m, 2H), 4.68–5.02 
(m, 4H), 4.20 (br s, 1H), 4.04–4.08 (m, 1H), 3.98–4.00 (m, 1H), 3.70–3.73 (2 x s, 3H), 3.31–
3.41 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 164.05–164.10 (2 x s), 160.1–160.2 (2 x s), 
155.7 (d, JC,P = 11.0 Hz), 151.05–151.11 (2 x s), 141.4, 136.0 (d, JC,P = 6.3 Hz), 135.8 (d, JC,P 
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= 6.3 Hz), 129.5–129.7 (2 x d, JC,P = 5.0 Hz), 128.7, 128.6, 128.5, 127.98, 127.95, 127.9, 
125.4, 114.1–114.2 (m), 102.6–102.7 (2 x s), 91.8–91.9 (2 x s), 82.6, 73.96–74.02 (2 x s), 
71.1–71.2 (2 x d, JC,P = 175.0 Hz), 70.9–71.0 (2 x s), 68.7–68.9 (m), 55.3–55.4 (2 x s), 42.7–
43.0 (2 x s). 31P NMR (162 MHz, CDCl3) δ 20.32–20.46 (2 x s). HRMS (ESI) calcd for 
C32H34N3O11PNa [M + Na]+, 690.1846; Found 690.1829. IR (FTIR) νmax 3312, 1702, 1245, 
1081, 812.  
(Bis(benzyloxy)phosphoryl)(3-cyclopentoxy-4-methoxyphenyl)methyl(uridin-5′-yl)carbama-
te (5.26h).  
From 5.25h (189 mg, 205 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.18) to afford 5.26h (109 mg, 71%) as a white solid. mp 95.1–96.8ºC. [α]D25 +18.7 
(c = 1.0, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.37 (br s, 1H), 7.19–7.33 (m, 9H), 7.08–
7.10 (m, 2H), 6.90–6.96 (m, 2H), 6.72–6.75 (m, 1H), 6.37 (br s, 1H), 6.01–6.07 (m, 1H), 
5.62–5.66 (m, 1.5H), 5.57 (d, J = 8.0 Hz, 0.5H), 4.74–5.02 (m, 4H), 4.53 (br s, 1H), 4.21 (br s, 
1H), 4.00–4.06 (m, 2H), 3.74–3.75 (2 x s, 3H), 3.30–3.54 (m, 2H), 1.72 (br s, 6H), 1.48 (br 
s, 2H). 13C NMR (125 MHz, CDCl3) δ 164.2, 155.67–155.71 (2 x d, JC,P = 10.5 Hz), 151.08–
151.11 (2 x s), 150.47–150.54 (2 x d, JC,P = 2.5 Hz), 147.5–147.6 (2 x s), 141.2–141.4 (2 x s), 
135.9 (d, JC,P = 6.3 Hz), 135.7 (d, JC,P = 6.3 Hz), 128.64, 128.56, 128.53, 128.00, 128.95, 
128.91, 128.90, 125.5, 120.6–120.7 (m), 114.65–114.69 (m), 111.8, 102.6–102.7 (2 x s), 
91.5–91.8 (2 x s), 82.5, 80.4, 74.0, 71.29–71.34 (2 x d, JC,P = 172.5 Hz), 70.8–71.0 (2 x s), 
68.7–68.9 (m), 56.0–56.1 (2 x s), 42.8–43.0 (2 x s), 32.7, 24.1. 31P NMR (162 MHz, CDCl3) 
δ 20.49–20.52 (2 x s). LRMS (ESI) calcd for C37H42N3O12PNa [M + Na]+, 774.2404; Found 
774.2398. IR (FTIR) νmax 3329, 2935, 1685, 1237, 1034, 736, 695.  
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(Bis(benzyloxy)phosphoryl)(3-cyclopentoxyphenyl)methyl(uridin-5′-yl)carbamate (5.26i). 
From 5.25i (145 mg, 163 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.15) to afford 5.26i (107 mg, 92%) as a white solid. mp 63.6–67.0ºC. [α]D25 −27.1 
(c = 1.0, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.26 (br s, 1H), 7.10–7.29 (m, 12H), 6.94–
6.97 (m, 1H), 6.89–6.90 (m, 1H), 6.75–6.79 (m, 1H), 6.29 (br s, 1H), 6.05–6.11 (m, 1H), 
5.55–5.65 (m, 2H), 4.74–4.98 (m, 4H), 4.58 (br s, 1H), 4.21 (br s, 1H), 4.01–4.08 (m, 2H), 
3.31–3.50 (m, 2H), 1.70–1.77 (m, 6H), 1.52 (br s, 2H). 13C NMR (125 MHz, CDCl3) δ 164.0, 
158.2, 155.5–155.6 (2 x d, JC,P = 10.0 Hz), 151.1, 141.3–141.5 (2 x s), 135.7–135.9 (m), 
134.8, 129.66–129.69 (2 x s), 128.7, 128.6, 128.5, 128.01, 127.98, 127.9, 119.7, 116.1–116.2 
(m), 115.0–115.1 (m), 102.65–102.72 (2 x s), 91.8–92.1 (2 x s), 82.5–82.6 (2 x s), 79.3, 74.0, 
71.37–71.45 (2 x d, JC,P = 161.2 Hz), 70.8, 68.8–69.0 (m), 42.8–43.0 (2 x s), 32.8–32.9 
(2 x s), 24.1. 31P NMR (162 MHz, CDCl3) δ 20.08. HRMS (ESI) calcd for C36H40N3O11PNa 
[M + Na]+, 744.2298; Found 744.22920. IR (FTIR) νmax 3304, 1681, 1240, 991, 733, 694.  
(Bis(benzyloxy)phosphoryl)(phenyl)methyl(uridin-5′-yl)carbamate (5.26j). 
From 5.25j (214 mg, 266 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.10) to afford 5.26j (137 mg, 80%) as a white solid. mp 112.2–114.1ºC. [α]D25 
−7.4 (c = 0.6, CHCl3). 1H NMR (400 MHz, CDCl3) δ 10.25–10.31 (2 x s, 1H), 7.36–7.38 (m, 
2H), 7.18–7.26 (br s, 12H), 7.05–7.06 (br s, 2H), 6.39–6.41 (m, 1H), 6.06–6.14 (m, 1H), 
5.49–5.64 (m, 2H), 4.68–4.96 (m, 4H), 4.17 (br s, 1H), 4.00–4.04 (m, 2H), 3.33–3.46 (m, 
2H). 13C NMR (100 MHz, CDCl3) δ 164.1–164.2 (2 x s), 155.7 (d, JC,P = 11.3 Hz), 151.09–
151.14 (2 x s), 141.35–141.40 (2 x s), 135.8 (d, JC,P = 5.7 Hz), 135.7 (d, JC,P = 6.1 Hz), 133.5, 
128.7, 128.6, 128.02, 127.97, 127.9, 102.6, 91.6–91.9 (2 x s), 82.5, 74.0, 70.8–71.0 (2 x s), 
71.5–71.6 (2 x d, JC,P = 170.0 Hz), 68.8–69.0 (m), 42.7–43.0 (2 x s).31P NMR (162 MHz, 
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CDCl3) δ 20.19–20.25 (2 x s). HRMS (ESI) calcd for C31H32N3O10PNa [M + Na]+, 660.1718; 
Found 660.1719. IR (FTIR) νmax 3288, 1678, 1239, 1012, 810, 735, 694.  
(Bis(benzyloxy)phosphoryl)(benzo[b]thiophen-2-yl)methyl(uridin-5′-yl)carbamate (5.26k). 
From 5.25k (54.2 mg, 62.9 μmol): purification by column chromatography (CH2Cl2:MeOH, 
95:5; Rf = 0.10) to afford 5.26k (42.3 mg, 97%) as a white solid. mp 104.0–105.0ºC. 
[α]D25 +1.4 (c = 1.0, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.04 (br s, 1H), 7.66–7.72 (m, 
1H), 7.57–7.63 (m, 1H), 7.10–7.30 (m, 14H), 6.40–6.47 (m, 1H), 6.33 (br s, 1H), 5.51–5.59 
(m, 2H), 4.85–5.06 (m, 4H), 4.22–4.24 (m, 1H), 4.10–4.16 (m, 1H), 4.00–4.03 (m, 1H), 3.37–
3.50 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 163.8–163.9 (2 x s), 155.4 (d, JC,P = 10.3 Hz), 
151.1, 141.8, 141.5, 140.17–140.21 (m), 139.0–139.1 (m), 135.5–136.0 (m), 128.7, 128.6, 
128.2, 128.12, 128.09, 128.05, 125.0–125.3 (m), 124.6–124.7 (2 x s), 124.1–124.2 (2 x s), 
122.4–122.5 (2 x s), 102.7, 92.4–93.0 (2 x s), 82.5–82.6 (2 x s), 73.9, 70.7–70.9 (2 x s), 
69.2–69.4 (m), 67.8–67.9 (2 x d, JC,P = 176.3 Hz), 42.7–43.0 (2 x s). 31P NMR (162 MHz, 
CDCl3) δ 18.36–18.45 (2 x s). HRMS (ESI) calcd for C33H32N3O10PSNa [M + Na]+, 
716.1444; Found 716.1439. IR (FTIR) νmax 3280, 2929, 1687, 1220, 994, 733, 696. 
(Bis(benzyloxy)phosphoryl)(benzo[b]thiophen-3-yl)methyl(uridin-5ʹ-yl)carbamate (5.26l). 
From 5.25l (300 mg, 348 μmol): purification by column chromatography (CH2Cl2:MeOH, 
98:2; Rf = 0.05) to afford 5.26l (170 mg, 70%) as a white solid. mp 88.0–92.0ºC. [α]D25 +1.2 
(c = 2.0, MeOH). 1H NMR (500 MHz, CDCl3) δ 10.17 (br s, 1H), 7.68–7.88 (m, 3H), 7.18–
7.27 (m, 11H), 6.96 (br s, 2H), 6.51–6.58 (m, 1H), 6.24–6.31 (m, 1H), 5.44–5.57 (m, 2H), 
4.67–5.00 (m, 4H), 4.07–4.19 (m, 2H), 3.98 (br s, 1H), 3.31–3.48 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ 163.8, 155.7, 151.1, 141.7, 140.1, 137.3, 135.8, 135.5, 128.7, 128.6, 128.1, 
128.0, 127.7, 125.0, 124.7, 122.8, 122.6, 102.7, 82.6, 73.9, 70.7, 69.0, 66.1–66.3 (2 x d, JC,P 
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= 175.0 Hz), 42.5. 31P NMR (162 MHz, CDCl3) δ 19.74. IR (FTIR) 3301, 2923, 1678, 1242, 
993. HRMS (ESI) calcd for C33H32N3O10PSNa [M + Na]+, 716.1444; Found 716.1468.  
5.5.7 Preparation of Sodium Salts  
To remove both Cbz and benzyl protecting groups the following procedure was undertaken. 
To a solution of protected compound (5.26a–l or 5.28) in MeOH, 10% Pd/C by mass was 
added. The mixture was stirred at rt, with H2 gas bubbled through. Upon consumption of 
starting material (generally after 1 h) the reaction mixture was filtered through a bed of 
Celite with the filtrate concentrated under reduced pressure to yield a crude mix of 
diastereoisomers. The diastereoisomers were further separated by preparative RP-HPLC 
(buffer system: CH3CN/0.05 M triethylammonium bicarbonate (TEAB) buffer, pH 7.2−7.5 
unless otherwise stated) and converted to the form of sodium salt by ion exchange resin (IR 
120 Na+) and lyophilised from water to give compound s and l as amorphous solids. 
Disodium [(3-phenoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27a). 
From 5.26a (250 mg, 343 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27a-s 
(91.8 mg, 90%) and 5.27a-l (93.8 mg, 92%) as white powders. 5.27a-s: RP-HPLC, 0−40 min 
linear gradient 13−18% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 15.60 min; mp 
decomp. > 400.0ºC. [α]D25 +39.3 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 7.58 (d, J = 
7.7 Hz, 1H), 7.45−7.50 (m, 3H), 7.37 (d, J = 7.6 Hz, 1H), 7.23–7.28 (m, 2H), 6.99−7.05 (m, 
3H), 5.95 (d, J = 3.8 Hz, 1H), 5.89 (d, J = 7.7 Hz, 1H), 5.62 (d, JH,P = 13.8 Hz, 1H), 
4.16−4.19 (m, 1H), 3.96−3.99 (m, 1H), 3.88–3.91 (m, 1H), 3.71 (dd, J = 15.0 Hz, J = 5.2 Hz, 
1H), 3.55 (dd, J = 15.0 Hz, J = 3.1 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 174.7, 
159.5 (d, JC,P = 12.8 Hz), 157.9, 156.5, 142.5, 140.5, 130.8, 130.2, 123.9, 123.7 (d, 
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JC,P = 3.4 Hz), 118.8, 118.5, 117.7, 103.6, 89.9, 82.5, 76.5 (d, JC,P = 146.1 Hz), 74.5, 70.4, 
41.9. 31P NMR (162 MHz, CDCl3) δ 12.46. HRMS (ESI) calcd for C23H24N3O11PNa 
[M + Na]+, 572.1046; Found 572.1063. IR (FTIR) νmax 3270, 1664, 1484, 1251, 1071, 968, 
749, 690. 5.27a-l: RP-HPLC, 0−40 min linear gradient 13−18% CH3CN, 0.05 M TEAB 
buffer, 15 mL/min flow; tR = 16.90 min; mp decomp. > 400.0ºC. [α]D25 +5.6 (c = 0.2, H2O). 
1H NMR (400 MHz, D2O) δ 7.47−7.56 (m, 4H), 7.31−7.39 (m, 2H), 7.26 (s, 1H), 7.15 (d, 
J = 8.0 Hz, 2H), 7.03 (d, J = 8.0 Hz, 1H), 5.93 (d, J = 4.2 Hz, 1H), 5.65 (d, JH,P = 13.7 Hz, 
1H), 5.57 (d, J = 8.0 Hz, 1H), 4.21−4.28 (m, 3H), 3.80 (dd, J = 15.6 Hz, J = 2.8 Hz, 1H), 
3.48 (dd, J = 15.6 Hz, J = 4.8 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 168.2, 159.6 
(d, JC,P = 12.0 Hz), 157.6, 157.5, 153.5, 142.6, 141.7, 131.0, 130.5, 124.8, 123.4 (d, 
JC,P = 3.0 Hz), 119.8, 118.1, 117.7 (d, JC,P = 3.0 Hz), 103.3, 89.9, 83.4, 76.7 (d, 
JC,P = 145.0 Hz), 74.5, 70.8, 42.4. 31P NMR (162 MHz, CDCl3) δ 12.51. HRMS (ESI) calcd 
for C23H24N3O11PNa [M + Na]+, 572.1046; Found 572.1071. IR (FTIR) νmax 3286, 1690, 
1486, 1252, 1071, 968, 692.  
Disodium [(4-fluoro-3-phenoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27b). 
From 5.26b (371 mg, 496 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27b-s 
(146 mg, 96%) and 5.27b-l (148 mg, 97%) as white powders. 5.27b-s: RP-HPLC, 0−40 min 
linear gradient 13−18% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 17.40 min; mp 
decomp. > 240.0ºC. [α]D25 −10.3 (c = 0.4, H2O). 1H NMR (400 MHz, D2O) δ 7.65 (d, J = 8.0 
Hz, 1H), 7.50 (t, J = 7.8 Hz, 2H), 7.26−7.39 (m, 4H), 7.03 (d, J = 8.0 Hz, 2H), 5.92–5.94 (m, 
2H), 5.57 (d, JH,P = 13.6 Hz, 1H), 4.17−4.21 (m, 1H), 3.95−3.97 (m, 1H), 3.87–3.90 (m, 1H), 
3.75 (dd, J = 15.1 Hz, J = 5.5 Hz, 1H), 3.55 (dd, J = 15.1 Hz, J = 3.1 Hz, 1H). 13C NMR 
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(100 MHz, D2O/MeOH-d4) δ 169.8, 159.7 (d, JC,P = 12.6 Hz), 158.1, 154.3, 154.0 (d, 
JC,F = 244.0 Hz), 142.5 (d, JC,F = 13.0 Hz), 141.1, 137.9, 131.0, 125.6, 124.1, 120.8, 117.4 (d, 
JC,F = 18.7 Hz), 116.9, 103.3, 89.8, 82.9, 76.2 (d, JC,P = 146.4 Hz), 74.7, 70.5, 42.0. 31P NMR 
(162 MHz, CDCl3) δ 12.34 (d, JP,F = 3.5 Hz). 19F NMR (235.3 MHz, CDCl3) δ −70.70. 
HRMS (ESI) calcd for C23H23N3O11PFNa [M + Na]+, 590.0952; Found 590.0977. IR (FTIR) 
νmax 3244, 1689, 1633, 1590, 1460, 1270, 1207, 1072, 970. 5.27b-l: RP-HPLC, 0−40 min 
linear gradient 13−18% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 25.10 min; mp 
decomp. > 240.0ºC. [α]D25 +23.7 (c = 0.3, H2O). 1H NMR (400 MHz, D2O) δ 7.59 (d, 
J = 7.9 Hz, 1H), 7.43–7.54 (m, 5H), 7.32 (t, J = 7.8 Hz, 1H), 7.15 (d, J = 8.0 Hz, 2H), 5.99 
(d, J = 4.1 Hz, 1H), 5.73–5.76 (m, 2H), 4.35 (br s, 1H), 4.29 (br s, 2H), 3.84 (d, J = 12.0 Hz, 
1H), 3.56 (d, J = 14.3 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 169.1, 158.9 (d, 
JC,P = 11.4 Hz), 157.4, 154.0, 153.5 (d, JC,F = 245.0 Hz), 142.9 (d, JC,F = 11.0 Hz), 141.3, 
137.1, 130.6, 124.7, 124.2, 120.7, 117.5, 117.2 (d, JC,F = 18.2 Hz), 103.0, 89.9, 82.6, 75.6 (d, 
JC,P = 146.7 Hz), 74.1, 70.4, 42.0. 31P NMR (162 MHz, CDCl3): δ 12.68 (d, JP,F = 2.1 Hz). 
19F NMR (235.3 MHz, CDCl3) δ −70.96. HRMS (ESI) calcd for C23H23N3O11PFNa 
[M + Na]+, 590.0952; Found 590.0959. IR (FTIR) νmax 3205, 1680, 1634, 1508, 1490, 1270, 
1208, 1070, 967.  
Disodium [(4-fluoro)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27c). 
From 5.26c (100 mg, 152 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27c-s 
(31.4 mg, 80%) and 5.27c-l (33.0 mg, 83%) as white powders. 5.27c-s: RP-HPLC, 0−50 min 
linear gradient 5−10% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 19.60 min; mp 
decomp. > 280.0ºC. [α]D25 +2.2 (c = 0.1, H2O). 1H NMR (500 MHz, D2O) δ 7.50 (d, J = 
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7.8 Hz, 1H), 7.42–7.44 (m, 2H), 7.06–7.09 (m, 2H), 5.97 (d, J = 5.7 Hz, 1H), 5.74 (d, J = 
7.8 Hz, 1H), 5.47 (d, JH,P = 13.2 Hz, 1H), 4.24–4.26 (m, 1H), 4.13–4.16 (m, 1H), 4.03–4.05 
(m, 1H), 3.57 (dd, J = 14.7 Hz, J = 7.4 Hz, 1H), 3.45 (dd, J = 14.7 Hz, J = 3.7 Hz, 1H). 13C 
NMR (125 MHz, D2O/MeOH-d4) δ 174.4, 162.4 (d, JC,F = 243.2 Hz), 159.7 (d, JC,P = 12.5 
Hz), 158.1, 141.2, 136.0, 129.2–129.3 (m), 115.4 (d, JC,F = 21.0 Hz), 103.7, 89.4, 83.3, 76.7 
(d, JC,P = 166.3 Hz), 74.1, 71.3, 43.0. 31P NMR (162 MHz, D2O) δ 12.56. 19F NMR (235.3 
MHz, D2O) δ −53.7 (d, JF,P = 3.4 Hz). HRMS (ESI) calcd for C17H18N3O10PF [M − H]−, 
474.0714; Found 474.0720. IR (FTIR) νmax 3268, 1690, 1510, 1269, 1207, 1075, 970. 5.27c-l: 
RP-HPLC, 0−50 min linear gradient 5−10% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; 
tR = 24.80 min; mp decomp. > 280.0ºC. [α]D25 −1.9 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) 
δ 7.53–7.56 (m, 2H), 7.47 (d, J = 7.8 Hz, 1H), 7.21–7.25 (m, 2H), 5.98 (d, J = 4.8 Hz, 1H), 
5.65 (d, J = 7.8 Hz, 1H), 5.60 (d, JH,P = 13.3 Hz, 1H), 4.27–4.32 (m, 2H), 4.20 (br s, 1H), 
3.57 (dd, J = 14.8 Hz, J = 2.6 Hz, 1H), 3.50 (dd, J = 14.8 Hz, J = 5.1 Hz, 1H). 13C NMR (100 
MHz, D2O/MeOH-d4) δ 172.5, 162.4 (d, JC,F = 241.0 Hz), 159.4 (d, JC,P = 14.9 Hz), 156.7, 
141.3, 135.9, 129.2 (d, JC,F = 6.5 Hz), 115.6 (d, JC,F = 21.0 Hz), 103.5, 89.6, 83.3, 76.3 (d, 
JC,P = 148.0 Hz), 74.1, 71.0, 42.5. 31P NMR (162 MHz, CDCl3) δ 12.77 (d, JP,F = 1.6 Hz). 19F 
NMR (235.3 MHz, D2O) δ −53.55 (d, JF,P = 2.8 Hz). HRMS (ESI) calcd for 
C17H19N3O10PFNa [M + Na]+, 498.3119; Found 498.3125. IR (FTIR) νmax 3382, 1687, 1264, 
1079, 963.  
Disodium [(3-fluoro)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27d).  
From 5.26d (102 mg, 154 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27d-s 
(28.8 mg, 72%) and 5.27d-l (28.0 mg, 70%) as white powders. 5.27d-s: RP-HPLC, 0−50 min 
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linear gradient 5−10% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 18.10 min; mp 
decomp. > 260.0ºC. [α]D25 +1.5 (c = 0.1, H2O). 1H NMR (500 MHz, D2O) δ 7.48–7.52 (m, 
1H), 7.35–7.42 (m, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 12.3 Hz, 1H), 7.00–7.07 (m, 
1H), 6.03 (d, J = 5.9 Hz, 1H), 5.71 (d, J = 8.1 Hz, 1H), 5.60 (d, JH,P = 13.7 Hz, 1H), 4.28–
4.31 (m, 1H), 4.17–4.21 (m, 1H), 4.10–4.12 (m, 1H), 3.47–3.64 (m, 2H). 13C NMR 
(125 MHz, D2O/MeOH-d4) δ 172.0, 163.1 (d, JC,F = 243.8 Hz), 159.5–159.7 (m), 156.4, 
142.6–142.8 (m), 130.3–130.4 (m), 123.3, 113.9–114.7 (m), 103.5, 92.8, 81.0, 76.6 (d, 
JC,P = 140.0 Hz), 74.1, 71.3, 43.4. 31P NMR (162 MHz, D2O) δ 12.30. 19F NMR (235.3 MHz, 
D2O): δ −51.79. HRMS (ESI) calcd for C17H19N3O10PF [M + Na]+, 498.3119; Found 
498.3115. IR (FTIR) νmax 3346, 1679, 1631, 1265, 1080, 971. 5.27d-l: RP-HPLC, 0−50 min 
linear gradient 5−10% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 25.80 min; mp 
decomp. > 280.0ºC. [α]D25 −1.6 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 7.42–7.47 (m, 
2H), 7.31 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 10.4 Hz, 1H), 7.09–7.13 (m, 1H), 5.94 (d, J = 
5.1 Hz, 1H), 5.62 (d, J = 7.9 Hz, 1H), 5.55 (d, JH,P = 13.6 Hz, 1H), 4.23–4.29 (m, 2H), 4.15–
4.18 (m, 1H), 3.66 (dd, J = 15.6 Hz, J = 4.0 Hz, 1H), 3.47 (dd, J = 14.8 Hz, J = 5.4 Hz, 1H). 
13C NMR (125 MHz, D2O/MeOH-d4) δ 172.0, 163.3 (d, JC,F = 237.5 Hz), 159.3 (d, 
JC,P = 11.3 Hz), 156.2, 142.7, 141.3, 130.5–130.6 (m), 123.3, 114.5 (d, JC,F = 29.0 Hz), 114.0 
(d, JC,F = 13.0 Hz), 103.4, 89.4, 83.3, 76.3 (d, JC,P = 148.8 Hz), 74.2, 71.0, 42.5. 31P NMR 
(162 MHz, D2O) δ 12.53 (d, JP,F = 13.9 Hz). 19F NMR (235.3 MHz, D2O) δ −51.43 (d, 
JF,P = 9.1 Hz). HRMS (ESI) calcd for C17H18N3O10PF [M − H]−, 474.0714; Found 474.0710. 
IR (FTIR) νmax 3359, 1635, 1262, 1077, 970.  
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Disodium [(3-propoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27e). 
From 5.26e (150 mg, 216 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27e-s 
(48.2 mg, 83%) and 5.27e-l (54.0 mg, 93%) as white powders. 5.27e-s: RP-HPLC, 0−50 min 
linear gradient 9−14% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 20.20 min; mp 
decomp. > 230.0ºC. [α]D25 +4.8 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 7.59 (d, J = 7.8 
Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.18 (d, J = 7.1 Hz, 1H), 7.11 (s, 1H), 6.97 (d, J = 8.2 Hz, 
1H), 6.10 (d, J = 5.7 Hz, 1H), 5.73 (d, J = 7.8 Hz, 1H), 5.59 (d, JH,P = 13.8 Hz, 1H), 4.30–
4.31 (m, 2H), 4.10–4.18 (m, 3H), 3.72 (dd, J = 13.8 Hz, J = 6.9 Hz, 1H), 3.56 (d, J = 14.4 
Hz, 1H), 1.89 (sxt, J = 6.8 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, 
D2O/MeOH-d4) δ 171.4, 159.4 (d, JC,P = 12.7 Hz), 158.6, 155.8, 141.8, 141.1, 129.7, 120.6 
(d, JC,P = 3.8 Hz), 113.6, 113.2, 103.3, 89.0, 83.2, 76.7 (d, JC,P = 146.3 Hz), 74.3, 71.1, 70.8, 
42.9, 22.6, 10.5. 31P NMR (162 MHz, D2O) δ 12.88. HRMS (ESI) calcd for C20H25N3O11P 
[M − H]−, 514.1227; Found 514.1225. IR (FTIR) νmax 3365, 1611, 1264, 1019, 690. 5.27e-l: 
RP-HPLC, 0−50 min linear gradient 9−14% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; 
tR = 25.90 min; mp decomp. > 230.0ºC. [α]D25 −2.8 (c = 0.3, H2O). 1H NMR (400 MHz, D2O) 
δ 7.59 (t, J = 7.9 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 7.6 Hz, 1H), 7.24 (s, 1H), 
7.15 (d, J = 7.8 Hz, 1H), 6.09 (d, J = 5.4 Hz, 1H), 5.76 (d, JH,P = 13.8 Hz, 1H), 5.49 (d, J = 
7.9 Hz, 1H), 4.41–4.44 (m, 1H), 4.34–4.37 (m, 2H), 4.24 (t, J = 6.6 Hz, 1H), 3.91 (dd, J = 
15.2 Hz, J = 2.5 Hz, 1H), 3.62 (dd, J = 15.2 Hz, J = 4.4 Hz, 1H), 1.97 (sxt, J = 7.0 Hz, 2H), 
1.19 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 169.0, 159.2 (d, 
JC,P = 11.2 Hz), 158.5, 154.1, 141.6, 140.9, 130.0, 120.5 (d, JC,P = 3.6 Hz), 113.8, 113.6, 
103.0, 88.8, 83.5, 76.3 (d, JC,P = 146.8 Hz), 74.2, 70.9, 70.6, 42.2, 22.4, 10.5. 31P NMR 
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(162 MHz, D2O) δ 13.05. HRMS (ESI) calcd for C20H25N3O11P [M − H]−, 514.1227; Found 
514.1241. IR (FTIR) νmax 3373, 1663, 1264, 1066, 696.  
Disodium [(3-methoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27f). 
From 5.26f (107 mg, 160 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27f-s 
(40 mg, 94%) and 5.27f-l (35 mg, 82%) as white powders. 5.27f-s: RP-HPLC, 0−50 min 
linear gradient 4−9% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 24.90 min; mp 
decomp. > 260.0ºC. [α]D25 +3.9 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 7.53 (d, J = 
7.7 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 7.08 (s, 1H), 6.94 (d, J = 7.6 
Hz, 1H), 6.07 (d, J = 5.9 Hz, 1H), 5.71 (d, J = 7.7 Hz, 1H), 5.55 (d, JH,P = 13.6 Hz, 1H), 4.25–
4.31 (m, 2H), 4.12–4.15 (m, 1H), 3.92 (s, 3H), 3.68 (dd, J = 14.7 Hz, J = 8.1 Hz, 1H), 3.53 
(dd, J = 14.3 Hz, J = 3.1 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 174.1, 159.5 (d, 
JC,P = 12.1 Hz), 159.1, 157.8, 141.8, 140.9, 129.7, 120.5, 112.8–113.1 (m), 103.5, 89.1, 83.1, 
76.9 (d, JC,P = 146.1 Hz), 74.2, 71.2, 56.0, 43.0. 31P NMR (162 MHz, D2O) δ 12.76. HRMS 
(ESI) calcd for C18H21N3O11P [M − H]−, 486.0919; Found 486.0921. IR (FTIR) νmax 3299, 
2928, 1687, 1246, 1010, 739, 695. 5.27f-l: RP-HPLC, 0−50 min linear gradient 4−9% 
CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 31.90 min; mp decomp. > 260.0ºC. 
[α]D25 -0.8 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 7.46 (t, J = 7.9 Hz, 1H), 7.36 (d, J = 
7.7 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 7.15 (s, 1H), 7.03 (d, J = 7.7 Hz, 1H), 6.00 (d, J = 
5.2 Hz, 1H), 5.61 (d, JH,P = 13.7 Hz, 1H), 5.54 (d, J = 7.7 Hz, 1H), 4.21–4.31 (m, 3H), 3.95 
(s, 3H), 3.75 (dd, J = 15.2 Hz, J = 2.8 Hz, 1H), 3.51 (dd, J = 15.0 Hz, J = 4.8 Hz, 1H). 
13C NMR (100 MHz, D2O/MeOH-d4) 175.4, 159.3–159.5 (m), 158.8, 141.7, 140.7, 130.1, 
120.5, 113.2, 103.5, 89.2, 83.4, 76.7 (d, JC,P = 145.0 Hz), 74.2, 71.0, 56.2, 42.6. 31P NMR 
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(162 MHz, D2O) δ 12.73. HRMS (ESI) calcd for C18H21N3O11P [M − H]−, 486.0919; Found 
486.0922. IR (FTIR) νmax 3342, 2929, 1687, 1260, 1010, 738, 696.  
Disodium [(4-methoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27g). 
From 5.26g (298 mg, 446 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27g-s 
(100 mg, 85%) and 5.27g-l (104 mg, 88%) as white powders. 5.27g-s: RP-HPLC, 0−40 min 
linear gradient 3−8% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 20.10 min; mp 
decomp. > 215.0ºC. [α]D25 −63.6 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 7.66 (d, J = 
7.8 Hz, 1H), 7.57 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 6.12 (d, J = 5.2 Hz, 1H), 5.90 
(d, J = 7.8 Hz, 1H), 5.66 (d, JH,P = 13.1 Hz, 1H), 4.35–4.44 (m, 2H), 4.16–4.18 (m, 1H), 4.02 
(s, 3H), 3.76 (dd, J = 15.0 Hz, J = 7.5 Hz, 1H), 3.63 (d, J = 15.0 Hz, 1H). 13C NMR (100 
MHz, D2O/MeOH-d4) δ 172.1, 159.3 (d, JC,P = 12.6 Hz), 158.3, 156.4, 141.0, 132.2, 128.8 
(d, JC,P = 3.2 Hz), 113.9, 103.3, 89.1, 83.0, 76.3 (d, JC,P = 159.9 Hz), 74.0, 70.9, 56.1, 42.6. 
31P NMR (162 MHz, D2O) δ 13.57. HRMS (ESI) calcd for C18H22N3O11PNa [M + Na]+, 
510.0890; Found 510.0900. IR (FTIR) νmax 3278, 1682, 1635, 1511, 1458, 1247, 1071, 972. 
5.27g-l: RP-HPLC, 0−40 min linear gradient 3−8% CH3CN, 0.05 M TEAB buffer, 15 
mL/min flow; tR = 24.60 min. mp decomp. > 215.0ºC. [α]D25 −73.4 (c 0.1, H2O). 1H NMR 
(400 MHz, D2O) δ 7.64 (d, J = 7.9 Hz, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.6 Hz, 
2H), 6.06 (d, J = 4.4 Hz, 1H), 5.74 (d, JH,P = 13.2 Hz, 1H), 5.57 (d, J = 8.0 Hz, 1H), 4.35 
(br s, 3H), 4.05 (s, 3H), 3.89 (d, J = 14.8 Hz, 1H), 3.61 (dd, J = 14.8 Hz, J = 3.2 Hz, 1H). 
13C NMR (100 MHz, D2O/MeOH-d4) δ 166.9, 159.2 (d, JC,P = 11.7 Hz), 158.5, 152.5, 141.3, 
132.3, 128.9 (d, JC,P = 2.6 Hz), 114.3, 103.0, 88.9, 83.5, 76.0 (d, JC,P = 149.1 Hz), 74.1, 70.5, 
56.3, 42.1. 31P NMR (162 MHz, D2O) δ 13.58. HRMS (ESI) calcd for C18H21N3O11P 
Chapter 5: Synthesis and Evaluation of Carbamate-Linked Sialyltransferase Inhibitors 
166 
[M − H]−, 486.0919; Found 486.0930. IR (FTIR) νmax 3225, 1690, 1512, 1461, 1273, 1247, 
1073, 974.  
Disodium [(3-cyclopentoxy-4-methoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate 
(5.27h). 
From 5.26h (109 mg, 145 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27h-s 
(41.6 mg, 93%) and 5.27h-l (36.2 mg, 81%) as white powders. 5.27h-s: RP-HPLC, 0−50 min 
linear gradient 10−16% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 20.00 min; mp 
decomp. > 230.0ºC. [α]D25 +2.2 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 7.58 (d, J = 7.8 
Hz, 1H), 7.18 (s, 1H), 7.05–7.12 (m, 2H), 6.01 (d, J = 4.9 Hz, 1H), 5.71 (d, J = 7.8 Hz, 1H), 
5.51 (d, JH,P = 13.2 Hz, 1H), 4.98 (br s, 1H), 4.22–4.28 (m, 2H), 4.10–4.12 (m, 1H), 3.93 (s, 
3H), 3.67 (dd, J = 14.8 Hz, J = 8.4 Hz, 1H), 3.52 (dd, J = 14.8 Hz, J = 3.2 Hz, 1H), 1.70–
1.93 (m, 8H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 171.7, 159.5, 156.0–156.1 (m), 148.5, 
146.6, 141.2, 133.0, 120.9 (d, JC,P = 3.7 Hz), 114.3, 112.2, 103.2, 89.3, 83.1, 81.9, 76.7 (d, 
JC,P = 149.7 Hz), 74.6, 71.3, 56.5, 43.0, 33.0, 32.9, 24.32, 24.27. 31P NMR (162 MHz, D2O) 
δ 13.13. HRMS (ESI) calcd for C23H29N3O12P [M − H]−, 570.1489; Found 570.1500. IR 
(FTIR) νmax 3279, 2928, 1690, 1631, 1512, 1261, 1075, 973. 5.27h-l: RP-HPLC, 0−50 min 
linear gradient 10−16% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 24.00 min; mp 
decomp. > 240.0ºC. [α]D25 +0.5 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 7.41 (d, 
J = 8.0 Hz, 1H), 7.22 (s, 1H), 7.15 (s, 2H), 5.93 (d, J = 4.1 Hz, 1H), 5.59 (d, JH,P = 13.1 Hz, 
1H), 5.34 (d, J = 7.7 Hz, 1H), 5.01 (br s, 1H), 4.21–4.28 (m, 3H), 3.96 (s, 3H), 3.80 (dd, 
J = 15.0 Hz, J = 2.4 Hz, 1H), 3.48 (dd, J = 15.0 Hz, J = 4.4 Hz, 1H), 1.70–2.11 (m, 8H). 13C 
NMR (125 MHz, D2O/MeOH-d4) δ 166.8, 158.9–159.1 (m), 149.1, 146.8, 141.3, 131.6, 
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120.8, 114.4, 112.6, 102.9, 89.5, 83.6, 81.8, 75.3 (d, JC,P = 153.8 Hz), 74.5, 70.6, 56.6, 42.1, 
32.9, 32.8, 24.2. 31P NMR (162 MHz, D2O) δ 13.02. HRMS (ESI) calcd for C23H29N3O12P 
[M − H]−, 570.1489; Found 570.1465. IR (FTIR) νmax 3365, 2929, 1690, 1512, 1261, 1075.  
Disodium [(3-cyclopentoxy)phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27i). 
From 5.26i (118 mg, 164 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27i-s 
(41.8 mg, 87%) and 5.27i-l (40.3 mg, 84%) as white powders. 5.27i-s: RP-HPLC, 0−50 min 
linear gradient 13−18% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 18.30 min; mp 
decomp. > 250.0ºC. [α]D25 +2.7 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 7.64 (d, 
J = 8.0 Hz, 1H), 7.41–7.44 (m, 1H), 7.18 (d, J = 7.2 Hz, 1H), 7.09 (s, 1H), 6.97 (d, J = 8.0 Hz, 
1H), 6.09 (br s, 1H), 5.75 (d, J = 6.7 Hz, 1H), 5.59 (d, JH,P = 13.8 Hz, 1H), 5.01 (br s, 1H), 
4.34 (br s, 2H), 4.19 (br s, 1H), 3.72–3.77 (m, 1H), 3.57–3.60 (m, 1H), 2.12 (br s, 2H), 1.80–
1.87 (m, 6H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 171.0, 161.9 (d, JC,P = 10.7 Hz), 157.5, 
141.9, 141.4, 129.7, 120.7, 114.8, 114.3, 103.3, 89.0, 83.3, 81.2, 76.8 (d, JC,P = 141.0 Hz), 
74.3, 71.1, 42.9, 33.0, 32.9, 24.24, 24.21. 31P NMR (162 MHz, D2O) δ 12.80. HRMS (ESI) 
calcd for C22H27N3O11P [M − H]−, 540.1383; Found 540.1407. IR (FTIR) νmax 3137, 2964, 
1604, 1357, 1262, 1080, 832, 795. 5.27i-l: RP-HPLC, 0−50 min linear gradient 13−18% 
CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 21.60 min; mp decomp. > 250.0ºC. 
[α]D25 −3.4 (c = 0.1, H2O). 1H NMR (500 MHz, D2O) δ 7.45 (t, J = 7.8 Hz, 1H), 7.40 (d, 
J = 8.1 Hz, 1H), 7.18 (d, J = 7.8 Hz, 1H), 7.09 (s, 1H), 7.00 (d, J = 8.0 Hz, 1H), 5.95–5.96 
(m, 1H), 5.63 (d, JH,P = 13.3 Hz, 1H), 5.32 (d, J = 7.7 Hz, 1H), 5.00 (br s, 1H), 4.25–4.31 (m, 
3H), 3.81 (d, J = 15.0 Hz, 1H), 3.50 (d, J = 15.0 Hz, 1H), 2.06 (br s, 2H), 1.76–1.83 (m, 6H). 
13C NMR (125 MHz, D2O/MeOH-d4) δ 174.6, 159.5 (d, JC,P = 12.5 Hz), 157.7, 141.9, 141.2, 
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130.1, 120.7, 115.0, 114.5, 103.0, 89.1, 83.7, 81.3, 76.5 (d, JC,P = 152.5 Hz), 74.6, 70.8, 42.3, 
33.0, 32.9, 24.2. 31P NMR (162 MHz, D2O) δ 12.68. HRMS (ESI) calcd for C22H27N3O11P 
[M − H]−, 540.1383; Found 540.1389. IR (FTIR) νmax 3237, 2960, 1687, 1260, 1010, 967.  
Disodium [phenylphosphonatomethyl]-uridin-5′-yl-carbamate (5.27j). 
From 5.26j (147 mg, 231 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27j-s 
(52 mg, 90%) and 5.27j-l (47 mg, 81%) as white powders. 5.27j-s: RP-HPLC, 0−50 min 
linear gradient 3−8% CH3CN, 0.05 M TEAB buffer, 19 mL/min flow; tR = 22.20 min; mp 
decomp. > 320.0ºC. [α]D25 +20.1 (c = 0.2, H2O). 1H NMR (500 MHz, D2O) δ 7.71 (d, 
J = 7.5 Hz, 1H), 7.46−7.57 (m, 5H), 6.10 (d, J = 3.9 Hz, 1H), 5.89 (d, J = 7.7 Hz, 1H), 5.66 
(d, JH,P = 13.4 Hz, 1H), 4.45 (br s, 1H), 4.33 (br s, 1H), 4.23 (br s, 1H), 3.70−3.74 (m, 1H), 
3.53 (d, J = 13.8 Hz, 1H). 13C NMR (125 MHz, D2O/MeOH-d4) δ 166.6, 159.3 (d, 
JC,P = 13.1 Hz), 152.3, 142.0, 139.3, 128.6, 127.9, 127.2, 103.2, 88.8, 83.5, 76.6 (d, 
JC,P = 148.8 Hz), 73.7, 71.0, 42.8. 31P NMR (162 MHz, D2O) δ 13.34. HRMS (ESI) calcd for 
C17H20N3O10PNa [M + Na]+, 480.0784; Found 480.0800. IR (FTIR) νmax 3373, 1636, 1264, 
1078, 970. 5.27j-l: RP-HPLC, 0−50 min linear gradient 3−8% CH3CN, 0.05 M TEAB 
buffer, 19 mL/min flow; tR = 26.40 min; mp decomp. > 310.0ºC. [α]D25 +1.5 (c 0.2, H2O). 1H 
NMR (500 MHz, D2O) δ 7.52−7.59 (m, 5H), 7.47 (d, J = 7.0 Hz, 1H), 5.98 (d, J = 5.0 Hz, 
1H), 5.64–5.66 (m, 2H), 4.32−4.37 (m, 2H), 4.24−4.26 (m, 1H), 3.76 (dd, J = 15.2 Hz, 
J = 3.1 Hz, 1H), 3.53 (dd, J = 15.2 Hz, J = 5.3 Hz, 1H). 13C NMR (125 MHz, D2O/MeOH-d4) 
δ 167.0, 159.5 (d, JC,P = 11.3 Hz), 152.6, 141.9, 139.9, 129.0, 128.0, 127.5, 103.3, 89.4, 83.6, 
76.8 (d, JC,P = 147.5 Hz), 74.0, 70.9, 42.4. 31P NMR (162 MHz, D2O) δ 13.03. HRMS (ESI) 
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calcd for C17H19N3O10P [M − H]−, 456.0808; Found 456.0809. IR (FTIR) νmax 3397, 1681, 
1266, 1077, 962. 
Disodium [(benzo[b]thiophen-2-yl)phosphonatomethyl]-uridin-5′-yl-carbamate (5.27k). 
From 5.26k (342 mg, 493 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27k-s 
(118 mg, 86%) and 5.27k-l (121 mg, 88%) as white powders. 5.27k-s: RP-HPLC, 0−50 min 
linear gradient 8−13% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 19.20 min; mp 
decomp. > 200ºC. [α]D25 −10.0 (c = 0.1, H2O). 1H NMR (500 MHz, D2O) δ 7.84 (d, J = 
7.5 Hz, 1H), 7.74 (d, J = 7.5 Hz, 1H), 7.34–7.41 (m, 3H), 7.30 (d, J = 2.8 Hz, 1H), 5.88 (d, J 
= 5.8 Hz, 1H), 5.79 (d, JH,P = 14.0 Hz, 1H), 5.48 (d, J = 7.9 Hz, 1H), 4.17–4.21 (m, 1H), 
4.09–4.11 (m, 1H), 4.00–4.02 (m, 1H), 3.65 (dd, J = 14.6 Hz, J = 9.1 Hz, 1H), 3.43 (dd, J = 
14.6 Hz, J = 3.7 Hz, 1H). 13C NMR (125 MHz, D2O/MeOH-d4) δ 167.6, 159.7 (d, JC,P = 12.0 
Hz), 153.2, 143.9, 141.3, 140.1, 139.9, 125.2, 124.9, 123.7, 122.9, 122.2 (d, JC,P = 6.0 Hz), 
102.7, 88.7, 83.6, 74.6, 73.6 (d, JC,P = 147.3 Hz), 71.3, 43.2. 31P NMR (162 MHz, D2O) δ 
12.25. HRMS (ESI) calcd for C19H19N3O10PS [M − H]−, 512.0529; Found 512.0537. IR 
(FTIR) νmax 3380, 2978, 2602, 2496, 1686, 1172, 1036, 907. 5.27k-l: RP-HPLC, 0−50 min 
linear gradient 8−13% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 26.90 min; mp 
decomp. > 200ºC. [α]D25 +46.6 (c = 0.1, H2O). 1H NMR (500 MHz, D2O) δ 7.99 (d, J = 
7.8 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.45–7.53 (m, 3H), 7.35 (d, J = 2.8 Hz, 1H), 5.99 (d, 
JH,P = 13.6 Hz, 1H), 5.90 (d, J = 4.6 Hz, 1H), 5.29 (d, J = 7.7 Hz, 1H), 4.33 (br s, 1H), 4.26–
4.27 (m, 2H), 3.83 (d, J = 15.2 Hz, 1H), 3.52 (d, J = 15.2 Hz, 1H). 13C NMR (125 MHz, 
D2O/MeOH-d4) δ 167.5, 159.3 (d, JC,P = 11.1 Hz), 153.1, 143.9, 140.9, 140.2, 139.7, 125.3, 
124.9, 124.1, 123.1, 122.4, 102.6, 88.9, 83.8, 74.5, 73.2 (d, JC,P = 148.2 Hz), 70.7, 42.2.  31P 
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NMR (162 MHz, D2O) δ 11.47. HRMS (ESI) calcd for C19H19N3O10PS [M − H]−, 512.0529; 
Found 512.0532. IR (FTIR) νmax 3379, 2978, 2602, 2496, 1475, 1172, 1036, 907. 
Disodium [(benzo[b]thiophen-3-yl)phosphonatomethyl]-uridin-5′-yl-carbamate (5.27l). 
From 5.26l (89.0 mg, 128 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.27l-s 
(24.3mg, 68%) and 5.27l-l (25.0 mg, 70%) as white powders. 5.27l-s: RP-HPLC, 0−60 min 
linear gradient 8−13% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 22.20 min; mp 
decomp. > 205ºC. [α]D25 −3.6 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 8.10 (d, J = 8.1 Hz, 
1H), 7.91 (d, J = 7.8 Hz, 1H), 7.63 (s, 1H), 7.46 (t, J = 7.4 Hz, 1H), 7.40 (t, J = 7.3 Hz, 1H), 
7.31 (d, J = 7.9 Hz, 1H), 5.95 (d, JH,P = 13.5 Hz, 1H), 5.81 (d, J = 5.1 Hz, 1H), 5.22 (d, 
J = 8.0 Hz, 1H), 4.09–4.14 (m, 2H), 3.96–3.98 (m, 1H), 3.56–3.62 (m, 1H), 3.41 (d, 
J = 15.0 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 167.8, 159.9 (d, JC,P = 12.5 Hz), 
153.2, 141.4, 140.6, 138.9, 135.0, 125.1, 124.7, 123.9, 123.5, 102.7, 89.1, 83.5, 74.5, 72.3 
(d, JC,P = 152.0 Hz), 71.1, 42.8. 31P NMR (162 MHz, D2O) δ 12.56. HRMS (ESI) calcd for 
C19H19N3O10PS [M − H]−, 512.0529; Found 512.0547. IR (FTIR) νmax 3362, 1634, 1073. 
5.27l-l: RP-HPLC, 0−60 min linear gradient 8−13% CH3CN, 0.05 M TEAB buffer, 15 
mL/min flow; tR = 26.50 min; mp decomp. > 205ºC. [α]D25 +3.2 (c = 0.05, H2O). 1H NMR 
(400 MHz, D2O) δ 8.17 (d, J = 8.3 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.65 (s, 1H), 7.43–7.54 
(m, 2H), 7.09 (d, J = 7.8 Hz, 1H), 6.01 (d, JH,P = 13.5 Hz, 1H), 5.82 (d, J = 5.4 Hz, 1H), 4.98 
(d, J = 7.9 Hz, 1H), 4.17–4.19 (m, 1H), 4.10–4.12 (m, 1H), 4.02–4.05 (m, 1H), 3.64–3.71 
(m, 1H), 3.37–3.42 (m, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 174.1, 159.7 (d, 
JC,P = 9.5 Hz), 154.8, 141.0, 139.0, 136.7, 135.1, 125.3, 124.9, 124.1, 123.8, 103.0, 89.2, 
83.8, 74.4, 72.4 (d, JC,P = 153.1 Hz), 70.9, 42.3. 31P NMR (162 MHz, D2O) δ 12.54. HRMS 
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(ESI) calcd for C19H19N3O10PS [M − H]−, 512.0529; Found 512.0534. IR (FTIR) νmax 3363, 
1660, 1078. 
Disodium cytidin-5′-yl-[(3-phenoxy)phenylphosphonatomethyl]-carbamate (5.29).  
From 5.28 (324 mg, 287 μmol): purification by RP-HPLC, converted to the form of sodium 
salt by ion exchange (IR 120 Na+) and lyophilised from water to afford diastereomers 5.29-s 
(70.0 mg, 89%) and 5.29-l (72.4 mg, 92%) as white powders. 5.29-s: RP-HPLC, 0−60 min 
linear gradient 12−17% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 15.20 min; mp 
decomp. > 230ºC. [α]D25 −10.3 (c = 0.1, H2O). 1H NMR (400 MHz, D2O) δ 7.63 (d, J = 
7.5 Hz, 1H), 7.37−7.42 (m, 3H), 7.31 (d, J = 7.6 Hz, 1H), 7.13–7.19 (m, 2H), 6.92–6.94 (m, 
3H), 6.05 (d, J = 7.5 Hz, 1H), 5.85 (d, J = 3.1 Hz, 1H), 5.53 (d, JH,P = 13.9 Hz, 1H), 
4.07−4.13 (m, 1H), 3.83−3.85 (m, 1H), 3.67–3.76 (m, 2H), 3.50 (dd, J = 15.2 Hz, J = 3.0 Hz, 
1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 166.7, 159.8 (d, JC,P = 12.0 Hz), 158.3, 158.0, 
156.5, 142.8, 141.0, 130.8, 130.3, 124.1 (d, JC,P = 4.0 Hz), 123.8, 119.0, 118.1, 117.9 (d, 
JC,P = 3.5 Hz), 97.2, 90.4, 82.5, 76.8 (d, JC,P = 145.8 Hz), 75.1, 70.2, 41.5. 31P NMR (162 
MHz, CDCl3) δ 12.18. HRMS (ESI) calcd for C23H24N4O10P [M − H]−, 547.1225; Found 
547.1241. IR (FTIR) νmax 3292, 1647, 1487, 1250, 1069, 968, 783, 692. 5.29-l: RP-HPLC, 
0−50 min linear gradient 12−17% CH3CN, 0.05 M TEAB buffer, 15 mL/min flow; tR = 
20.80 min; mp decomp. > 220ºC. [α]D25 +6.8 (c = 0.2, H2O). 1H NMR (400 MHz, D2O) δ 
7.46–7.53 (m, 4H), 7.37 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 8.1 Hz, 1H), 7.24 (s, 1H), 7.11 (d, J 
= 8.1 Hz, 2H), 7.04 (d, J = 8.0 Hz, 1H), 5.91 (d, J = 4.0 Hz, 1H), 5.70 (d, J = 7.5 Hz, 1H), 
5.64 (d, JH,P = 13.9 Hz, 1H), 4.19 (br s, 3H), 3.82 (d, J = 14.0 Hz, 1H), 3.49 (dd, J = 15.8 Hz, 
J = 4.0 Hz, 1H). 13C NMR (100 MHz, D2O/MeOH-d4) δ 166.6, 159.5 (d, JC,P = 12.0 Hz), 
158.2, 157.43, 157.36, 142.5, 141.5, 130.8, 130.3, 124.6, 123.4 (d, JC,P = 3.0 Hz), 119.6, 
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117.9, 117.4, 96.9, 90.4, 82.9, 76.5 (d, JC,P = 144.0 Hz), 74.9, 70.6, 42.0. 31P NMR (162 
MHz, CDCl3) δ 12.45. HRMS (ESI) calcd for C23H24N4O10P [M − H]−, 547.1225; Found 
547.1240. IR (FTIR) νmax 3332, 1647, 1487, 1249, 1067, 967, 783, 692. 
5.5.8 Enzymatic Assay 
The assay was performed based on the CMP-Glo™ assay developed by Promega and as 
detailed by Das et al.41 For details of the procedures, see Appendix C.  
5.6 Associated Content 
HPLC purity of the target compounds, details of biological assays, and NMR spectral data 
can be found in Appendix C.  
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FOREWORD TO CHAPTER 6 
This chapter reports further investigations that supplement and provide context to the 
synthetic work described in the manuscript prepared for the Journal of Medicinal 
Chemistry that constitutes Chapter 5. This chapter describes the process of the 
development of the key carbamate coupling step using model compounds and how the 
optimised conditions were translated to our first generation of compounds, which had the 
2′ and 3′-hydroxyl groups of the nucleoside protected as an acetonide. The optimisation 
of the deprotection of these compounds and the evolution of the final protecting group 
strategy that was used in Chapter 5 will also be discussed. NMR data of novel 
compounds from this chapter can be found in Appendix D (p. 370).
Chapter 6: Development of Key Coupling and Protecting Group Methodologies 
178 
6.1 Development of Carbamate Coupling Conditions 
6.1.1 Carbamate Coupling 
Organic carbamates have a key role in organic synthesis, particularly in those molecules 
that have biological activity. A variety of methods have been developed for the synthesis 
of carbamates as reviewed in detail by Ghosh and Brindisi.1 A majority of these methods 
are based on the reaction of an alcohol with an isocyanate that has been prepared by the 
Hofmann rearrangement of primary amides,2-4 the Curtius rearrangement of acyl azides5-6 
or from the reaction of an amine with phosgene derivatives.7  
To overcome the issues associated with these traditional methods of carbamate 
preparation, in particular the toxicity of reagents such as phosgene, a variety of alternate 
strategies have been developed.1 One such strategy relies on the generation of the 
carbamate anion via the reaction of carbon dioxide and amines, followed by the reaction 
with electrophiles, generally alkyl halides.8-9 Another approach is the synthesis of 
carbamates via an activated intermediate. Mixed carbonates with a 4-nitrophenyl moiety 
are often used in this way. For example, 4-NPC (6.1) when treated with an alcohol in the 
presence of base, produces the corresponding activated carbonate, which can then be 
reacted with the desired amine.10 Similar to the 4-NPC methodology, 
1,1′-carbonyldiimidazole (CDI, 6.2) can also be used to generate a reactive N- or 
O-carbonylimidazolide intermediate that can be used in the preparation of 
carbamates.11-12 Both 4-NPC and CDI (Scheme 6.1) based methodologies were explored 
as part of this thesis as low-cost and safer alternatives to the traditional methods of 
carbamate synthesis. 
Chapter 6: Development of Key Coupling and Protecting Group Methodologies 
179 
 
Scheme 6.1: The reagents 4-nitrophenyl chloroformate (4-NPC, 6.1) and 1,1′-carbonyldiimidazole (CDI, 
6.2) in the synthesis of carbamate containing compounds. 
 
6.1.2 Modelling the Carbamate Coupling Reaction 
Prior to the synthesis of the target carbamates (5.27a–5.27l and 5.29, Chapter 5), a series 
of model compounds were synthesised to determine the optimum coupling conditions. In 
the model reactions the nucleoside fragment was replaced with benzylamine on the basis 
that the amine of this compound would be in an electronically and sterically similar 
environment to that of the 5′-aminonucleosides. Two αHPs were utilised, the 4-methoxy 
substituted diethyl αHP 6.3 and the corresponding dibenzyl αHP 6.4 (prepared as per 
Scheme 5.1, p. 118).  
Using the above reagents both the diethyl carbamate 6.5 and the dibenzyl 
carbamate 6.6 were prepared using CDI (Table 6.1). The first set of conditions (Entry 1, 
Table 6.1) attempted were based on the “one pot” method reported by Ashton et al.13 αHP 
6.3 was added to a suspension of CDI in the presence of triethylamine and allowed to stir 
at rt for 24 h, after which TLC analysis indicated the consumption of the αHP starting 
material. Following this reaction three equivalents of benzylamine was added and the 
reaction was allowed to proceed until the consumption of the O-carbonylimidazolide 
intermediate. Under these conditions the desired carbamate 6.5 was isolated in a yield of 
15%, with suspected carbonate dimers of αHP 6.3 and urea dimers of benzylamine 
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observed in the crude product mixture. Reflux of the initial reaction (Entry 2, Table 6.1),14 
was performed to test the effect of heat on both the reaction kinetics and yield. These 
conditions, upon consumption of starting material, resulted in no expected intermediate 
that was observable by TLC or mass spectrometry, instead a complex mixture of 
carbonate and urea dimers as well as other unidentifiable compounds was detected. In an 
attempt to prevent the formation of carbonate dimers the dropwise addition of αHP 6.3 to 
a 0ºC suspension of CDI was tried (Entry 3, Table 6.1). This method was successful and 
led to a substantial increase in yield (38%) of the target carbamate 6.5. The next trial 
replaced the “one pot” method used previously with the isolation of the 
O-carbonylimidazolide intermediate (Entry 4, Table 6.1). This change resulted in a 
significant reduction in the urea-linked benzylamine dimer and resulted in the highest 
yield. However, the partially optimised conditions were unsuccessfully translated to the 
synthesis of the dibenzyl carbamate 6.6 (Entry 5, Table 6.1). Based on the poor results 
obtained using CDI, an alternative reagent was examined. 
The alternate reagent to CDI that was examined was 4-NPC. The first trial was 
undertaken under anhydrous conditions (Entry 6, Table 6.1), where αHP 6.3 was added 
to a 0ºC suspension of 4-NPC in the presence of triethylamine and subsequently allowed 
to stir at rt. After 3 h when all starting material had been consumed, benzylamine was 
added and the reaction was stirred for a further 24 h to give a 59% yield of the desired 
carbamate 6.5. According to Gilad et al.,15 a small amount of catalyst was utilised. The 
catalysts trialled included DBU (Entry 7, Table 6.1) and DMAP (Entry 8, Table 6.1), both 
of which led to an increase in yield of diethyl carbamate 6.5 to 74% and 76% respectively. 
Due to accessibility, DMAP was the preferred catalyst for the translation of conditions to 
the production of the dibenzyl carbamate 6.6 (Entry 9, Table 6.1). Using the optimised 
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conditions, 6.6 was obtained in an excellent yield of 85%. These conditions were then 
used for the preparation of the target carbamate compounds. 
Table 6.1: Optimisation of the synthesis of diethyl carbamate (6.5) and dibenzyl carbamate (6.6) using 
CDIa and 4-NPCb 
 




1 6.3 CDI triethylamine, CH2Cl2, N2, 24 h No 6.5: 15% 
2 6.3 CDI triethylamine, CH2Cl2, N2, reflux, 16 h No 6.5: 0% 
3 6.3 CDI triethylamine, CH2Cl2, N2, 0ºC–rt, 24 h No 6.5: 38% 
4 6.3 CDI triethylamine, CH2Cl2, N2, 0ºC–rt, 24 h Yes 6.5: 40% 
5 6.4 CDI triethylamine, CH2Cl2, N2, 0ºC–rt, 24 h Yes 6.6: 0% 
6 6.3 4-NPC triethylamine, CH2Cl2, N2, 0ºC–rt, 3 h No 6.5: 59% 
7 6.3 4-NPC triethylamine, DBU, CH2Cl2, N2, 0ºC–rt, 3 h No 6.5: 74% 
8 6.3 4-NPC triethylamine, DMAP, CH2Cl2, N2, 0ºC–rt, 3 h No 6.5: 76% 
9 6.4 4-NPC triethylamine, DMAP, CH2Cl2, N2, 0ºC–rt, 3 h No 6.6: 85% 
aAll reactions were trialled with 1 molar equivalent of αHP 6.3 or 6.4, 2 molar equivalents of CDI, 2 molar 
equivalents of triethylamine and 3 molar equivalents of benzylamine. bAll reactions were trialled with 1 molar 
equivalent of αHP 6.3 or 6.4, 1.1 molar equivalents of 4-NPC, 2 molar equivalents of triethylamine and 1.2 
molar equivalents of benzylamine. 0.1 molar equivalents of DBU and DMAP were used.  
 
6.1.3 Preparation of First-Generation Carbamate-Linked Compounds  
6.1.3.1 Coupling 
The first generation of carbamate-linked compounds prepared in this project were from 
the benzyl protected αHPs 6.4 and 6.7–6.9 (prepared as per Scheme 5.1, p. 118) and 
acetonide protected uridine derivatives using the optimised conditions as shown in Table 
6.1 (Entry 9). To prepare the acetonide protected derivatives commercially available 
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uridine (6.10) was selectively protected at the 2′- and 3′-hydroxyl groups using acetone 
and a catalytic amount of concentrated sulphuric acid to give the acetonide protected 6.11 
in an excellent yield of 97%.16 Next, the free 5′-hydroxyl of 6.11 was converted to an 
azide in two steps. Initially via treatment with mesyl chloride, which affords the crude 
mesylated product that is subsequently reacted with sodium azide to produce the 
5′-azidouridine derivative 6.12 in 71% yield over both steps.17 The final step in the 
preparation of the target 5′-aminourinde fragment 6.13 is the catalytic hydrogenation of 
the 5′-azidouridine derivative 6.12 in an essentially quantitative yield (99%).18 The four 
step synthesis described was able to be undertaken on multigram scales to produce 6.13 
in an excellent overall yield of 67%. 
 
Scheme 6.2: Preparation of acetonide protected 5′-aminouridine derivative (6.13). Reagents and 
Conditions: (a) Acetone, concd H2SO4, rt, 16 h, 97%; (b) (i) mesyl chloride, triethylamine, CH2Cl2, rt, 16 h; 
(ii) NaN3, DMF, reflux, 48 h, 71% over two steps; (c) 10% Pd/C, 1 atm H2, MeOH rt, 1 h, 99%. 
 
With the key fragments in hand, the carbamate coupling was undertaken to 
produce compounds 6.14–6.17 in good yields (Table 6.2). Due to the αHP starting 
materials being racemic each reaction produced a 1:1 mixture of diastereoisomers that 
were not sufficiently different enough in their physical properties to enable separation 
during purification. The small series of compounds prepared provide an indication that 
incorporation of an electron donating group in either the 3- or 4-position of the αHP 
fragment does not have a significant impact on the overall yield of the carbamate coupling 
reaction. 
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Table 6.2: Preparation of acetonide protected carbamates 6.14–6.17. 
 
Entry αHP R1 R2 Coupling Product 
1 6.4 H OMe 6.14: 63% 
2 6.7 OProp H 6.15: 57% 
3 6.8 OPh H 6.16: 65% 
4 6.9 H H 6.17: 60% 
aReagents and Conditions: (i) Triethylamine, DMAP, 
CH2Cl2, N2, 0ºC–rt, 3 h; (ii) 6.13, N2, rt, 24 h. 
 
6.1.3.2 Deprotection 
To obtain the target carbamate-linked compounds a two-step deprotection was planned, 
followed by HPLC purification to separate the diastereoisomers ready for biological 
evaluation. The two deprotection steps could be carried out under standard conditions, 
firstly acetonide deprotection via treatment with TFA(aq) followed by benzyl deprotection 
via catalytic hydrogenation.  
Reported deprotection methods for acetonide protected nucleosides generally use 
short reaction times and concentrated TFA(aq) solutions.18-19 Due to concerns about 
decomposition, compound 6.14 was treated with a 30% TFA(aq) solution for 2 h (Entry 1, 
Table 6.3), which only gave the deprotected compound 6.18 in 30% yield. Substantial 
decomposition of starting material via carbamate cleavage contributed to the low yield. 
As a result, other conditions were explored including decreasing the reaction time to 
15 min (Entry 2, Table 6.3) and using a 90% TFA(aq) solution. Under these conditions an 
increased yield of 57% was obtained albeit with decomposition of starting material still 
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observed. Repeating these conditions on larger scale, as well as with 6.15 and 6.17 as 
starting material, resulted in yields of 43%–55% along with significant decomposition. 
Table 6.3: Preparation of acetonide deprotected carbamates 6.18 
 
Entry aConditions Yield 
1 30% TFA(aq), rt, 2 h 30% 
2 90% TFA(aq), rt, 15 min 57% 
3 In(OTf)3 1mol%, CH3CN:H2O (9:1), reflux, 18 h 0%a 
4 In(OTf)3 3mol%, CH3CN:H2O (9:1), reflux, 18 h 0%a 
5 In(OTf)3 1mol%, CH3CN:H2O (9:1), MW, 120ºC, 30 min 0%a 
6 In(OTf)3 1mol%, CH3CN:H2O (9:1), MW, 120ºC, 1 h 0%a 
7 In(OTf)3 1mol%, MeOH:H2O (9:1), MW, 120ºC, 30 min 0%b 
a100% of starting material recovered. bMixture of decomposition products. 
 
To avoid the carbamate cleavage issue, alternative mild conditions using In(OTf)3 
as a Lewis acid catalyst were explored.20 The reaction was initially scoped by refluxing 
6.12 and 1 mol% of In(OTf)3 in a 9:1 CH3CN:H2O solvent system for 18 h to produce the 
deprotected 6.19 in an excellent yield of 95% (Scheme 6.3). Encouraged by this, these 
conditions were applied to the deprotection of the 4-methoxy compound 6.14. However, 
the deprotected compound 6.18 was not obtained, with only starting material recovered 
(Entry 3, Table 6.3). To drive the reaction forward, the amount of catalyst was increased 
to 3 mol%, but again only starting material was recovered (Entry 4, Table 6.3). As well 
as the reflux conditions reported by Golden et al., microwave conditions have also been 
reported.20 Therefore, the reaction was attempted using 1 mol% of In(OTf)3 in a 9:1 
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CH3CN:H2O solvent system and heating under microwave conditions (300W) for either 
30 or 60 min, with again only starting material recovered (Entry 5 and 6, Table 6.3). 
Changing the solvent system to 9:1 MeOH:H2O resulted in starting material being 
completely consumed, with a complex mixture of decomposition products obtained 
(Entry 7, Table 6.3). With the unsuccessful attempts above, we hypothesised that 
chelation of In3+ by 6.14 was preventing its catalytic action.  
 
Scheme 6.3: Preparation of 5′-azido-5′-deoxyuridine (6.19). Reagents and Conditions: (a) In(OTf)3 1mol%, 
CH3CN:H2O (9:1), reflux, 18 h, 95%. 
 
The difficulty in obtaining suitable deprotection conditions prompted us to 
reconsider the protecting strategy of the 2′- and 3′-hydroxyl groups of the nucleoside 
component of our inhibitors. The evolution of our protecting group strategy to that 
described in manuscript-based Chapter 5 is discussed in the following section.  
6.2 Evolution of Final Protecting Group Strategies  
To overcome the acetonide deprotection issue discussed above, a new protecting group 
strategy had to be developed. The focus of the new strategy was on the nucleoside due to 
the large library of benzyl protected αHPs within our group, resulting in the decision to 
retain the benzyl protecting system. For the uridine fragment three new strategies were 
trialled to protect the 2′- and 3′-hydroxyl groups: TBDMS, Alloc and Cbz. 
First, TBDMS groups were tested as they can be easily removed by a fluoride 
source, which is expected to be compatible with the carbamate linker of the target 
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compounds. This strategy also would not change the number of deprotection steps 
required compared to the acetonide strategy. Thus, uridine (6.10) was selectively 
converted to the 5′-azido derivative 6.19 in 97% yield using a Mitsunobu reaction,21 and 
subsequently reacted with two equivalents of TBDMS chloride to protect the 2′- and 
3′-hydroxyl groups and produce 6.20 in 67% yield.22 The TBDMS protected azide 6.20 
then underwent catalytic hydrogenation using a Pd/C catalyst to give the desired 5′-amino 
fragment 6.21 in a near quantitative yield.22 
 
Scheme 6.4: Synthesis of TBDMS protected 5′-aminouridine derivative (6.21). Reagents and Conditions: 
(a) Triphenylphosphine, DIAD, HN3, THF, 0ºC–rt, 16 h, 97%; (b) TBDMS chloride, imidazole, pyridine, 
rt, 24 h, 67%; (c) 10% Pd/C, 1 atm. H2, MeOH, rt, 90 min, 98%. 
 
Alloc groups were also examined as they are a robust protecting system that can 
be easily removed by reaction with catalytic Pd(PPh3)4, which is expected to be unreactive 
towards the carbamate linker. This strategy would also not change the number of 
deprotection steps required when compared to the acetonide strategy. The preparation of 
the Alloc protected 5′-aminouridine 5.21 in an overall yield of 61% has already been 
discussed in Chapter 5 of this thesis (see section 5.5.4). 
Cbz groups were also evaluated (Scheme 6.5) as a protecting system as they are 
easily removed by catalytic hydrogenation, facilitating the production of a coupled 
compound that can be globally deprotected in a single step. To trial Cbz groups the 
5′-azido derivative 6.19, prepared as described previously (Scheme 6.4), was reacted with 
benzyl chloroformate to produce the Cbz protected 5′-azidourdine derivative 6.22 in 72% 
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yield. The desired 5′-amino fragment 6.23 was generated via the reduction of the 5′-azido 
group under Staudinger conditions in a yield of 50%. 
 
Scheme 6.5: Synthesis of Cbz protected 5′-aminouridine derivative (6.23). Reagents and Conditions: (a) 
Triphenylphosphine, DIAD, HN3, THF, 0ºC–rt, 16 h, 97%; (b) benzyl chloroformate, CH2Cl2, 0ºC–rt, 16 h, 
72%; (d) (i) triphenylphosphine, THF, rt, 2 h; (ii) H2O, reflux, 6 h, 50% over two steps. 
 
With the new series of protected 5′-amino uridine derivatives in hand, carbamate 
coupling was undertaken with the 4-methoxy αHP 6.4 in order to provide a comparison 
to the acetonide protected 6.14 (Table 6.4). As for the acetonide series each carbamate 
was also obtained as a 1:1 mixture of diastereoisomers. From the coupling reactions, the 
TBDMS protected derivative 6.24 was obtained in 35% yield, the Alloc protected 
derivative 6.25 in 65% yield and the Cbz protected derivative 6.26 in 43% yield. Thus, 
the Alloc protected coupled compounds were produced in a comparable yield to the 
acetonide protected derivatives 6.14, with the bulkier TBDMS and Cbz groups having a 
negative impact on the yield of the carbamate coupling reaction.  
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Table 6.4: Comparison of yields of protected carbamates 6.14 and 6.24–6.26. 
 
Entry Amine R Coupling Product 
1 6.13 C(CH3)2 63% 
2 6.21 TBDMS 35% 
3 5.21 Alloc 65% 
4 6.23 Cbz 43% 
aReagents and Conditions: (i) Triethylamine, DMAP, CH2Cl2, N2, 0ºC–rt, 3 h; 
(ii) amine, N2, rt, 24 h. 
 
The protected carbamate compounds 6.24–6.26 were deprotected in high yields 
without any cleavage of the carbamate linker observed (Scheme 6.6). The TBDMS 
protected 6.24 was first reacted with TBAF to produce the partially deprotected 6.18 in 
an excellent yield of 90%. The Alloc protected 6.25 was also partially deprotected using 
Pd(PPh3)4 to produce 6.18 in 85% yield. The partially deprotected carbamate 6.18 from 
both TBDMS and Alloc case could then be subjected to hydrogenation using a Pd/C 
catalyst to produce a 1:1 mixture of diastereoisomers of 6.27 in an 87% crude yield. The 
Cbz protected carbamate 6.26 was globally deprotected via hydrogenation with a Pd/C 
catalyst. Under these conditions both Cbz and benzyl protecting groups were removed to 
produce a crude 1:1 mixture of diastereoisomers of 6.27 in 90% yield. 
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Scheme 6.6: The various deprotection methods evaluated in the production of target compound 6.27. 
Reagents and Conditions: (a) (i) TBAF, CH3COOH, THF, 0ºC–rt, 16 h, 90%; (ii) 6.18, 10% Pd/C, 1 atm 
H2, MeOH, rt, 1 h, 87%; (b) (i) Pd(PPh3)4, dimedone, THF, rt, 30 min, 85%; (ii) 6.18, 10% Pd/C, 1 atm H2, 
MeOH, rt, 1 h, 87%; (c) 10% Pd/C, 1 atm H2, MeOH, rt, 1 h, 90%. 
 
The crude 1:1 mixture of diastereoisomers of 6.27 was able to be separated under 
RP-HPLC conditions using TEAB(aq) buffer and a gradient of  3–8% CH3CN over 40 min. 
A small gradient was required to be used for these compounds to ensure baseline 
separation of peaks could be achieved. As described in Chapter 5 of this thesis, each 
isomer was converted to the sodium salt (s-isomer in 85% yield and l-isomer in 88% 
yield) for biological evaluation and characterisation. With the regards to characterisation 
and using isolated isomer 5.27g-s as an example, key coupling interactions and HMBC 
correlations could be observed to show carbamate coupling had been achieved 
(Figure 6.1). The coupling that was focused on particularly was the 3-bond 31P–13C 
coupling between the carbonyl carbon of the carbamate (159.3 ppm) and the phosphorous 
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of the αHP fragment. 1H–13C HMBC correlation between the adjacent proton (5.66 ppm) 
of the αHP fragment and the 5′-proton of the uridine fragment (3.63 ppm) to the 
carbamate carbonyl were also used as key determinants of carbamate coupling. 
 
Figure 6.1: Key 31P coupling and HMBC correlation data supporting the structural assignment of target 
compound 5.27g-s.  
 
In conclusion, the overall yield of the target compound 6.27 prior to final HPLC 
separation of diastereoisomers and ion exchange discussed above, is 14% for the Cbz 
route (over 5 steps), 17% for TBDMS route (over 6 steps), 21% for acetonide route (over 
7 steps) and 28% for the Alloc route (over 6 steps). Based on this, the Alloc protecting 
system was selected for the synthesis of uridine-based carbamate compounds. For 
cytidine-based targets where the amine of the pyrimidine base needs to be considered, 
Cbz was favoured to avoid any difficult purification of partially deprotected 
intermediates. Although this work does not appear in detail in the manuscript prepared 
for the Journal of Medicinal Chemistry outlined in Chapter 5, it provides important 
background into the selected coupling methods and protection strategies and as such is 
included here as additional material. 
6.3 Experimental Data 
For general chemistry information refer to section 5.5.2 of Chapter 5 (p. 129). To remain 
consistent with Chapter 5 NMR assignments are not provided herein according to the 
guidelines for the Journal of Medicinal Chemistry. Instead for novel compounds, copies 
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of both the 1H and 13C data are included in Appendix D (p. 370), along with optical 
rotations, FTIR, HRMS for all compounds and melting points for solids included below. 
6.3.1 Synthesis of α-Hydroxyphosphonates 
6.3.1.1 Diethyl α-Hydroxyphosphonates 
Diethyl α-hydroxy(4-methoxy)benzylphosphonate (6.3) 
To a mixture of diethyl phosphite (1.04 mL, 8.09 mmol) and 4-methoxybenzaldehyde 
(1.00 g, 7.35 mmol) in CH2Cl2, triethylamine was added (2.05 mL, 14.7 mmol). The 
reaction mixture was stirred a rt for 1 h, with the reaction monitored by TLC. Upon 
completion the reaction mixture was diluted with CH2Cl2, washed with saturated 
NaHCO3 solution and brine. The organic phase was separated and then dried with 
anhydrous MgSO4, filtered and the filtrate evaporated, with the resultant product purified 
by column chromatography (ethyl acetate:petroleum spirit, 7:3, Rf = 0.11) to give αHP 
6.3 (1.23 g, 60%) as a white solid. mp 120.0–121.5ºC (lit. mp 121–122ºC).23 1H NMR 
(500 MHz, CDCl3) δ 7.41 (d, J = 6.8 Hz, 2H), 6.91 (d, J = 8.3 Hz, 2H), 4.95 (d, JH,P = 
9.8 Hz, 1H), 3.94–4.08 (m, 4H), 3.81 (s, 3H), 1.29 (t, J = 6.9 Hz, 3H), 1.23 (t, J = 6.9 Hz, 
3H). The spectral data match those reported.23 
6.3.1.2 Dibenzyl α-Hydroxyphosphonates 
The synthetic protocol for the preparation of dibenzyl αHPs 6.4, 6.7, 6.8 and 6.9 and the 
corresponding characterisation data can be found in section 5.5.3 of Chapter 5 as 5.13, 
5.11, 5.7 and 5.16 respectively. 
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6.3.2 Synthesis of Model Carbamates 
(Diethoxyphosphoryl)(4-methoxyphenyl)methyl benzylcarbamate (6.5) 
Method A: 4-Methoxy αHP 6.3 (100 mg, 360 μmol) was dissolved in CH2Cl2 and CDI 
(117 mg, 720 μmol) was added. After 10 min of stirring, triethylamine (100 μL, 
720 μmol) was added and the solution was left to stir at rt for 24 h. After this time, 
benzylamine (118 μL, 1.08 mmol) was added and the reaction was left to stir for a further 
24 h at rt. Upon completion, the organic layer was diluted with CH2Cl2, washed with 
brine, dried with anhydrous MgSO4, filtered and concentrated under reduced pressure to 
generate a crude oil that was purified by column chromatography (ethyl acetate, Rf = 0.60) 
to yield carbamate 6.5 as a cream-coloured solid (22.0 mg, 15%). 
Method B: As per Method A, with the only change being the reaction between CDI and 
αHP 6.3 being performed at reflux for 16 h. No product was isolated. 
Method C: As per Method A, with only the following change to the initial setup of the 
reaction. To a 0ºC suspension of CDI and triethylamine in CH2Cl2 a solution of 4-methoxy 
αHP 6.3 in CH2Cl2 was added in a dropwise manner. Using this method carbamate 6.5 
was obtained as a cream-coloured solid (55.7 mg, 38%). 
Method D: As per Method C, except once the reaction between CDI and 4-methoxy αHP 
6.3 was complete the reaction mixture was diluted with CH2Cl2 and quenched with H2O. 
The aqueous layer was extracted with CH2Cl2, the combined organic layers were dried 
over anhydrous MgSO4, filtered and concentrated under reduced pressure to yield the 
carbamoylimidazole intermediate, which  was resuspended in CH2Cl2 prior to the addition 
of benzylamine. Using this method carbamate 6.5 was obtained as a cream-coloured solid 
(58.7 mg, 40%).  
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Method E: 4-NPC (162 mg, 802 μmol) was added dropwise to a solution of 4-methoxy 
αHP 6.3 (200 mg, 720 μmol) and an excess of triethylamine (200 μL, 1.46 mmol) in dry 
CH2Cl2 at 0°C. The ice bath was removed, and the solution stirred at rt for 3 h. Upon 
completion, benzylamine (120 μL, 1.09 mmol) was added and the reaction stirred at rt for 
24 h. Upon completion, the reaction mixture was evaporated and the crude product 
purified by column chromatography (ethyl acetate:petroleum spirit, 7:3, Rf = 0.21) to 
afford carbamate 6.5 as a cream-coloured solid (175 mg, 59%). 
Method F: Undertaken as per method E, with the only variations being the addition of a 
catalytic amount of DBU (0.2 mL, 22mg, 145 μmol) to the initial solution at 0°C and that 
upon removal of the ice bath the solution was stirred at rt for 1.5 h. Using this method 
carbamate 6.5 was obtained as a cream-coloured solid (210 mg, 74%). 
Method G: Undertaken as per method E with the only variation being the addition of a 
catalytic amount of DMAP to the initial solution at 0°C. Using this method carbamate 6.5 
was obtained as a cream-coloured solid (224 mg, 76%). mp 60.0–63.0ºC. 1H NMR (500 
MHz, CDCl3) δ 7.44 (d, J = 7.8 Hz, 2H), 7.22–7.30 (m, 5H), 6.87 (d, J = 8.5 Hz, 2H), 
6.02 (d, JH,P = 13.5 Hz, 1H), 5.79 (t, J = 5.8 Hz, 1H), 4.37 (dd, J = 15.0, J = 6.1 Hz, 1H), 
4.28 (dd, J = 15.0, J = 5.8 Hz, 1H), 3.92–4.12 (m, 2H), 3.81–3.88 (m, 2H), 3.78 (s, 3H), 
1.26 (t, J = 6.9 Hz, 3H), 1.15 (t, J = 6.9 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 159.7, 
155.1 (d, JC,P = 11.0 Hz), 138.4, 129.4 (d, JC,P = 6.6 Hz), 128.3, 127.2, 127.1, 125.8, 
113.7, 70.4 (d, JC,P = 172.9 Hz), 63.1 (d, JC,P = 7.4 Hz), 62.9 (d, JC,P = 7.1 Hz), 55.0, 45.0, 
16.3 (d, JC,P = 5.9 Hz), 16.1 (d, JC,P = 6.0 Hz). 31P NMR (162 MHz, CDCl3) δ 19.75. 
HRMS (ESI) calcd for C20H26NO6PNa [M + Na]+, 430.1395; Found 430.1409. IR (FTIR) 
νmax 3271, 2933, 1726, 1513, 1248, 1013, 754, 700. 
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(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl benzylcarbamate (6.6) 
Method A: Undertaken as per Method D of the synthesis of carbamate 6.5 starting with 
4-methoxy αHP 6.4 (200 mg, 502 μmol). Using this method no product was isolated. 
Method B: Undertaken as per Method G of the synthesis of carbamate 6.5 starting with 
4-methoxy αHP 6.4 (200 mg, 502 μmol). Using this method and purification by column 
chromatography (ethyl acetate:hexane, 7:3, Rf = 0.28) carbamate 6.6 was obtained as a 
white solid (227 mg, 85%). mp 98.5–100.5ºC. 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J 
= 8.4 Hz, 2H), 7.25–7.29 (m, 10H), 7.16–7.20 (m, 5H), 6.86 (d, J = 8.6 Hz, 2H), 6.08 (d, 
JH,P = 13.5 Hz, 1H), 5.13 (t, J = 5.6 Hz, 1H), 4.76–5.02 (m, 4H), 4.23–4.34 (m, 2H), 3.80 
(s, 3H). 13C NMR (125 MHz, CDCl3) δ 160.1, 155.0 (d, JC,P = 11.4 Hz), 138.0, 136.2 (d, 
JC,P = 6.1 Hz), 136.0 (d, JC,P = 6.4 Hz), 129.7 (d, JC,P = 6.7 Hz), 128.1, 127.2, 127.0, 125.6, 
114.1 (d, JC,P = 1.9  Hz), 71.0 (d, JC,P = 171.6 Hz), 68.6 (d, JC,P = 1.9 Hz), 68.5 (d, JC,P = 
2.0 Hz), 55.4, 45.4. 31P NMR (162 MHz, CDCl3) δ 20.71. HRMS (ESI) calcd for 
C30H30NO6PNa [M + Na]+, 554.1708; Found 554.1702. IR (FTIR) νmax 3251, 2937, 1726, 
1512, 1241, 999, 740, 694. 
6.3.3 Synthesis of Nucleoside Fragments 
The synthetic protocol for the preparation of Alloc protected uridine derivative 5.21 and 
the corresponding characterisation data can be found in section 5.5.4 of Chapter 5 
(p. 137). 
2′,3′-O-(1-Methylethylidene)uridine (6.11) 
A suspension of uridine (6.10, 2.00 g, 8.19 mmol) in 150 mL of acetone was cooled to 
0ºC and 1 mL of concentrated H2SO4 was added in a dropwise manner. The reaction 
mixture was allowed to stir for 16 h at rt, after which it was neutralised by the addition of 
triethylamine and then evaporated under reduced pressure with diethyl ether utilised to 
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co-evaporate the acetone. The crude white product obtained was purified by column 
chromatography (2.32 g, 97%). mp 172.0–173.0ºC (lit. mp 172–174ºC).24 1H NMR (500 
MHz, MeOH-d4) δ 7.39 (d, J = 8.0 Hz, 1H), 5.88 (d, J = 2.8 Hz, 1H), 5.70 (d, J = 8.0 Hz, 
1H), 4.92 (dd, J = 6.3 , J = 2.8 Hz, 1H), 4.83 (dd, J = 6.3 Hz, J = 3.4 Hz, 1H), 4.20–4.23 
(m, 1H), 3.79 (dd, J = 11.9 Hz, J= 3.6 Hz, 1H), 3.73 (dd, J = 11.9 Hz, J= 4.5 Hz, 1H), 
1.56 (s, 3H), 1.36 (s, 3H). The spectral data match those reported.18 
5′-Azido-5′-deoxy-2′,3′-O-(1-methylethylidene)uridine (6.12) 
Acetonide-protected uridine 6.11 (2.32 g, 8.17 mmol) was dissolved at rt in CH2Cl2. 
triethylamine (1.70 mL, 1.24 g, 12.2 mmol) was added dropwise, with the resulting 
solution allowed to stir for 5 min after the addition. The solution was cooled in an ice bath 
and mesyl chloride (0.8 mL, 1.22 g, 10.6 mmol) was slowly added. The reaction was 
allowed to warm to rt and stirred for 16 h. Upon completion the reaction mixture was 
washed with saturated NaHCO3 until gas release stopped. The aqueous extracts were 
washed with ethyl acetate, with the organic phase was pooled with the initial CH2Cl2 
organic layer and dried over anhydrous MgSO4 and filtered. The solvent was evaporated 
under reduced pressure to give a crude residue that was subsequently dissolved in a 
minimum amount of DMF, with tert-butylammonium iodide (463 mg, 1.50 mmol) and 
sodium azide (1.46 g, 22.4 mmol) added. The suspension was then refluxed for 48 h. 
Upon completion the reaction solution was poured into 10 g of crushed ice and extracted 
with CH2Cl2. The organic phase was washed with brine, dried with anhydrous MgSO4, 
filtered and evaporated under reduced pressure. The resulting crude was purified by 
column chromatography (ethyl acetate:petroleum spirit, 6:4, Rf = 0.39) to afford 6.12 as 
a white powder (1.79 g, 71%). mp 129.0–131.4ºC, (lit. mp 129–132ºC).25 1H NMR (500 
MHz, CDCl3) δ 9.99 (br s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 5.78 (d, J = 8.0 Hz, 1H), 5.67 
(s, 1H), 5.02 (dd, J = 6.0 Hz, J = 2.0 Hz, 1H), 4.83 (dd, J = 6.0 Hz, J = 4.0 Hz, 1H), 4.23–
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4.26 (m, 1H), 3.63 (d, J = 4.4 Hz, 2H), 1.57 (s, 3H), 1.36 (s, 3H). The spectral data match 
those reported.26 
5′-Amino-5′-deoxy-2′,3′-O-(1-methylethylidene)uridine (6.13) 
Azide 6.12 (312 mg, 1.01 mmol) was suspended in MeOH and 10% Pd/C was added. The 
mixture was stirred at rt, with H2 gas bubbled through for 90 min. The resulting reaction 
mixture was then filtered over a bed of Celite, with the filtrate concentrated under 
reduced pressure to yield 6.13 as a white solid (284 mg, 99%) that was judged sufficiently 
pure, by 1H NMR, for further reaction. mp 84.0–87.0ºC, (lit. mp 85–87ºC).26 1H NMR 
(500 MHz, DMSO-d6) δ 7.83 (d, J = 8.0 Hz, 1H), 5.78 (d, J = 2.8 Hz, 1H), 5.63 (d, 
J = 8.0 Hz, 1H), 4.94 (dd, J = 6.5 Hz, J = 2.8 Hz, 1H), 4.74 (dd, J = 6.5 Hz, J = 3.9 Hz, 
1H), 3.94–3.96 (m, 1H), 3.17 (br s, 2H), 2.77 (d, J = 5.5 Hz, 1H), 1.48 (s, 3H), 1.29 (s, 
3H). The spectral data match those reported.26 
5′-Azido-5′-deoxyuridine (6.19) 
Method A: To a flask charged with azide 6.13 (100 mg, 324 μmol) and CH3CN:H2O 
(9:1, v/v) In(OTf)3 (1 mol%, 2 mg) was added. The reaction was heated to reflux and 
allowed to stir for 18 h. Upon completion the solvent was removed under reduced 
pressure and the crude product was purified by column chromatography (CHCl3:MeOH, 
9:1, Rf = 0.20) to afford 6.19 as a white foam (83.3 mg, 95%).  
Method B: The synthetic procedure for the Mitsunobu reaction to produce azide 6.19 
from commercially available uridine (6.10) as well as the corresponding characterisation 
data can be found for 5.19 in section 5.5.4 of Chapter 5 (p. 136). 
5′-Azido-2′, 3′-O-bis(tert-butyldimethylsilyl)-5′-deoxyuridine (6.20) 
To a solution of azide 6.19 (195 mg, 723 μmol) in pyridine, imidazole (246 mg, 
3.61 mmol) and TBDMS chloride (436 mg, 2.89 mmol) were added slowly. The resulting 
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solution was stirred for 24 h at rt. Volatiles were co-evaporated with toluene to ensure all 
pyridine was removed, and the crude residue was partitioned (NaHCO3/H2O//CHCl3). 
The aqueous layer was further extracted with CHCl3, and the combined organic phase 
was dried with anhydrous MgSO4, filtered and evaporated under reduced pressure to give 
6.20 as a white foam (243 mg, 67%) that was judged to have sufficient purity by 1H NMR. 
mp 205.0–207.6ºC. Rf = 0.20 (ethyl acetate:petroleum spirit, 2:8). 1H NMR (500 MHz, 
CDCl3) δ 8.83 (br s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 5.76 (d, J = 8.5 Hz, 1H), 5.67 (d, 
J = 3.5 Hz, 1H), 4.19–4.20 (m, 1H), 4.10–4.14 (m, 1H), 3.93–3.99 (m, 1H), 3.82 (dd, 
J = 13.0 Hz, J = 3.0 Hz, 1H), 3.61 (dd, J = 13.5 Hz, J = 2.5 Hz, 1H), 0.91 (br s, 9H), 0.90 
(br s, 9H), 0.12 (s, 6H), 0.09 (s, 6H). The spectral data match those reported.22 
5′-Amino-2′, 3′-O-bis(tert-butyldimethylsilyl)-5′-deoxyuridine (6.21). 
Azide 6.20 (200 mg, 402 μmol) was suspended in MeOH and 10% Pd/C (20 mg) was 
added. The mixture was stirred at rt, with H2 gas bubbled through for 90 min. Upon 
completion the resulting reaction mixture was then filtered over a bed of Celite, with 
the filtrate concentrated under reduced pressure to yield 6.21 as a white solid (186 mg, 
98%) that was judged sufficiently pure for further reaction by 1H NMR. mp decomp. 
>196.0ºC, (lit. mp decomp. ~198ºC).22 Rf = 0.52 (CH2Cl2:MeOH, 9:1). 1H NMR (500 
MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 1H), 5.73 (d, J = 8.1 Hz, 1H), 5.66 (d, J = 3.4 Hz, 
1H), 4.25 (t, J = 3.9 Hz, 1H), 4.02–4.07 (m, 1H), 3.96 (dd, J = 5.6 Hz, J = 4.6 Hz, 1H), 
3.09 (dd, J = 13.9 Hz, J = 2.7 Hz, 1H), 2.90 (dd, J = 13.9 Hz, J = 5.6 Hz, 1H), 0.90 (br s, 
9H), 0.89 (br s, 9H), 0.11 (s, 3H), 0.092 (s, 6H), 0.086 (s, 3H). The spectral data match 
those reported.22 
5′-Azido-2′, 3′-O-bis(benzyloxycarbonyl)-5′-deoxyuridine (6.22). 
Azide 6.19 (439 mg, 1.63 mmol) and DMAP (548 mg, 4.89 mmol) were dissolved in 
CH2Cl2 and the resulting suspension was cooled to 0ºC. Benzyl chloroformate (0.7 mL, 
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4.89 mmol) was added dropwise and the suspension stirred at rt. After 16 h the solution 
was diluted with CH2Cl2 and washed with H2O, followed by NaHCO3 and brine. The 
organic phase was collected, dried with MgSO4 and concentrated under reduced pressure. 
The resulting crude product was purified by column chromatography (CH2Cl2:ethyl 
acetate, 85:15, Rf = 0.44) to produce 6.22 as a white crystalline solid (626 mg, 72%). mp 
63.4–65.5ºC. [α]D25 +1.0 (c = 4.4, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.50 (br s, 1H), 
7.37 (d, J = 8.0 Hz, 1H), 7.32–7.33 (m, 10H), 5.94 (d, J = 5.0 Hz, 1H), 5.78 (d, 
J = 8.0 Hz, 1H), 5.40 (t, J = 4.0 Hz, 1H), 5.33 (t, J = 4.0 Hz, 1H), 5.10–5.12 (m, 4H), 
4.25–4.27 (m, 1H), 3.73 (dd, J = 12.0 Hz, J = 4.0 Hz, 1H), 3.63 (dd, J = 12.0 Hz, J = 
4.0 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 163.2, 154.0, 153.9, 150.2, 140.5, 134.6, 
134.5, 128.9, 128.73, 128.70, 128.6, 128.5, 103.6, 88.7, 80.1, 75.6, 73.6, 70.7, 70.6, 51.6. 
HRMS (ESI) calcd for C25H23N5O9Na [M + Na]+, 560.1393; Found 560.1370. IR (FTIR) 
νmax 2106, 1749, 1688, 1259, 1229, 1080, 696. 
5′-Amino-2′, 3′-O-bis(benzyloxycarbonyl)-5′-deoxyuridine (6.23). 
To a solution of azide 6.22 (422 mg, 951 μmol) in dry THF, triphenylphosphine (499 mg, 
1.90 mmol) was added with the resulting solution allowed to stir at rt. After 2 h a few 
drops of H2O was added and the solution was heated at reflux for 5 h. Upon completion 
volatiles were removed under reduced pressure and the subsequent crude purified by 
column chromatography (CH2Cl2:MeOH, 95:5, Rf = 0.33) to yield 6.23 as a white solid 
(243 mg, 50%). mp 74.0–76.0ºC. [α]D25 +1.1 (c = 1.9, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 7.58 (d, J = 7.8 Hz, 1H), 7.32–7.33 (m, 10H), 5.87 (d, J = 3.7 Hz, 1H), 5.74 (d, 
J = 8.0 Hz, 1H), 5.48–5.50 (m, 1H), 5.34–5.36 (m, 1H), 5.10–5.12 (m, 4H), 4.18 (br s, 
1H), 3.14 (d, J = 14.2 Hz, 1H), 3.01 (d, J = 11.8 Hz, 1H), 2.22 (br s, 1H). 13C NMR (100 
MHz, CDCl3) δ 162.7, 154.3, 154.1, 150.0, 141.4, 134.7, 134.6, 128.93, 128.90, 128.8, 
128.63, 128.57, 103.2, 89.0, 82.4, 76.1, 73.5, 70.7, 70.6, 42.1. HRMS (ESI) calcd for 
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C25H25N3O9 [M + H]+, 512.1669; Found 512.1690. IR (FTIR) νmax 3060, 3033, 1687, 
1260, 1073, 696. 
6.3.4 Carbamate Coupling 
4-NPC (1.1 equiv.) was added dropwise to a solution of dibenzyl αHP (1 equiv.), an 
excess of triethylamine (2 equiv.) and a catalytic amount of DMAP (0.1 equiv.) in dry 
CH2Cl2 at 0°C. The ice bath was removed, and the solution stirred at rt for 3 h. Upon 
completion, 5′-aminonucleoside (1.2 equiv.; 6.13, 5.21, 6.21 or 6.23) was added and the 
reaction stirred at rt for 24 h. Upon completion the reaction mixture was washed with 
H2O and brine. The organic phase was separated and then dried with anhydrous MgSO4, 




From 6.4 (268 mg, 672 μmol): purification by column chromatography (ethyl acetate, 
Rf = 0.59) to afford 6.14 (295 mg, 63%) as a white solid. mp 86.6–88.0 ºC. [α]D25 −5.0 
(c = 0.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.92–10.01 (2 x br s, 1H), 7.37–7.40 (m, 
2H), 7.26–7.31 (m, 8H), 7.10–7.15 (m, 3H), 6.85 (d, J = 8.0 Hz, 2H), 6.02–6.06 (m, 1H), 
5.87–5.92 (br s, 1H), 5.65–5.68 (m, 1H), 5.40–5.42 (2 x s, 1H), 4.69–5.07 (m, 6H), 4.12–
4.14 (m, 1H), 3.77 (s, 3H), 3.44–3.47 (m, 2H), 1.50–1.51 (2 x s, 3H), 1.26–1.27 (2 x s, 
3H). 13C NMR (125 MHz, CDCl3) δ 163.4–163.5 (2 x s), 160.00–160.03 (m), 155.2–
155.3 (m), 150.39–150.41 (2 x s), 143.2, 132.9–136.3 (m), 129.6–129.7 (2 x s), 128.6, 
128.5, 128.4, 127.91, 127.88, 127.86, 125.6, 114.65–114.69 (2 x s), 113.99–114.03 (m), 
102.8–102.9 (2 x s), 95.9–96.1 (2 x s), 85.7–85.9 (2 x s), 83.9–84.1 (2 x s), 81.1–81.2 
(2 x s), 71.0–71.1 (2 x d, JC,P = 172.5 Hz), 68.5–68.7 (m), 55.3, 42.7–42.9 (2 x s), 27.2–
27.3 (2 x s), 25.3–25.4 (2 x s). 31P NMR (162 MHz, CDCl3) δ 20.61–20.69 (2 x s). HRMS 
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(ESI) calcd for C35H38N3O11PNa [M + Na]+, 730.2158; Found 730.2142. IR (FTIR) νmax 
2920, 1686, 1512, 1245, 1023, 837, 734, 696. 
(Bis(benzyloxy)phosphoryl)(3-propoxyphenyl)methyl(2′, 3′-O-(1-methylethylidene)uridi-
n-5′-yl)carbamate (6.15). 
From 6.7 (210 mg, 492 μmol): purification by column chromatography (ethyl 
acetate:petroleum spirit, 6:4, Rf = 0.38) to afford 6.15 (295 mg, 57%) as a white solid. mp 
65.0–68.0 ºC. [α]D25 +14.0 (c = 0.05, CHCl3). 1H NMR (500 MHz, CDCl3) δ 9.49–9.60 
(2 x br s, 1H), 7.18–7.29 (m, 11H), 7.10–7.13 (2 x d, J = 10.0 Hz, 1H), 6.97–7.04 (d, 2H), 
6.84 (d, J = 8.0 Hz, 1H), 6.04–6.09 (m, 1H), 5.76–5.81 (m, 1H), 5.65–5.69 (m, 1H), 5.38–
5.41 (2 x s, 1H), 4.70–5.05 (m, 6H), 4.13–4.14 (m, 1H), 3.79–3.86 (s, 2H), 3.46 (br s, 
2H), 1.75 (sxt, J = 7.0 Hz, 2H), 1.51 (s, 3H), 1.26–1.28 (m, 3H), 0.99 (t, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ 163.31–163.41 (2 x s), 159.2, 155.1–155.2 (m), 150.3, 
143.2, 136.1–136.2 (m), 135.91–136.01 (m), 135.1, 129.5, 128.6, 128.5, 128.4, 128.0, 
127.94, 127.90, 120.0–120.1 (2 x s), 115.1, 114.68–114.71 (2 x s), 113.8, 102.8–102.9 
(2 x s), 95.9–96.1 (2 x s), 85.7–85.9 (2 x s), 83.9–84.1 (2 x s), 81.18–81.23, 71.4–71.5 
(2 x d, JC,P = 170.0 Hz), 69.5, 68.6–68.8 (m), 42.8–42.9 (2 x s), 27.2–27.3 (2 x s), 25.3–
25.4 (2 x s), 22.6, 10.6. 31P NMR (162 MHz, CDCl3) δ 20.06–20.13 (2 x s). HRMS (ESI) 
calcd for C37H42N3O11PNa [M + Na]+, 758.2455; Found 758.2467. IR (FTIR) νmax 2930, 
1689, 1455, 1380, 1245, 998, 861, 735, 695. 
(Bis(benzyloxy)phosphoryl)(3-phenoxyphenyl)methyl(2′, 3′-O-(1-methylethylidene)uridi-
n-5′-yl)carbamate (6.16). 
From 6.8 (204 mg, 444 μmol): purification by column chromatography (CHCl3:CH3CN 
99:1, 1% triethylamine, Rf = 0.31) to afford 6.16 (222 mg, 65%) as a white solid. mp 
78.6–80.1ºC. [α]D25 −7.7 (c = 0.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.24–7.29 (m, 
14H), 7.16–7.19 (m, 2H), 7.06–7.12 (m, 2H), 6.92–6.95 (m, 2H), 6.05–6.08 (m, 1H), 
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5.80–5.82 (m, 0.5H), 5.73–5.75 (m, 0.5H), 5.65–5.68 (m, 1H), 5.35–5.39 (2 x s, 1H), 
4.86–5.05 (m, 5H), 4.78–4.80 (m, 0.5H), 4.69–4.71 (m, 0.5H), 4.13 (d, J = 4.0 Hz, 1H), 
3.43–3.51 (m, 2H), 1.51–1.52 (2 x s, 3H), 1.28 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 
163.25–163.34 (2 x s), 157.4, 157.0, 155.1 (d, JC,P = 12.0 Hz), 150.3–150.4 (2 x s), 143.3, 
135.8–136.1 (m), 129.9, 128.7, 128.6, 128.0, 127.9, 123.5, 122.67–122.70 (2 x s), 119.0–
119.1 (2 x s), 118.20–118.24 (2 x s), 114.75–114.80 (2 x s), 102.87–102.92 (2 x s), 96.2–
96.5 (2 x s), 85.7–85.9 (2 x s), 83.9–84.1 (2 x s), 81.1–81.2 (2 x s), 71.2–71.3 (2 x d, JC,P 
= 170.0 Hz), 68.7–68.9 (m), 42.8–42.9 (2 x s), 27.27–27.30 (2 x s), 25.3–25.4 (2 x s). 31P 
NMR (162 MHz, CDCl3) δ 19.73–19.79 (2 x s). HRMS (ESI) calcd for C40H41N3O11P [M 
+ H]+, 770.2479; Found 770.2452. IR (FTIR) νmax 1657, 1455, 1379, 1242, 995, 735, 695. 
(Bis(benzyloxy)phosphoryl)(phenyl)methyl(2′, 3′-O-(1-methylethylidene)uridin-5′-yl) 
carbamate (6.17). 
From 6.9 (228 mg, 619 μmol): purification by column chromatography (ethyl 
acetate:petroleum spirit, 9:1, 1% triethylamine, Rf = 0.63) to afford 6.17 (205 mg, 60%) 
as a white solid. mp 82.7–85.6ºC. [α]D25 −9.2 (c = 0.1, CHCl3). 1H NMR (500 MHz, 
CDCl3) δ 9.15–9.31 (2 x br s, 1H), 7.43–7.46 (m, 3H), 7.25–7.32 (m, 10H), 7.17 (br s, 
2H), 7.09–7.13 (2 x d, J = 8.0 Hz, 1H), 6.07–6.11 (m, 1H), 5.77–5.79 (m, 1H), 5.66–5.70 
(m, 1H), 5.36–5.39 (2 x s, 1H), 4.70–5.07 (m, 6H), 4.13–4.15 (m, 1H), 3.45–3.50 (m, 
2H), 1.52 (s, 3H), 1.28–1.29 (2 x s, 3H). 13C NMR (125 MHz, CDCl3) δ 162.9–163.0 (2 x 
s), 155.1–155.2 (m), 150.3, 143.3, 136.18–136.23 (m), 135.96–136.02, 133.8, 128.9, 
128.7, 128.6, 128.5, 128.1, 128.04, 127.96, 127.9, 114.8–114.9 (2 x s), 102.96–102.99 
(2 x s), 96.3–96.6 (2 x s), 85.7–86.0 (2 x s), 83.9–84.1 (2 x s), 81.1–81.2 (2 x s), 71.5–
71.7 (2 x d, JC,P = 169.8 Hz), 68.6–68.8 (m), 42.7–42.9 (2 x s), 27.3–27.4 (2 x s), 25.3–
25.4. 31P NMR (162 MHz, CDCl3) δ 20.22–20.28 (2 x s). HRMS (ESI) calcd for 
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C34H36N3O10PNa [M + Na]+, 700.2036; Found 700.2052. IR (FTIR) νmax 1686, 1454, 
1379, 1246, 994, 860, 735, 695. 
(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl(2′, 3′-O-bis(tert-butyldimethylsily-
l)uridin-5′-yl)carbamate (6.24). 
From 6.4 (72.0 mg, 358 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
8:2, Rf = 0.09) to afford 6.24 as a clear film (99.0 mg, 35%). mp 54.0–59.0 ºC. [α]D25 −1.8 
(c = 0.1, CHCl3). 1H NMR (500 MHz, CDCl3) δ 8.74 (br s, 1H), 7.37–7.40 (m, 2H), 7.26–
7.30 (m, 9H), 7.16–7.20 (m, 2H), 6.82–6.85 (m, 2H), 6.05 (d, JH,P = 13.5 Hz, 1H), 5.79 
(br s, 0.5H), 5.64–5.68 (m, 1H), 5.52 (br s, 0.5H), 5.39–5.44 (m, 1H), 4.77–5.02 (m, 4H), 
4.38–4.39 (m, 1H), 4.00–4.03 (m, 1H), 3.84–3.85 (m, 1H), 3.78–3.79 (2 x s, 3H), 3.27–
3.47 (m, 2H), 0.83–0.88 (m, 18H), −0.07–0.04 (m, 12H). 13C NMR (125 MHz, CDCl3) δ 
162.9–163.0 (2 x s), 160.1–160.2 (2 x s), 155.3 (d, JC,P = 11.1 Hz), 150.0–150.1 (2 x s), 
141.6–142.6 (m), 136.2–136.3 (m), 136.0–136.1 (m), 129.5–129.9 (2 x d, JC,P = 5.0 Hz), 
128.8, 128.7, 128.4, 128.3, 128.2, 128.1, 127.8, 125.6, 114.09–114.14 (2 x s), 102.4–
102.6 (2 x s), 93.9–94.0 (2 x s), 83.9–84.1 (2 x s), 73.0–73.9 (m), 71.1–71.3 (m, JC,P = 
174.0 Hz), 68.2–68.9 (m), 55.3–55.5 (2 x s), 43.3–43.5 (m), 29.8, 25.7–26.2 (m), 18.0–
18.1 (m), −4.8 – −4.3. 31P NMR (162 MHz, CDCl3) δ 20.48–20.51 (2 x s). HRMS (ESI) 
calcd for C44H62N3O11PSi2Na [M + Na]+, 918.3558; Found 918.3554. IR (FTIR) νmax 
2929, 1688, 1512, 1034, 832, 776, 733, 695. 
(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl(2ʹ, 3ʹ-O-bis(allyloxycarbonyl)urid-
in-5′-yl)carbamate (6.25). 
The synthetic procedure for the preparation of Alloc protected carbamate 6.25 and the 
corresponding characterisation data can be found for 5.25g in section 5.5.5 of Chapter 5 
(p. 145). 
  




From 6.4 (68.7 mg, 172 μmol): purification by column chromatography (CH2Cl2:CH3CN, 
7:3, Rf = 0.35) to afford 6.26 as a clear film (69.0 mg, 43%). mp 89.1–91.1 ºC. [α]D25 −1.2 
(c = 1.5, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.27–7.38 (m, 20H), 7.14–7.19 (m, 2H), 
7.03–7.06 (m, 1H), 6.84 (d, J = 8.5 Hz, 2H), 5.99–6.03 (m, 1H), 5.68–5.71 (m, 0.5H), 
5.64 (d, J = 8.0 Hz, 0.5H), 5.56 (d, J = 8.0 Hz, 0.5H), 5.45–5.51 (m, 2H), 5.33–5.36 (m, 
0.5H), 5.28–5.30 (m, 1H), 4.75–5.14 (m, 8H), 4.15 (br s, 1H), 3.77–3.78 (2 x s, 3H), 3.37–
3.57 (m, 2H). 13C NMR (125 MHz, CDCl3) δ 162.8, 160.07–160.14 (2 x s), 155.2–155.4 
(m), 154.0, 150.0, 142.0–142.1 (2 x s), 136.0–136.3 (m), 134.5–134.7 (2 x s), 129.6–
129.8 (2 x d, JC,P = 6.3 Hz), 128.96, 128.95, 128.9, 128.84, 128.77, 128.64, 128.60, 
128.56, 128.53, 128.50, 128.45, 128.1, 128.03, 128.01, 127.97, 125.6 (d, JC,P = 8.8 Hz), 
114.1, 103.2, 92.4–92.5 (2 x s), 80.2, 75.9–76.1 (2 x s), 73.06–73.13 (2 x s), 71.4–71.5 (2 
x d, JC,P = 172.5 Hz), 70.6–70.7 (m), 68.6–68.8 (m), 55.4, 41.6–41.9 (2 x s). 31P NMR 
(162 MHz, CDCl3) δ 20.39. HRMS (ESI) calcd for C48H46N3O15PNa [M + Na]+, 
958.2564; Found 958.2584. IR (FTIR) νmax 1696, 1457, 1239, 995, 837. 
6.3.5 Deprotection of Protected Carbamates 
(Bis(benzyloxy)phosphoryl)(4-methoxyphenyl)methyl(uridin-5′-yl)carbamate (6.18). 
Method A: To a flask containing 6.14 (100 mg, 141 μmol), a 30% TFA(aq) solution was 
added and the reaction allowed to stir at rt for 2 h. At this time, the solution was 
concentrated under reduced pressure with repeated co-evaporation with toluene to remove 
residual water. The product was purified by column chromatography (CH2Cl2:MeOH, 
9:1, Rf = 0.50) to produce 6.18 as an off-white solid (25.5 mg, 30%). The corresponding 
characterisation data can be found as 5.26g in section 5.5.6 of Chapter 5 (p. 154). 
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Method B: As per method A, except 90% TFA(aq) was added and the reaction allowed to 
stir at rt for 15 min. Under these conditions 6.18 was obtained as an off-white solid 
(48.5 mg, 57%). 
Method C: To a flask containing 6.14 (84.3 mg, 133 μmol) and CH3CN/H2O (9:1, v/v) 
In(OTf)3 (1 mol%, 1 mg) was added. The reaction was heated to reflux and allowed to 
stir for 18 h. After this time only starting material was recovered. 
Method D: As per method C, except the amount of In(OTf)3 was increased to 3 mol%. 
Under these conditions only starting material was recovered. 
Method E: To a microwave process tube with stir bar charged with 6.14 (84.3 mg, 
133 μmol) and CH3CN:H2O (9:1, v/v) In(OTf)3 (1 mol%, 1 mg) was added. The resulting 
mixture was heated under microwave conditions (300W) at 120ºC for 30 min. After this 
time only starting material was recovered. 
Method F: As per method E, except the reaction mixture was heated under microwave 
conditions (300W) at 120ºC for 1 h. After this time only starting material was recovered. 
Method G: As per method E, except the solvent was changed to methanol/H2O (9:1, v/v). 
All staring material was consumed and a complex mixture of side products was obtained. 
Method H: TBDMS protected carbamate 6.24 (99.0 mg, 110 μmol) was dissolved in 
THF and glacial acetic acid (7.50 μL, 132 μmol) was added. The reaction mixture was 
cooled to 0ºC and 1.0 M TBAF in THF (24.2 μL, 242 μmol) was added in a dropwise 
manner. The resulting reaction mixture was allowed to gradually warm to rt over 2 h and 
left to stir at rt for an additional 16 h. After such time, the volatile reactants were removed 
under reduced pressure with the resulting crude product was purified by column 
chromatography (CH2Cl2:MeOH, 9:1, Rf = 0.50) to produce 6.18 as a white solid 
(66.3 mg, 90%). 
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Method I: Alloc protected carbamate 6.25 was deprotected to produce 6.18 as described 
for 5.26g in section 5.5.6 of Chapter 5 (p. 154). 
(4-Methoxyphenyl)methyl)[(uridin-5′-yl)carbamoyl]phosphonic acid (6.27). 
Method A: Dibenzyl protected carbamate 6.18 was deprotected to produce 6.27 as 
described for 5.27g in section 5.5.7 of Chapter 5 (p. 165). 
Method B: To a solution of Cbz protected carbamate 6.26 (69.0 mg, 73.7 μmol) in 
MeOH, 10% Pd/C by mass (7 mg) was added. The mixture was stirred at rt, with H2 gas 
bubbled through. Upon consumption of starting material, the reaction mixture was filtered 
through a bed of Celite with the filtrate concentrated under reduced pressure to yield a 
crude mix of diastereoisomers of 6.27 (32.0 mg, 90%). Separation of diastereomers of 
6.27, subsequent ion exchange and characterisation data are described for 5.27g in section 
5.5.7 of Chapter 5 (p. 165). 
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Using a multi-disciplinary approach, considerable progress has been made towards the 
development of carbamate-linked ST inhibitors. The key findings from this study can be 
summarised into the three areas of computational, synthesis and biological results. 
Molecular docking and MD simulations were performed to investigate the 
replacement of the charged phosphodiester linker used in reported transition-state 
analogue ST inhibitors with a carbamate or a 1,2,3-triazole (Chapter 3).1 As part of this 
work a molecular docking protocol was developed and was able to successfully replicate 
experimental trends for reported inhibitors. Using this procedure, 48 potential inhibitors 
were examined and the potential to use a carbamate or a 1,2,3-triazole linker as an 
isosteric replacement for the phosphodiester in transition-state analogue ST inhibitors was 
demonstrated. MD simulations of four different ligands complexed with hST6Gal I were 
performed and interactions in the complexes were characterised by monitoring 
interactions with the active site. This analysis replicated all the reported hydrogen bonds 
observed in the hST6Gal I-CMP complex crystal structure and identified that the phenoxy 
substituent of the lead compounds are oriented towards the proposed sialyl acceptor site. 
This site is expected to be the major point of difference between the active sites of the 
different ST subtypes (ST3, ST6 and ST8) encouraging the targeting of this site as a 
potential route to design selective inhibitors. Furthermore, these MD simulations 
provided evidence that a carbamate linker will maintain similar interactions to those the 
phosphodiester linker has with the hST6Gal I active site. 
To expand on our previous computational studies additional MD simulations and 
FEP calculations were performed (Chapter 4).2 Prior to these calculations being 
performed, force fields generated using the CGenFF for the phosphodiester-linked lead 
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compound and the carbamate- and 1,2,3-triazole-linked derivatives were optimised using 
GAAMP. With the force fields in hand MD simulations with the (R)- and 
(S)-diastereomers of the three ligands, which only differed in the linker, complexed with 
hST6Gal I or in a water box were performed. As with our previous work (Chapter 3), 
hydrogen bonds and hydrophobic contacts of the ligands with hST6Gal I were monitored 
over the course of the simulations and have demonstrated that no matter which linker is 
used, key interactions with the active site are able to be maintained. FEP calculations 
demonstrated that when the phosphodiester linker was perturbed to either a carbamate or 
1,2,3-triazole a slightly more favourable binding to hST6Gal I was observed, with 
carbamate being marginally more preferential. We rationalised this surprising result with 
a hypothesis of an enthalpy-entropy compensation, which was supported by free energy 
component analysis, quasi-harmonic and cluster analysis. With these analyses we were 
able to demonstrate that the conformational restriction, and thus entropic favourability for 
binding, imparted by the 1,2,3-trizole and carbamate linkers when compared to the 
phosphodiester linker is enough to compensate the resulting enthalpic penalty. These 
results provided further evidence to suggest that the use of a carbamate or a 1,2,3-triazole 
as phosphodiester isosteres has potential and should be explored synthetically. Further to 
the computational modelling described in Chapters 3 and 4, an additional FEP 
calculation that examined the change of nucleoside fragment from a cytidine to a uridine 
for carbamate-linked compounds that are bound to hST6Gal I, was performed 
(Chapter 5). This calculation was able to demonstrate that uridine is a potential viable 
alternative to cytidine that should be explored.  
To build upon and validate the computational work of this study a series of 
carbamate-linked compounds were synthesised, with this work totalling in 73 novel 
compounds being produced (Chapters 5 and 6). For the preparation of target 
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carbamate-linked compounds, α-HP and 5′-amino nucleosides were required to be 
prepared. With these key fragments in hand, carbamate coupling conditions were 
developed (Chapter 6). Next, two coupling reagents, CDI and 4-NPC, were trialled in 
the preparation of model carbamate-linked compounds 6.5 and 6.6. From these trials, the 
method using 4-NPC was found to be the highest yielding and hence was translated to the 
preparation of target carbamate compounds. The initial method saw the acetonide 
protected 5′-aminouridine 6.13 coupled to a small series of αHPs to produce four 
carbamate-linked compounds (6.14–6.17) in good yields of 57%–65%. When the fully 
protected carbamate-linked compound 6.14 was subjected to standard acetonide 
deprotection conditions, the deprotected derivative 6.18 was isolated in low yields with 
significant decomposition observed. This forced the protection of the 2′- and 3′-hydroxyls 
to be re-examined, with 5′-aminouridine protected with Alloc (5.21), TBDMS (6.21) and 
Cbz (6.23) prepared and coupled to 4-methoxy αHP (6.4) to successfully produce the 
desired carbamate-linked derivatives. All three compounds were able to be fully 
deprotected to produce the target inhibitor 6.27. Of the methods trialled the Alloc route 
was favoured as it had the highest overall yield (28% over 6 steps) observed. 
Using the developed carbamate coupling conditions, along with the Alloc 
protecting strategy, we examined the replacement of the phosphodiester linker and 
cytidine of classical ST inhibitors with a carbamate and uridine respectively (Chapter 5). 
With this in mind, 26 carbamate-linked compounds (5.27a–5.27l and 5.29) were designed 
and synthesised as sodium salts for biological evaluation against recombinant hST6Gal I. 
The inhibitory activities were evaluated at 10 μM, with all compounds exhibiting activity, 
demonstrating that a carbamate linker is a suitable motif in inhibitors of hST6Gal I. From 
this data a number of key trends were observed (Table 7.1), in particular that 
uridine-based inhibitors were well tolerated and were more potent than their 
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cytidine-based counterpart (5.27a vs 5.29). As cytidine was previously considered 
essential for activity3-6 this result provides an important rationale for exploring further 
variations to the nucleoside fragment. The remaining SAR information was gained for 
the αHP fragment (sialic acid mimic). In particular the saturated alkyl 3-cyclopentoxy 
derivative 5.27i-l (Ki = 12 ± 6 μM) was identified as a more potent inhibitor than its 
3-propoxy, 3-methoxy and 3-phenoxy counterparts, which all had comparable levels of 
activity. Substitution at the 4-position on its own was shown to be tolerated, particularly 
with the 4-fluoro derivative 5.27c-l (Ki = 0.9 ± 0.3 μM), which was one of the most potent 
in the series. However, when substituents were present at both the 3- and 4-position a 
decrease in activity was observed. Finally, with the identification of the promising 
2-benzothiophene derivative 5.27k-s (Ki = 4 ± 2 μM), we were able to show that both 
stereochemistry and regiochemistry are crucial considerations in the future if similar 
heterocycles are explored as sialic acid mimics. 
The inhibitory activity observed for the carbamate-linked compounds (5.27a–
5.27l and 5.29) can be compared to the computational findings of Chapters 3–5. The 
findings from the molecular docking (Chapter 3) and MD simulations (Chapters 3 
and 4), which suggested that a carbamate linker could be a feasible phosphodiester 
isostere are supported by the carbamate linker being tolerated in inhibitors of recombinant 
hST6Gal I. The FEP calculation examining the impact of changing from a cytidine-based 
to a uridine-based inhibitor (Chapter 5) was also validated by uridine-based inhibitor 
5.27a being shown as a more potent inhibitor of hST6Gal I than its cytidine-based 
counterpart 5.29. However, the results of the FEP calculations (Chapter 4), which 
suggested that a carbamate-linked inhibitor would bind comparably to the corresponding 
phosphodiester-linked inhibitor were not validated by the biological results. In fact, Ki 
values of our most potent compounds carbamate-linked compounds were one to three 
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orders of magnitude less potent than comparable phosphodiester-linked compounds 
reported.3-6  
Multiple potential factors may contribute to this discrepancy. First of all, the 
accuracy of relative binding free energy simulations critically depends on the quality of 
the developed force field parameters. Similar to previous work, the force field parameters 
used were automatically generated with ParamChem and then optimised by fitting to the 
chosen ab initio/DFT calculations adopted by the CGenFF based on electrostatic 
potential, water binding and torsional profile. However, as the force fields developed in 
this work represent charged molecules using non-polarisable models, there is potential 
for inaccuracies in the modelling of atom-atom interactions in nonuniform environments, 
such as a protein-active site. To overcome this further work to validate force fields against 
thermodynamic properties, particularly hydration free energies in water and non-aqueous 
solutions7 should be undertaken and polarisable force fields8 could be explored.  
A second critical approximation in the simulations performed was that based on 
PROPKA predictions, the protonation states of the ligands remained consistent upon 
binding. Unfortunately, no experimental data is currently available, and we can envision 
that a change in ligand protonation state, which was not accounted for in our calculations, 
could occur upon binding. It is expected that such protonation changes may have an effect 
in the potency of inhibitors.9 To account for the possible pH dependence of binding free 
energies, protocols such as that described by Kim et al10-11 could be considered. This 
protocol, which has successfully demonstrated the pH dependence of inhibitors to 
BACE-1, applies the binding polynomial formalism to a constant pH MD framework.10 
Finally, the convergence of the simulations is another critical factor. As shown in 
Table 4.1 (see p. 99) the thermodynamic cycle of both the 288 K and 298 K simulations 
closed with an error −1.5 kcal/mol and −0.8 kcal/mol respectively. However, in the 
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simulations, we did notice that multiple bound conformations are possible, due the 
relatively large size of the hST6Gal I binding pocket. Further simulations are required to 
completely rule out this as a potential source of error. To ensure all binding conformations 
are sampled in future simulations, a Hamiltonian replica exchange MD scheme12 could 
be used. 
Table 7.1: Summary of SAR information gained for carbamate-linked transition-state analogue ST 
inhibitors against recombinant hST6Gal I.  
 
Sialic Acid Mimic Linker Nucleoside 




Uridine > Cytidine 
 
Stereochemistry not crucial 
R2: cyclopentoxy > propoxy, methoxy, phenoxy 
R2: propoxy ≈ methoxy ≈ phenoxy 
R3: F >> methoxy 
3,4-disubstitution not tolerated 
When R is 
 
 
2-benzothiophene >> 3-benzothiophene 
Stereochemistry crucial 
 
7.2 Future Directions  
Based on the conclusions from this body of work, a number of future directions are put 
forward in each of the computational, biological and synthetic aspects of the project. 
For the computational part of the project, efforts could be made to further optimise 
the force fields that were generated as part of Chapter 4 and to examine the effect the 
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protonation state of inhibitors has on predicted binding to STs. In addition, with the 
availability of further human sialyltransferase crystal structures such as that of 
hST8Sia III and hST6GalNAc II, a platform to perform similar calculations to those in 
this thesis to make predictions about selectivity is available. On this note work is currently 
underway within our research group using both of these structures.13 
In terms of the biological component of this project the 26 carbamate-linked 
compounds synthesised during this work are currently under evaluation in a series of 
enzymatic and cell assays. The enzymatic assays that are currently being performed 
include those to determine the Ki values of 5.27c-l, 5.27i-l and 5.27k-s against 
recombinant hST6Gal I. Also planned, is the evaluation of the activity of the prepared 
carbamate series against recombinant hST3Gal I, which will provide information about 
selectivity for specific ST subtypes. In addition, these compounds are also being screened 
against ST3, ST6 and ST8 bacterial STs. The cell-based assays that are currently 
underway include scratch assays as a model of metastasis with pancreatic cancer cells 
(MIAPaCa-2), SNA (Sambucus nigra) lectin binding assay to monitor the effect our 
compounds have on cell surface sialylation of U937 myeloid leukemia cells and assays 
to monitor the growth rate and migration of cancerous liver progenitor cells. In addition, 
all compounds of this series have been submitted to the antimicrobial screening services 
of Compounds Australia and CO-ADD. 
Using the SAR information acquired from the initial screening of the 26 
carbamate-linked compounds (Table 7.1) produced as part of this thesis, a second 
generation of compounds could be investigated. Based on the identification of 
2-benzothiophene as a motif of the αHP fragment that imparts a level of potency towards 
hST6Gal I, it is imperative that various substitutions around this scaffold are explored. 
To supplement this study other similar heterocyclic scaffolds such as indole or benzofuran 
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should be investigated. Further to this, examination of other cyclic alkyl ethers at the 
3-position of aryl αHP fragments warrant further investigation based on the promising 
activity of the cyclopentoxy derivative 5.27i-l. Finally, as we have shown that activity is 
retained upon changing cytidine to uridine it is important to examine further variations to 
the nucleoside fragment in the continued search for synthetically accessible and selective 
sialyltransferase inhibitors for the potential application in cancer treatment. 
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Figure C9: Analytical HPLC trace (Column B; 0–40 min linear gradient 13–18% CH3CN) of (A) 
5.27i-s (99% pure) and (B) 5.27i-l (99% pure). 
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Figure C10: Analytical HPLC trace (Column A; 0–40 min linear gradient 3–8% CH3CN) of (A) 
5.27j-s (97% pure) and (B) 5.27j-l (98% pure). 
264 
Figure C11: Analytical HPLC trace (Column B; 0–40 min linear gradient 3–8% CH3CN) of (A) 
5.27k-s (97% pure) and (B) 5.27k-l (96% pure). 
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Figure C12: Analytical HPLC trace (Column B; 0–40 min linear gradient 8–13% CH3CN) of (A) 
5.27l-s (96% pure) and (B) 5.27l-l (95% pure). 
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Figure C13: Analytical HPLC trace (Column B; 0–40 min linear gradient 12–17% CH3CN) of (A) 
5.29-s (99% pure) and (B) 5.29-l (98% pure). 
265 
Figure C14: Luminescence vs quantity of enzyme curve for recombinant hST6Gal I used to 
determine amount of enzyme to be used per well. 
266 
Figure C15: Non-linear regression analysis in Michaelis-Menten equation of CMP-Neu5Ac with 
recombinant hST6Gal I. 
267 
Figure C16. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] 
with recombinant hST6Gal I at three 5.27c-l concentrations and the Lineweaver-Burk double 
reciprocal plots. 
268 
Figure C17. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] 
with recombinant hST6Gal I at three 5.27i-l concentrations and the Lineweaver-Burk double 
reciprocal plots. 
269 
Figure C18. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] 
with recombinant hST6Gal I at three 5.27k-s concentrations and the Lineweaver-Burk double 
reciprocal plots. 
269 
NMR data of novel compounds  270 
Appendix D: NMR Data of Novel Compounds from Chapter 6 370 
Appendix A: Supplementary Information to Chapter 3 
220 
APPENDIX A: Supplementary Information to Chapter 3 
Residues Highlighted in hST6Gal I-CMP Complex Crystal Structure 
 
Figure A1: CMP binding to hST6Gal I (PDB id 4JS2). CMP and protein residues of interest are shown as 
pipes. The protein backbone is represented as grey ribbons. Red spheres represent water molecules. 
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Replication of the Experimental Binding Mode of CMP-1 using AutoDock Vina  
 
Figure A2: Docking of CMP-1 into the hST6Gal I structure. The crystal structure position of CMP and the 
protein residues in contact with it are shown as pipes, with CMP being translucent. The binding model 
predicted by AutoDock Vina for CMP-1 is shown as a red ball-and-stick. 
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Statistical Analysis for Docking of Reported Inhibitors 
Table A1: Two-tailed t-test significant (P < 0.05) results for compounds docked under Apo conditions 
Testa P-value Testa P-value Testa P-value 
3.1 vs (R)-3.6 0.004826 3.2 vs 3.10 7.34 x10-5 (S)-3.5 vs 3.11 0.001299 
3.1 vs (S)-3.6 0.003153 3.2 vs 3.11 0.0001621 (R)-3.6 vs 3.7 0.06141 
3.1 vs (S)-3.5 0.03522 (R)-3.5 vs (R)-3.6 0.0219 (R)-3.6 vs 3.8 0.01804 
3.1 vs 3.7 5.302x10-5 (R)-3.5 vs (S)-3.6 0.0007815 (R)-3.6 vs 3.9 0.00351 
3.1 vs 3.8 2.193x10-5 (R)-3.5 vs 3.7 8.127x10-5 (R)-3.6 vs 3.10 0.001976 
3.1 vs 3.9 6.94x10-6 (R)-3.5 vs 3.8 4.309x10-5 (R)-3.6 vs 3.11 0.003591 
3.1 vs 3.10 1.05 x10-5 (R)-3.5 vs 3.9 2.85 x10-6 (S)-3.6 vs 3.8 0.03884 
3.1 vs 3.11 6.42x10-6 (R)-3.5 vs 3.10 4.77x10-5 (S)-3.6 vs 3.9 0.002741 
3.2 vs (R)-3.6 0.01413 (R)-3.5 vs 3.11 1.12 x10-5 (S)-3.6 vs 3.10 0.003703 
3.2 vs (S)-3.6 0.003338 (S)-3.5 vs (S)-3.6 0.08986 (S)-3.6 vs 3.11 0.004691 
3.2 vs (S)-3.5 0.06437 (S)-3.5 vs 3.7 0.01531 3.8 vs 3.9 0.03314 
3.2 vs 3.7 0.0009568 (S)-5 vs 8 0.00512 3.8 vs 3.10 0.0238 
3.2 vs 3.8 0.0004129 (S)-5 vs 9 0.00148 3.8 vs 3.11 0.04772 
3.2 vs 3.9 0.0002469 (S)-5 vs 10 0.0006897 - - 
aAll other possible combinations returned differences that were not significant 
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Table A2: Two-tailed t-test significant (P < 0.05) results for compounds docked under CMP1 conditions 
Testa P-value Testa P-value Testa P-value 
3.1 vs (R)-3.6 0.01153 3.2 vs 3.11 3.48x10-5 (R)-3.6 vs 3.9 3.84x10-5 
3.1 vs (S)-3.6 0.0005191 (R)-3.5 vs 3.7 0.002836 (R)-3.6 vs 3.10 2.18x10-5 
3.1 vs 3.7 6.90x10-5 (R)-3.5 vs 3.8 0.002589 (R)-3.6 vs 3.11 6.96x10-5 
3.1 vs 3.8 0.0002871 (R)-3.5 vs 3.9 6.15x10-5 (S)-3.6 vs (R)-3.5 0.01568 
3.1 vs 3.9 7.73x10-7 (R)-3.5 vs 3.10 2.69x10-5 (S)-3.6 vs 3.9 0.0001803 
3.1 vs 3.10 1.29x10-6 (R)-3.5 vs 3.11 3.80x10-5 (S)-3.6 vs 3.10 0.0001211 
3.1 vs 3.11 1.15x10-5 (S)-3.5 vs 3.7 0.03663 (S)-3.6 vs 3.11 0.0004557 
3.2 vs (R)-3.6 0.03702 (S)-3.5 vs 3.8 0.0299 3.7 vs 3.9 0.004621 
3.2 vs (S)-3.6 0.005157 (S)-3.5 vs 3.9 0.0014 3.7 vs 3.10 0.002696 
3.2 vs 3.7 0.001371 (S)-3.5 vs 3.10 0.0008216 3.7 vs 3.11 0.006659 
3.2 vs 3.8 0.001087 (S)-3.5 vs 3.11 0.0009248 3.8 vs 3.9 0.001003 
3.2 vs 3.9 7.73x10-7 (R)-3.6 vs 3.7 0.01369 3.8 vs 3.10 0.0006958- 
3.2 vs 3.10 3.42x10-5 (R)-3.6 vs 3.8 0.01465 3.8 vs 3.11 0.002574 
aAll other possible combinations returned differences that were not significant 
 
Table A3: Two-tailed t-test significant (P < 0.05) results for Apo versus CMP1 docking conditions 
Testa P-value 
3.1 0.04941 
aAll other possible combinations returned differences that were not significant  
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Statistical Analysis for Docking of Reported Inhibitors Versus Proposed Inhibitors  
Table A4: Two-tailed t-test results for reported versus proposed inhibitor docking  
Test P-value Significant (S) or Not Significant (NS) 
3.2 vs (R)-3.3 0.7164 NS 
3.2 vs (R)-3.4 0.6582 NS 
(R)-3.5 vs (R)-3.12 0.3203 NS 
(R)-3.5 vs (R)-3.23 0.6784 NS 
(S)-3.5 vs (S)-3.23 0.2041 NS 
(R)-3.6 vs (R)-3.16 0.2648 NS 
(S)-3.6 vs (S)-3.16 0.1328 NS 
(R)-3.6 vs (R)-3.27 0.5702 NS 
(S)-3.6 vs (S)-3.27 0.6461 NS 
(S)-3.5 vs (S)-3.12 0.04682 S 
 
Statistical Analysis for Docking of Proposed Inhibitors 
Table A5: Two-tailed t-test significant (P < 0.05) results for proposed 1,2,3-triazole-linked inhibitors vs 
proposed carbamate-linked inhibitors 
Testa P-value Testa P-value 
(S)-3.13 vs (S)-3.24 0.03785 (R)-3.21 vs (R)-3.32 0.03722 
(S)-3.20 vs (S)-3.31 0.01765 (R)-3.22 vs (R)-3.33 0.0684 
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Table A7: Two-tailed t-test significant (P < 0.05) results for proposed carbamate-linked inhibitors 
Testa P-value Testa P-value Testa P-value 
(R)-3.4 vs (R)-3.24 0.03232 (S)-3.4 vs (S)-3.28 0.001822 (S)-3.23 vs (R)-3.28 0.004563 
(R)-3.4 vs (S)-3.24 0.03598 (S)-3.4 vs (R)-3.29 0.004638 (S)-3.23 vs (S)-3.28 0.002154 
(R)-3.4 vs (R)-3.25 0.006054 (S)-3.4 vs (S)-3.29 0.00814 (S)-3.23 vs (R)-3.29 0.005998 
(R)-3.4 vs (S)-3.25 0.02949 (S)-3.4 vs (R)-3.30 0.006082 (S)-3.23 vs (S)-3.29 0.01094 
(R)-3.4 vs (R)-3.26 0.004212 (S)-3.4 vs (S)-3.30 0.01836 (S)-3.23 vs (R)-3.30 0.007426 
(R)-3.4 vs (S)-3.26 0.007699 (S)-3.4 vs (S)-3.31 0.02604 (S)-3.23 vs (S)-3.30 0.02374 
(R)-3.4 vs (R)-3.27 0.01447 (S)-3.4 vs (R)-3.32 0.04378 (S)-3.23 vs (S)-3.31 0.0335 
(R)-3.4 vs (S)-3.27 0.008427 (S)-3.4 vs (R)-3.33 0.04387 (R)-3.25 vs (S)-3.32 0.01301 
(R)-3.4 vs (R)-3.28 0.005526 (R)-3.23 vs (R)-3.25 0.004437 (R)-3.26 vs (S)-3.32 0.007753 
(R)-3.4 vs (S)-3.28 0.002097 (R)-3.23 vs (R)-3.26 0.001486 (R)-3.26 vs (S)-3.33 0.03589 
(R)-3.4 vs (R)-3.29 0.004793 (R)-3.23 vs (S)-3.26 0.002728 (S)-3.26 vs (S)-3.32 0.01544 
(R)-3.4 vs (S)-3.29 0.007896 (R)-3.23 vs (R)-3.27 0.02154 (R)-3.27 vs (S)-3.32 0.03742 
(R)-3.4 vs (R)-3.30 0.006632 (R)-3.23 vs (S)-3.27 0.005461 (S)-3.27 vs (S)-3.32 0.01859 
(R)-3.4 vs (S)-3.30 0.01875 (R)-3.23 vs (R)-3.28 0.000735 (R)-3.28 vs (S)-3.31 0.03446 
(R)-3.4 vs (S)-3.31 0.02721 (R)-3.23 vs (S)-3.28 0.002195 (R)-3.28 vs (S)-3.32 0.008778 
(R)-3.4 vs (R)-3.32 0.03954 (R)-3.23 vs (R)-3.29 0.009955 (R)-3.28 vs (S)-3.33 0.03106 
(R)-3.4 vs (R)-3.33 0.03904 (R)-3.23 vs (S)-3.29 0.02047 (S)-3.28 vs (S)-3.31 0.03203 
(S)-3.4 vs (R)-3.24 0.03615 (R)-3.23 vs (R)-3.30 0.005228 (S)-3.28 vs (S)-3.32 0.004044 
(S)-3.4 vs (S)-3.24 0.04045 (R)-3.23 vs (S)-3.30 0.01613 (S)-3.28 vs (S)-3.33 0.01994 
(S)-3.4 vs (R)-3.25 0.005481 (R)-3.23 vs (S)-3.31 0.01535 (R)-3.29 vs (S)-3.32 0.01043 
(S)-3.4 vs (S)-3.25 0.03306 (S)-3.23 vs (R)-3.25 0.006625 (R)-3.29 vs (S)-3.33 0.06003 
(S)-3.4 vs (R)-3.26 0.003476 (S)-3.23 vs (S)-3.25 0.04655 (S)-3.29 vs (S)-3.32 0.01808 
(S)-3.4 vs (S)-3.26 0.006658 (S)-3.23 vs (R)-3.26 0.003918 (R)-3.30 vs (S)-3.32 0.01457 
(S)-3.4 vs (R)-3.27 0.01473 (S)-3.23 vs (S)-3.26 0.007798 (S)-3.30 vs (S)-3.32 0.04651 
(S)-3.4 vs (S)-3.27 0.007712 (S)-3.23 vs (R)-3.27 0.01954 - - 
(S)-3.4 vs (R)-3.28 0.004216 (S)-3.23 vs (S)-3.27 0.00941 - - 
aAll other possible combinations returned differences that were not significant 
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Apo and CMP-hST6Gal I Complex 
 
Figure A3: RMSD of the Cα atoms across the 90 ns of free simulation for Apo (purple), CMP1 (green), 
CMP2 (light blue) and CMP3 (orange) simulations. 
 
 
Figure A4: RMSF of the Cα atoms across the 90 ns of free simulation for Apo (purple), CMP1 (green), 
CMP2 (light blue) and CMP3 (orange) simulations.  
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hST6Gal I Complexes 
 
Figure A5: RMSD of the Cα atoms across the 90 ns of free simulation for PL1 (red), PL2 (yellow), CAR1 
(dark blue) and CAR2 (green) simulations. 
 
 
Figure A6: RMSF of the Cα atoms across the 90 ns of free simulation for PL1 (red), PL2 (yellow), CAR1 
(dark blue) and CAR2 (green) simulations.  
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Non-Bonded Interactions of CMP 
 
Table A8: Hydrogen bonding and H2O bridge interactions observed for the CMP simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
CMPa,b HG1Ser189-O1CMP 18 OE2Glu375-O7CMP 37 
 HG1Ser189-OH2-O1CMP 35 HZ1Lys376-O8CMP 20 
 HD22Asn212-O1CMP 29 HZ2Lys376-O8CMP 21 
 OHTyr356-H2O-O1CMP 31 HZ3Lys376-O8CMP 20 
 HG1Ser189-O2CMP 17 HZ1Lys376-N2CMP 12 
 OPhe211-O2CMP 11 HZ2Lys376-N2CMP 12 
 HHTyr354-O2CMP 25 HZ3Lys376-N2CMP 13 
 HD22Asn212-O3CMP 23 OCys353-H9CMP 12 
 HG1Ser189-O4CMP 13 OG1Thr365-H10CMP 13 
 HNGly324-O6CMP 16 - - 
aOccupancies indicated are averages of the values obtained from the CMP1, CMP2 and CMP3 
simulations. bResidues highlighted include Ser189, Phe211, Asn212, Gly324, Cys353, Tyr356, 
Thr365 and Lys376. 
 
Table A9: Hydrophobic contacts observed for the CMP simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
CMPa,b CBSer189-C1CMP 61 CBAla190-C7CMP 60 
 CBPhe211-C1CMP 14 CBAla190-C8CMP 24 
 CGPhe211-C1CMP 64 CD1Tyr354-C8CMP 31 
 CD2Phe211-C2CMP 36 CE1Tyr354-C8CMP 55 
 CD2Leu372-C4CMP 13 CE1Tyr354-C9CMP 21 
 CBAla190-C6CMP 12 - - 
aOccupancies indicated are averages of the values obtained from the CMP1, CMP2 and CMP3 
simulations. bResidues highlighted include Ser189, Ala190, Phe211, Tyr354 and Leu372. 
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Non-Bonded Interactions of Phosphodiester-Linked Inhibitor 3.1 
 
Table A10: Hydrogen bonding and H2O bridge interactions observed for the PL1 simulation 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
PL1a OGSer322-HPL1 67 HNGly324-OH2-O3PL1 36 
 HNGly324-OH2-O1PL1 39 HD22Asn212-OH2-O10PL1 32 
 HD22Asn212-O3PL1 50 HHTyr354-O10PL1 61 
 HNSer323-OH2-O3PL1 60 HNGly213-OH2-O11PL1 70 
 HG1Ser323-OH2-O3PL1 48 OHTyr354-HOH-O11PL1 38 
 HNGly324-OH2-O3PL1 61 HZ1Lys376-N2PL1 24 
 NE2His370-HOH-O3PL1 52 HZ2Lys376-N2PL1 23 
 HD21Asn233-O4PL1 21 HZ3Lys376-N2PL1 24 
 HE21Gln235-O4PL1 19 HG1Ser188-O13PL1 13 
 HHTyr354-O5PL1 68 HZ1Lys376-O13PL1 30 
 HE22Gln235-O7PL1 21 HZ2Lys376-O13PL1 30 
 HE21Gln235-O8PL1 15 HZ3Lys376-O13PL1 30 
 HD22Asn212-O9PL1 10 HNTyr369-O14PL1 11 
 HNSer323-OH2-O9PL1 54 HNGly191-OH2-H17PL1 35 
 HG1Ser323-OH2-O9PL1 48 OVal352-H2O-H17PL1 55 
aResidues highlighted include Ser188, Gly191, Asn212, Gly213, Asn233, Gln235, Ser322, Ser323, 
Gly324, Val352, Tyr354, Tyr369, His370 and Lys376. 
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Table A11: Hydrophobic contacts observed for the PL1 simulation 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
PL1a CD1Leu372-CPL1 48 CD1Tyr369-C9PL1 17 
 CD2Leu372-CPL1 74 CE1Tyr369-C9PL1 45 
 CD2Leu372-C1PL1 39 CBAsn233-C11PL1 50 
 CZPhe211-C2PL1 12 CZ2Trp257-C11PL1 36 
 CE2Phe211-C2PL1 12 CH2Trp257-C11PL1 55 
 CE2Phe211-C3PL1 50 CGPro259-C11PL1 37 
 CBGln235-C5PL1 42 CE1Tyr369-C11PL1 37 
 CGGln235-C5PL1 10 CBAsn233-C13PL1 32 
 CD1Tyr369-C5PL1 13 CE1Tyr369-C13PL1 37 
 CE1Tyr369-C5PL1 41 CE1His370-C13PL1 54 
 CZTyr369-C5PL1 15 CH2Trp257-C14PL1 51 
 CD1Tyr354-C6PL1 73 CE1Tyr369-C14PL1 24 
 CZTyr354-C6PL1 14 CE1His370-C13PL1 73 
 CBGln235-C8PL1 10 CBAla190-C18PL1 32 
 CGPro259-C8PL1 23 CG2Thr365-C19PL1 42 
 CE1Tyr275-C8PL1 20 CBAla190-C20PL1 74 
 CE1Tyr369-C8PL1 43 CBThr365-C20PL1 18 
 CZTyr369-C8PL1 29 CG2Thr365-C20PL1 23 
 CBGln235-C9PL1 11 CGGln235-C22PL1 10 
aResidues highlighted include Ala190, Phe211, Asn233, Gln235, Trp257, Pro259, Tyr275, Tyr354, 
Thr365, Tyr369, His370 and Leu372. 
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Non-Bonded Interactions of Phosphodiester-Linked Inhibitor 3.2 
 
Table A12: Hydrogen bonding and H2O bridge interactions observed for the PL1 simulation 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
PL2a OGSer322-H7PL2 20 HZ1Lys376-N1PL2 13 
 HD21Asn212-O1PL2 27 HZ2Lys376-N1PL2 13 
 HG1Ser189-OH2-O3PL2 48 HZ3Lys376-N1PL2 14 
 OPhe211-HOH-O3PL2 41 HG1Ser188-O11PL2 17 
 HD21Asn212-O3PL2 37 HZ1Lys376-O11PL2 18 
 HD21Asn212-OH2-O3PL2 31 HZ2Lys376-O11PL2 18 
 HHTyr354-O3PL2 50 HZ3Lys376-O11PL2 18 
 HNGly324-OH2-O4PL2 33 OVal352-H2O-H22PL2 30 
 HHTyr354-O6PL2 17 - - 
aResidues highlighted include Ser188, Ser189, Phe211, Asn212, Ser322, Gly324, Tyr354, Val352 and 
Lys376. 
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Table A13: Hydrophobic contacts observed for the PL2 simulation 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
PL2a CBAsn233-CPL2 23 CZTyr369-C3PL2 25 
 CZ2Trp257-CPL2 35 NE1His370-C3PL2 24 
 CH2Trp257-CPL2 30 CBAsn212-C4PL2 23 
 CGPro259-CPL2 28 CBAsn212-C5PL2 23 
 CE1Tyr369-CPL2 38 CBAsn233-C8PL2 37 
 CZTyr369-CPL2 15 CBGln235-C9PL2 17 
 CE1His370-CPL2 56 CBAsn233-C11PL2 20 
 CBAsn233-C1PL2 40 CD1Leu372-C13PL2 26 
 CZ2Trp257-C1PL2 25 CD2Leu372-C13PL2 21 
 CH2Trp257-C1PL2 15 CD1Leu372-C14PL2 13 
 CE1Tyr369-C1PL2 10 CD2Leu372-C14PL2 14 
 CE1His370-C1PL2 41 CD1Tyr354-C15PL2 12 
 CBGln235-C2PL2 24 CE1Tyr354-C15PL2 32 
 CE1Tyr275-C2PL2 10 CE2Phe211-C16PL2 25 
 CE1Tyr369-C2PL2 19 CBAla190-C18PL2 11 
 CBGln235-C3PL2 12 CBAla190-C19PL2 17 
 CH2Trp257-C3PL2 12 CBAla190-C20PL2 35 
 CGPro259-C3PL2 34 CBAla190-C21PL2 42 
 CE1Tyr369-C3PL2 51 - - 
aResidues highlighted include Ala190, Phe211, Asn212, Asn233, Gln235, Trp257, Tyr275, Pro259, 
Tyr354, Tyr369, His370 and Leu372. 
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Non-Bonded Interactions of Carbamate-Linked Inhibitor (R)-3.4 
 
Table A14: Hydrogen bonding and H2O bridge interactions observed for the CAR simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
CARa,b HNSer189-OCAR 50 HHTyr354-O8CAR 31 
 HNGly324-O1CAR 19 HHTyr356-OH2-O8CAR 31 
 HNGly324-O2CAR 41 HZ1Lys376-N2CAR 20 
 HD21Asn233-O3CAR 31 HZ2Lys376-N2CAR 17 
 OGSer322-H3CAR 55 HZ3Lys376-N2CAR 17 
 OGSer322-H4CAR 32 OVal352-H2O-H22CAR 33 
 HD21Asn212-O5CAR 19 OG1Thr365-H22CAR 11 
 HD21Asn212-O6CAR 34 OVal352-H2O-H22CAR 31 
 HD22Asn212-O6CAR 17 OCys353-H23CAR 17 
 HG1Ser323-OH2-O6CAR 55 OG1Thr365-H23CAR 15 
 NE2His370-HOH-O6CAR 52 HZ1Lys376-O9CAR 28 
 OHTyr354-H17CAR 13 HZ2Lys376-O9CAR 27 
 HD21Asn233-O7CAR 12 HZ3Lys376-O9CAR 26 
 HHTyr354-O7CAR 37 - - 
aOccupancies indicated are averages of the values obtained from the CAR1 and CAR2 simulations. 
bResidues highlighted include Ser189, Asn212, Asn233, Ser322, Ser323, Gly324, Val 352, Cys353, 
Tyr354, Tyr356, Thr365, His370 and Lys376. 
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Table A15: Hydrophobic contacts observed for the CAR simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
CARa,b CD1Leu372-CCAR 21 CE1His370-C8CAR 20 
 CD2Leu372-CCAR 22 CBAsn233-C9CAR 34 
 CD2Phe211-C2CAR 29 CBGln235-C9CAR 23 
 CBSer189-C3CAR 35 CZ2Trp257-C9CAR 19 
 CBPhe211-C3CAR 32 CH2Trp257-C9CAR 16 
 CGPhe211-C3CAR 45 CDPro259-C9CAR 12 
 CD2Phe211-C3CAR 44 CGPro259-C9CAR 28 
 CE1Tyr354-C3CAR 10 CE1Tyr275-C9CAR 11 
 CBAsn233-C5CAR 44 CE1Tyr369-C9CAR 14 
 CBGln235-C5CAR 10 CD1Tyr369-C10CAR 17 
 CDPro259-C5CAR 28 CE1Tyr369-C10CAR 28 
 CGPro259-C5CAR 49 CD1Tyr369-C11CAR 12 
 CE1Tyr275-C5CAR 16 CE1Tyr369-C11CAR 26 
 CE1Tyr369-C5CAR 10 CD2His370-C11CAR 22 
 CBAsn233-C6CAR 28 CD1Tyr369-C12CAR 10 
 CBGln235-C6CAR 28 CD2His370-C12CAR 62 
 CZ2Trp257-C6CAR 16 CD2His370-C13CAR 17 
 CH2Trp257-C6CAR 13 CD2His370-C15CAR 42 
 CE1Tyr275-C6CAR 18 CD2Leu372-C19CAR 15 
 CZTyr275-C6CAR 13 CBAla190-C20CAR 19 
 CE1Tyr369-C6CAR 18 CE1Tyr354-C20CAR 21 
 CBSer322-C7CAR 11 CBAla190-C21CAR 53 
 CBAsn233-C8CAR 13 CE1Tyr354-C21CAR 20 
 CE1Tyr369-C8CAR 25 CBAla190-C22CAR 66 
aOccupancies indicated are averages of the values obtained from the CAR1 and CAR2 simulations. 
bResidues highlighted include Ser189, Ala190, Phe211, Asn233, Gln235, Trp257, Pro259, Tyr275, 
Ser322, Tyr354, Tyr369, His370, and Leu372. 
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APPENDIX B: Supplementary Information of Chapter 4 
Force Field Optimisation 
 
Figure B1: The atom designation used during GAAMP optimisation of the phosphodiester- (4.2), triazole- 
(4.3) and carbamate-linked (4.4) derivatives force fields. The black region on each compound represents 
atoms where the atom charge was fixed to be consistent with the value observed after GAAMP optimisation 
of the phosphodiester-linked compound. Red regions represent components where partial charge was 
independently optimised by GAAMP. The final parameters for these three inhibitors can be accessed at 
https://doi.org/10.6084/m9.figshare.5372788.v1 
 
Table B1: GAAMP optimisation of MM chargesa  
Compound χ2 b  χESP2 ± SE c χEmin2± SE c χRmin2 ± SE c χCG2 ± SE c 
4.2 1.60 0.398 ± 0.006 1 ± 2 0.02 ± 0.05 0.0 ± 0.1 
4.3 2.23  1.80 ± 0.01 0.3 ± 0.9 0.1 ± 0.1 0.0 ± 0.2 
4.4 1.98 1.04 ± 0.01 1 ± 1 0.1 ± 0.1 0.0 ± 0.2 
aOptimisation occurs at the HF/6-31G* level without basis set superposition error 
correction. b χ2  =  χESP2  + χwat_int2 + χCG2; where χwat_int2 = χEmin2 + χRmin2. χ2 is the objective 
function used in the optimisation procedure of the MM charges. It is written as the sum 
of three terms: the objective functions for the electrostatic potential (χESP2), 
compound-water interactions (χwat_int2) and the restraints on reference charges (χCG2). SE 
= Standard error. 













Figure B2: (a) Comparison of QM, GAAMP and CGenFF dihedral energy profiles for phosphodiester-
linked derivative 4.2. ɸ1 represents the dihedral O9-P1-C9-O7 and ɸ2 represents the dihedral C10-C9-O7-P. 
(b) Comparison of QM, GAAMP and CGenFF dihedral energy profiles for triazole-linked derivative 4.3. 
ɸ1 represents the dihedral O1-C7-C8-N3 and ɸ2 represents the dihedral N5-C10-C11-C12. (c) Comparison 
of QM, GAAMP and CGenFF dihedral energy profiles for carbamate-linked derivative 4.4. ɸ1 represents 
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Overview of Simulations 
Table B2: Overview of Simulations 
Name Ligand Equilibration (ns) Free Simulation (ns) 
hST6Gal I inhibitor complex MD simulationsa,b 
PC1 ( 3) (R)-4.2 10 90 
PC2 ( 3) (S)-4.2 10 90 
TC1( 3) (R)-4.3 10 90 
TC2 ( 3) (S)-4.3 10 90 
CC1 ( 3) (R)-4.4 10 90 
CC2 ( 3) (S)-4.4 10 90 
Inhibitor in water box MD simulationsb,c 
PL1 ( 3) (R)-4.2 - 20 
PL2 ( 3) (S)-4.2 - 20 
TL1 ( 3) (R)-4.3 - 20 
TL2 ( 3) (S)-4.3 - 20 
CL1 ( 3) (R)-4.4 - 20 
CL2 ( 3) (S)-4.4 - 20 
Free energy perturbation simulationsd,e 
PL1 → CL1 (288 K) (R)-4.2 to (R)-4.4 - 140 
PL1 → CL1 (298 K) (R)-4.2 to (R)-4.4 - 200 
PL1 → TL1 (288 K) (R)-4.2 to (R)-4.3 - 140 
PL1 → TL1 (298 K) (R)-4.2 to (R)-4.3 - 200 
CL1 → TL1 (288 K) (R)-4.4 to (R)-4.3 - 140 
CL1 → TL1 (298 K) (R)-4.4 to (R)-4.3 - 200 
aThe systems consist of approximately 49000 atoms with a box size of 82 Å × 82 Å × 82 Å. bEach 
simulation was replicated three times by generating different starting coordinates using three 
different initial minimisation steps (2000, 2500 and 3000 steps) and initial velocities. cThe systems 
consist of approximately 50000 atoms with a box size of 82 Å × 82 Å × 82 Å. dEach system consists 
of 20 uniformly distributed λ values between 0 and 1 (0.0, 0.05, 0.1, … , 0.9, 0.95, 1.0) with the 
transformation simulated in reverse directions beginning from the 0. 5 λ values (e.g. 0.0  0.05 → 
0.1). eThe systems consist of approximately 58000 atoms with a box size of 86 Å × 86 Å × 86 Å. 
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Monitoring of Quasi-harmonic Approximation Convergence 
Table B3: Monitoring convergence of configurational entropy change upon binding of the 
phosphodiester-linked 4.2, 1,2,3-triazole-linked 4.3 and carbamate-linked 4.4 derivatives to hST6Gal I. 
Compound 
-TΔSconf (kcal/mol)a 
11–100 ns/   
1–20 nsb 
11–55 ns/     
1–20 nsc 
56–100 ns/   
1–20 nsd 




(R)-4.2* 37 ± 3 37 ± 3 40 ± 2 33 ± 2 34 ± 4 
(S)-4.2 41 ± 6 40 ± 6 42 ± 4 36 ± 6 35 ± 5 
(R)-4.3 23 ± 4 29 ± 2 28 ± 4 27 ± 2 20 ± 5 
(S)-4.3 27 ± 4 32 ± 1 31 ± 5 27 ± 2 27 ± 5 
(R)-4.4* 20 ± 2 22.1 ± 0.7 21 ± 3 17 ± 3 17 ± 3 
(S)-4.4 25 ± 6 25 ± 6 31 ± 6 24 ± 5 26 ± 5 
aArithmetic mean ΔSconf multiplied by -298.15 K ± SEM obtained from triplicate simulations of each 
compound. bCalculated using the MD trajectories of 11–100 ns of hST6Gal I inhibitor complex and 1–
20 ns of ligand in a water box; c11–55 ns of hST6Gal I inhibitor complex and 1–20 ns of ligand a water 
box; d56–100 ns of hST6Gal I inhibitor complex and 1–20 ns of ligand in a water box; e1–55 ns of 
hST6Gal I inhibitor complex and 1–10 ns of ligand a water box; f56–100 ns of hST6Gal I inhibitor 
complex and 11–20 ns of ligand a water box. *P < 0.05 
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Figure B3: PC1 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the phosphodiester-linked compound (R)-4.2 across the 90 ns of free simulation. (c) 
RMSF of the Cα atoms across the 90 ns of free simulation. RMSD and RMSF were calculated after 









Figure B4: PC2 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the phosphodiester-linked compound (S)-4.2 across the 90 ns of free simulation (large 
fluctuations in ligand RMSD during the PC1-2000 simulation can be attributed to the phenoxy group not 
being locked into a single conformation). (c) RMSF of the Cα atoms across the 90 ns of free simulation. 
RMSD and RMSF were calculated after superposition to the starting structure with respect to the position 









Figure B5: TC1 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the triazole-linked (R)-4.3 across the 90 ns of free simulation (the large increase in 
ligand RMSD during the TC1-2000 and -3000 simulations can be attributed to a rotation of the phosphonate 
and phenoxy group and a phenoxy positional shift respectively. In both cases the phenoxy substituent 
remained within the expected pocket). (c) RMSF of the Cα atoms across the 90 ns of free simulation. RMSD 









Figure B6: TC2 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the triazole-linked (S)-4.3 across the 90 ns of free simulation. (c) RMSF of the Cα atoms 
across the 90 ns of free simulation. RMSD and RMSF were calculated after superposition to the starting 









Figure B7: CC1 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the carbamate-linked (R)-4.4 across the 90 ns of free simulation. (c) RMSF of the Cα 
atoms across the 90 ns of free simulation. RMSD and RMSF were calculated after superposition to the 









Figure B8: CC2 simulations. (a) RMSD of the Cα atoms across the 90 ns of free simulation. (b) RMSD of 
the heavy atoms of the carbamate-linked (S)-4.4 across the 90 ns of free simulation (large RMSD values, 
in particular for the CC2-2000 simulation, can be attributed to a slight phenoxy rotation from the starting 
structure to maintain interactions with Tyr369). (c) RMSF of the Cα atoms across the 90 ns of free 
simulation. RMSD and RMSF were calculated after superposition to the starting structure with respect to 
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Non-Bonded Interactions of Phosphodiester-Linked Inhibitor (R)-4.2 
 
Table B4: Hydrogen bonding and water bridge interactions observed for the PC1 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
PC1a,b HZ1Lys376-OPC1 30 HNAla368-O9PC1 26 
 HZ2Lys376-OPC1 31 HNAla368-O10PC1 37 
 HZ3Lys376-OPC1 29 HNTyr369-O10PC1 25 
 NHGly324-O2PC1 18 HNHis370-O10PC1 26 
 HNSer323-OH2-O3PC1 31 HZ1Lys376-N1PC1 20 
 HHTyr354-O5PC1 18 HZ2Lys376-N1PC1 21 
 HD21Asn212-O6PC1 18 HZ3Lys376-N1PC1 20 
 HD21Asn212-OH2-O6PC1 35 OG1Thr365-HPC1 39 
 HD22Asn212-OH2-O6PC1 41 OThr350-OH2-H1PC1 53 
 HNSer323-OH2-O6PC1 33 OVal352-OH2-H1PC1 49 
 OG1Ser323-H2O-O6PC1 51 OGSer322-H2PC1 17 
 NE2His370-OH2-O7PC1 42 OCys364-H4PC1 44 
aOccupancies indicated are averages of the values obtained from the PC1 simulations. bResidues 
highlighted include Asn212, Ser322, Ser323, Gly324, Thr350, Val352, Tyr354, Cys364, Thr365, 
Ala368, Tyr369, His370 and Lys376. 
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Table B5: Hydrophobic contacts observed for the PC1 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
PC1a,b CBAla190-CPC1 28 CBAla368-C10PC1 32 
 CBAla190-C1PC1 40 CBAla368-C10PC1 58 
 CBAla190-C2PC1 53 CBAla368-C12PC1 44 
 CBAla190-C3PC1 17 CBTyr369-C12PC1 11 
 CD2Leu372-C3PC1 40 CBAla368-C13PC1 41 
 CD1Leu372-C5PC1 68 CBTyr369-C13PC1 12 
 CD2Leu372-C5PC1 56 CBAla368-C14PC1 52 
 CD2Leu372-C6PC1 18 CBTyr369-C14PC1 32 
 CZPhe211-C7PC1 23 CBAla368-C15PC1 35 
 CE2Phe211-C7PC1 23 CBTyr369-C15PC1 64 
 CBSer189-C8PC1 11 CD2His370-C15PC1 13 
 CE2Phe211-C8PC1 12 CBTyr369-C16PC1 14 
 CE1Tyr354-C8PC1 42 CBTyr369-C17PC1 11 
aOccupancies indicated are averages of the values obtained from the PC1 simulations. bResidues 
highlighted include Ser189, Ala190, Phe211, Tyr354, Ala368, Tyr369, His370 and Leu372. 
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Non-Bonded Interactions of Phosphodiester-Linked Inhibitor (S)-4.2 
 
Table B6: Hydrogen bonding and water bridge interactions observed for the PC2 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
PC2a,b HZ1Lys376-OPC2 28 HD22Asn233-O10PC2 19 
 HZ2Lys376-OPC2 28 HD21Asn233-OH2-O10PC2 37 
 HZ3Lys376-OPC2 29 HE22Gln235-OH2-O10PC2 44 
 NHSer189-O1PC2 35 HZ1Lys376-N1PC2 21 
 NHGly324-O2PC2 35 HZ2Lys376-N1PC2 22 
 HD21Asn212-O4PC2 34 HZ3Lys376-N1PC2 22 
 HD22Asn212-OH2-O4PC2 38 OCys353-HPC2 26 
 HD21Asn212-O5PC2 43 HNGly191-OH2-HPC2 32 
 HNSer323-O5PC2 12 OThr350-H2O-HPC2 31 
 HG1Ser323-O5PC2 18 OVal352-H2O-HPC2 52 
 HD22Asn212-O8PC2 64 OGThr365-H1PC2 24 
 OHTyr356-HOH-O8PC2 54 OGSer322-H2PC2 20 
 HHTyr356-OH2-O8PC2 33 OTyr354-H4PC2 33 
 HD22Asn212-O10PC2 12 - - 
aOccupancies indicated are averages of the values obtained from the PC2 simulations. bResidues 
highlighted include Ser189, Gly191, Asn212, Asn233, Gln235, Ser322, Ser323, Gly324, Thr350, Val352, 
Cys353, Tyr354, Tyr356, Thr365 and Lys376  
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Table B7: Hydrophobic contacts observed for the PC2 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
PC2a CBAla190-CPC2 46b CE2Tyr354-C13PC2 41c 
 CBAla190-C1PC2 62b CZTyr354-C14PC2 12c 
 CD1Tyr354-C1PC2 16b CE2Tyr354-C14PC2 21c 
 CE1Tyr354-C1PC2 22b CZTyr354-C15PC2 25c 
 CBAla190-C2PC2 16b CE2Tyr354-C15PC2 11c 
 CE1Tyr354-C2PC2 24b CGAsn233-C17PC2 17d 
 CD2Leu372-C3PC2 22b CBGln235-C17PC2 11d 
 CD1Leu372-C5PC2 21b CE1Tyr275-C17PC2 30d 
 CD2Leu372-C5PC2 49b CZTyr275-C17PC2 23d 
 CD2Leu372-C6PC2 21b CBAsn233-C18PC2 55d 
 CZPhe211-C7PC2 30b CGAsn233-C18PC2 25d 
 CE2Phe211-C7PC2 14b CBGln235-C18PC2 26d 
 CE2Phe211-C8PC2 37b CDPro259-C18PC2 28d 
 CE1Tyr354-C8PC2 23b CGPro259-C18PC2 33d 
 CE1Tyr354-C9PC2 18c CE1Tyr275-C18PC2 36d 
 CE1Tyr354-C10PC2 23c CBAsn233-C19PC2 16d 
 CZTyr354-C10PC2 55c CGAsn233-C19PC2 21d 
 CE2Tyr354-C10PC2 14c CZ2Trp257-C19PC2 54d 
 CGTyr354-C11PC2 13c CH2Trp257-C19PC2 52d 
 CD1Tyr354-C11PC2 19c CDPro259-C19PC2 66d 
 CE1Tyr354-C11PC2 41c CGPro259-C19PC2 42d 
 CD2Tyr354-C11PC2 33c CBAsn233-C20PC2 48d 
 CE2Tyr354-C11PC2 65c CGAsn233-C20PC2 11d 
 CGTyr354-C12PC2 14c CH2Trp257-C20PC2 58d 
 CZTyr354-C12PC2 36c CE1Tyr369-C20PC2 51d 
 CD2Tyr354-C12PC2 46c CD1Tyr369-C21PC2 28d 
 CE2Tyr354-C12PC2 66c CE1Tyr369-C21PC2 51d 
 CD2Tyr354-C13PC2 16c CE1His370-C21PC2 31d 
aResidues highlighted include Ala190, Phe211, Asn233, Gln235, Trp257, Pro259, Tyr275, Tyr354, Tyr369, 
His370 and Leu372. bOccupancies indicated are averages of the values obtained from all of the PC2 
simulations. cOccupancies indicated are the values obtained from the PC2-2000 simulation. dOccupancies 
indicated are averages of the values obtained from the PC2-2500 and PC2-3000 simulations. 
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Non-Bonded Interactions of Triazole-Linked Inhibitor (R)-4.3 
 
Table B8: Hydrogen bonding and water bridge interactions observed for the TC1 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
TC1a,b HZ1Lys376-OTC1 28 HD22Asn212-N5TC1 10 
 HZ2Lys376-OTC1 27 OG1Thr365-HTC1 15 
 HZ3Lys376-OTC1 28 OG1Thr365-H2O- HTC1 33 
 HNGly324-O2TC1 29 HNGly191-H2O-H1TC1 43 
 HHTyr354-O4TC1 22 OThr350-H2O-H1TC1 51 
 HZ1Lys376-N1TC1 24 OVal352-H2O-H1TC1 41 
 HZ2Lys376-N1TC1 23 OCys353-H1TC1 16 
 HZ3Lys376-N1TC1 23 OGSer322-H6TC1 35 
 HD21Asn212-N4TC1 20 OGSer322-H8TC1 18 
 HD22Asn212-N4TC1 18 OHTyr354-H12TC1 26 
 HD21Asn212-N5TC1 17 NE2His370-H14TC1 30 
aOccupancies indicated are averages of the values obtained from the TC1 simulations. bResidues 
highlighted include Gly191, Asn212, Ser322, Gly324, Thr350, Val352, Cys353, Tyr354, Thr365, 
His370 and Lys376. 
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Table B9: Hydrophobic contacts observed for the TC1 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
TC1a,b CBAla190-CTC1 66 CGTyr369-C15TC1 26 
 CBAla190-C1TC1 29 CD1Tyr369-C15TC1 28 
 CD1Tyr354-C1TC1 11 CE1Tyr369-C18TC1 13 
 CE1Tyr354-C1TC1 14 CBGln235-C19TC1 17 
 CBAla190-C2TC1 17 CBAsn233-C20TC1 24 
 CE1Tyr354-C2TC1 13 CBGln235-C20TC1 18 
 CD2Leu372-C3TC1 15 CZ2Trp257-C20TC1 16 
 CZPhe211-C4TC1 36 CH2Trp257-C20TC1 13 
 CE2Phe211-C4TC1 25 CDPro259-C20TC1 10 
 CD1Leu372-C5TC1 59 CGPro259-C20TC1 18 
 CD2Leu372-C5TC1 44 CE1Tyr275-C20TC1 11 
 CD2Leu372-C6TC1 35 CBAsn233-C21TC1 15 
 CZPhe211-C7TC1 23 CDPro259-C21TC1 38 
 CE2Phe211-C7TC1 48 CGPro259-C21TC1 37 
 CE2Phe211-C8TC1 22 CE1Tyr275-C21TC1 11 
 CE1Tyr354-C8TC1 14 CBAsn233-C22TC1 19 
 CZTyr354-C9TC1 12 CBGln235-C22TC1 22 
 CE1Tyr369-C12TC1 15 CZ2Trp257-C22TC1 13 
 CE1His370-C12TC1 12 CH2Trp257-C22TC1 14 
 CD2His370-C13TC1 20 CGPro259-C22TC1 14 
 CBTyr369-C14TC1 18 CE1Tyr275-C22TC1 23 
 CD1Tyr369-C14TC1 21 CZTyr275-C22TC1 11 
 CD2His370-C14TC1 39 CE2Tyr369-C22TC1 13 
 CGGln235-C15TC1 17 CBGln235-C23TC1 19 
 CBTyr369-C15TC1 24 CE1Tyr369-C23TC1 16 
aOccupancies indicated are averages of the values obtained from the TC1 simulations. bResidues 
highlighted include Ala190, Phe211, Asn233, Gln235, Trp257, Pro259, Tyr275, Tyr354, Tyr369, 
His370 and Leu372. 
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Non-Bonded Interactions of Triazole-Linked Inhibitor (S)-4.3 
 
Table B10: Hydrogen bonding and water bridge interactions observed for the TC2 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
TC2a,b HZ1Lys376-OTC2 30 HZ3Lys376-N1TC2 22 
 HZ2Lys376-OTC2 30 HD22Asn212-N4TC2 10 
 HZ3Lys376-OTC2 26 NE2His370-H2O-N4TC2 43 
 HNGly324-O2TC2 43 HD21Asn212-N5TC2 28 
 HHTyr354-O4TC2 21 HNSer323-H2O-N5TC2 35 
 HHTyr354-OH2-O4TC2 33 HG1Ser323-H2O-N5TC2 34 
 HHTyr354-O5TC2 14 OCys353-HTC2 14 
 HNAla368-OH2-O5TC2 30 HNGly191-H2O-HTC2 45 
 HNHis370-OH2-O5TC2 30 OG1Thr365-H1TC2 15 
 HZ1Lys376-N1TC2 26 OGSer322-H6TC2 31 
 HZ2Lys376-N1TC2 27 OHTyr354-H12TC2 22 
aOccupancies indicated are averages of the values obtained from the TC2 simulations. bResidues 
highlighted include Gly191, Asn212, Ser322, Ser323, Gly324, Cys353, Tyr354, Thr365, Ala368, 
His370 and Lys376. 
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Table B11: Hydrophobic contacts observed for the TC2 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
TC2a,b CBAla190-CTC2 44 CBAsn233-C20TC2 12 
 CBAla190-C1TC2 53 CBGln235-C20TC2 12 
 CD1Tyr354-C1TC2 12 CGPro259-C20TC2 18 
 CE1Tyr354-C1TC2 18 CE1Tyr275-C20TC2 11 
 CBCys364-C1TC2 33 CE1Tyr369-C20TC2 18 
 CBAla190-C2TC2 31 CEZTyr369-C20TC2 15 
 CE1Tyr354-C2TC2 20 CE1His370-C20TC2 15 
 CBCys364-C2TC2 14 CBAsn233-C21TC2 11 
 CD2Leu372-C3TC2 10 CBGln235-C21TC2 10 
 CZPhe211-C4TC2 34 CH2Trp257-C21TC2 14 
 CE2Phe211-C4TC2 23 CGPro259-C21TC2 45 
 CD1Leu372-C5TC2 54 CE1Tyr275-C21TC2 10 
 CD2Leu372-C5TC2 43 CE1Tyr369-C21TC2 39 
 CD2Leu372-C6TC2 25 CEZTyr369-C21TC2 26 
 CZPhe211-C7TC2 22 CBAsn233-C22TC2 12 
 CE2Phe211-C7TC2 28 CBGln235-C22TC2 15 
 CE2Phe211-C8TC2 18 CZ2Trp257-C22TC2 13 
 CE1Tyr354-C8TC2 33 CH2Trp257-C22TC2 13 
 CZTyr354-C8TC2 10 CGPro259-C22TC2 23 
 CZTyr354-C9TC2 17 CE1Tyr275-C22TC2 13 
 CD2His370-C11TC2 18 CE1Tyr369-C22TC2 17 
 CBLeu236-C14TC2 12 CZTyr369-C22TC2 12 
 CBGln235-C18TC2 17 CE1His370-C22TC2 20 
 CE1Tyr369-C18TC2 11 CBAsn233-C23TC2 13 
 CBGln235-C19TC2 22 CBGln235-C23TC2 22 
 CE1Tyr369-C19TC2 10 - - 
aOccupancies indicated are averages of the values obtained from the TC2 simulations. bResidues 
highlighted include Ala190, Phe211, Asn233, Leu236, Gln235, Trp257, Pro259, Tyr275, Tyr354, 
Cys364, Tyr369, His370 and Leu372 
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Non-Bonded Interactions of Carbamate-Linked Inhibitor (R)-4.4 
 
Table B12: Hydrogen bonding and water bridge interactions observed for the CC1 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
CC1a,b HZ1Lys376-OCC1 20 HNTyr369-O7CC1 43 
 HZ2Lys376-OCC1 24 HNHis370-O7CC1 43 
 HZ3Lys376-OCC1 19 HNAla368-O8CC1 34 
 HG1Ser189-O2CC1 10 HZ1Lys376-N1CC1 20 
 HHTyr354-O4CC1 29 HZ2Lys376-N1CC1 23 
 HNAla368-O6CC1 11 HZ3Lys376-N1CC1 19 
 HNTyr369-O6CC1 53 OVal352-H2O-HCAR 31 
 HNHis370-O6CC1 35 OG1Thr365-H1CC1 18 
 HNAla368-O7CC1 19 OGSer188-H6CC1 34 
aOccupancies indicated are averages of the values obtained from the CC1 simulations. bResidues 
highlighted include Ser188, Ser189, Val 352, Tyr354, Thr365, Ala368, Tyr369, His370 and Lys376. 
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Table B13: Hydrophobic contacts observed for the CC1 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
CC1a,b CBAla190-CCC1 16 CD2His370-C9CC1 14 
 CBAla190-C1CC1 28 CD2His370-C16CC1 53 
 CBCys364-C1CC1 27 CD1Tyr369-C17CC1 33 
 CBAla190-C2CC1 28 CE1Tyr369-C17CC1 25 
 CBAla190-C3CC1 28 CE1His370-C17CC1 11 
 CBSer322-C6CC1 27 CGTyr369-C18CC1 16 
 CD2Leu372-C6CC1 18 CD1Tyr369-C18CC1 20 
 CZPhe211-C7CC1 15 CE1Tyr369-C18CC1 20 
 CE2Phe211-C7CC1 23 CBAsn233-C20CC1 17 
 CE2Phe211-C8CC1 21 CGTyr369-C22CC1 12 
 CBSer322-C8CC1 15 CD1Tyr369-C22CC1 22 
 CD1Leu372-C8CC1 18 CE1Tyr369-C22CC1 26 
 CD2Leu372-C8CC1 12 - - 
aOccupancies indicated are averages of the values obtained from the CC1 simulations. bResidues 
highlighted include Ala190, Phe211, Asn233, Ser322, Cys364, Tyr369, His370 and Leu372. 
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Non-Bonded Interactions of Carbamate-Linked Inhibitor (S)-4.4 
 
Table B14: Hydrogen bonding and water bridge interactions observed for the CC2 simulations 
Simulation Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
CC2a,b HG1Thr365-OCC2 15 HNSer323-OH2-O7CC2 32 
 HZ1Lys376-OCC2 35 HG1Thr365-N1CC2 21 
 HZ2Lys376-OCC2 31 HZ1Lys376-N1CC2 18 
 HZ3Lys376-OCC2 26 HZ2Lys376-N1CC2 19 
 NHGly324-O2CC2 43 HZ3Lys376-N1CC2 16 
 NHSer323-O3CC2 22 OCys353-HCC2 26 
 NHGly324-O3CC2 32 OG1Thr365-H1CC2 24 
 HD21Asn212-O4CC2 12 OThr365-H1CC2 11 
 HD22Asn212-O4CC2 43 OGSer322-H6CC2 25 
 HHTyr354-O4CC2 15 OG1Ser189-H12CC2 18 
 HHTyr354-O6CC2 11 - - 
aOccupancies indicated are averages of the values obtained from the CC2 simulations. bResidues 
highlighted include Ser189, Asn212, Ser322, Ser323, Gly324, Cys353, Tyr354, Thr365 and Lys376  
  
Appendix B: Supplementary Information to Chapter 4 
257 
Table B15. Hydrophobic contacts observed for the CC2 simulations 
Simulation Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
CC2a,b CBAla190-CCC2 54 CD2Phe211-C8CC2 41 
 CBAla190-C1CC2 34 CZTyr354-C11CC2 13 
 CD1Tyr354-C1CC2 27 CD2His370-C12CC2 22 
 CE1Tyr354-C1CC2 12 CD2Leu236-C13CC2 11 
 CE1Tyr354-C2CC2 15 CBCys353-C13CC2 20 
 CD2Leu372-C3CC2 14 CBCys364-C13CC2 10 
 CD1Leu372-C5CC2 14 CBCys364-C14CC2 11 
 CD2Leu372-C5CC2 11 CE1Tyr354-C16CC2 31 
 CD2Phe211-C7CC2 31 CD2Tyr354-C17CC2 17 
 CBSer189-C8CC2 25 CE2Tyr354-C18CC2 24 
 CBPhe211-C8CC2 16 CD2Tyr354-C22CC2 10 
 CGPhe211-C8CC2 39 CE2Tyr354-C22CC2 11 
aOccupancies indicated are averages of the values obtained from the CC1 simulations. bResidues 
highlighted include Ser189, Ala190, Phe211, Leu236, Cys353, Tyr354, Cys364, His370 and Leu372. 
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Cluster Analysis of Complexed MD Simulations 
 
Figure B9: The most populated clusters of each respective ligand from the hST6Gal I-ligand complex 
simulations. Clusters were generated using combined trajectories that represented every 10 ps of the 
triplicate simulations during their 90 ns production runs (i.e. 27000 structures in total per simulation type). 
The clusters shown represent the following percentage of simulation time: PC1 68%; TC1 49%; CC1 31%; 
PC2 67%; TC2 42%; CC2 67%. 
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Cluster Analysis of Ligand MD Simulations 
 
 
Figure B10: The distribution of cluster population for the (R)- (a) and (S)-inhibitors (b) in water box MD 
simulations. Clusters were generated using combined trajectories that represented every 10 ps of the 
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APPENDIX C: Supplementary Information of Chapter 5 
FEP Error Analysis  
Table C1: Bennett acceptance-ratio combined ΔG values for perturbation of cytidine-based inhibitor 
(R)-5.5 to uridine-based inhibitor (R)-5.6 when in complex with hST6Gal I 
- 0.5 ns 1.0 ns 1.5 ns 2.0 ns Average 
ΔG (kcal/mol) 10.39 9.42 9.47 8.80 9.52 
Error (kcal/mol) 0.22 0.16 0.18 0.15 0.18 
 
Table C2: Bennett acceptance-ratio combined ΔG values for perturbation of uridine-based inhibitor (R)-5.6 
to cytidine-based inhibitor (R)-5.5 when in aqueous solution 
- 0.5 ns 1.0 ns 1.5 ns 2.0 ns Average 
ΔG (kcal/mol) 10.12 10.23 11.22 11.12 10.67 
Error (kcal/mol) 0.11 0.11 0.10 0.09 0.10 
 
Non-Bonded Interactions of Carbamate-Linked Inhibitor (R)-5.6 
 
Table C3: Hydrogen bonding and water bridge interactions observed for the (R)-5.6 simulationsa,b 
Hydrogen Bonds Occupancy (%) Hydrogen Bonds Occupancy (%) 
HG1Ser322-OA(R)-5.6 36 OG1Ser188-O2(R)-5.6 37 
HG1Thr365-OA(R)-5.6 15 HG1Ser322-O3(R)-5.6 61 
OVal352-HOH- O1A(R)-5.6 38 NHGly324- O3(R)-5.6 28 
aOccupancies indicated are averages of the values obtained from the (R)-5.6 simulations. 
bResidues highlighted include Ser188, Ser322, Gly324, Val352, Thr365. 
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Table C4: Hydrophobic contacts observed for the (R)-5.6 simulations 
Hydrophobic Contact Occupancy (%) Hydrophobic Contact Occupancy (%) 
CBCys353-C1(R)-5.6 18 CD2Leu372-C2(R)-5.6 15 
CD2Leu372-C1(R)-5.6 16 CZPhe343-C5(R)-5.6 15 
CE1Tyr369-C2(R)-5.6 44 CE2Phe211-C7(R)-5.6 56 
CD1Leu372-C2(R)-5.6 11 CZPhe211-C7(R)-5.6 20 
aOccupancies indicated are averages of the values obtained from the (R)-5.6 simulations. 
bResidues highlighted include Phe211, Phe343, Cys353, Tyr369, and Leu372. 
 
HPLC Purity Determination 
Analytical HPLC was performed on a Shimadzu Prominence I LC 2030C system and the 
data was collected at 254 nm, using a (A) Luna C18 (2) 100Å (Phenomenex, 3 μm, 4.6 
mm x 150 mm) or a (B) Shim-Pack GIS (Shimadzu, 5 μm, 4.6 mm x 150 mm) column. 
All compounds utilised a 1 mL/min flow rate and a solvent system of a CH3CN/0.05 M 
TEAB buffer (pH 7.2−7.5). The CH3CN gradient used (over 40 min) was based on the 
conditions used to purify the compounds and will be highlighted in the figure legends. 
 
Figure C1: Analytical HPLC trace (Column B; 0–40 min linear gradient 13–18% CH3CN) of (A) 5.27a-s 
(99% pure) and (B) 5.27a-l (96% pure). 
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Figure C2: Analytical HPLC trace (Column A; 0–40 min linear gradient 13–18% CH3CN) of (A) 5.27b-s 
(99% pure) and (B) 5.27b-s (99% pure). 
 
 
Figure C3: Analytical HPLC trace (Column A; 0–40 min linear gradient 5–10% CH3CN) of (A) 5.27c-s 
(97% pure) and (B) 5.27c-l (98% pure). 
 
 
Figure C4: Analytical HPLC trace (Column A; 0–40 min linear gradient 5–10% CH3CN) of (A) 5.27d-s 
(95% pure) and (B) 5.27d-l (95% pure). 
 
Appendix C: Supplementary Information to Chapter 5 
263 
 
Figure C5: Analytical HPLC trace (Column A; 0–40 min linear gradient 9–14% CH3CN) of (A) 5.27e-s 
(99% pure) and (B) 5.27e-l (99% pure). 
 
 
Figure C6: Analytical HPLC trace (Column A; 0–40 min linear gradient 4–9% CH3CN) of (A) 5.27f-s 
(97% pure) and (B) 5.27f-l (97% pure). 
 
 
Figure C7: Analytical HPLC trace (Column B; 0–40 min linear gradient 3–8% CH3CN) of (A) 5.27g-s 
(98% pure) and (B) 5.27g-l (99% pure). 
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Figure C8: Analytical HPLC trace (Column B; 0–40 min linear gradient 10–16% CH3CN) of (A) 5.27h-s 
(95% pure) and (B) 5.27h-l (95% pure). 
 
 
Figure C9: Analytical HPLC trace (Column B; 0–40 min linear gradient 13–18% CH3CN) of (A) 5.27i-s 
(99% pure) and (B) 5.27i-l (99% pure). 
 
 
Figure C10: Analytical HPLC trace (Column A; 0–40 min linear gradient 3–8% CH3CN) of (A) 5.27j-s 
(97% pure) and (B) 5.27j-l (98% pure). 
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Figure C11: Analytical HPLC trace (Column B; 0–40 min linear gradient 3–8% CH3CN) of (A) 5.27k-s 
(97% pure) and (B) 5.27k-l (96% pure). 
 
 
Figure C12: Analytical HPLC trace (Column B; 0–40 min linear gradient 8–13% CH3CN) of (A) 5.27l-s 
(96% pure) and (B) 5.27l-l (95% pure). 
 
 
Figure C13: Analytical HPLC trace (Column B; 0–40 min linear gradient 12–17% CH3CN) of (A) 5.29-s 
(99% pure) and (B) 5.29-l (98% pure). 
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CMP-Glo™-based Sialyltransferase Assay 
Recombinant hST6Gal I was obtained from R&D Systems, CMP-Neu5Ac and LacNac 
were from Carbosynth. Assays were performed in sodium cacodylate buffer (5.0 mM 
sodium cacdylate, 15.0 μM NaCl, 0.05% Triton X-100). Assays were performed in a solid 
white 96-well plate, in a 25 μL volume for one hour and incubated at rt. CMP detection 
reagent was prepared as per Promega’s guidelines, and 25 μL was added, with 
luminescence measured after a further hour of incubation. In each assay a CMP standard 
curve was established in duplicate, with concentrations ranging from 0–50 μM. 
Enzyme Activity Curve 
To determine the amount of enzyme to use in each case, an assay was performed using 
amounts of enzyme ranging from 0–2000 ng/well. The amount of enzyme was added in 
15 μL of assay buffer, to which 10 μL of a mixture containing 25 μM of CMP-Neu5Ac 
and 2.5 mM of the LacNAc acceptor was added. The resultant sigmoidal curve of 
luminescence vs quantity of enzyme showed a linear response, which gave a guideline as 
to the amount of enzyme that should be used for subsequent reactions. 
 
Figure C14: Luminescence vs quantity of enzyme curve for recombinant hST6Gal I used to determine 
amount of enzyme to be used per well. 
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Determination of CMP-Neu5Ac Km Against Recombinant hST6Gal I 
CMP-Neu5Ac was diluted to 1250, 625, 312.5, 156.3, 78.1, 39.1, 19.5, 9.8, 4.9, 2.4, 1.2 
and 0 μM, while the enzyme was diluted to 60 ng/5 μL. In duplicate on a solid white 
96-well plate, 10 μL of donor, 10 μL of 2.5 mM acceptor, and 5 μL of enzyme were 
added. The assay was then performed as per the general procedure detailed above. The 
Km was calculated using non-linear regression analysis with GraphPad Prism 7. 
Figure C15: Non-linear regression analysis in Michaelis-Menten equation of CMP-Neu5Ac with 
recombinant hST6Gal I. 
 
Single Point Inhibition at 10 μM 
Enzyme was diluted to 60 ng/5 μL of recombinant hST6Gal I. To a solid white 96 well 
plate, 10 μL of a mixture of 2.5 mM of LacNAc and 250 μM of CMP-Neu5Ac in assay 
buffer, 10 μL of a 25 μM solution of inhibitor in assay buffer, and 5 μL of enzyme 
solution were added to each well. This was performed in duplicate for each inhibitor. A 
positive control with no inhibitor was also prepared, as well as a negative control where 
no enzyme was present. The assay was then performed as per the general procedure 
detailed above. Percentage inhibition was calculated relative to the positive control, with 
the negative control used as a blank. 
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Determination of Inhibitor Ki 
CMP-Neu5Ac was diluted to 1250, 625, 312.5, 156.3, 78.1, 39.1, 19.5, 9.8, 4.9, 2.4, 1.2 
and 0 μM, while recombinant hST6Gal I was diluted 60 ng/5 μL. Inhibitors were diluted 
to three concentrations, usually between 0.01–10 μM. To a solid white 96 well plate, 5 μL 
of 5 mM acceptor in assay buffer, 10 μL of inhibitor solution, and 5 μL of enzyme 
solution were added to each well. This was performed in duplicate for each inhibitor. The 
assay was then performed as per the general procedure detailed above. The Ki was 
calculated using non-linear regression analysis with GraphPad Prism 7. 
 
Figure C16. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] with 
recombinant hST6Gal I at three 5.27c-l concentrations and the Lineweaver-Burk double reciprocal plots. 
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Figure C17. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] with 
recombinant hST6Gal I at three 5.27i-l concentrations and the Lineweaver-Burk double reciprocal plots. 
 
 
Figure C18. Non-linear regression analysis in mixed inhibition mode of velocity vs [CMP-NeuAc] with 
recombinant hST6Gal I at three 5.27k-s concentrations and the Lineweaver-Burk double reciprocal plots.  
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1H NMR of 4-fluoro-3-phenoxy αHP 5.8. 
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31P NMR of 4-fluoro-3-phenoxy αHP 5.8. 
 
19F NMR of 4-fluoro-3-phenoxy αHP 5.8. 
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1H NMR of 4-fluoro αHP 5.9. 
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31P NMR of 4-fluoro αHP 5.9. 
 
19F NMR of 4-fluoro αHP 5.9. 
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1H NMR of 3-fluoro αHP 5.10. 
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31P NMR of 3-fluoro αHP 5.10. 
 
19F NMR of 3-fluoro αHP 5.10. 
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1H NMR of 3-propoxy αHP 5.11. 
 
13C NMR of 3-fluoro αHP 5.11. 
TMS 
CDCl3 
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31P NMR of 3-fluoro αHP 5.11. 
 
1H NMR of 3-cyclopentoxy-4-methoxy αHP 5.14. 
TMS 
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13C NMR of 3-cyclopentoxy-4-methoxy αHP 5.14. 
 
31P NMR of 3-cyclopentoxy-4-methoxy αHP 5.14. 
TMS 
CDCl3 
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1H NMR of 3-cyclopentoxy αHP 5.15. 
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31P NMR of 3-cyclopentoxy αHP 5.15. 
 
1H NMR of benzo[b]thiophen-2-yl αHP 5.17. 
TMS 
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13C NMR of benzo[b]thiophen-2-yl αHP 5.17. 
 
31P NMR of benzo[b]thiophen-2-yl αHP 5.17. 
CDCl3 
TMS 
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1H NMR of benzo[b]thiophen-3-yl αHP 5.18. 
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13C NMR of benzo[b]thiophen-3-yl αHP 5.18. 
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13C NMR of Alloc protected 5′-azidouridine derivative 5.20.  
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13C NMR of Alloc protected 5′-aminouridine 5.21.  
 
1H NMR Cbz protected 5′-azidocytidine of 5.23.  
DMSO-d6 
TMS 
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13C NMR of Cbz protected 5′-azidocytidine 5.23. 
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13C NMR of Cbz protected 5′-aminocytidine 5.24.  
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13C NMR of 3-phenoxy protected carbamate 5.25a. 
 
31P NMR of 3-phenoxy protected carbamate 5.25a. 
TMS 
CDCl3 
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1H NMR of 4-fluoro-3-phenoxy protected carbamate 5.25b.  
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31P NMR of 4-fluoro-3-phenoxy protected carbamate 5.25b. 
 
19F NMR of 4-fluoro-3-phenoxy protected carbamate 5.25b.  
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1H NMR of 4-fluoro protected carbamate 5.25c.  
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31P NMR of 4-fluoro protected carbamate 5.25c. 
 
19F NMR of 4-fluoro protected carbamate 5.25c. 
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1H NMR of 3-fluoro protected carbamate 5.25d.  
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31P NMR of 3-fluoro protected carbamate 5.25d.  
 
19F NMR of 3-fluoro protected carbamate 5.25d. 
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1H NMR of 3-propoxy protected carbamate 5.25e.  
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31P NMR of 3-propoxy protected carbamate 5.25e.  
  
1H NMR of 3-methoxy protected carbamate 5.25f.  
TMS 
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13C NMR of 3-methoxy protected carbamate 5.25f. 
 
31P NMR of 3-methoxy protected carbamate 5.25f. 
TMS 
CDCl3 
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1H NMR of 4-methoxy protected carbamate 5.25g.  
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31P NMR of 4-methoxy protected carbamate 5.25g.  
 
1H NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.25h.  
TMS 
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13C NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.25h.  
 
31P NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.25h. 
TMS 
CDCl3 
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1H NMR of 3-cyclopentoxy protected carbamate 5.25i. 
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31P NMR 3-cyclopentoxy protected carbamate 5.25i. 
 
1H NMR of phenyl protected carbamate 5.25j.  
TMS 
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13C NMR of phenyl protected carbamate 5.25j. 
 
31P NMR of phenyl protected carbamate 5.25j. 
CDCl3 
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1H NMR of benzo[b]thiophen-2-yl protected carbamate 5.25k.  
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31P NMR of benzo[b]thiophen-2-yl protected carbamate 5.25k. 
 
1H NMR of benzo[b]thiophen-3-yl protected carbamate 5.25l.  
TMS 
Appendix C: Supplementary Information to Chapter 5 
306 
 
13C NMR of benzo[b]thiophen-3-yl protected carbamate 5.25l.  
 
31P NMR of benzo[b]thiophen-3-yl protected carbamate 5.25l.  
TMS 
CDCl3 
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1H NMR of 3-phenoxy protected carbamate 5.28.  
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31P NMR of 3-phenoxy protected carbamate 5.28.  
 
1H NMR of 3-phenoxy protected carbamate 5.26a. 
TMS 
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13C NMR of 3-phenoxy protected carbamate 5.26a.  
 
31P NMR of 3-phenoxy protected carbamate 5.26a.  
TMS 
CDCl3 
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1H NMR of 4-fluoro-3-phenoxy protected carbamate 5.26b.  
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31P NMR of 4-fluoro-3-phenoxy protected carbamate 5.26b.  
 
19F NMR of 4-fluoro-3-phenoxy protected carbamate 5.26b.  
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1H NMR of 4-fluoro protected carbamate 5.26c. 
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31P NMR of 4-fluoro protected carbamate 5.26c. 
 
19F NMR of 4-fluoro protected carbamate 5.26c. 
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1H NMR of 3-fluoro protected carbamate 5.26d. 
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31P NMR of 3-fluoro protected carbamate 5.26d. 
 
19F NMR of 3-fluoro protected carbamate 5.26d. 
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1H NMR of 3-propoxy protected carbamate 5.26e.  
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31P NMR of 3-propoxy protected carbamate 5.26e. 
 
1H NMR of 3-methoxy protected carbamate 5.26f.  
TMS 
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13C NMR of 3-methoxy protected carbamate 5.26f.  
 
31P NMR of 3-methoxy protected carbamate 5.26f. 
TMS 
CDCl3 
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1H NMR of 4-methoxy protected carbamate 5.26g.  
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31P NMR of 4-methoxy protected carbamate 5.26g. 
 
1H NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.26h. 
TMS 
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13C NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.26h. 
 
31P NMR of 3-cyclopentoxy-4-methoxy protected carbamate 5.26h. 
TMS 
CDCl3 
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1H NMR of 3-cyclopentoxy protected carbamate 5.26i. 
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31P NMR of 3-cyclopentoxy protected carbamate 5.26i. 
 
1H NMR of phenyl protected carbamate 5.26j.  
TMS 
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13C NMR of phenyl protected carbamate 5.26j.  
 
31P NMR of phenyl protected carbamate 5.26j.  
TMS 
CDCl3 
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1H NMR of benzo[b]thiophen-2-yl protected carbamate 5.26k. 
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31P NMR of benzo[b]thiophen-2-yl protected carbamate 5.26k. 
 
1H NMR of benzo[b]thiophen-3-yl protected carbamate 5.26l. 
TMS 
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13C NMR of benzo[b]thiophen-3-yl protected carbamate 5.26l. 
 
31P NMR of benzo[b]thiophen-3-yl protected carbamate 5.26l. 
CDCl3 
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1H NMR of 3-phenoxy carbamate 5.27a-s. 
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31P NMR of 3-phenoxy carbamate 5.27a-s. 
 
1H NMR of 3-phenoxy carbamate 5.27a-l. 
D2O 
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13C NMR of 3-phenoxy carbamate 5.27a-l. 
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1H NMR of 4-fluoro-3-phenoxy carbamate 5.27b-s. 
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31P NMR of 4-fluoro-3-phenoxy carbamate 5.27b-s. 
 
19F NMR of 4-fluoro-3-phenoxy carbamate 5.27b-s. 
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1H NMR of 4-fluoro-3-phenoxy carbamate 5.27b-l. 
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31P NMR of 4-fluoro-3-phenoxy carbamate 5.27b-l. 
 
19F NMR of 4-fluoro-3-phenoxy carbamate 5.27b-l. 
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1H NMR of 4-fluoro carbamate 5.27c-s. 
 
13C NMR of 4-fluoro carbamate 5.27c-s. 
D2O 
MeOH-d4 
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31P NMR of 4-fluoro carbamate 5.27c-s. 
 
19F NMR of 4-fluoro carbamate 5.27c-s. 
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1H NMR of 4-fluoro carbamate 5.27c-l. 
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31P NMR of 4-fluoro carbamate 5.27c-l. 
 
19F NMR of 4-fluoro carbamate 5.27c-l. 
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1H NMR of 3-fluoro carbamate 5.27d-s. 
 
13C NMR of 3-fluoro carbamate 5.27d-s. 
D2O 
MeOH-d4 
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31P NMR of 3-fluoro carbamate 5.27d-s. 
 
19F NMR of 3-fluoro carbamate 5.27d-s. 
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1H NMR of 3-fluoro carbamate 5.27d-l. 
 
13C NMR of 3-fluoro carbamate 5.27d-l. 
D2O 
MeOH-d4 
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31P NMR of 3-fluoro carbamate 5.27d-l. 
 
19F NMR of 3-fluoro carbamate 5.27d-l. 
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1H NMR of 3-propoxy carbamate 5.27e-s. 
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31P NMR of 3-propoxy carbamate 5.27e-s. 
 
1H NMR of 3-propoxy carbamate 5.27e-l. 
D2O 
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13C NMR of 3-propoxy carbamate 5.27e-l. 
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1H NMR of 3-methoxy carbamate 5.27f-s. 
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31P NMR of 3-methoxy carbamate 5.27f-s. 
 
1H NMR of 3-methoxy carbamate 5.27f-l. 
D2O 
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13C NMR of 3-methoxy carbamate 5.27f-l. 
 






Appendix C: Supplementary Information to Chapter 5 
349 
 
1H NMR of 4-methoxy carbamate 5.27g-s. 
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31P NMR of 4-methoxy carbamate 5.27g-s. 
 
1H NMR of 4-methoxy carbamate 5.27g-l. 
D2O 
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13C NMR of 4-methoxy carbamate 5.27g-l. 
 
31P NMR of 4-methoxy carbamate 5.27g-l. 
MeOH-d4 
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1H NMR of 3-cyclopentoxy-4-methoxy carbamate 5.27h-s. 
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31P NMR of 3-cyclopentoxy-4-methoxy carbamate 5.27h-s. 
 
1H NMR of 3-cyclopentoxy-4-methoxy carbamate 5.27h-l. 
D2O 
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13C NMR of 3-cyclopentoxy-4-methoxy carbamate 5.27h-l.  
 
31P NMR of 3-cyclopentoxy-4-methoxy carbamate 5.27h-l. 
MeOH-d4 
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1H NMR of 3-cyclopentoxy carbamate 5.27i-s. 
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31P NMR of 3-cyclopentoxy carbamate 5.27i-s. 
 
1H NMR of 3-cyclopentoxy carbamate 5.27i-l. 
D2O 
Appendix C: Supplementary Information to Chapter 5 
357 
 
13C NMR of 3-cyclopentoxy carbamate 5.27i-l. 
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1H NMR of phenyl carbamate 5.27j-s. 
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31P NMR of phenyl carbamate 5.27j-s. 
 
1H NMR of phenyl carbamate 5.27j-l. 
D2O 
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13C NMR of phenyl carbamate 5.27j-l. 
 
31P NMR of phenyl carbamate 5.27j-l. 
MeOH-d4 
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1H NMR of benzo[b]thiophen-2-yl carbamate 5.27k-s. 
 




Appendix C: Supplementary Information to Chapter 5 
362 
 
31P NMR of benzo[b]thiophen-2-yl carbamate 5.27k-s. 
 
1H NMR of benzo[b]thiophen-2-yl carbamate 5.27k-l. 
D2O 
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13C NMR of benzo[b]thiophen-2-yl carbamate 5.27k-l. 
 
31P NMR of benzo[b]thiophen-2-yl carbamate 5.27k-l. 
MeOH-d4 
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1H NMR of benzo[b]thiophen-3-yl carbamate 5.27l-s. 
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31P NMR of benzo[b]thiophen-3-yl carbamate 5.27l-s. 
 
1H NMR of benzo[b]thiophen-3-yl carbamate 5.27l-l. 
D2O 
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13C NMR of benzo[b]thiophen-3-yl carbamate 5.27l-l. 
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1H NMR of 3-phenoxy carbamate 5.29-s. 
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31P NMR of 3-phenoxy carbamate 5.29-s. 
 
1H NMR of 3-phenoxy carbamate 5.29-l. 
D2O 
Appendix C: Supplementary Information to Chapter 5 
369 
 
13C NMR of 3-phenoxy carbamate 5.29-l. 
 
31P NMR of 3-phenoxy carbamate 5.29-l. 
MeOH-d4 
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APPENDIX D: NMR Data of Novel Compounds from Chapter 6 
 
1H NMR of carbamate 6.5. 
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31P NMR of carbamate 6.5. 
 
1H NMR of carbamate 6.6. 
TMS 
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13C NMR of carbamate 6.6. 
 
31P NMR of carbamate 6.6. 
CDCl3 
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1H NMR of azide 6.22. 
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1H NMR of amine 6.23. 
 
13C NMR of amine 6.23. 
TMS 
CDCl3 
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1H NMR of 4-methoxy acetonide protected carbamate 6.14.  
 
13C NMR of 4-methoxy acetonide protected carbamate 6.14. 
TMS 
CDCl3 
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31P NMR of 4-methoxy acetonide protected carbamate 6.14.  
 
1H NMR of 3-propoxy acetonide protected carbamate 6.15. 
TMS 
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13C NMR of 3-propoxy acetonide protected carbamate 6.15. 
 
31P NMR of 3-propoxy acetonide protected carbamate 6.15. 
CDCl3 
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1H NMR of 3-phenoxy acetonide protected carbamate 6.16. 
 
13C NMR of 3-phenoxy acetonide protected carbamate 6.16. 
TMS 
CDCl3 
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31P NMR of 3-phenoxy acetonide protected carbamate 6.16. 
 
1H NMR of phenyl acetonide protected carbamate 6.17. 
TMS 
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13C NMR of phenyl acetonide protected carbamate 6.17. 
 
31P NMR of phenyl acetonide protected carbamate 6.17. 
CDCl3 
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1H NMR of 4-methoxy TBDMS protected carbamate 6.24.  
 
13C NMR of 4-methoxy TBDMS protected carbamate 6.24. 
CDCl3 
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31P NMR of 4-methoxy TBDMS protected carbamate 6.24. 
 
1H NMR of 4-methoxy Cbz protected carbamate 6.26. 
TMS 
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13C NMR of 4-methoxy Cbz protected carbamate 6.26. 
 
31P NMR of 4-methoxy Cbz protected carbamate 6.26. 
CDCl3 
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HMBC of 4-methoxy carbamate 5.27g-s. 
